U.S. patent application number 13/911415 was filed with the patent office on 2014-10-09 for heteroaryl compounds useful as inhibitors of e1 activating enzymes.
This patent application is currently assigned to MILLENNIUM PHARMACEUTICALS, INC.. The applicant listed for this patent is MILLENNIUM PHARMACEUTICALS, INC.. Invention is credited to Christopher F. Claiborne, Stephen Critchley, Courtney A. Cullis, Steven P. Langston, Hirotake Mizutani, Edward J. Olhava, Stephane Peluso, Irache Visiers, Stepan Vyskocil, Gabriel S. Weatherhead.
Application Number | 20140303193 13/911415 |
Document ID | / |
Family ID | 39197453 |
Filed Date | 2014-10-09 |
United States Patent
Application |
20140303193 |
Kind Code |
A9 |
Claiborne; Christopher F. ;
et al. |
October 9, 2014 |
HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING
ENZYMES
Abstract
This invention relates to compounds that inhibit E1 activating
enzymes, pharmaceutical compositions comprising the compounds, and
methods of using the compounds. The compounds are useful for
treating disorders, particularly cell proliferation disorders,
including cancers, inflammatory and neurodegenerative disorders;
and inflammation associated with infection and cachexia.
Inventors: |
Claiborne; Christopher F.;
(Cambridge, MA) ; Critchley; Stephen; (Braintree,
MA) ; Cullis; Courtney A.; (Bedford, MA) ;
Langston; Steven P.; (North Andover, MA) ; Mizutani;
Hirotake; (Cambridge, MA) ; Olhava; Edward J.;
(Newton, MA) ; Peluso; Stephane; (Somerville,
MA) ; Visiers; Irache; (Arlington, MA) ;
Vyskocil; Stepan; (Arlington, MA) ; Weatherhead;
Gabriel S.; (Tewksbury, MA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
MILLENNIUM PHARMACEUTICALS, INC. |
Cambridge |
MA |
US |
|
|
Assignee: |
MILLENNIUM PHARMACEUTICALS,
INC.
Cambridge
MA
|
Prior
Publication: |
|
Document Identifier |
Publication Date |
|
US 20130345242 A1 |
December 26, 2013 |
|
|
Family ID: |
39197453 |
Appl. No.: |
13/911415 |
Filed: |
June 6, 2013 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13216352 |
Aug 24, 2011 |
8481550 |
|
|
13911415 |
|
|
|
|
11890338 |
Aug 6, 2007 |
8008307 |
|
|
13216352 |
|
|
|
|
60836158 |
Aug 8, 2006 |
|
|
|
Current U.S.
Class: |
514/263.3 ;
435/184; 544/276 |
Current CPC
Class: |
C07D 251/48 20130101;
C07D 401/06 20130101; C07D 473/34 20130101; C07D 401/04 20130101;
C07D 213/81 20130101; C07D 251/18 20130101; C07D 213/69 20130101;
C07D 487/04 20130101; A61P 35/00 20180101; C07D 473/30 20130101;
C07D 213/82 20130101; C07D 471/04 20130101; A61K 31/53 20130101;
C07D 213/74 20130101; C07D 239/48 20130101; C07D 471/08 20130101;
C07D 213/56 20130101; C07D 239/42 20130101; A61P 37/00 20180101;
C07D 403/04 20130101; C07D 239/36 20130101 |
Class at
Publication: |
514/263.3 ;
544/276; 435/184 |
International
Class: |
C07D 473/30 20060101
C07D473/30; C07D 473/34 20060101 C07D473/34 |
Claims
1-19. (canceled)
20. A compound of formula (VII): ##STR00183## or a pharmaceutically
acceptable salt thereof, wherein: each R.sup.h independently is
hydrogen, halo, --CN--, --OR.sup.5, --N(R.sup.4).sub.2, --SR.sup.6,
or an optionally substituted C.sub.1-4 aliphatic group: each
R.sup.k independently is hydrogen, halo, --NO.sub.2, --CN,
--OR.sup.5, --SR.sup.6, --S(O)R.sup.6, --SO.sub.2R.sup.6,
--SO.sub.2N(R.sup.4).sub.2, --N(R.sup.4).sub.2,
--NR.sup.4C(O)R.sup.5, --NR.sup.4C(O)N(R.sup.4).sub.2,
--N(R.sup.4)C(.dbd.NR.sup.4)--N(R.sup.4).sub.2,
--N(R.sup.4)C(.dbd.NR.sup.4)--R.sup.6, --NR.sup.4CO.sub.2R.sup.6,
--N(R.sup.4)SO.sub.2R.sup.6, --N(R.sup.4)SO.sub.2N(R.sup.4),
--O--C(O)R.sup.5, --OCO.sub.2R.sup.6, --OC(O)N(R.sup.4).sub.2,
--C(O)R.sup.5, --CO.sub.2R.sup.5, --C(O)N(R.sup.4).sub.2,
--C(O)N(R.sup.4)--OR.sup.5,
--C(O)N(R.sup.4)C(.dbd.NR.sup.4)--N(R.sup.4),
--N(R.sup.4)C(.dbd.NR.sup.4)--N(R.sup.4)--C(O)R.sup.5,
--C(.dbd.NR.sup.4)--N(R.sup.4).sub.2, --C(.dbd.NR.sup.4)--OR.sup.5,
--N(R.sup.4)--N(R.sup.4).sub.2, --N(R.sup.4)--OR.sup.5,
--C(.dbd.NR.sup.4)--N(R.sup.4)--OR.sup.5,
--C(R.sup.6).dbd.N--OR.sup.5, or an optionally substituted
aliphatic, aryl, heteroaryl, or heterocyclyl; and W is
--CH.sub.2--, --CHF--, --CF.sub.2--, --NH--, --O, --S--, or
--NHC(O)--; X is --CH.sub.2--, --CHF--, --CF--, --NH--, or --O--; Y
is --O--, --S--, or --C(R.sup.m)(R.sup.n)--; R.sup.a is selected
from the group consisting of hydrogen, fluoro, --CN, --N.sub.3,
--OR.sup.5, --N(R.sup.4).sub.2, --NR.sup.4CO.sub.2R.sup.6,
--NR.sup.4C(O)R.sup.5, --C(O)N(R.sup.4).sub.2, --C(O)R.sup.5,
--OC(O)N(R.sup.4).sub.2, --OC(O)R.sup.5, --OCO.sub.2R.sup.6, or a
C.sub.1-4 aliphatic or C.sub.1-4 fluoroaliphatic optionally
substituted with one or two substituents independently selected
from the group consisting of --OR.sup.5x, --N(R.sup.4x)(R.sup.4y),
--CO.sub.2R.sup.5x, or --C(O)N(R.sup.4x)(R.sup.4y); or R.sup.a and
R.sup.c together form a bond; R.sup.b is selected from the group
consisting of hydrogen, fluoro, C.sub.1-4, aliphatic, and C.sub.1-4
fluoroaliphatic; R.sup.c is selected from the group consisting of
hydrogen, fluoro, --CN, --N.sub.3, --OR.sup.5, --N(R.sup.4).sub.2,
--NR.sup.4CO.sub.2 R.sup.6, --NR.sup.4C(O)R.sup.5,
--C(O)N(R.sup.4).sub.2, --C(O)R.sup.5, --OC(O)N(R.sup.4).sub.2,
--OC(O)R.sup.5, --OCO.sub.2R.sup.6, or a C.sub.1-4 aliphatic or
C.sub.1-4 fluoroaliphatic optionally substituted with one or two
substituents independently selected from the group consisting of
--OR.sup.5x, --N(R.sup.4)(R.sup.4y), --CO.sub.2R.sup.5, or
--C(O)N(R.sup.4x)(R.sup.4y); or R.sup.a and R.sup.c together form a
bond; R.sup.d is selected from the group consisting of hydrogen,
fluoro, C.sub.1-4 aliphatic, and C.sub.1-4 fluoroaliphatic; R.sup.e
is hydrogen, or C.sub.1-4 aliphatic; or R.sup.e, taken together
with one R.sup.f and the intervening carbon atoms, forms a 3- to
6-membered spirocyclic ring; or R.sup.e, taken together with
R.sup.m and the intervening carbon atoms, forms a fused
cyclopropane ring, which is optionally substituted with one or two
substituents independently selected from fluoro or C.sub.1-4
aliphatic; R.sup.e' is hydrogen or C.sub.1-4 aliphatic; or
R.sup.e', taken together with R.sup.m and the intervening carbon
atoms, forms a fused cyclopropane ring, which is optionally
substituted with one or two substituents independently selected
from fluoro or C.sub.1-4 aliphatic; each R.sup.f is independently
hydrogen, fluoro, C.sub.1-4 aliphatic, or C.sub.1-4
fluoroaliphatic; or two R.sup.f taken together form .dbd.O; or two
R.sup.f, taken together with the carbon atom to which they are
attached, form a 3- to 6-membered carbocyclic ring; or one R.sup.f,
taken together with R.sup.e and the intervening carbon atoms, forms
a 3- to 6-membered spirocyclic ring; R.sup.m is hydrogen, fluoro,
--N(R.sup.4).sub.2, or an optionally substituted C.sub.1-4
aliphatic group; or R.sup.m and R.sup.n together form .dbd.O or
.dbd.C(R.sup.5).sub.2; or R.sup.m and R.sup.e, taken together with
the intervening carbon atoms, form a fused cyclopropane ring, which
is optionally substituted with one or two substituents
independently selected from fluoro or C.sub.1-4 aliphatic; or
R.sup.m and R.sup.e', taken together with the intervening carbon
atoms, form a fused cyclopropane ring, which is optionally
substituted with one or two substituents independently selected
from fluoro or C.sub.1-4 aliphatic; R.sup.n is hydrogen, fluoro, or
an optionally substituted C.sub.1-4 aliphatic group; or R.sup.m and
R.sup.n together form .dbd.O or .dbd.C(R.sup.5).sub.2; each R.sup.4
independently is hydrogen or an optionally substituted aliphatic,
aryl, heteroaryl, or heterocyclyl group; or two R.sup.4 on the same
nitrogen atom, taken together with the nitrogen atom, form an
optionally substituted 4- to 8-membered heterocyclyl ring having,
in addition to the nitrogen atom, 0-2 ring heteroatoms
independently selected from N, O, and S; R.sup.4x is hydrogen.
C.sub.1-4 alkyl, C.sub.1-4 fluoroalkyl, or C.sub.6-10
ar(C.sub.1-4)alkyl, the aryl portion of which may be optionally
substituted; R.sup.4y is hydrogen, C.sub.1-4 alkyl, C.sub.1-4
fluoroalkyl, C.sub.6-10 ar(C.sub.1-4)alkyl, the aryl portion of
which may be optionally substituted, or an optionally substituted
5- or 6-membered aryl, heteroaryl, or heterocyclyl ring; or
R.sup.4x and R.sup.4y, taken together with the nitrogen atom to
which they are attached, form an optionally substituted 4- to
8-membered heterocyclyl ring having, in addition to the nitrogen
atom, 0-2 ring heteroatoms independently selected from N, O, and S;
and each R.sup.5 independently is hydrogen or an optionally
substituted aliphatic, aryl, heteroaryl, or heterocyclyl group;
each R.sup.5x independently is hydrogen, C.sub.1-4 alkyl, C.sub.1-4
fluoroalkyl, or an optionally substituted C.sub.6-10 aryl or
C.sub.6-10 ar(C.sub.1-4)alkyl; each R.sup.6 independently is an
optionally substituted aliphatic, aryl, or heteroaryl group; m is
1, 2, or 3: E is --N.dbd. or --C(R.sup.h).dbd.; F is
--N(R.sup.9k)--, --O--, or --S--; and G is .dbd.N-- or
.dbd.C(R.sup.k)--; and R.sup.9k is hydrogen, --C(O)R.sup.5,
--C(O)N(R.sup.4).sub.2, --CO.sub.2R.sup.6, --SO.sub.2R.sup.6,
--SO.sub.2N(R.sup.4).sub.2, or a C.sub.1-4 aliphatic optionally
substituted with R.sup.7; R.sup.7 is an optionally substituted aryl
or heteroaryl ring.
21. The compound of claim 20, characterized by formula (VII-C) or
(VII-D): ##STR00184## or a pharmaceutically acceptable salt
thereof, wherein: dashed lines indicate single or double bonds;
each R.sup.2 independently is hydrogen, halo, --OR.sup.5x,
--N(R.sup.4x)(R.sup.4y), or a C.sub.1-4 aliphatic or C.sub.1-4
fluoroaliphatic optionally substituted with --OR.sup.5x,
--N(R.sup.4x)(R.sup.4y), --CO.sub.2R.sup.5x, or
--C(O)N(R.sup.4x)(R.sup.4y); or both R.sup.2f, taken together with
the intervening ring carbon atoms, form an optionally substituted
fused 5- or 6-membered cycloaliphatic, aryl, heteroaryl, or
heterocyclic ring.
22. (canceled)
23. (canceled)
24. A pharmaceutical composition, comprising a compound of claim 20
and a pharmaceutically acceptable carrier.
25. The pharmaceutical composition of claim 24, formulated for
administration to a human patient.
26. A method of decreasing an E1 enzyme activity in a sample,
comprising contacting the sample with a compound of claim 20.
27. The method of claim 26, wherein the E1 enzyme is selected from
the group consisting of NAE, UAE, and SAE.
28. The method of claim 27, wherein the E1 enzyme is NAE.
29. A method for treating cancer in a patient in need thereof,
comprising administering to the patient a compound of claim 20.
30. The method of claim 29, wherein the cancer is lung cancer,
colorectal cancer, ovarian cancer, or a hematological cancer.
31. A method for treating an immune response disorder or vascular
cell proliferation disorder in a patient in need thereof,
comprising administering to the patient a compound of claim 20.
32. A compound of claim 20, selected from I-3
[(1R,2R,3S,4R)-2,3-dihydroxy-4-(9H-purin-6-ylamino)cyclopentyl]methyl
sulfamate; I-9 {(1R,2R,3S,4R)-2,3-dihydroxy-4-[8-phenyl-9H
purin-6-yl)amino]cyclopentyl}-methyl sulfamate; I-34
((1S,2S,4R)-4-{[8-(2-chlorophenyl)-9H-purin-6-yl]amino}-2-hydroxycyclopen-
tyl)methyl sulfamate; I-36
{(1S,2S,4R)-2-hydroxy-4-[(7-methyl-8-phenyl-7H-purin-6-yl)-amino]cyclopen-
tyl}methyl sulfamate; I-37
((1S,2S,4R)-2-hydroxy-4-{[8-(2-phenoxyphenyl)-9H-purin-6-yl]amino}-cyclop-
entyl)methyl sulfamate; I-38
{(1S,2S,4R)-2-hydroxy-4-[(6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino-
]cyclopentyl}methyl sulfamate; I-39
{(1S,2S,4R)-4-[(8-dibenzo[b,d]furan-4-yl-9H-purin-6-yl)amino]-2-hydroxycy-
clopentyl}methyl sulfamate; I-41
((1S,2S,4R)-4-{[8-(2,3-dihydro-1,4-benzodioxin-5-yl)-9H-purin-6-yl]amino}-
-2-hydroxycyclopentyl)methyl sulfamate; I-46
((1S,2S,4R)-2-hydroxy-4-{methyl[8-(1-naphthyl)-9H-purin-6-yl]amino}-cyclo-
pentyl)methyl sulfamate; I-48
{(1S,2S,4R)-4-[(8-biphenyl-2-yl-9H-purin-6-yl)amino]-2-hydroxycyclopentyl-
}-methyl sulfamate; I-49
((1S,2S,4R)-2-hydroxy-4-{[8-(1-naphthyl)-9H-purin-6-yl]amino}cyclopentyl)-
-methyl sulfamate; I-56
((1S,2S,4R)-4-{[6-chloro-2-(1-naphthyl)-3H-imidazo[4,5-b]pyridin-7-yl]ami-
no}-2-hydroxycyclopentyl)methyl sulfamate; I-60
((1S,2S,4R)-4-{[8-(3-chlorophenyl)-9H-purin-6-yl]amino}-2-hydroxycyclopen-
tyl)methyl sulfamate; I-62
[(1S,2S,4R)-2-hydroxy-4-({8-[2-(trifluoromethoxy)phenyl]-9H-purin-6-yl}-a-
mino)cyclopentyl]methyl sulfamate; I-63
{(1S,2S,4R)-2-hydroxy-4-[(8-phenyl-9H-purin-6-yl)oxy]cyclopentyl}methyl
sulfamate; I-64
[(1S,2S,4R)-4-({8-[4(dimethylamino)-1-naphthyl]-9H-purin-6-yl}amino)-2-hy-
droxycyclopentyl]methyl sulfamate; I-67
((1S,2S,4R)-4-{[8-(2,3-dimethoxyphenyl)-9H-purin-6-yl]amino}-2-hydroxycyc-
lopentyl)methyl sulfamate; I-68
[(1S,2S,4R)-4-({8-[2-(benzyloxy)phenyl]-9H-purin-6-yl}amino)-2-hydroxycyc-
lopentyl]methyl sulfamate; I-69
{(1S,2S,4R)-2-hydroxy-4-[(8-phenyl-9H-purin-6-yl)amino]cyclopentyl}methyl
sulfamate; I-73
((1S,2S,4R)-4-{[8(7-chloroquinolin-4-yl)-7H-purin-6-yl]oxy}-2-hydroxycycl-
opentyl)methyl sulfamate; I-74 ((1S,2S,4R)-2-hydroxy-4-{[6
(1-naphthyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amino}cyclopentyl)methyl
sulfamate; I-80
{(1S,2S,4R)-4-[(9-benzyl-9H-purin-6-yl)oxy]-2-hydroxycyclopentyl}methyl
sulfamate; I-84
{(1S,2S,4R)-2-hydroxy-4-[(8-quinolin-8-yl-7H-purin-6-yl)amino]cyclopentyl-
}-methyl sulfamate; I-87
((1S,2S,4R)-2-hydroxy-4-{[8-(1-naphthyl)-9H-purin-6-yl]oxy}cyclopentyl)me-
thyl sulfamate; I-88
{(1S,2S,4R)-4-[(8-benzyl-9H-purin-6-yl)amino]-2-hydroxycyclopentyl}methyl
sulfamate; I-90
{(1S,2S,4R)-2-hydroxy-4-[(2-phenyl[1,3]oxazolo[5,4-d]pyrimidin-7-yl)-amin-
o]cyclopentyl}methyl sulfamate; I-93
((1S,2S,4R)-4-{[8-(2,6-dimethoxyphenyl)-9H-purin-6-yl]amino}-2-hydroxycyc-
lopentyl)methyl sulfamate; I-99
((1S,2S,4R)-2-hydroxy-4-{[8-(3-methoxyphenyl)-9H-purin-6-yl]amino}-cyclop-
entyl)methyl sulfamate; I-100
((1S,2S,4R)-4-{[8-(2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl)-9H-purin-6-
-yl]-amino}-2-hydroxycyclopentyl)methyl sulfamate; I-101
[(1S,2S,4R)-2-hydroxy-4-({8-[(3-methylphenyl)sulfonyl]-9H-purin-6-yl}-oxy-
)cyclopentyl]methyl sulfamate; I-102
[(1S,2S,4R)-4-({8-[4-(benzyloxy)phenyl]-7H-purin-6-yl}amino)-2-hydroxycyc-
lopentyl]methyl sulfamate; I-103
[(1S,2S,4R)-4-({8-[4-(dimethylamino)-1-naphthyl]-7H-purin-6-yl}oxy)-2-hyd-
roxycyclopentyl]methyl sulfamate; I-105
{(1S,2S,4R)-4-[(8-biphenyl-3-yl-9H-purin-6-yl)amino]-2-hydroxycyclopentyl-
}-methyl sulfamate; I-107
((1S,2S,4R)-2-hydroxy-4-{[8-(2-methylphenyl)-9H-purin-6-yl]amino}-cyclope-
ntyl)methyl sulfamate; I-109
((1S,2S,4R)-2-hydroxy-4-{[2-(1-naphthyl)-3H-imidazo[4,5-b]pyridin-7-yl]ox-
y}-cyclopentyl)methyl sulfamate; I-110
(1S,2S,4R)-2-(hydroxymethyl)-4-{[8-(5,6,7,8-tetrahydronaphthalen-1-yl)-9H-
-purin-6-yl]amino}cyclopentanol; I-111
((1S,2S,4R)-4-{[8-(4-chlorophenyl)-9H-purin-6-yl]amino}-2-hydroxycyclopen-
tyl)methyl sulfamate; I-112
{(1S,2S,4R)-2-hydroxy-4-[(8-isoquinolin-4-yl-7H-purin-6-yl)oxy]cyclopenty-
l}-methyl sulfamate; I-117
((1S,2S,4R)-4-{[8-(2,3-dihydro-1-benzofuran-7-yl)-7H-purin-6-yl]amino}-2--
hydroxycyclopentyl)methyl sulfamate; I-121
((1S,2S,4R)-2-hydroxy-4-{[8-(1,2,3,4-tetrahydronaphthalen-1-yl)-9H-purin--
6-yl]-amino}cyclopentyl)methyl sulfamate; I-122
[(1S,2S,4R)-2-hydroxy-4-({8-[2-(trifluoromethyl)phenyl]-9H-purin-6-yl}-am-
ino)cyclopentyl]methyl sulfamate; I-123
{(1S,2S,4R)-2-hydroxy-4-[methyl(9-methyl-8-phenyl-9H-purin-6-yl)-amino]cy-
clopentyl}methyl sulfamate; I-126 ((1S,2S,4R)-2-hydroxy-4-{[8
(5,6,7,8-tetrahydronaphthalen-1-yl)-9H-purin-6-yl]-amino}cyclopentyl)meth-
yl sulfamate; I-128
{(1S,2S,4R)-4-[(8-cyclohexyl-9H-purin-6-yl)amino]-2-hydroxycyclopentyl}-m-
ethyl sulfamate; I-129
((1S,2S,4R)-4-{[8-(1-benzyl-1H-pyrazol-4-yl)-7H-purin-6-yl]oxy}-2-hydroxy-
cyclopentyl)methyl sulfamate; I-130
{(1S,2S,4R)-2-hydroxy-4-[(9-methyl-8-phenyl-9H-purin-6-yl)-amino]cyclopen-
tyl}methyl sulfamate; I-131
{(1S,2S,4R)-4-[(8-tert-butyl-9H-purin-6-yl)amino]-2-hydroxycyclopentyl}me-
thyl sulfamate; I-133
((1S,2S,4R)-2-hydroxy-4-{[8(2-methoxyphenyl)-9H-purin-6-yl]amino}-cyclope-
ntyl)methyl sulfamate; I-136
[(1S,2S,4R)-2-hydroxy-4-({8-[(3-methylphenyl)sulfanyl]-7H-purin-6-yl}-oxy-
)cyclopentyl]methyl sulfamate; I-137
[(1S,2S,4R)-4-({8-[2-(dimethylamino)phenyl]-9H-purin-6-yl}amino)-2-hydrox-
ycyclopentyl]methyl sulfamate; I-139
((1S,2S,4R)-2-hydroxy-4-{[8-(4-pyrrolidin-1-yl-1-naphthyl)-7H-purin-6-yl]-
oxy}-cyclopentyl)methyl sulfamate; I-140
((1S,2S,4R)-2-hydroxy-4-{[8-(1H-indol-3-yl)-7H-purin-6-yl]oxy}cyclopentyl-
)-methyl sulfamate; I-152
((1S,3S)-3-{[8-(1-naphthyl)-9H-purin-6-yl]oxy}cyclopentyl)methyl
sulfamate.
Description
PRIORITY CLAIM
[0001] This application is a Continuation of U.S. patent
application Ser. No. 11/890,338, filed Aug. 6, 2007, which claims
the benefit of U.S. Provisional Patent Application Ser. No.
60/836,158, filed on Aug. 8, 2006, which are hereby incorporated by
reference in their entirety.
FIELD OF THE INVENTION
[0002] This invention relates to compounds, compositions and
methods for the treatment of various disorders, particularly
disorders of cell proliferation, including cancers, and
inflammatory disorders. In particular, the invention provides
compounds which inhibit the activity of E1 type activating
enzymes.
BACKGROUND OF THE INVENTION
[0003] The post-translational modification of proteins by
ubiquitin-like molecules (ubis) is an important regulatory process
within cells, playing key roles in controlling many biological
processes including cell division, cell signaling and the immune
response. Ubls are small proteins that are covalently attached to a
lysine on a target protein via an isopeptide linkage with a
C-terminal glycine of the ubl. The ubiquitin-like molecule alters
the molecular surface of the target protein and can affect such
properties as protein-protein interactions, enzymatic activity,
stability and cellular localization of the target.
[0004] Ubiquitin and other ubls are activated by a specific E1
enzyme which catalyzes the formation of an acyl-adenylate
intermediate with the C-terminal glycine of the ubl. The activated
ubl molecule is then transferred to the catalytic cysteine residue
within the E1 enzyme through formation of a thioester bond
intermediate. The E1-ubl intermediate and an E2 associate,
resulting in a thioester exchange wherein the ubl is transferred to
the active site cysteine of the E2. The ubl is then conjugated to
the target protein, either directly or in conjunction with an E3
ligase, through isopeptide bond formation with the amino group of a
lysine side chain in the target protein.
[0005] The biological consequence of ubl modification depends on
the target in question. Ubiquitin is the best characterized of the
ubls and a consequence of modification by ubiquitination is the
degradation of poly-ubiquitinated proteins by the 26S proteasome.
Ubiquitin is conjugated to its target proteins through an enzymatic
cascade involving its specific E1 activating enzyme, Uba1
(ubiquitin activating enzyme, UAE), a conjugating enzyme from the
family of E2s, and a ubiquitin ligase from either the RING or HECT
classes of E3s. See, Huang et al., Oncogene, 23:1958-71 (2004).
Target specificity is controlled by the particular combination of
E2 and E3 protein, with >40 E2s and >100 E3s being known at
present. In addition to ubiquitin, there are at least 10
ubiquitin-like proteins, each believed to be activated by a
specific E1 activating enzyme and processed through similar but
distinct downstream conjugation pathways. Other ubls for which E1
activating enzymes have been identified include Nedd8
(APPBPI-Uba3), ISG15 (UBE1L) and the SUMO family (Aos1-Uba2).
[0006] The ubl Nedd8 is activated by the heterodimer
Nedd8-activating enzyme (APPBP1-Uba3) (NAE) and is transferred to a
single E2 (Ubc12), ultimately resulting in ligation to cullin
proteins. The function of neddylation is the activation of
cullin-based ubiquitin ligases involved in the ubiquitination and
hence turnover of many cell cycle and cell signaling proteins,
including p27 and I-.kappa.B. See Pan et al., Oncogene. 23:1985-97
(2004). The ubl SUMO is activated by the heterodimer sumo
activating enzyme (Aos1-Uba2) (SAE) and is transferred to a single
E2 (Ubc9), followed by coordination with multiple E3 ligases,
ultimately resulting in sumoylation of target proteins. Sumo
modification can affect the cellular localization of target
proteins and proteins modified by SUMO family members are involved
in nuclear transport, signal transduction and the stress response.
See Seeler and Dejean, Nat Rev Mol Cell Biol. 4:690-9, (2003). The
function of sumoylation includes activation of cell signaling
pathways (e.g., cytokine, WNT, growth factor, and steroid hormone
signaling) involved in transcription regulation; as well as
pathways involved in control of genomic integrity (e.g., DNA
replication, response to DNA damage, recombination and repair). See
Muller et al, Oncogene. 23:1998-2006, (2004). There are other ubls
(e.g., ISG15, FAT10, Apg12p) for which the biological functions are
still under investigation.
[0007] A particular pathway of importance which is regulated via E1
activating enzyme activities is the ubiquitin-proteasome pathway
(UPP). As discussed above, the enzymes UAE and NAE regulate the UPP
at two different steps in the ubiquitination cascade. UAE activates
ubiquitin in the first step of the cascade, while NAE, via
activation of Nedd8, is responsible for the activation of the
cullin based ligases, which in turn are required for the final
transfer of ubiquitin to certain target proteins A functional UPP
pathway is required for normal cell maintenance. The UPP plays a
central role in the turnover of many key regulatory proteins
involved in transcription, cell cycle progression and apoptosis,
all of which are important in disease states, including tumor
cells. See, e.g., King et al., Science 274: 1652-1659 (1996);
Vorhees et al., Clin. Cancer Res., 9: 6316-6325 (2003); and Adams
et al., Nat. Rev. Cancer, 4: 349-360 (2004). Proliferating cells
are particularly sensitive to inhibition of the UPP. See, Drexler,
Proc. Natl. Acad. Sci., USA 94: 855-860 (1977). The role of the UPP
pathway in oncogenesis has led to the investigation of proteasome
inhibition as a potential anticancer therapy. For example,
modulation of the UPP pathway by inhibition of the 26S proteasome
by VELCADE.RTM. (bortezomib) has proven to be an effective
treatment in certain cancers and is approved for the treatment of
multiple myeloma and mantle cell lymphoma patients who have
received at least one prior therapy. Examples of proteins whose
levels are controlled by cullin-based ubiquitin ligases which are
downstream of NAE and UAE activity include the CDK inhibitor
p27.sup.Kip1 and the inhibitor of NF.kappa.B, I.kappa.B. See,
Podust et al., Proc. Natl. Acad. Sci., 97: 4579-4584 (2000), and
Read et al., Mol. Cell. Biol., 20:2326-2333 (2000). Inhibition of
the degradation of p27 is expected to block the progression of
cells through the G1 and S phases of the cell cycle. Interfering
with the degradation of I.kappa.B should prevent the nuclear
localization of NF-.kappa.B, transcription of various
NF-.kappa.B-dependent genes associated with the malignant
phenotype, and resistance to standard cytotoxic therapies.
Additionally, NF-.kappa.B plays a key role in the expression of a
number of pro-inflammatory mediators, implicating a role for such
inhibitors in inflammatory diseases. Furthermore, inhibition of UPP
has been implicated as a useful target for additional therapeutics,
such as inflammatory disorders, including, e.g., rheumatoid
arthritis, asthma, multiple sclerosis, psoriasis and reperfusion
injury; neurodegenerative disorders, including e.g., Parkinson's
disease, Alzheimer's disease, triplet repeat disorders; neuropathic
pain; ischemic disorders, e.g., stroke, infarction, kidney
disorders; and cachexia. See, e.g., Elliott and Ross, Am. J. Clin.
Pathol., 116:637-46 (2001); Elliott et al., J. Mol. Med., 81:235-45
(2003); Tarlac and Storey, J. Neurosci. Res. 74:406-416 (2003);
Mori et al., Neuropath. Appl. Neurobiol., 31: 53-61 (2005);
Manning, Curr. Pain Headache Rep., 8: 192-8 (2004); Dawson and
Dawson, Science, 302: 819-822 (2003); Kukan, J. Physiol.
Pharmacol., 55: 3-15 (2004); Wojcik and DiNapoli, Stroke,
35:1506-18 (2004); Lazarus et al., Am J. Physiol., 27:E332-41
(1999).
[0008] Targeting E1 activating enzymes provides a unique
opportunity to interfere with a variety of biochemical pathways
important for maintaining the integrity of cell division and cell
signaling. E1 activating enzymes function at the first step of ubl
conjugation pathways; thus, inhibition of an E1 activating enzyme
will specifically modulate the downstream biological consequences
of the ubl modification. As such, inhibition of these activating
enzymes, and the resultant inhibition of downstream effects of
ubl-conjugation, represents a method of interfering with the
integrity of cell division, cell signaling, and several aspects of
cellular physiology which are important for disease mechanisms.
Thus, E1 enzymes such as UAE, NAE, and SAE, as regulators of
diverse cellular functions, are potentially important therapeutic
targets for the identification of novel approaches to treatment of
diseases and disorders.
DESCRIPTION OF THE INVENTION
[0009] This invention provides compounds that are effective
inhibitors of E1 activating enzymes, particularly NAE. The
compounds are useful for inhibiting E1 activity in vitro and in
vivo, and are useful for the treatment of disorders of cell
proliferation, particularly cancers, and other disorders associated
with E1 activity. Compounds of the invention are of the general
formula (I):
##STR00001##
[0010] or a pharmaceutically acceptable salt thereof, wherein:
[0011] Ring A is a 6-membered nitrogen-containing heteroaryl ring,
optionally fused to a 5- or 6-membered aryl, heteroaryl,
cycloaliphatic or heterocyclic ring, wherein either or both rings
is optionally substituted and one ring nitrogen atom is optionally
oxidized; [0012] W is --CH.sub.2--, --CHF--, --CF.sub.2--,
--CH(R.sup.1)--, --CF(R.sup.1)--, --NH--, --N(R.sup.1)--, --O--,
--S--, or --NHC(O)--; [0013] R.sup.1 is C aliphatic or C.sub.1-4
fluoroaliphatic; or R.sup.1 is a C.sub.2-4 alkylene chain that is
attached to a ring position on Ring A to form a 5-, 6-, or
7-membered fused ring, wherein the alkylene chain optionally is
substituted with C.sub.1-4 aliphatic, C.sub.1-4 fluoroaliphatic,
.dbd.O, --CN, or --C(O)N(R.sup.4).sub.2; [0014] X is --CH.sub.2--,
--CHF--, --CF--, --NH--, or --O--; [0015] Y is --O--, --S--, or
--C(R.sup.m)(R.sup.n)--; [0016] R.sup.a is selected from the group
consisting of hydrogen, fluoro, --CN, --N.sub.3, --OR.sup.5,
--N(R.sup.4).sub.2, --NR.sup.4CO.sub.2R.sup.6,
--NR.sup.4C(O)R.sup.5, --C(O)N(R.sup.4).sub.2, --C(O)R.sup.5,
--OC(O)N(R.sup.4).sub.2, --OC(O)R.sup.5, --OCO.sub.2R.sup.6, or a
C.sub.1-4 aliphatic or C.sub.1-4 fluoroaliphatic optionally
substituted with one or two substituents independently selected
from the group consisting of --OR.sup.5x, --N(R.sup.4x)(R.sup.4y),
--CO.sub.2R.sup.5x, or --C(O)N(R.sup.4x)(R.sup.4y); or R.sup.a and
R.sup.c together form a bond; [0017] R.sup.b is selected from the
group consisting of hydrogen, fluoro, C.sub.1-4 aliphatic, and
C.sub.1-4 fluoroaliphatic; [0018] R.sup.c is selected from the
group consisting of hydrogen, fluoro, --CN, --N.sub.3, --OR.sup.5,
--N(R).sub.2, --NR.sup.4CO.sub.2R.sup.6, --NR.sup.4C(O)R.sup.5,
--C(O)N(R.sup.4).sub.2, --C(O)R.sup.5, --OC(O)N(R.sup.4).sub.2,
--OC(O)R.sup.5, --OCO.sub.2R.sup.6, or a C.sub.1-4 aliphatic or
C.sub.1-4 fluoroaliphatic optionally substituted with one or two
substituents independently selected from the group consisting of
--OR.sup.5x, --N(R.sup.4x)(R.sup.4y), --CO.sub.2R.sup.5x, or
--C(O)N(R.sup.4x)(R.sup.4y); or R.sup.a and R.sup.c together form a
bond; [0019] R.sup.d is selected from the group consisting of
hydrogen, fluoro, C.sub.1-4 aliphatic, and C.sub.1-4
fluoroaliphatic; [0020] R.sup.e is hydrogen, or C.sub.1-4
aliphatic; or R.sup.e, taken together with one R.sup.f and the
intervening carbon atoms, forms a 3- to 6-membered spirocyclic
ring; or R.sup.e, taken together with R.sup.m and the intervening
carbon atoms, forms a fused cyclopropane ring, which is optionally
substituted with one or two substituents independently selected
from fluoro or C.sub.1-4 aliphatic; [0021] R.sup.e' is hydrogen or
C.sub.1-4 aliphatic; or R.sup.e', taken together with R.sup.m and
the intervening carbon atoms, forms a fused cyclopropane ring,
which is optionally substituted with one or two substituents
independently selected from fluoro or C.sub.1-4 aliphatic; [0022]
each R.sup.f is independently hydrogen, fluoro, C.sub.1-4
aliphatic, or C.sub.1-4 fluoroaliphatic; or two R.sup.f taken
together form .dbd.O; or two R.sup.f, taken together with the
carbon atom to which they are attached, form a 3- to 6-membered
carbocyclic ring; or one R.sup.f, taken together with R.sup.e and
the intervening carbon atoms, forms a 3- to 6-membered spirocyclic
ring; [0023] R.sup.m is hydrogen, fluoro, --N(R.sup.4), or an
optionally substituted C.sub.1-4 aliphatic group; or R.sup.m and
R.sup.n together form .dbd.O or .dbd.C(R.sup.5).sub.2; or R.sup.m
and R.sup.n, taken together with the intervening carbon atoms, form
a fused cyclopropane ring, which is optionally substituted with one
or two substituents independently selected from fluoro or C.sub.1-4
aliphatic; or R.sup.m and R.sup.e', taken together with the
intervening carbon atoms, form a fused cyclopropane ring, which is
optionally substituted with one or two substituents independently
selected from fluoro or C.sub.1-4 aliphatic; [0024] R.sup.n is
hydrogen, fluoro, or an optionally substituted C.sub.1-4 aliphatic
group; or R.sup.m and R.sup.n together form .dbd.O or
--C(R.sup.5).sub.2; [0025] each R.sup.4 independently is hydrogen
or an optionally substituted aliphatic, aryl, heteroaryl, or
heterocyclyl group; or two R.sup.4 on the same nitrogen atom, taken
together with the nitrogen atom, form an optionally substituted 4-
to 8-membered heterocyclyl ring having, in addition to the nitrogen
atom, 0-2 ring heteroatoms independently selected from N, O, and S;
[0026] R.sup.4x is hydrogen, C.sub.1-4 alkyl, C.sub.1-4
fluoroalkyl, or C.sub.6-10 ar(C.sub.1-4)alkyl, the aryl portion of
which may be optionally substituted; [0027] R.sup.4y is hydrogen,
C.sub.1-4 alkyl, C.sub.1-4 fluoroalkyl, C.sub.6-10
ar(C.sub.1-4)alkyl, the aryl portion of which may be optionally
substituted, or an optionally substituted 5- or 6-membered aryl,
heteroaryl, or heterocyclyl ring; or [0028] R.sup.4x and R.sup.4y,
taken together with the nitrogen atom to which they are attached,
form an optionally substituted 4- to 8-membered heterocyclyl ring
having, in addition to the nitrogen atom, 0-2 ring heteroatoms
independently selected from N, O, and S; and [0029] each R.sup.5
independently is hydrogen or an optionally substituted aliphatic,
aryl, heteroaryl, or heterocycyl group; [0030] each R.sup.5x
independently is hydrogen, C.sub.1-4 alkyl, C.sub.1-4 fluoroalkyl,
or an optionally substituted C.sub.6-10 aryl or C.sub.6-10
ar(C.sub.1-4)alkyl; [0031] each R.sup.6 independently is an
optionally substituted aliphatic, aryl, or heteroaryl group; and
[0032] m is 1, 2, or 3.
[0033] Compounds of the invention include those described generally
above, and are further defined and illustrated by the detailed
description and examples herein.
[0034] As used herein, the term "E1," "E1 enzyme," or "E1
activating enzyme" refers to any one of a family of related
ATP-dependent activating enzymes involved in activating or
promoting ubiquitin or ubiquitin-like (collectively "ubl")
conjugation to target molecules. E1 activating enzymes function
through an adenylation/thioester intermediate formation to transfer
the appropriate ubl to the respective E2 conjugating enzyme through
a transthiolation reaction. The resulting activated ubl-E2 promotes
ultimate conjugation of the ubl to a target protein. A variety of
cellular proteins that play a role in cell signaling, cell cycle,
and protein turnover are substrates for ubl conjugation which is
regulated through E1 activating enzymes (e.g., NAE, UAE, SAE).
Unless otherwise indicated by context, the term "E1 enzyme" is
meant to refer to any E1 activating enzyme protein, including,
without limitation, nedd8 activating enzyme (NAE (APPBP1/Uba3)),
ubiquitin activating enzyme (UAE (Uba1)), sumo activating enzyme
(SAE (Aos1/Uba2)), or ISG15 activating enzyme (Ube1L). Preferably,
the term "E1 enzyme" refers to human NAE, SAE or UAE, and more
preferably refers to NAE.
[0035] The term "E1 enzyme inhibitor" or "inhibitor of E1 enzyme"
is used to signify a compound having a structure as defined herein,
which is capable of interacting with an E1 enzyme and inhibiting
its enzymatic activity. Inhibiting E1 enzymatic activity means
reducing the ability of an E1 enzyme to activate ubiquitin like
(ubl) conjugation to a substrate peptide or protein (e.g.,
ubiquitination, neddylation, sumoylation). In various embodiments,
such reduction of E1 enzyme activity is at least about 50%, at
least about 75%, at least about 90%, at least about 95%, or at
least about 99%. In various embodiments, the concentration of E1
enzyme inhibitor required to reduce an E1 enzymatic activity is
less than about 1 .mu.M, less than about 500 nM, less than about
100 nM, less than about 50 nM, or less than about 10 nM.
[0036] In some embodiments, such inhibition is selective, i.e., the
E1 enzyme inhibitor reduces the ability of one or more E1 enzymes
(e.g., NAE, UAE, or SAE) to promote ubl conjugation to substrate
peptide or protein at a concentration that is lower, preferably at
least 2-fold, 5-fold, 10-fold, 50-fold, or 100-fold lower, than the
concentration of the inhibitor that is required to produce another,
unrelated biological effect. In some such embodiments, the E1
enzyme inhibitor reduces the activity of one E1 enzyme at a
concentration that is lower than the concentration of the inhibitor
that is required to reduce enzymatic activity of a different E1
enzyme. In other embodiments, the E1 enzyme inhibitor also reduces
the enzymatic activity of another E1 enzyme, preferably one that is
implicated in regulation of pathways involved in cancer (e.g., NAE
and UAE).
[0037] The term "about" is used herein to mean approximately, in
the region of, roughly, or around. When the term "about" is used in
conjunction with a numerical range, it modifies that range by
extending the boundaries above and below the numerical values set
forth. In general, the term "about" is used herein to modify a
numerical value above and below the stated value by a variance of
10%.
[0038] The term "aliphatic", as used herein, means straight-chain,
branched or cyclic C.sub.1-C.sub.12 hydrocarbons which are
completely saturated or which contain one or more units of
unsaturation, but which are not aromatic. For example, suitable
aliphatic groups include substituted or unsubstituted linear,
branched or cyclic alkyl, alkenyl, alkynyl groups and hybrids
thereof, such as cycloalkyl, (cycloalkyl)alkyl, (cycloalkenyl)alkyl
or (cycloalkyl)-alkenyl. In various embodiments, the aliphatic
group has one to ten, one to eight, one to six, one to four, or
one, two, or three carbons.
[0039] The terms "alkyl", "alkenyl", and "alkynyl", used alone or
as part of a larger moiety, refer to a straight and branched chain
aliphatic group having from one to twelve carbon atoms. For
purposes of the present invention, the term "alkyl" will be used
when the carbon atom attaching the aliphatic group to the rest of
the molecule is a saturated carbon atom. However, an alkyl group
may include unsaturation at other carbon atoms. Thus, alkyl groups
include, without limitation, methyl, ethyl, propyl, allyl,
propargyl, butyl, pentyl, and hexyl. The term "alkoxy" refers to an
--O-alkyl radical.
[0040] For purposes of the present invention, the term "alkenyl"
will be used when the carbon atom attaching the aliphatic group to
the rest of the molecule forms part of a carbon-carbon double bond.
Alkenyl groups include, without limitation, vinyl, 1-propenyl,
1-butenyl, 1-pentenyl, and 1-hexenyl.
[0041] For purposes of the present invention, the term "alkynyl"
will be used when the carbon atom attaching the aliphatic group to
the rest of the molecule forms part of a carbon-carbon triple bond.
Alkynyl groups include, without limitation, ethynyl, 1-propynyl,
1-butynyl, 1-pentynyl, and 1-hexynyl.
[0042] The term "cycloaliphatic", used alone or as part of a larger
moiety, refers to a saturated or partially unsaturated cyclic
aliphatic ring system having from 3 to about 14 members, wherein
the aliphatic ring system is optionally substituted. In some
embodiments, the cycloaliphatic is a monocyclic hydrocarbon having
3-8 or 3-6 ring carbon atoms. Nonlimiting examples include
cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl,
cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, cyclooctenyl,
and cyclooctadienyl. In some embodiments, the cycloaliphatic is a
bridged or fused bicyclic hydrocarbon having 6-12, 6-10, or 6-8
ring carbon atoms, wherein any individual ring in the bicyclic ring
system has 3-8 members.
[0043] In some embodiments, two adjacent substituents on a
cycloaliphatic ring, taken together with the intervening ring
atoms, form an optionally substituted fused 5- to 6-membered
aromatic or 3- to 8-membered non-aromatic ring having 0-3 ring
heteroatoms selected from the group consisting of O, N, and S.
Thus, the term "cycloaliphatic" includes aliphatic rings that are
fused to one or more aryl, heteroaryl, or heterocyclyl rings, where
the radical or point of attachment is on the aliphatic ring.
Nonlimiting examples include indanyl,
5,6,7,8-tetrahydroquinoxalinyl, decahydronaphthyl, or
tetrahydronaphthyl, where the radical or point of attachment is on
the aliphatic ring.
[0044] The terms "haloaliphatic", "haloalkyl", "haloalkenyl" and
"haloalkoxy" refer to an aliphatic, alkyl, alkenyl or alkoxy group,
as the case may be, which is substituted with one or more halogen
atoms. As used herein, the term "halogen" or "halo" means F, Cl,
Br, or I. The term "fluoroaliphatic" refers to a haloaliphatic
wherein the halogen is fluoro. Nonlimiting examples of
fluoroaliphatics include --CH.sub.2F, --CHF.sub.2, --CF.sub.3,
--CH.sub.2CF, --CF.sub.2CH.sub.3, and --CF.sub.2CF.sub.3.
[0045] The terms "aryl" and "ar-", used alone or as part of a
larger moiety, e.g., "aralkyl", "aralkoxy", or "aryloxyalkyl",
refer to a C.sub.6 to C.sub.14 aromatic hydrocarbon, comprising one
to three rings, each of which is optionally substituted.
Preferably, the aryl group is a C.sub.6-10 aryl group. Aryl groups
include, without limitation, phenyl, naphthyl, and anthracenyl. In
some embodiments, two adjacent substituents on an aryl ring, taken
together with the intervening ring atoms, form an optionally
substituted fused 5- to 6-membered aromatic or 4- to 8-membered
non-aromatic ring having 0-3 ring heteroatoms selected from the
group consisting of O, N, and S. Thus, the term "aryl", as used
herein, includes groups in which an aromatic ring is fused to one
or more heteroaryl, cycloaliphatic, or heterocyclyl rings, where
the radical or point of attachment is on the aromatic ring.
Nonlimiting examples of such fused ring systems include indolyl,
isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl,
benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl,
phthalazinyl, quinazolinyl, quinoxalinyl, carbazolyl, acridinyl,
phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl,
tetrahydroisoquinolinyl, fluorenyl, indanyl, phenanthridinyl,
tetrahydronaphthyl, indolinyl, phenoxazinyl, benzodioxanyl, and
benzodioxolyl. An aryl group may be mono-, bi-, tri-, or
polycyclic, preferably mono-, bi-, or tricyclic, more preferably
mono- or bicyclic. The term "aryl" may be used interchangeably with
the terms "aryl group", "aryl moiety", and "aryl ring".
[0046] An "aralkyl" or "arylalkyl" group comprises an aryl group
covalently attached to an alkyl group, either of which
independently is optionally substituted. Preferably, the aralkyl
group is C.sub.6-10 aryl(C.sub.1-6)alkyl, including, without
limitation, benzyl, phenethyl, and naphthylmethyl.
[0047] The terms "heteroaryl" and "heteroar-", used alone or as
part of a larger moiety, e.g., heteroaralkyl, or "heteroaralkoxy",
refer to groups having 5 to 14 ring atoms, preferably 5, 6, 9, or
10 ring atoms; having 6, 10, or 14 it electrons shared in a cyclic
array; and having, in addition to carbon atoms, from one to four
heteroatoms. The term "heteroatom" refers to nitrogen, oxygen, or
sulfur, and includes any oxidized form of nitrogen or sulfur, and
any quaternized form of a basic nitrogen. Thus, when used in
reference to a ring atom of a heteroaryl, the term "nitrogen"
includes an oxidized nitrogen (as in pyridine N-oxide). Certain
nitrogen atoms of 5-membered heteroaryl groups also are
substitutable, as further defined below. Heteroaryl groups include,
without limitation, thienyl, furanyl, pyrrolyl, imidazolyl,
pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl,
oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl,
pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl,
naphthyridinyl, and pteridinyl.
[0048] In some embodiments, two adjacent substituents on a
heteroaryl ring, taken together with the intervening ring atoms,
form an optionally substituted fused 5- to 6-membered aromatic or
4- to 8-membered non-aromatic ring having 0-3 ring heteroatoms
selected from the group consisting of O, N, and S. Thus, the terms
"heteroaryl" and "heteroar-", as used herein, also include groups
in which a heteroaromatic ring is fused to one or more aryl,
cycloaliphatic, or heterocyclyl rings, where the radical or point
of attachment is on the heteroaromatic ring. Nonlimiting examples
include indolyl, isoindolyl, benzothienyl, benzofuranyl,
dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl,
isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl,
4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl,
phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and
pyrido[2,3-b]-1,4-oxazin-3(4H)-one. A heteroaryl group may be
mono-, bi-, tri-, or polycyclic, preferably mono-, bi-, or
tricyclic, more preferably mono- or bicyclic. The term "heteroaryl"
may be used interchangeably with the terms "heteroaryl ring", or
"heteroaryl group", any of which terms include rings that are
optionally substituted. The term "heteroaralkyl" refers to an alkyl
group substituted by a heteroaryl, wherein the alkyl and heteroaryl
portions independently are optionally substituted.
[0049] As used herein, the terms "aromatic ring" and "aromatic ring
system" refer to an optionally substituted mono-, bi-, or tricyclic
group having 0-6, preferably 0-4 ring heteroatoms, and having 6,
10, or 14 .pi. electrons shared in a cyclic array. Thus, the terms
"aromatic ring" and "aromatic ring system" encompass both aryl and
heteroaryl groups.
[0050] As used herein, the terms "heterocycle", "heterocyclyl",
"heterocyclic radical", and "heterocyclic ring" are used
interchangeably and refer to a stable 3- to 7-membered monocyclic,
or to a fused 7- to 10-membered or bridged 6- to 10-membered
bicyclic heterocyclic moiety that is either saturated or partially
unsaturated, and having, in addition to carbon atoms, one or more,
preferably one to four, heteroatoms, as defined above. When used in
reference to a ring atom of a heterocycle, the term "nitrogen"
includes a substituted nitrogen. As an example, in a heterocyclyl
ring having 1-3 heteroatoms selected from oxygen, sulfur or
nitrogen, the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH
(as in pyrrolidinyl), or *NR (as in N-substituted pyrrolidinyl). A
heterocyclic ring can be attached to its pendant group at any
heteroatom or carbon atom that results in a stable structure, and
any of the ring atoms can be optionally substituted. Examples of
such saturated or partially unsaturated heterocyclic radicals
include, without limitation, tetrahydrofuranyl, tetrahydrothienyl,
pyrrolidinyl, pyrrolidonyl, piperidinyl, pyrrolinyl,
tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl,
oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl,
oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl.
[0051] In some embodiments, two adjacent substituents on a
heterocyclic ring, taken together with the intervening ring atoms,
form an optionally substituted fused 5- to 6-membered aromatic or
3- to 8-membered non-aromatic ring having 0-3 ring heteroatoms
selected from the group consisting of O, N, and S. Thus, the terms
"heterocycle", "heterocyclyl", "heterocyclyl ring", "heterocyclic
group", "heterocydic moiety", and "heterocyclic radical", are used
interchangeably herein, and include groups in which a heterocyclyl
ring is fused to one or more aryl, heteroaryl, or cycloaliphatic
rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl,
or tetrahydroquinolinyl, where the radical or point of attachment
is on the heterocydyl ring. A heterocyclyl group may be mono-, bi-,
tri-, or polycyclic, preferably mono-, bi-, or tricyclic, more
preferably mono- or bicyclic. The term "heterocyclylalkyl" refers
to an alkyl group substituted by a heterocydyl, wherein the alkyl
and heterocyclyl portions independently are optionally
substituted.
[0052] As used herein, the term "partially unsaturated" refers to a
ring moiety that includes at least one double or triple bond
between ring atoms. The term "partially unsaturated" is intended to
encompass rings having multiple sites of unsaturation, but is not
intended to include aryl or heteroaryl moieties, as herein
defined.
[0053] The term "linker group" or "linker" means an organic moiety
that connects two parts of a compound. Linkers typically comprise
an atom such as oxygen or sulfur, a unit such as --NH--,
--CH.sub.2--, --C(O)--, --C(O)NH--, or a chain of atoms, such as an
alkylene chain. The molecular mass of a linker is typically in the
range of about 14 to 200, preferably in the range of 14 to 96 with
a length of up to about six atoms. In some embodiments, the linker
is a C.sub.1-6 alkylene chain which is optionally substituted.
[0054] The term "alkylene" refers to a bivalent alkyl group. An
"alkylene chain" is a polymethylene group, i.e.,
--(CH.sub.2).sub.n--, wherein n is a positive integer, preferably
from one to six, from one to four, from one to three, from one to
two, or from two to three. A substituted alkylene chain is a
polymethylene group in which one or more methylene hydrogen atoms
is replaced with a substituent. Suitable substituents include those
described below for a substituted aliphatic group. An alkylene
chain also may be substituted at one or more positions with an
aliphatic group or a substituted aliphatic group.
[0055] An alkylene chain also can be optionally interrupted by a
functional group. An alkylene chain is "interrupted" by a
functional group when an internal methylene unit is replaced with
the functional group. Examples of suitable "interrupting functional
groups" include --C(R*).dbd.C(R*)--, --C.ident.C--, --O--, --S--,
--S(O)--, --S(O).sub.2--, --S(O).sub.2N(R.sup.+)--, --N(R*)--,
--N(R.sup.+)CO--, --N(R.sup.+)C(O)N(R.sup.+)--,
--N(R.sup.+)CO.sub.2--, --C(O)N(R*)--, --C(O)--, --C(O)--C(O)--,
--CO.sub.2--, --OC(O)--, --OC(O)O--, --OC(O)N(R)--,
--C(NR.sup.+).dbd.N, --C(OR*).dbd.N--, --N(R)--N(R.sup.+)--, or
--N(R.sup.+)S(O).sub.2--. Each R.sup.+, independently, is hydrogen
or an optionally substituted aliphatic, aryl, heteroaryl, or
heterocyclyl group, or two R.sup.+ on the same nitrogen atom, taken
together with the nitrogen atom, form a five to eight membered
aromatic or non-aromatic ring having, in addition to the nitrogen
atom, zero to two ring heteroatoms selected from N, O, and S. Each
R* independently is hydrogen or an optionally substituted
aliphatic, aryl, heteroaryl, or heterocyclyl group.
[0056] Examples of C.sub.3-6 alkylene chains that have been
"interrupted" with --O-- include --CH.sub.2OCH.sub.2--,
--CH.sub.2O(CH.sub.2).sub.2--, --CH.sub.2O(CH.sub.2).sub.3--,
--CH.sub.2O(CH.sub.2).sub.4--, --(CH.sub.2).sub.2OCH.sub.2--,
--(CH.sub.2).sub.2O(CH.sub.2).sub.2--,
--(CH.sub.2).sub.2O(CH.sub.2).sub.3--,
--(CH.sub.2).sub.3O(CH.sub.2)--,
--(CH.sub.2).sub.3O(CH.sub.2).sub.2--, and
--(C.sub.2).sub.4O(CH.sub.2)--. Other examples of alkylene chains
that are "interrupted" with functional groups include
--CH.sub.2GCH.sub.2--, --CH.sub.2G(CH.sub.2).sub.2--,
--CH.sub.2G(CH.sub.2).sub.3--, --CH.sub.2G(CH.sub.2).sub.4--,
--(CH.sub.2).sub.2GCH.sub.2--, --(CH.sub.2)G(CH.sub.2).sub.2--,
--(CH.sub.2).sub.2G(CH.sub.2).sub.3--,
--(CH.sub.2).sub.3G(CH.sub.2)--,
--(CH.sub.2).sub.3G(CH.sub.2).sub.2--, and
--(CH.sub.2).sub.4G(CH.sub.2)--, wherein G is one of the
"interrupting" functional groups listed above.
[0057] For purposes of clarity, all bivalent groups described
herein, including, e.g., the alkylene chain linkers described above
and the variables D, E, F, G, Q U, W, Y, V.sup.1, T.sup.1, T.sup.2,
T.sup.3, and T.sup.4 are intended to be read from left to right,
with a corresponding left-to-right reading of the formula or
structure in which the variable appears. When the bivalent group is
contained within a ring, a left-to-right reading of the variable
corresponds to a clockwise reading of the ring structure in which
the variable appears.
[0058] One of ordinary skill in the art will recognize that when an
alkylene chain having an interruption is attached to a functional
group, certain combinations are not sufficiently stable for
pharmaceutical use. Only stable or chemically feasible compounds
are within the scope of the present invention. A stable or
chemically feasible compound is one in which the chemical structure
is not substantially altered when kept at a temperature from about
-80.degree. C. to about +40.degree. C., preferably from about
-20.degree. C. to about +40.degree. C., in the absence of moisture
or other chemically reactive conditions, for at least a week, or a
compound which maintains its integrity long enough to be useful for
therapeutic or prophylactic administration to a patient.
[0059] The term "substituted", as used herein, means that a
hydrogen radical of the designated moiety is replaced with the
radical of a specified substituent, provided that the substitution
results in a stable or chemically feasible compound. The term
"substitutable", when used in reference to a designated atom, means
that attached to the atom is a hydrogen radical, which can be
replaced with the radical of a suitable substituent.
[0060] The phrase "one or more substituents", as used herein,
refers to a number of substituents that equals from one to the
maximum number of substituents possible based on the number of
available bonding sites, provided that the above conditions of
stability and chemical feasibility are met. Unless otherwise
indicated, an optionally substituted group may have a substituent
at each substitutable position of the group, and the substituents
may be either the same or different. As used herein, the term
"independently selected" means that the same or different values
may be selected for multiple instances of a given variable in a
single compound.
[0061] An aryl (including the aryl moiety in aralkyl, aralkoxy,
aryloxyalkyl and the like) or heteroaryl (including the heteroaryl
moiety in heteroaralkyl and heteroaralkoxy and the like) group may
contain one or more substituents. Examples of suitable substituents
on the unsaturated carbon atom of an aryl or heteroaryl group
include -halo, --NO.sub.2, --CN, --R*, --C(R*).dbd.C(R*).sub.2,
--C.ident.C--R*, --OR*, --SR.sup.o, --S(O)R.sup.o,
--SO.sub.2R.sup.o, --SO.sub.2N(R*).sub.2, --N(R.sup.+).sub.2,
--NR.sup.+C(O)R*, --NR.sup.+C(O)N(R.sup.+).sub.2,
--NR.sup.+CO.sub.2R.sup.o, --O--CO.dbd.R.sup.o,
--OC(O)N(R.sup.+).sub.2, --O--C(O)R*, --CO.sub.2R*, --C(O)--C(O)R*,
--C(O)R*, --C(O)N(R.sup.+).sub.2, --C(O)N(R.sup.+)OR*,
--C(O)N(R.sup.+)C(.dbd.NR.sup.+)--N(R.sup.o),
--C(.dbd.NR.sup.+)--N(R.sup.o)--,
--C(.dbd.NR.sup.+)--N(R.sup.+)--OR*, --C(.dbd.NR.sup.4)--OR*,
--C(R).dbd.N--OR*, --N(R.sup.+)--N(R.sup.+).sub.2, --N(R.sup.+)OR*,
--N(R.sup.+)C(.dbd.NR.sup.+)--N(R.sup.+).sub.2,
--N(R.sup.30)C(.dbd.NR)--N(R)--C(O)R*,
--N(R.sup.+)C(.dbd.NR.sup.+)--R.sup.o, --NR.sup.+SO.sub.2R.sup.o,
--NR.sup.+SO.sub.2N(R).sub.2, --P(O)(R*).sub.2, --P(O)(OR*).sub.2,
--O--P(O)--OR*, and --P(O)(NR.sup.+)--N(R.sup.+).sub.2, wherein
R.sup.o is an optionally substituted aliphatic or aryl group, and
R.sup.+ and R* are as defined above, or two adjacent substituents,
taken together with their intervening atoms, form a 5- to
6-membered unsaturated or partially unsaturated ring having 0-3
ring atoms selected from the group consisting of N, O, and S.
[0062] An aliphatic group or a non-aromatic heterocydclic ring may
be substituted with one or more substituents. Examples of suitable
substituents on the saturated carbon of an aliphatic group or of a
non-aromatic heterocyclic ring include, without limitation, those
listed above for the unsaturated carbon of an aryl or heteroaryl
group and the following: .dbd.O, .dbd.S, .dbd.C(R*).sub.2,
.dbd.N--N(R*).sub.2, .dbd.N--OR*, .dbd.N--NHC(O)R*,
.dbd.N--NHCO.sub.2R.sup.o, .dbd.N--NHSO.sub.2R.sup.o, or
.dbd.N--R*, where .dbd. represents a double bond, and each R*and
R.sup.o is as defined above. One of ordinary skill in the art will
recognize that substituents that are attached by way of a double
bond requires replacement of two hydrogen radicals on the
substitutable carbon atom. For the purposes of clarity, the term
"substituted aliphatic" refers to an aliphatic group having at
least one non-aliphatic substituent.
[0063] Suitable substituents on a substitutable nitrogen atom of a
heteroaryl or heterocyclic ring include --R*, --N(R*).sub.2,
--C(O)R*, --CO.sub.2R.sup.o, --C(O)--C(O)R*--C(O)CH.sub.2C(O)R*,
--SO.sub.2R.sup.o, --SO.sub.2(R*).sub.2, --C(.dbd.S)N(R*).sub.2,
--C(.dbd.NH)--N(R*).sub.2, and --NR*SO.sub.2R.sup.o; wherein each
R* and R.sup.o is as defined above.
[0064] Unless otherwise stated, structures depicted herein are
meant to include compounds which differ only in the presence of one
or more isotopically enriched atoms. For example, compounds having
the present structure except for the replacement of a hydrogen atom
by a deuterium or tritium, or the replacement of a carbon atom by a
.sup.13C-- or .sup.14C-enriched carbon are within the scope of the
invention.
[0065] It also will be apparent to one skilled in the art that
certain compounds of this invention may exist in tautomeric forms,
all such tautomeric forms of the compounds being within the scope
of the invention. Unless stereochemical configuration is expressly
defined, structures depicted herein are meant to include all
stereochemical forms of the structure; i.e., the R and S
configurations for each asymmetric center. Therefore, unless
otherwise indicated, single stereochemical isomers as well as
enantiomeric and diastereomeric mixtures of the present compounds
are within the scope of the invention. By way of example, the
compounds of formula (I) wherein R.sup.a is hydroxy can have R or S
configuration at the carbon atom bearing R.sup.a. Both the R and
the S stereochemical isomers, as well as all mixtures thereof, are
included within the scope of the invention.
[0066] Where stereochemical configuration at a given asymmetric
center is defined by structure, unless stated otherwise, the
depicted configuration indicates stereochemistry relative to other
asymmetric centers in the molecule. Where stereochemical
configuration is defined by chemical name, the designations (rel),
(R*), and (S*) indicate relative stereochemistry, while the
designations (+), (-), (R), (S), and (abs) indicate absolute
stereochemistry.
[0067] In the compounds of formula (I), where relative
stereochemistry is defined, the diastereomeric purity of the
compound preferably is at least 80%, more preferably at least 90%,
still more preferably at least 95%, and most preferably at least
99%. As used herein, the term "diastereomeric purity" refers to the
amount of a compound having the depicted relative stereochemistry,
expressed as a percentage of the total amount of all diastereomers
present.
[0068] In some embodiments, stereochemical configurations depicted
at asterisked positions indicate absolute as well as relative
stereochemistry. Preferably, the enantiomeric purity of the
compound is at least 80%, more preferably at least 90%, still more
preferably at least 95%, and most preferably at least 99%. As used
herein, the term "enantiomeric purity" refers to the amount of a
compound having the depicted absolute stereochemistry, expressed as
a percentage of the total amount of the depicted compound and its
enantiomer.
[0069] Methods for determining diastereomeric and enantiomeric
purity are well-known in the art. Diastereomeric purity can be
determined by any analytical method capable of quantitatively
distinguishing between a compound and its diastereomers. Examples
of suitable analytical methods include, without limitation, nuclear
magnetic resonance spectroscopy (NMR), gas chromatography (GC), and
high performance liquid chromatography (HPLC). Similarly,
enantiomeric purity can be determined by any analytical method
capable of quantitatively distinguishing between a compound and its
enantiomer. Examples of suitable analytical methods include,
without limitation, GC or HPLC, using a chiral column packing
material. Enantiomers may also be distinguishable by NMR if first
derivatized with an optically enriched derivatizing agent, e.g.,
Mosher's acid.
[0070] In the compounds of formula (I), X is --CH.sub.2--, --CHF--,
--CF.sub.2--, --NH--, or --O--. In some embodiments, X is
--CH.sub.2--, --NH--, or --O--. In certain embodiments, X is --NH--
or --O--. In certain particular embodiments, X is --O--.
[0071] In the compounds of formula (I), Y is --O--, --S--, or
--C(R.sup.m)(R.sup.n)--, where R.sup.m and R.sup.n are as described
above. In some embodiments, R.sup.m is hydrogen, fluoro,
--NH.sub.2, --NH(C.sub.1-4 aliphatic), --N(C.sub.1-4
aliphatic).sub.2, or C.sub.1-4 aliphatic. In some other
embodiments, R.sup.m and R.sup.n together form .dbd.O. In other
embodiments, R.sup.m and R.sup.n, taken together with the
intervening carbon atoms, form a fused cyclopropane ring, which is
optionally substituted with one or two substituents independently
selected from fluoro or C.sub.1-4 aliphatic; or R.sup.m and
R.sup.e', taken together with the intervening carbon atoms, form a
fused cyclopropane ring, which is optionally substituted with one
or two substituents independently selected from fluoro or C.sub.1-4
aliphatic. In certain embodiments, Y is --O-- or --C--I. In certain
particular embodiments, Y is --CH.sub.2.
[0072] In the compounds of formula (I), W is --CH.sub.2--, --CHF--,
--CF.sub.2--, --CH(R.sup.1)--, --CF(R.sup.1)--, --NH--,
--N(R.sup.1)--, --O--, --S--, or --NHC(O)--, where R.sup.1 is
C.sub.1-4 aliphatic or C.sub.1-4 fluoroaliphatic, or R.sup.1 is a
C.sub.2-4 alkylene chain that is attached to a ring position on
Ring A to form a 5-, 6-, or 7-membered fused ring, wherein the
alkylene chain optionally is substituted with C.sub.1-4 aliphatic,
C.sub.1-4 fluoroaliphatic, .dbd.O, --CN, or --C(O)N(R.sup.4).sub.2.
In some embodiments, W is --CH(R.sup.1)-- or --N(R.sup.1), and
R.sup.1 is a C.sub.2-3 alkylene chain that is attached to a ring
position on Ring A to form a 5- or 6-membered fused ring, wherein
the alkylene chain optionally is substituted with C.sub.1-4
aliphatic, C.sub.1-4 fluoroaliphatic, .dbd.O, --CN, or
--C(O)N(R.sup.4).sub.2. In some other embodiments, W is
--CH.sub.2--, --CHF--, --CF.sub.2--, --NH--, --O--, --S--, or
--NHC(O)--. In certain embodiments, W is --O--, --NH--, or
--NHC(O)--. In certain particular embodiments, W is --NH--.
[0073] In the compounds of formula (I), R.sup.a is selected from
the group consisting of hydrogen, fluoro, --CN, --N, --OR.sup.5,
--N(R.sup.4).sub.2, --NR.sup.4CO.sub.2R.sup.6,
--NR.sup.4C(O)R.sup.5, --C(O)N(R.sup.4).sub.2, --C(O)R.sup.5,
--OC(O)N(R.sup.4).sub.2, --OC(O)R.sup.5, --OCO.sub.2R.sup.6, or a
C.sub.1-4 aliphatic or C.sub.1-4 fluoroaliphatic optionally
substituted with one or two substituents independently selected
from the group consisting of --OR.sup.5x, --N(R.sup.4x)(R.sup.4y),
--CO.sub.2R.sup.5x, or --C(O)N(R.sup.4x)(R.sup.4y); or R.sup.a and
R.sup.c together form a bond. In some embodiments R.sup.a is
selected from the group consisting of hydrogen, fluoro, --CN,
N.sub.3, C.sub.1-4 aliphatic, C.sub.1-4 fluoroaliphatic,
--OR.sup.5x, --NH(R.sup.4), --N(H)CO.sub.2R.sup.5,
--N(H)C(O)R.sup.5, --C(O)NHR.sup.4, --C(O)R.sup.5,
--OC(O)NHR.sup.4, --OC(O)R.sup.5, and --OC(O)OR. In some
embodiments, R.sup.a is selected from the group consisting of
hydrogen, --OH, --OCH.sub.3, C.sub.1-4 aliphatic, C.sub.1-4
fluoroaliphatic, and fluoro. In certain embodiments, R.sup.a is
selected from the group consisting of hydrogen, --OH, --OCH.sub.3,
--CH.sub.3, and fluoro. In certain particular embodiments, R.sup.a
is --OH.
[0074] In the compounds of formula (I), R.sup.c is selected from
the group consisting of hydrogen, fluoro, --CN, --N.sub.3,
--OR.sup.5, --N(R.sup.4).sub.2, --NR.sup.4COR.sup.6,
--NR.sup.4C(O)R.sup.5, --C(O)N(R.sup.4).sub.2, --C(O)R.sup.5,
--OC(O)N(R.sup.4).sub.2, --OC(O)R.sup.3, --OCO.sub.2R.sup.6, or a
C.sub.1-4 aliphatic or C.sub.1-4 fluoroaliphatic optionally
substituted with one or two substituents independently selected
from the group consisting of --OR.sup.5x, --N(R.sup.4x)(R.sup.4y),
--CO.sub.2R.sup.5x, or --C(O)N(R.sup.4x)(R.sup.4y); or R.sup.a and
R.sup.c together form a bond. In some embodiments, R.sup.c is
hydrogen, fluoro, --CN, N.sub.3, C.sub.1-4 aliphatic, C.sub.1-4
fluoroaliphatic, --OR.sup.5x, --NH(R.sup.4), --N(H)CO.sub.2R.sup.5,
--N(H)C(O)R.sup.5, --C(O)NHR.sup.4, --C(O)R.sup.5,
--OC(O)NHR.sup.4, --OC(O)R.sup.5, and --OC(O)OR.sup.5. In certain
embodiments, R.sup.c is hydrogen, --OH, --OCH.sub.3, or fluoro. In
certain particular embodiments, R.sup.c is hydrogen or --OH.
[0075] In the compounds of formula (I), R.sup.b and R.sup.d are
each independently selected from the group consisting of hydrogen,
fluoro, C.sub.1-4, aliphatic, and C.sub.1-4 fluoroaliphatic. In
some embodiments, one of R.sup.b and R.sup.d is C.sub.1-4 aliphatic
and the other is hydrogen. In some embodiments, R.sup.b and R.sup.d
are each hydrogen.
[0076] In one embodiment, R.sup.a and R.sup.c are each --OH, and
R.sup.b and R.sup.d are each hydrogen. In another embodiment,
R.sup.a is --OH, and each of R.sup.b, R.sup.c, and R.sup.d is
hydrogen. In another embodiment, R.sup.a is --OH, R.sup.c is fluoro
or --OCH.sub.3, and R.sup.b and R.sup.d are each hydrogen. In
another embodiment, R.sup.a is --OH, R.sup.b is --CH.sub.3, R.sup.c
is hydrogen or --OH, and R.sup.d is hydrogen. In another
embodiment, R.sup.a and R.sup.c together form a bond, and R.sup.b
and R.sup.d are each hydrogen.
[0077] In the compounds of formula (I), each R.sup.f independently
is hydrogen, fluoro, C.sub.1-4 aliphatic, or C.sub.1-4
fluoroaliphatic; or two R.sup.f, taken together with the carbon
atom to which they are attached, form a 3- to 6-membered
cycloaliphatic ring; or one R.sup.f, taken together with R.sup.f
and the intervening carbon atoms, forms a 3- to 6-membered
spirocyclic ring; or two R.sup.f together form .dbd.O. In some
embodiments, R.sup.f is not fluoro if X is --O-- or --NH--. In some
embodiments, each R.sup.f independently is hydrogen or C.sub.1-4
aliphatic. In some such embodiments, each R.sup.f independently is
hydrogen or --CH.sub.3. In certain embodiments, one R.sup.f is
hydrogen or --CH.sub.3, and the other R.sup.f is hydrogen. In
certain particular embodiments, each R.sup.f is hydrogen.
[0078] In the compounds of formula (I), R.sup.e is hydrogen or
C.sub.1-4 aliphatic; or R.sup.e, taken together with one R.sup.f
and the intervening carbon atoms, forms a 3- to 6-membered
spirocyclic ring; or R.sup.e, taken together with R.sup.m and the
intervening carbon atoms, forms a fused cyclopropane ring, which is
optionally substituted with one or two substituents independently
selected from fluoro or C.sub.1-4 aliphatic. In some embodiments,
R.sup.e is hydrogen or C.sub.1-4 aliphatic. In some such
embodiments, R.sup.e is hydrogen or --CH.sub.3. In certain
embodiments, R.sup.e is hydrogen.
[0079] In the compounds of formula (I), R.sup.e' is hydrogen or
C.sub.1-4 aliphatic; or R.sup.e', taken together with R.sup.m and
the intervening carbon atoms, forms a fused cyclopropane ring,
which is optionally substituted with one or two substituents
independently selected from fluoro or C.sub.1-4 aliphatic. In some
embodiments, R.sup.e is hydrogen or C.sub.1-4 aliphatic. In some
such embodiments, R.sup.e' is hydrogen or --CH.sub.3. In certain
embodiments, R.sup.e' is hydrogen.
[0080] In the compounds of formula (I), the variable m is 1, 2, or
3. In some embodiments, m is 1.
[0081] In the compounds of formula (I), Ring A is a 6-membered
nitrogen-containing heteroaryl ring, optionally fused to a 5- or
6-membered aryl, heteroaryl, cycloaliphatic or heterocyclic ring,
wherein either or both rings are optionally substituted and one
ring nitrogen atom is optionally oxidized. In some embodiments,
Ring A is an optionally substituted pyridine, pyrimidine, or
1,3,5-triazine ring. In other embodiments, Ring A is a pyridine or
pyrimidine ring that is fused to a 5- or 6-membered aryl,
heteroaryl, cycloaliphatic or heterocyclic ring, wherein either or
both rings are optionally substituted. In some such embodiments,
Ring A is fused to an optionally substituted benzene, imidazole,
pyrrole, or oxazole ring.
[0082] In some embodiments, the invention relates to a compound of
formula (I) or a pharmaceutically acceptable salt thereof,
characterized by one or more of the following features:
[0083] (a) X is --O--;
[0084] (b) Y is --CH.sub.2--;
[0085] (c) W is --NH--;
[0086] (d) R.sup.a is --OH;
[0087] (e) R.sup.b and R.sup.d are each independently hydrogen or
C.sub.1-4 aliphatic;
[0088] (f) R.sup.c is hydrogen, fluoro, or --OR.sup.5;
[0089] (g) R.sup.e and R.sup.e' are each hydrogen;
[0090] (h) each R.sup.f is hydrogen; and
[0091] (i) m is 1.
[0092] In some embodiments, the invention relates to a subgenus of
the compounds of formula (I), characterized by formula (I-A) or
(I-B):
##STR00002##
[0093] or a pharmaceutically acceptable salt thereof, wherein Ring
A and the variables W, X, Y, R.sup.a, R.sup.b, R.sup.c, R.sup.d,
R.sup.e, R.sup.e', R.sup.f, and m have the values and preferred
values described above for formula (I).
[0094] In some embodiments, the invention relates to a subgenus of
the compounds of formula (I), characterized by formula (II),
(II-A), or (II-B):
##STR00003##
[0095] or a pharmaceutically acceptable salt thereof, wherein:
[0096] D is --N.dbd. or --C(R.sup.h).dbd.; [0097] E is --N.dbd. or
--C(R.sup.h).dbd.; [0098] R.sup.g is hydrogen, halo, cyano,
--C(R.sup.5).dbd.C(R.sup.5), --C.ident.C--R.sup.5, --OR,
--SR.sup.6, --S(O)R.sup.6, --SO.sub.2R.sup.6, --SO N(R).sub.2,
--N(R).sub.2, --NR.sup.4C(O)R.sup.5, --NRC(O)N(R.sup.4),
--N(R)C(.dbd.NR.sup.4)--N(R.sup.4).sub.2,
--N(R.sup.4)C(.dbd.NR.sup.4)--R.sup.6, --NR.sup.4CO.sub.2R.sup.6,
--N(R.sup.4)SO.sub.2R.sup.6, --N(R.sup.4)SO.sub.2N(R.sup.4).sub.2,
--O--C(O)R.sup.5, --OCO.sub.2R.sup.6, --OC(O)N(R.sup.4).sub.2,
--C(O)R.sup.5, --CO.sub.2R.sup.5, --C(O)N(R.sup.4),
--C(O)N(R.sup.4)--OR.sup.5,
--C(O)N(R.sup.4)C(.dbd.NR.sup.4)--N(R.sup.4).sub.2,
--N(R.sup.4)C(.dbd.NR.sup.4)--N(R)--C(O)R.sup.5,
--C(.dbd.NR)--N(R).sub.2, --C(.dbd.NR.sup.4)--OR.sup.3,
--N(R)--N(R.sup.4).sub.2, --N(R.sup.4)--OR.sup.5,
--C(.dbd.NR.sup.4)--N(R.sup.4)--OR.sup.5, --C(R).dbd.N--OR.sup.5,
or an optionally substituted aliphatic, aryl, heteroaryl, or
heterocyclyl; [0099] each Rh independently is hydrogen, halo,
--CN--, --OR.sup.5, --N(R).sub.2, --SR.sup.6, or an optionally
substituted C.sub.1-4 aliphatic group; and [0100] the variables W,
X, Y, R.sup.a, R.sup.b, R.sup.c, R.sup.d, R.sup.e, R.sup.e',
R.sup.f and m have the values and preferred values described above
for formula (I).
[0101] In some embodiments, each R.sup.h in formulae (II), (II-A),
and (II-B) independently is hydrogen, halo, --CN, --OH,
--O--(C.sub.1-4 aliphatic), --NH.sub.2, --NH--(C.sub.1-4
aliphatic), --N(C.sub.1-4 aliphatic).sub.2, --SH, --S--(C.sub.1-4
aliphatic), or an optionally substituted C.sub.1-4 aliphatic group.
In certain embodiments, each R.sup.h independently is hydrogen,
fluoro, --CH.sub.3, --CF.sub.3, or --OH. In certain particular
embodiments, R.sup.h is hydrogen.
[0102] In some embodiments, Ring A is selected from the group
consisting of:
##STR00004##
[0103] In some embodiments, R.sup.g is hydrogen, C.sub.1-6
aliphatic, C.sub.1-6 fluoroaliphatic, halo, --R.sup.1g, --R.sup.2g,
-T.sup.2-R.sup.1h, -T.sup.1-R.sup.2g, -V.sup.1-T.sup.1-R.sup.2g,
-V.sup.1-T.sup.1-R.sup.2g, -V.sup.1-R.sup.1g, or
-T.sup.1-V.sup.1-R.sup.1g, where the variables R.sup.1g, R.sup.2g,
V.sup.1, and T.sup.1 have the values described below.
[0104] T.sup.1 is a C.sub.1-6 alkylene chain substituted with 0-2
independently selected R.sup.3a or R.sup.3b, wherein the alkylene
chain optionally is interrupted by --C(R.sup.5).dbd.C(R.sup.5)--,
--C.ident.C--, --O--, --S--, --S(O)--, --S(O).sub.2--,
--SO.sub.2N(R.sup.4)--, --N(R.sup.4)--, --N(R.sup.4)C(O)--,
--NR.sup.4C(O)N(R.sup.4)--,
--N(R.sup.4)C(.dbd.NR.sup.4)--N(R.sup.4)--,
--N(R.sup.4)--C(.dbd.NR.sup.4)--, --N(R.sup.4)CO.sub.2--,
--N(R.sup.4)SO.sub.2--, --N(R.sup.4)SO.sub.2N(R.sup.4)--,
--OC(O)--, --OC(O)N(R.sup.4)--, --C(O)--, --CO.sub.2--,
--C(O)N(R.sup.4)--, --C(.dbd.NR.sup.4)--N(R.sup.4)--,
--C(NR.sup.4).dbd.N(R.sup.4)--, --C(.dbd.NR.sup.4)--O--, or
--C(R.sup.6).dbd.N--O--, and wherein T.sup.1 or a portion thereof
optionally forms part of a 3-7 membered ring. In some embodiments,
T.sup.1 is a C.sub.1-4 alkylene chain optionally substituted with
one or two groups independently selected from fluoro, C.sub.1-4
aliphatic, and C.sub.1-4 fluoroaliphatic.
[0105] Each R.sup.3a independently is selected from the group
consisting of --F, --OH, --O(C.sub.1-4 alkyl), --CN,
--N(R.sup.4).sub.2, --C(O)(C.sub.1-4 alkyl), --CO.sub.2H,
--CO.sub.2(C.sub.1-4 alkyl), --C(O)NH.sub.2, and --C(O)NH(C.sub.1-4
alkyl).
[0106] Each R.sup.3 independently is a C.sub.1-3 aliphatic
optionally substituted with R.sup.3a or R.sup.7, or two
substituents R on the same carbon atom, taken together with the
carbon atom to which they are attached, form a 3- to 6-membered
cycloaliphatic ring.
[0107] Each R.sup.7 independently is an optionally substituted aryl
or heteroaryl ring.
[0108] V.sup.1 is --C(R.sup.5).dbd.C(R.sup.5)--, --C.ident.C--,
--O--, --S--, --S(O)--, --S(O).sub.2--, --SO.sub.2N(R.sup.4)--,
--N(R.sup.4)--, --N(R.sup.4)C(O)--, --NR.sup.4C(O)N(R.sup.4)--,
--N(R.sup.4)C(.dbd.NR.sup.4)--N(R.sup.4)--,
--N(R.sup.4)C(.dbd.NR.sup.4)--, --N(R.sup.4)CO.sub.2--,
--N(R)SO.sub.2--, --N(R.sup.4)SO.sub.2N(R.sup.4)--, --OC(O)--,
--OC(O)N(R.sup.4)--, --C(O)--, --CO.sub.2--, --C(O)N(R.sup.4)--,
--C(O)N(R.sup.4)--O--,
--C(O)N(R.sup.4)C(.dbd.NR.sup.4)--N(R.sup.4)--,
--N(R.sup.4)C(.dbd.NR--N(R)--C(R.sup.4)--,
--C(.dbd.NR.sup.4)--N(R.sup.4)--, --C(NR.sup.4).dbd.N(R.sup.4)--,
--C(.dbd.NR.sup.4)--O--, or --C(R.sup.6).dbd.N--O--. In some
embodiments, V.sup.1 is --N(R.sup.4)C(O)--, --N(R)C(O)N(R.sup.4)--,
--N(R)SO.sub.2, --N(R.sup.4)SO.sub.2N(R.sup.4)--, or
--N(R.sup.4)CO--. In certain such embodiments, V.sup.1 is
--N(R)C(O)-- or --N(R.sup.4)C(O)N(R.sup.4)--. In other embodiments,
V.sup.1 is --C(R.sup.5).dbd.C(R.sup.5), --C.ident.C--, --O--,
--S--, or --N(R.sup.4)--.
[0109] Each R.sup.1g independently is an optionally substituted
aryl, heteroaryl, heterocyclyl, or cycloaliphatic ring.
[0110] Each R.sup.2g independently is --NO.sub.2, --CN,
--C(R.sup.5).dbd.C(R.sup.5).sub.2, --C.ident.C--R.sup.5,
--OR.sup.5, --SR.sup.6, --S(O)R.sup.6, --SO.sub.2R.sup.6,
--SO.sub.2N(R.sup.4), --N(R.sup.4).sub.2, --NR.sup.4C(O)R.sup.5,
--NR.sup.4C(O)N(R), --N(R.sup.4)C(.dbd.NR.sup.4)--N(R.sup.4).sub.2,
--N(R.sup.4C(.dbd.NR.sup.4)--R.sup.6, --NR.sup.4CO.sub.2R.sup.6,
--N(R.sup.4)SO.sub.2R.sup.6, --N(R.sup.4)SON(R.sup.4).sub.2,
--O--C(O)R.sup.5, --OCO.sub.2R.sup.6, --OC(O)N(R.sup.4).sub.2,
--C(O)R.sup.5, --CO.sub.2R.sup.5, --C(O)N(R).sub.2,
--C(O)N(R.sup.4)--OR.sup.5,
--C(O)N(R)C(.dbd.NR.sup.4)--N(R.sup.4).sub.2,
--N(R.sup.4C(.dbd.NR.sup.4)--N(R.sup.4)--C(O)R.sup.5,
--C(.dbd.NR.sup.4)--N(R.sup.4).sub.2, --C(.dbd.NR.sup.4)--OR.sup.5,
--N(R.sup.4)--N(R.sup.4).sub.2, --N(R.sup.4)--OR.sup.5,
--C(.dbd.NR.sup.4)--N(R.sup.4)--OR.sup.5, or
--C(R.sup.6).dbd.N--OR.sup.5.
[0111] The invention also relates to a subgenus of the compounds of
formula (I), characterized by formula (III):
##STR00005##
[0112] or a pharmaceutically acceptable salt thereof, wherein:
[0113] Q is -T.sup.1- or --V.sup.1-T.sup.1-; [0114] V.sup.1 is
--N(R.sup.8)--, --O--, or --S--; [0115] R.sup.8 is hydrogen or
C.sub.4 aliphatic; [0116] T.sup.1 is a C.sub.1-4 alkylene chain
optionally substituted with one or two groups independently
selected from fluoro, C.sub.1-4 aliphatic, and C.sub.1-4
fluoroaliphatic; [0117] Ring C is a 3- to 8-membered heterocyclyl
or cycloaliphatic ring, or a 5- or 6-membered aryl or heteroaryl
ring; and [0118] the variables D, E, W, X, Y, R.sup.a, R.sup.b,
R.sup.c, R.sup.d, R.sup.e, R.sup.e', R.sup.f, R.sup.h, and m have
the values and preferred values described above for formulae (I)
and (II).
[0119] The invention also relates to a subgenus of the compounds of
formula (III) characterized by formula (III-A), (III-B), (III-C),
or (III-D):
##STR00006## ##STR00007##
[0120] or a pharmaceutically acceptable salt thereof, wherein all
variables are as described for formula (III).
[0121] In some embodiments, Ring C is substituted with 0-2 R.sup.o
and 0-2 R.sup.8o, where: [0122] each R.sup.o independently is halo,
--NO.sub.2, --CN, --C(R.sup.5).dbd.C(R.sup.5),
--C.ident.C--R.sup.5, --OR.sup.5, --SR.sup.6, --S(O)R.sup.6,
--SO.sub.2R.sup.6, --SO.sub.2N(R.sup.4), --N(R.sup.4).sub.2,
--NR.sup.4C(O)R.sup.5, --NR.sup.4C(O)N(R.sup.4).sub.2,
--N(R.sup.4)C(.dbd.NR.sup.4)--N(R.sup.4).sub.2,
--N(R.sup.4)C(.dbd.NR.sup.4)--R.sup.6, --NR.sup.4CO.sub.2R.sup.6,
--N(R)SO.sub.2R.sup.6, --N(R.sup.4)SO.sub.2N(R.sup.4).sub.2,
--O--C(O)R.sup.5, --OCO.sub.2R.sup.6, --OC(O)N(R.sup.4).sub.2,
--C(O)R.sup.5, --CO.sub.2R.sup.5, --C(O)N(R.sup.4).sub.2,
--C(O)N(R)--OR.sup.5, --C(O)N(R)C(.dbd.NR.sup.4)--N(R.sup.4).sub.2,
--N(R.sup.4)C(.dbd.NR.sup.4)--N(R.sup.4)--C(O)R.sup.5,
--C(.dbd.NR.sup.4)--N(R.sup.4).sub.2, --C(.dbd.NR.sup.4)--OR.sup.5,
--C(.dbd.NR.sup.4)--N(R.sup.4)--OR.sup.5,
--C(R.sup.4).dbd.N--OR.sup.5, or an optionally substituted
aliphatic, or an optionally substituted aryl, heterocyclyl, or
heteroaryl group; or two R.sup.o on the same saturated ring carbon
atom, taken together with the carbon atom, form an optionally
substituted 3- to 8-membered spirocyclic cycloaliphatic or
heterocyclyl ring; or two adjacent R.sup.o, taken together with the
intervening ring atoms, form an optionally substituted fused 4- to
8-membered aromatic or non-aromatic ring having 0-3 ring
heteroatoms selected from the group consisting of O, N, and S;
[0123] each R independently is selected from the group consisting
of C.sub.1-4 aliphatic, C.sub.1-4 fluoroaliphatic, halo,
--OR.sup.5x, --N(R.sup.4x)(R.sup.4y), or a C.sub.1-4 aliphatic or
C.sub.1-4 fluoroaliphatic optionally substituted with --OR.sup.5x,
--N(R.sup.4x)(R.sup.4y), --CO.sub.2R.sup.5, or
--C(O)N(R.sup.4x)(R.sup.4y); and [0124] the variables R.sup.4x,
R.sup.4y, and R.sup.5x have the values described above for formula
(I).
[0125] In some such embodiments, Ring C is a C.sub.3-6
cycloaliphatic, phenyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl,
isoxazolyl, isothiazolyl, pyrazolyl, triazolyl, tetrazolyl,
oxadiazolyl, thiadiazolyl, pyrrolinyl, imidazolinyl, pyrazolinyl,
pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl,
morpholinyl, piperazinyl, pyridyl, pyridazinyl, pyrimidinyl,
pyrazinyl, or tetrahydropyrimidinyl ring, any of which is
substituted with 0-2 R.sup.o and 0-2 R.sup.8o. In certain
embodiments, Ring C is a C.sub.3-6 cycloaliphatic, phenyl,
oxazolyl, or isoxazolyl ring, any of which is substituted with 0-2
R.sup.8o and optionally is fused to an optionally substituted
benzene, dioxolane, or dioxane ring.
[0126] The invention also relates to a subgenus of the compounds of
formula (II), characterized by formula (IV), (IV-A), or (IV-B):
##STR00008##
[0127] or a pharmaceutically acceptable salt thereof, wherein:
[0128] V.sup.1 is --N(R.sup.8)--, --O--, or --S--; [0129] R.sup.8
is hydrogen or C.sub.1-4 aliphatic; [0130] Ring D is an optionally
substituted mono- or bicyclic ring system; and [0131] the variables
D, E, W, X, Y, R.sup.a, R.sup.b, R.sup.c, R.sup.d, R.sup.e,
R.sup.e', R.sup.f, R.sup.h, and m have the values and preferred
values described above for formula (II).
[0132] In some embodiments, Ring D an optionally substituted
furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl,
pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl,
thiadiazolyl, phenyl, naphthyl, pyranyl, pyridyl, pyridazinyl,
pyrimidinyl, pyrazinyl, triazinyl, indolizinyl, indolyl,
isoindolyl, indazolyl, benzimidazolyl, benzthiazolyl, benzothienyl,
benzofuranyl, purinyl, quinolyl, isoquinolyl, cinnolinyl,
phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl,
pteridinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl,
pyrrolidonyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl,
tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl,
piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl,
thiazepinyl, morpholinyl, quinudclidinyl, tetrahydroquinolinyl,
tetrahydroisoquinolinyl, indanyl, phenanthridinyl,
tetrahydronaphthyl, indolinyl, benzodioxanyl, benzodioxolyl,
chromanyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl,
cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl,
cyclooctenyl, cyclooctadienyl, bicycloheptanyl or bicyclooctanyl.
In some embodiments, Ring D is an optionally substituted
cyclopentyl or cyclohexyl. In some embodiments, Ring D is an
optionally substituted indanyl, tetrahydronaphthyl, or
chromanyl.
[0133] Ring D may be unsubstituted or may be substituted on either
or both of its component rings, and the substituents may be the
same or different. In particular, each substitutable saturated ring
carbon atom in Ring D is unsubstituted or substituted with .dbd.O,
.dbd.S, .dbd.C(R.sup.5).sub.2, .dbd.N--N(R.sup.4).sub.2,
.dbd.N--OR.sup.5, .dbd.N--NHC(O)R.sup.5, .dbd.N--NHCO.sub.2R.sup.6,
.dbd.N--NHSO.sub.2R.sup.6, .dbd.N--R.sup.5 or --R.sup.p. Each
substitutable unsaturated ring carbon atom in Ring D is
unsubstituted or substituted with --R.sup.p. Each substitutable
ring nitrogen atom in Ring D is unsubstituted or substituted with
--R.sup.9p. The variables R.sup.p and R.sup.9p have the values
described below.
[0134] Each R.sup.p independently is halo, --NO.sub.2, --CN,
--C(R.sup.5).dbd.C(R.sup.5).sub.2, --C.ident.C--R.sup.5,
--OR.sup.5, --SR.sup.6, --S(O)R.sup.6, --SO.sub.2R.sup.6,
--SO.sub.2N(R.sup.4).sub.2, --N(R.sup.4).sub.2,
--NR.sup.4C(O)R.sup.5, --NR.sup.4C(O)N(R.sup.4).sub.2,
--N(R.sup.4)C(.dbd.NR.sup.4)--N(R.sup.4).sub.2,
--N(R.sup.4)C(.dbd.NR.sup.4)--R.sup.6, --NR.sup.4COR.sup.6,
--N(R.sup.4)SOR.sup.6, --N(R.sup.4)SO.sub.2N(R.sup.4).sub.2,
--O--C(O)R.sup.5, --OCO.sub.2R.sup.6, --OC(O)N(R.sup.4).sub.2,
--C(O)R.sup.5, --CO.sub.2R.sup.5, --C(O)N(R.sup.4).sub.2,
--C(O)N(R.sup.4)--OR.sup.5,
--C(O)N(R.sup.4)C(.dbd.NR.sup.4)--N(R.sup.4).sub.2,
--N(R)C(.dbd.NR.sup.4)--N(R.sup.4)--C(O)R.sup.5,
--C(.dbd.NR.sup.4)--N(R).sub.2, --C(.dbd.NR.sup.4)--OR.sup.5,
--C(.dbd.NR.sup.4)--N(R.sup.4)--OR.sup.5,
--C(R.sup.6).dbd.N--OR.sup.5, or an optionally substituted
aliphatic, or an optionally substituted aryl, heterocyclyl, or
heteroaryl group; or two R.sup.p on the same saturated carbon atom,
taken together with the carbon atom to which they are attached,
form an optionally substituted 3- to 6-membered spirocyclic
cycloaliphatic ring.
[0135] Each R.sup.9p independently is --C(O)R.sup.5,
--C(O)N(R.sup.4).sub.2, --COR.sup.6, --SO.sub.2R.sup.6,
--SO.sub.2N(R.sup.4).sub.2, or a C.sub.1-4 aliphatic optionally
substituted with R.sup.3 or R.sup.7.
[0136] In some embodiments, each R.sup.p independently is selected
from the group consisting of halo, C.sub.1-6 aliphatic, C.sub.1-6
fluoroaliphatic, --R.sup.1p, --R.sup.2p, -T.sup.2-R.sup.1p, and
-T.sup.2-R.sup.2p; or two R.sup.p on the same saturated carbon
atom, taken together with the carbon atom to which they are
attached, form an optionally substituted 3- to 6-membered
spirocyclic cycloaliphatic ring. The variables R.sup.1p, R.sup.2p,
and T.sup.2 have the values described below.
[0137] T.sup.2 is a C.sub.1-6 alkylene chain optionally substituted
with R.sup.3a or R.sup.3b.
[0138] Each R.sup.1p independently is an optionally substituted
aryl, heteroaryl, or heterocyclyl group.
[0139] Each R.sup.2p independently is --NO.sub.2, --CN,
--C(R).dbd.C(R.sup.5), --C.ident.C--R.sup.5, --OR.sup.5,
--SR.sup.6, --S(O)R.sup.6, --SO.sub.2R.sup.6,
--SO.sub.2N(R.sup.4).sub.2, --N(R.sup.4).sub.2,
--NR.sup.4C(O)R.sup.5, --NR.sup.4C(O)N(R.sup.4),
--N(R.sup.4)C(.dbd.NR.sup.4)--N(R.sup.4),
--N(R.sup.4)C(.dbd.NR.sup.4)--R.sup.4, --NR.sup.4CO.sub.2R.sup.6,
--N(R.sup.4)SO.sub.2R.sup.6, --N(R.sup.4)SO.sub.2N(R.sup.4).sub.2,
--O--C(O)R.sup.5, --OCO.sub.2R.sup.6, --OC(O)N(R.sup.4).sub.2,
--C(O)R.sup.5, --CO.sub.2R.sup.5, --C(O)N(R.sup.4).sub.2,
--C(O)N(R)--OR.sup.5, --C(O)N(R)C(.dbd.NR.sup.4)--N(R.sup.4).sub.2,
--N(R)C(.dbd.NR.sup.4)--N(R.sup.4)--C(O)R.sup.5,
--C(.dbd.NR.sup.4)--N(R).sub.2, --C(.dbd.NR.sup.4--OR.sup.5,
C(--NR.sup.4)--N(R)--OR.sup.5, or --C(R.sup.6).dbd.N--OR.sup.5.
[0140] In some embodiments, Ring D is selected from the group
consisting of:
##STR00009## [0141] each R.sup.p independently is selected from the
group consisting of fluoro, --OR.sup.5x, --N(R.sup.4x)(R.sup.4y),
--CO.sub.2R.sup.5x, or --C(O)N(R.sup.4x)(R.sup.4y), or a C.sub.1-4
aliphatic or C.sub.1-4 fluoroaliphatic optionally substituted with
--OR.sup.5x, --N(R.sup.4x)(R.sup.4y), --CO.sub.2R.sup.5x, or
--C(O)N(R.sup.4x)(R.sup.4y); [0142] each R.sup.p independently is
selected from the group consisting of fluoro, --OR.sup.5x,
--N(R.sup.4x)(R.sup.4y), --CO.sub.2R.sup.5x, or
--C(O)N(R.sup.4x)(R.sup.4y), or a C.sub.1-4 aliphatic or C.sub.1-4
fluoroaliphatic optionally substituted with --OR.sup.5,
--N(R.sup.4x)(R.sup.4y), --CO.sub.2R.sup.5x, or
--C(O)N(R.sup.4x)(R.sup.4y); or two R.sup.8p on the same carbon
atom together form .dbd.O or .dbd.C(R.sup.5x).sub.2; provided that
R.sup.8p is other than --OR.sup.5x or --N(R.sup.4x)(R.sup.4y) when
located at a position adjacent to a ring oxygen atom; [0143] s is
0, 1, 2, 3, or 4; [0144] t is 0, 1, or 2; and [0145] the variables
R.sup.4x, R.sup.4y, R.sup.5x have the values described above for
formula (I).
[0146] In some embodiments, s is 0, 1, or 2. In some embodiments, s
is 0, 1, 2, or 3. In certain embodiments, Ring D is selected from
the group consisting of:
##STR00010## ##STR00011## ##STR00012##
[0147] In certain particular embodiments, Ring D is selected from
the group consisting of:
##STR00013## ##STR00014## ##STR00015##
[0148] wherein stereochemical designations indicate absolute
configurations.
[0149] The invention also relates to a subgenus of the compounds of
formula (II), wherein:
[0150] R.sup.g is --N(RS)(R);
[0151] R.sup.8 is hydrogen or C.sub.1-4 aliphatic;
[0152] R.sup.9 is hydrogen, C.sub.1-4 aliphatic, -T.sup.3-R.sup.9n
or -T.sup.4-R.sup.9b; [0153] T.sup.3 is a C.sub.1-6 alkylene chain
substituted with 0-2 independently selected R.sup.3a or R.sup.3b;
[0154] T.sup.4 is a C.sub.2, alkylene chain substituted with 0-2
independently selected R.sup.3a or R.sup.3b; [0155] R.sup.9a is
--C(R.sup.5).dbd.C(R.sup.5), --C.ident.C--R.sup.6, --S(O)R.sup.6,
--SO.sub.2R.sup.6, --SO, --N(R.sup.4), --C(R).dbd.N--OR.sup.5,
--C.sub.2R.sup.5, --C(O)--C(O)R.sup.5, --C(O)R.sup.3,
--C(O)N(R.sup.4).sub.2, --C(.dbd.NR.sup.4)--N(R.sup.4).sub.2, or
--C(.dbd.NR.sup.4)--OR; and [0156] R.sup.9b is halo, --NO, --CN,
--OR.sup.5, --SR.sup.6, --N(R.sup.4).sub.2,
--N(R.sup.4)C(O)R.sup.5, --N(R.sup.4)C(O)N(R.sup.4).sub.2,
--N(R.sup.4)CO.sub.2R.sup.5, --O--CO.sub.2--R.sup.5,
--OC(O)N(R.sup.4), --OC(O)R.sup.3, --N(R.sup.4)--N(R.sup.4).sub.2,
--N(R.sup.4)S(O).sub.2R.sup.6, or
--N(R.sup.4)SO.sub.2--N(R.sup.4).sub.2.
[0157] In some such embodiments, R.sup.9 is hydrogen or a C.sub.1-6
aliphatic or C.sub.1, fluoroaliphatic optionally substituted with
one or two substituents independently selected from the group
consisting of --OR.sup.5x, --N(R.sup.4x)(R.sup.4y),
--CO.sub.2R.sup.5x, --C(O)N(R.sup.4x)(R.sup.4y).
[0158] Another embodiment of the invention relates to a subgenus of
the compounds of formula (I) characterized by formula (V), (V-A),
or (V-B):
##STR00016## [0159] or a pharmaceutically acceptable salt thereof,
wherein: [0160] Ring E is a 5- or 6-membered aryl, heteroaryl,
cycloaliphatic or heterocyclic ring; [0161] E is --N.dbd. or
--C(R).dbd.; [0162] each R.sup.h independently is hydrogen, halo,
--CN--, --OR.sup.5, --N(R.sup.4).sub.2, --SR.sup.6, or an
optionally substituted C.sub.1-4 aliphatic group;
[0163] each R.sup.k independently is hydrogen, halo, --NO.sub.z,
--CN, --OR.sup.5, --SR.sup.5, --S(O)R.sup.6, --SO.sub.2R.sup.6,
--SO.sub.2N(R.sup.4), --N(R.sup.4), --NR.sup.4C(O)R.sup.5,
--NR.sup.4C(O)N(R.sup.4), --N(R.sup.4)C(.dbd.NR.sup.4)--N(R.sup.4),
--N(R.sup.4)C(.dbd.NR.sup.4)--R.sup.6, --NR.sup.4CO.sub.2R.sup.6,
--N(R.sup.4)SO.sub.2R.sup.4, --N(R.sup.4)SO.sub.2N(R.sup.4).sub.2,
--O--C(O)R.sup.5, --OCO.sub.2R.sup.6, --OC(O)N(R.sup.4).sub.2,
--C(O)R.sup.6, --CO.sub.2R.sup.5, --C(O)N(R.sup.4).sub.2,
--C(O)N(R)--OR.sup.5,
--C(O)N(R.sup.4)C(.dbd.NR.sup.4)--N(R.sup.4).sub.2,
--N(R.sup.4)C(.dbd.NR.sup.4)--N(R.sup.4)--C(O)R.sup.5,
--C(.dbd.NR.sup.4)--N(R.sup.4).sub.2, --C(.dbd.NR.sup.4)--OR.sup.5,
--N(R.sup.4)--N(R.sup.4).sub.2, --N(R.sup.4)--OR.sup.5,
--C(.dbd.NR.sup.4)--N(R.sup.4)--OR.sup.5,
--C(R.sup.6).dbd.N--OR.sup.5, or an optionally substituted
aliphatic, aryl, heteroaryl, or heterocyclyl; [0164] n is 0, 1, 2,
or 3; and [0165] the variables W, X, Y, R.sup.a, R.sup.b, R.sup.c,
R.sup.d, R.sup.e, R.sup.e', R.sup.f, and m have the values and
preferred values described above for formula (I).
[0166] In some embodiments, R.sup.k is an optionally substituted
C.sub.1-4 aliphatic, or an optionally substituted 5- or 6-membered
aryl, heteroaryl, or heteroaryl ring.
[0167] In some embodiments, the invention relates to a subgenus of
the compounds of formula (V) characterized by formula (VI), (VI-A),
or (VI-B):
##STR00017## [0168] or pharmaceutically acceptable salt thereof,
wherein: [0169] U is a covalent bond, C.sub.1-3 alkylene, --O--,
--S--, --S(O)--, or --S(O).sub.2--; [0170] Ring.sup.8k is halo,
C.sub.1-4 aliphatic, or C.sub.1*4 fluoroaliphatic; [0171] Ring F is
an optionally substituted mono-, bi-, or tricyclic ring system; and
[0172] Ring E, and the variables E, W, X, Y, R.sup.a, R.sup.b,
R.sup.c, R.sup.d, R.sup.e, R.sup.e', R.sup.f, R.sup.h, and m have
the values and preferred values described above for formula
(V).
[0173] In some embodiments, Ring F is selected from the group
consisting of furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl,
imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl,
triazolyl, thiadiazolyl, phenyl, naphthyl, pyranyl, pyridyl,
pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolizinyl,
indolyl, isoindolyl, indazolyl, benzimidazolyl, benzthiazolyl,
benzothienyl, benzofuranyl, purinyl, quinolyl, isoquinolyl,
cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl,
naphthyridinyl, pteridinyl, carbazolyl, fluorenyl, dibenzofuranyl
tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, pyrrolidonyl,
piperidinyl, pyrrolinyl, dihydrobenzofuranyl, dihydrobenzothienyl
tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl,
oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl,
oxazepinyl, thiazepinyl, morpholinyl, quinuclidinyl,
tetrahydroquinolinyl, tetrahydroisoquinolinyl, indanyl,
phenanthridinyl, tetrahydronaphthyl, indolinyl, benzodioxanyl,
benzodioxolyl, chromanyl, cyclopropyl, cyclobutyl, cyclopentyl,
cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl,
cycloheptenyl, cyclooctyl, cyclooctenyl, cyclooctadienyl,
bicycloheptanyl and bicyclooctanyl, any of which optionally is
substituted on any substitutable ring carbon atom and any
substitutable ring nitrogen atom.
[0174] In some embodiments, Ring F is selected from the group
consisting of thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl,
isoxazolyl, isothiazolyl, phenyl, naphthyl, indolyl, isoindolyl,
benzimidazolyl, benzthiazolyl, benzothienyl, benzofuranyl,
quinolyl, isoquinolyl, naphthyridinyl, carbazolyl, fluorenyl,
dibenzofuranyl, dihydrobenzofuranyl, dihydrobenzothienyl,
tetrahydroquinolinyl, tetrahydroisoquinolinyl, tetrahydronaphthyl,
indolinyl, benzodioxanyl, benzodioxolyl, cyclopentyl, cyclohexyl,
any of which optionally is substituted on any substitutable ring
carbon atom and any substitutable ring nitrogen atom. In particular
embodiments, Ring F is an optionally substituted phenyl, naphthyl,
tetrahydronaphthyl, or dihydrobenzofuranyl.
[0175] In some embodiments, each substitutable ring nitrogen atom
in Ring F is unsubstituted or is substituted with R.sup.9f, and the
substitutable ring carbon atoms are substituted with 0-4 R.sup.9f,
wherein: [0176] each R.sup.8f independently is selected from the
group consisting of C.sub.1-4 aliphatic, C.sub.1-4 fluoroaliphatic,
halo, --OR %, --N(R.sup.4x)(R.sup.4y), an optionally substituted 5-
or 6-membered aromatic ring, or a C.sub.1-4 aliphatic or C.sub.1-4
fluoroaliphatic optionally substituted with --OR.sup.5x,
--N(R.sup.4x)(R.sup.4y), --CO.sub.2R.sup.5x, or
--C(O)N(R.sup.4x)(R.sup.4y); [0177] R.sup.9f independently is
--C(O)R.sup.5, --C(O)N(R.sup.4)Z, --CO.sub.2R.sup.6,
--SO.sub.zR.sup.6, --SO.sub.2N(R.sup.4).sub.2, or a C.sub.1-4
aliphatic optionally substituted with R.sup.3 or R.sup.7; and
[0178] the variables R.sup.3, R.sup.4x, R.sup.4y, R.sup.5x, and
R.sup.7 have the values described above for formula (I).
[0179] The invention also relates to a subgenus of the compounds of
formula (V) characterized by formula (VII), (VII-A), or
(VII-B):
##STR00018## [0180] or a pharmaceutically acceptable salt thereof,
wherein: [0181] E is --N.dbd. or --C(R.sup.h).dbd.; [0182] F is
--N(R.sup.9k)--, --O--, or --S--; [0183] G is .dbd.N-- or
--C(R.sup.k)--; [0184] R.sup.9k is hydrogen, --C(O)R.sup.5,
--C(O)N(R.sup.4), --COR.sup.6, --SO.sub.2R.sup.6,
--SO.sub.2N(R.sup.4).sub.2, or a C.sub.1-4 aliphatic optionally
substituted with R.sup.3 or R.sup.7; [0185] each R.sup.h
independently is hydrogen, halo, --CN--, --OR.sup.5,
--N(R.sup.4).sub.2, --SR.sup.6, or an optionally substituted
C.sub.1-4 aliphatic group; [0186] each R.sup.k independently is
hydrogen, halo, --NO.sub.2, --CN, --OR.sup.5, --SR.sup.6,
--S(O)R.sup.6, --SO.sub.2R.sup.6, --SO N(R.sup.4),
--N(R.sup.4).sub.2, --NR.sup.4C(O)R.sup.4,
--NR.sup.4C(O)N(R.sup.4).sub.2,
--N(R.sup.4)C(.dbd.NR.sup.4)--N(R.sup.4).sub.2,
--N(R.sup.4)C(.dbd.NR.sup.4)--R.sup.6, --NR.sup.4COR.sup.6,
--N(R.sup.4)SO.sub.2R.sup.6, --N(R.sup.4)SO.sub.2N(R.sup.4).sub.2,
--O--C(O)R.sup.4, --OCO.sub.2R.sup.4, --OC(O)N(R.sup.4).sub.2,
--C(O)R.sup.5, --CO.sub.2R.sup.5, --C(O)N(R), --C(O)N(R.sup.4)--OR,
--C(O)N(R.sup.4)C(.dbd.NR.sup.4)--N(R.sup.4).sub.2,
--N(R.sup.4)C(.dbd.NR.sup.4)--N(R.sup.4)--C(O)R.sup.5,
--C(.dbd.NR.sup.4)--N(R), --C(.dbd.NR.sup.4)--OR.sup.5,
--N(R.sup.4)--N(R.sup.4), --N(R)--OR.sup.5,
--C(.dbd.NR.sup.4)--N(R.sup.4)--OR.sup.5, --C(R).dbd.N--OR.sup.3,
or an optionally substituted aliphatic, aryl, heteroaryl, or
heterocyclyl; and [0187] the variables W, X, Y, R.sup.a, R.sup.b,
R.sup.c, R.sup.d, R.sup.e, R.sup.e', R.sup.f, R.sup.3, R.sup.4,
R.sup.5, R.sup.6, R.sup.7, and m have the values and preferred
values described above for formula (I).
[0188] In certain embodiments, the invention relates to a subgenus
of the compounds of formula (VII), characterized by formula (VII-C)
or (VII-D):
##STR00019## [0189] or a pharmaceutically acceptable salt thereof,
wherein: [0190] dashed lines indicate single or double bonds;
[0191] each R.sup.2f independently is hydrogen, halo, --OR.sup.5x,
--N(R.sup.4x)(R.sup.4y), or a C.sub.1-4 aliphatic or C.sub.1-4
fluoroaliphatic optionally substituted with --OR.sup.5x,
--N(R.sup.4x)(R.sup.4y), --CO.sub.2R.sup.5x, or
--C(O)N(R.sup.4x)(R.sup.4y); or both R.sup.2f, taken together with
the intervening ring carbon atoms, form an optionally substituted
fused 5- or 6-membered cycloaliphatic, aryl, heteroaryl, or
heterocyclic ring.
[0192] The invention also relates to a subgenus of the compounds of
formula (V) characterized by formula (VIII), (VIII-A), or
(VIII-B):
##STR00020## [0193] or a pharmaceutically acceptable salt thereof,
wherein: [0194] the variables E, W, X, Y, R.sup.a, R.sup.b,
R.sup.c, R.sup.d, R.sup.e, R.sup.e', R.sup.f, R.sup.h, R.sup.k, and
m have the values and preferred values described above for formulae
(VI), (VII-A), and (VII-B).
[0195] In some embodiments, R.sup.k in formula (VII), (VII-A),
(VII-B), (VIII), (VIII-A), or (VIII-B) has the formula--U-Ring F,
wherein the variable U and Ring F have the values and preferred
values described above for formula (VI). In some such embodiments,
the variable U is a covalent bond.
[0196] In a particular embodiment, the invention relates to a
subgenus of the compounds of formula (I), characterized by formula
(IX-A) or (IX-B):
##STR00021##
##STR00022##
[0197] or a pharmaceutically acceptable salt thereof, wherein:
[0198] the variables D, E, R.sup.a, R.sup.b, R.sup.c, R.sup.d,
R.sup.p, R.sup.8p, s, and t have the values and preferred values
described above for formulae (I)-(IV).
[0199] In some embodiments, the stereochemical configurations
depicted at asterisked positions in any preceding formula indicate
relative stereochemistry. In other embodiments, stereochemical
configurations depicted at asterisked positions indicate absolute
stereochemistry. In certain particular embodiments, the invention
relates to compounds of formula (I-A), (II-A), (III-A), (IV-A)
(V-A), (VI-A), (VII-A), (VIII-A), or (IX-A), wherein the
stereochemical configurations depicted at asterisked positions
indicate absolute stereochemistry.
[0200] Subgenus definitions for Ring A and variables W, X, Y,
R.sup.a, R.sup.b, R.sup.c, R.sup.d, R.sup.e, R.sup.e', and R.sup.f
described for formula (I) also apply to formulae (II)-(IX).
Compounds embodying any combination of the preferred values for the
variables described herein are within the scope of the present
invention.
[0201] Representative examples of compounds of formula (I) are
shown in Table 1.
TABLE-US-00001 TABLE 1 E1 Activating Enzyme Inhibitors ##STR00023##
I-1 ##STR00024## I-2 ##STR00025## I-3 ##STR00026## I-4 ##STR00027##
I-5 ##STR00028## I-6 ##STR00029## I-7 ##STR00030## I-8 ##STR00031##
I-9 ##STR00032## I-10 ##STR00033## I-11 ##STR00034## I-12
##STR00035## I-13 ##STR00036## I-14 ##STR00037## I-15 ##STR00038##
I-16 ##STR00039## I-17 ##STR00040## I-18 ##STR00041## I-19
##STR00042## I-20 ##STR00043## I-21 ##STR00044## I-22 ##STR00045##
I-23 ##STR00046## I-24 ##STR00047## I-25 ##STR00048## I-26
##STR00049## I-27 ##STR00050## I-28 ##STR00051## I-29 ##STR00052##
I-30 ##STR00053## I-31 ##STR00054## I-32 ##STR00055## I-33
##STR00056## I-34 ##STR00057## I-35 ##STR00058## I-36 ##STR00059##
I-37 ##STR00060## I-38 ##STR00061## I-39 ##STR00062## I-40
##STR00063## I-41 ##STR00064## I-42 ##STR00065## I-43 ##STR00066##
I-45 ##STR00067## I-46 ##STR00068## I-47 ##STR00069## I-48
##STR00070## I-49 ##STR00071## I-53 ##STR00072## I-54 ##STR00073##
I-55 ##STR00074## I-56 ##STR00075## I-58 ##STR00076## I-60
##STR00077## I-61 ##STR00078## I-62 ##STR00079## I-63 ##STR00080##
I-64 ##STR00081## I-65 ##STR00082## I-66 ##STR00083## I-67
##STR00084## I-68 ##STR00085## I-69 ##STR00086## I-71 ##STR00087##
I-73 ##STR00088## I-74 ##STR00089## I-76 ##STR00090## I-77
##STR00091## I-79 ##STR00092## I-80 ##STR00093## I-81 ##STR00094##
I-82 ##STR00095## I-83 ##STR00096## I-84 ##STR00097## I-85
##STR00098## I-86 ##STR00099## I-87 ##STR00100## I-88 ##STR00101##
I-89 ##STR00102## I-90 ##STR00103## I-92 ##STR00104## I-93
##STR00105## I-94 ##STR00106## I-96 ##STR00107## I-97 ##STR00108##
I-98 ##STR00109## I-99 ##STR00110## I-100 ##STR00111## I-101
##STR00112## I-102 ##STR00113## I-103 ##STR00114## I-105
##STR00115## I-106 ##STR00116## I-107 ##STR00117## I-108
##STR00118## I-109 ##STR00119## I-110 ##STR00120## I-111
##STR00121## I-112 ##STR00122## I-113 ##STR00123## I-114
##STR00124## I-115 ##STR00125## I-117 ##STR00126## I-118
##STR00127## I-119 ##STR00128## I-120 ##STR00129## I-121
##STR00130## I-122 ##STR00131## I-123 ##STR00132## I-124
##STR00133## I-125 ##STR00134## I-126 ##STR00135## I-127
##STR00136## I-128 ##STR00137## I-129 ##STR00138## I-130
##STR00139## I-131 ##STR00140## I-132 ##STR00141## I-133
##STR00142## I-134 ##STR00143## I-136 ##STR00144## I-137
##STR00145## I-138
##STR00146## I-139 ##STR00147## I-140 ##STR00148## I-141
##STR00149## I-142 ##STR00150## I-143 ##STR00151## I-144
##STR00152## I-145 ##STR00153## I-146 ##STR00154## I-147
##STR00155## I-148 ##STR00156## I-149 ##STR00157## I-150
##STR00158## I-151 ##STR00159## I-152 ##STR00160## I-153
[0202] The compounds in Table 1 above may also be identified by the
following chemical names:
Chemical Name
[0203] I-1
{(1R,2R,3S,4R)-4-[(6-{[(1S)-4-fluoro-2,3-dihydro-1H-inden-1-yl]amino}-pyr-
imidin-4-yl)amino]-2,3-dihydroxycylopentyl}methyl sulfamate [0204]
I-2
{(1R,2R,3S,4R)-2,3-dihydroxy-4-[(6-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-ind-
en-1-yl]amino}pyrimidin-4-yl)amino]cyclopentyl}methyl sulfamate
[0205] I-3
[(1R,2R,3S,4R)-2,3-dihydroxy-4-(9H-purin-6-ylamino)cyclopentyl]methyl
sulfamate [0206] I-4
[(1R,2R,3S,4R)-4-({2-[(cyclohexylmethyl)amino]pyrimidin-4-yl}amino)-2,3-d-
ihydroxycyclopentyl]methyl sulfamate [0207] I-5
[(1S,2S,4R)-4-({6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}ami-
no)-2-hydroxycyclopentyl]methyl sulfamate [0208] I-6
{(1R,2R,3S,4R)-4-[(6-{[(1S)-4,7-difluoro-2,3-dihydro-1H-inden-1-yl]amino}-
-pyrimidin-4-yl)amino]-2,3-dihydroxycyclopentyl}methyl sulfamate
[0209] I-7
((1R,2R,3S,4R)-4-{[2-(benzylamino)pyrimidin-4-yl]amino}-2,3-dihydroxy-
cyclopentyl)methyl sulfamate [0210] I-8
[(1R,2R,3S,4R)-4-({6-[(1R)-2,3-dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}-
-amino)-2,3-dihydroxycyclopentyl]methyl sulfamate [0211] I-9
{(1R,2R,3S,4R)-2,3-dihydroxy-4-[8-phenyl-9H
purin-6-yl)amino]cyclopentyl}-methyl sulfamate [0212] I-10
[(1R,2R,3S,4R)-2,3-dihydroxy-4-({2-[(3-methyl-2,3-dihydro-1H-inden-1-yl)--
amino]pyrimidin-4-yl}amino)cyclopentyl]methyl sulfamate [0213] I-11
[(1S,2S,3S,4R)-4-({6-[1S)-2,3-dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}--
amino)-2,3-dihydroxycyclopentyl]methyl sulfamate [0214] I-12
[(1R,2R,3S,4R)-2,3-dihydroxy-4-({6-[(1S)-1,2,3,4-tetrahydronaphthalen-1-y-
lamino]pyrimidin-4-yl}amino)cyclopentyl]methyl sulfamate [0215]
I-13
{(1R,2R,3S,4R)-4-[(6-amino-2-methylpyrimidin-4-yl)amino]-2,3-dihydroxycyc-
lopentyl}methyl sulfamate [0216] I-14
[(1R,2R,3S,4R)-4-({6-[(cyclohexylmethyl)amino]pyrimidin-4-yl}amino)-2,3-d-
ihydroxycyclopentyl]methyl sulfamate [0217] I-15
{(1R,2R,3S,4R)-4-[(2-{[(1S)-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl]amino}-
-pyrimidin-4-yl)amino]-2,3-dihydroxycyclopentyl}methyl sulfamate
[0218] I-16
{(1R,2R,3S,4R)-2,3-dihydroxy-4-[(pyridin-3-ylcarbonyl)amino]cyclopen-
tyl}-methyl sulfamate [0219] I-17
{(1R,2R,3S,4R)-4-[(6-{[(1S)-5,6-difluoro-2,3-dihydro-1H-inden-1-yl]amino}-
-pyrimidin-4-yl)amino]-2,3-dihydroxycyclopentyl}methyl sulfamate
[0220] I-18
[(1R,2R,3S,4R)-4-({6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-2-methylp-
yrimidin-4-yl}amino)-2,3-dihydroxycyclopentyl]methyl sulfamate
[0221] I-19
{(1R,2R,3S,4R)-4-[(6-{[(1S)-5-chloro-2,3-dihydro-1H-inden-1-yl]amino}-pyr-
imidin-4-yl)amino]-2,3-dihydroxycyclopentyl}methyl sulfamate [0222]
I-20
[(1R,2R,3S,4R)-4-({2-[benzyl(methyl)amino]pyrimidin-4-yl}amino)-2,3-dihyd-
roxycyclopentyl]methyl sulfamate [0223]
I-21{(1R,2R,3S,4R)-4-[(6-{[(1S)-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl]am-
ino}-pyrimidin-4-yl)amino]-2,3-dihydroxycyclopentyl}methyl
sulfamate [0224] I-22
[(1R,2R,3S,4R)-4-({6-[benzyl(methyl)amino]pyrimidin-4-yl}amino)-2,3-dihyd-
roxycyclopentyl]methyl sulfamate [0225] I-23
{(1R,2R,3S,4R)-2,3-dihydroxy-4-[(pyridin-2-ylcarbonyl)amino]cyclopentyl}--
methyl sulfamate [0226] I-24
{(1R,2R,3S,4R)-4-[(6-{[(1S)-4-chloro-2,3-dihydro-1H-inden-1-yl]amino}-pyr-
imidin-4-yl)amino]-2,3-dihydroxycyclopentyl}methyl sulfamate [0227]
I-25
[(1R,2S,4R)-4-({6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}ami-
no)-2-hydroxycyclopentyl]methyl sulfamate [0228] I-26
[(1R,2R,3S,4R)-4-({4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-1,3,5-triazin--
2-yl}-amino)-2,3-dihydroxycyclopentyl]methyl sulfamate [0229] I-27
((1R,2R,3S,4R)-4-{[6-(benzylamino)pyrimidin-4-yl]amino}-2,3-dihydroxycycl-
opentyl)methyl sulfamate [0230] I-28
[(1R,2R,3S,4R)-2,3-dihydroxy-4-(isonicotinoylamino)cyclopentyl]methyl
sulfamate [0231] I-29
[(1R,2R,3S,4R)-4-({6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}-
-amino)-2,3-dihydroxycyclopentyl]methyl sulfamate [0232] I-30
((1R,2R,3S,4R)-4-{[6-(benzylamino)-2-methylpyrimidin-4-yl]amino}-2,3-dihy-
droxycyclopentyl)methyl sulfamate [0233] I-31
[(1S,2S,4R)-4-({6-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}oxy-
)-2-hydroxycyclopentyl]methyl sulfamate [0234] I-32
[(1S,2S,4R)-4-({6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-5-methylpyrimidin-
-4-yl}oxy)-2-hydroxycyclopentyl]methyl sulfamate [0235] I-33
[(1S,2S,4S)-4-({6-[(1S)-2,3-dihydro-1H
inden-1-ylamino]pyrimidin-4-yl}methyl)-2-hydroxycyclopentyl]methyl
sulfamate [0236] I-34
((1S,2S,4R)-4-{[8-(2-chlorophenyl)-9H-purin-6-yl]amino}-2-hydroxycyclopen-
tyl)methyl sulfamate [0237] I-35
{(1S,2S,4R)-4-[(2-{[(1S)-5-chloro-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl]-
-amino}pyridin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate
[0238] I-36
{(1S,2S,4R)-2-hydroxy-4-[(7-methyl-8-phenyl-7H-purin-6-yl)-amino]cyclopen-
tyl}methyl sulfamate [0239] I-37
((1S,2S,4R)-2-hydroxy-4-{[8-(2-phenoxyphenyl)-9H-purin-6-yl]amino}-cyclop-
entyl)methyl sulfamate [0240] I-38
{(1S,2S,4R)-2-hydroxy-4-[(6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino-
]cyclopentyl}methyl sulfamate [0241] I-39
{(1S,2S,4R)-4-[(8-dibenzo[b,d]furan-4-yl-9H-purin-6-yl)amino]-2-hydroxycy-
clopentyl}methyl sulfamate [0242] I-40
[(1S,2S,4R)-2-hydroxy-4-({6-[(1S)-1,2,3,4-tetrahydronaphthalen-1-ylamino]-
pyrimidin-4-yl}oxy)cyclopentyl]methyl sulfamate [0243] I-41
((1S,2S,4R)-4-{[8-(2,3-dihydro-1,4-benzodioxin-5-yl)-9H-purin-6-yl]amino}-
-2-hydroxycyclopentyl)methyl sulfamate [0244] I-42
[(1S,2S,4R)-2-hydroxy-4({6-[(1-naphthylmethyl)amino]pyrimidin-4-yl}-oxy)c-
yclopentyl]methyl sulfamate [0245] I-43
{(1S,2S,4R)-2-hydroxy-4-[(6-{[(1S,2S)-2-methyl-2,3-dihydro-1H-inden-1-yl]-
-amino}pyrimidin-4-yl)oxy]cyclopentyl}methyl sulfamate [0246] I-45
[(1R,2R,3S,4R)-4-({4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-6-methyl-1,3,5-
-triazin-2-yl}amino)-2,3-dihydroxycyclopentyl]methyl sulfamate
[0247] I-46
((1S,2S,4R)-2-hydroxy-4-{methyl[8-(1-naphthyl)-9H-purin-6-yl]amino}-cyclo-
pentyl)methyl sulfamate [0248] I-47
{(1S,2S,4R)-2-hydroxy-4-[(6-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl-
]-amino}pyrimidin-4-yl)amino]cyclopentyl}methyl sulfamate [0249]
I-48
{(1S,2S,4R)-4-[(8-biphenyl-2-yl-9H-purin-6-yl)amino]-2-hydroxycyclopentyl-
}-methyl sulfamate [0250] I-49
((1S,2S,4R)-2-hydroxy-4-{[8-(1-naphthyl)-9H-purin-6-yl]amino}cyclopentyl)-
-methyl sulfamate [0251] I-53
(1S,2S,4R)-4-{[6-({(1S,2R)-2-[(dimethylamino)methyl]-2,3-dihydro-1H-inden-
-1-yl}amino)pyrimidin-4-yl]oxy}-2-hydroxycyclopentyl)methyl
sulfamate [0252] I-54
[(1S,2S,4R)-4-({6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-2-oxo-2,3-dihydro-
pyrimidin-4-yl}amino)-2-hydroxycylopentyl]methyl sulfamate [0253]
I-55
{(1S,2S,4R)-2,3-dihydroxy-4-[(4-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden--
1-yl]amino}-1,3,5-triazin-2-yl)amino]cyclopentyl}methyl sulfamate
[0254] I-56
((1S,2S,4R)-4-{[6-chloro-2-(1-naphthyl)-3H-imidazo[4,5-b]pyridin-7-y-
l]amino}-2-hydroxycyclopentyl)methyl sulfamate [0255] I-58
[(1R,3R,4R)-3-({6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}-am-
ino)-4-hydroxycyclopentyl]methyl sulfamate [0256] I-60
((1S,2S,4R)-4-{[8-(3-chlorophenyl)-9H-purin-6-yl]amino}-2-hydroxycyclopen-
tyl)methyl sulfamate [0257] I-61
((1S,2S,4R)-4-{[6-(3,4-dihydroisoquinolin-2(1H)-yl)pyrimidin-4-yl]oxy}-2--
hydroxycyclopentyl)methyl sulfamate [0258] I-62
[(1S,2S,4R)-2-hydroxy-4-({8-[2-(trifluoromethoxy)phenyl]-9H-purin-6-yl}-a-
mino)cyclopentyl]methyl sulfamate [0259] I-63
{(1S,2S,4R)-2-hydroxy-4-[(8-phenyl-9H-purin-6-yl)oxy]cyclopentyl}methyl
sulfamate [0260] I-64
[(1S,2S,4R)-4-({8-[4(dimethylamino)-1-naphthyl]-9H-purin-6-yl}amino)-2-hy-
droxycyclopentyl]methyl sulfamate [0261] I-65
{(1S,2S,4R)-4-[(6-{[(1S)-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl]amino}-py-
rimidin-4-yl)amino]-2-hydroxycyclopentyl}methyl sulfamate [0262]
I-66
((1S,2S,4R)-4-{[6-({(1S,2S)-2-[(dimethylamino)carbonyl]-2,3-dihydro-1H-in-
den-1-yl}amino)pyrimidin-4-yl]oxy}-2-hydroxycyclopentyl)methyl
sulfamate [0263] I-67
((1S,2S,4R)-4-{[8-(2,3-dimethoxyphenyl)-9H-purin-6-yl]amino}-2-hydroxycyc-
lopentyl)methyl sulfamate [0264] I-68
[(1S,2S,4R)-4-({8-[2-(benzyloxy)phenyl]-9H-purin-6-yl}amino)-2-hydroxycyc-
lopentyl]methyl sulfamate [0265] I-69
{(1S,2S,4R)-2-hydroxy-4-[(8-phenyl-9H-purin-6-yl)amino]cyclopentyl}methyl
sulfamate [0266] I-71
{(1S,2S,4R)-4-[(6-{[(1S)-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl]amino}-5--
fluoropyrimidin-4-yl)amino]-2-hydroxycyclopentyl}methyl sulfamate
[0267] I-73
((1S,2S,4R)-4-{[8(7-chloroquinolin-4-yl)-7H-purin-6-yl]oxy}-2-hydrox-
ycyclopentyl)methyl sulfamate [0268] I-74
((1S,2S,4R)-2-hydroxy-4-{[6
(1-naphthyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amino}cyclopentyl)methyl
sulfamate [0269] I-76
[(1S,3R,4R)-3-({6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}ami-
no)-4-hydroxycyclopentyl]methyl sulfamate [0270] I-77
{(1S,2S,4R)-2-hydroxy-4-[(6-([(1S,2R)-1-methoxy-2,3-dihydro-1H-inden-2-yl-
]-oxy)pyrimidin-4-yl)oxy]cyclopentyl}methyl sulfamate [0271] I-79
{(1S,2S,4R)-2-hydroxy-4-[(6-{([(1R,2S)-1-methoxy-2,3-dihydro-1H-inden-2-y-
l]-oxy}pyrimidin-4-yl)oxy]cyclopentyl}methyl sulfamate [0272] I-80
{(1S,2S,4R)-4-[(9-benzyl-9H-purin-6-yl)oxy]-2-hydroxycyclopentyl}methyl
sulfamate [0273] I-81
((1S,2S,4R)-2-hydroxy-4-{[6-(2-phenylethyl)pyrimidin-4-yl]amino}cyclopent-
yl)-methyl sulfamate [0274] I-82
N-({(1S,2S,4R)-2-hydroxy-4-[(6-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-
-yl]amino}pyrimidin-4-yl)oxy]cyclopentyl}methyl)sulfamide [0275]
I-83
{(1S,2S,4R)-4-[(5-fluoro-6-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]-
-amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate
[0276] I-84
{(1S,2S,4R)-2-hydroxy-4-[(8-quinolin-8-yl-7H-purin-6-yl)amino]cyclop-
entyl}-methyl sulfamate [0277] I-85
{(1R,2R,3S,4R)-4-[(6-{[(1R,2R)-2-(benzyloxy)cyclopentyl]amino}pyrimidin-4-
-yl)-amino]-2,3-dihydroxycyclopentyl}methyl sulfamate [0278] I-86
((1R,2R,3S,4R)-2,3-dihydroxy-4-{[6-(2-phenylethyl)pyrimidin-4-yl]amino}-c-
yclopentyl)methyl sulfamate [0279] I-87
((1S,2S,4R)-2-hydroxy-4-{[8-(1-naphthyl)-9H-purin-6-yl]oxy}cyclopentyl)me-
thyl sulfamate [0280] I-88
{(1S,2S,4R)-4-[(8-benzyl-9H-purin-6-yl)amino]-2-hydroxycyclopentyl}methyl
sulfamate [0281] I-89
[(1S,2S,4R)-4-({6-[(4-chlorobenzyl)oxy]pyrimidin-4-yl}oxy)-2-hydroxycyclo-
pentyl]methyl sulfamate [0282] I-90
{(1S,2S,4R)-2-hydroxy-4-[(2-phenyl[1,3]oxazolo[5,4-d]pyrimidin-7-yl)-amin-
o]cyclopentyl}methyl sulfamate [0283] I-92
{(1R,2R,3S,4R)-4-[(6-{[(1S,2S)-2-(benzyloxy)cyclopentyl]amino}pyrimidin-4-
-yl)-amino]-2,3-dihydroxycyclopentyl}methyl sulfamate [0284] I-93
((1S,2S,4R)-4-{[8-(2,6-dimethoxyphenyl)-9H-purin-6-yl]amino}-2-hydroxycyc-
lopentyl)methyl sulfamate [0285] I-94
[(1S,2S,4R)-4-({2-[(1S)-2,3-dihydro-1H-inden-1-ylamino]pyridin-4-yl}oxy)--
2-hydroxycyclopentyl]methyl sulfamate [0286] I-96
{(1S,2S,4R)-2-hydroxy-4-[(6-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl-
]-oxy}pyrimidin-4-yl)oxy]cyclopentyl}methyl sulfamate [0287] I-97
[(1S,2S,4R)-2-hydroxy-4-(pyrimidin-4-yloxy)cyclopentyl]methyl
sulfamate [0288] I-98
{(1S,2S,4R)-2-hydroxy-4-[(6-{[(1S,2R)-2-methoxy-2,3-dihydro-1H-inden-1-yl-
]-oxy}pyrimidin-4-yl)oxy]cyclopentyl}methyl sulfamate [0289] I-99
((1S,2S,4R)-2-hydroxy-4-{[8-(3-methoxyphenyl)-9H-purin-6-yl]amino}-cyclop-
entyl)methyl sulfamate [0290] I-100
((1S,2S,4R)-4-{[8-(2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl)-9H-purin-6-
-yl]-amino}-2-hydroxycyclopentyl)methyl sulfamate [0291] I-101
[(1S,2S,4R)-2-hydroxy-4-({8-[(3-methylphenyl)sulfonyl]-9H-purin-6-yl}-oxy-
)cyclopentyl]methyl sulfamate [0292] I-102
[(1S,2S,4R)-4-({8-[4-(benzyloxy)phenyl]-7H-purin-6-yl}amino)-2-hydroxycyc-
lopentyl]methyl sulfamate [0293] I-103
[(1S,2S,4R)-4-({8-[4-(dimethylamino)-1-naphthyl]-7H-purin-6-yl}oxy)-2-hyd-
roxycyclopentyl]methyl sulfamate [0294] I-105
{(1S,2S,4R)-4-[(8-biphenyl-3-yl-9H-purin-6-yl)amino]-2-hydroxycyclopentyl-
}-methyl sulfamate [0295] I-106
{(1R,2R,3S,4R)-4-[{6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}-
-(methyl)amino]-2,3-dihydroxycyclopentyl}methyl sulfamate [0296]
I-107
((1S,2S,4R)-2-hydroxy-4-{[8-(2-methylphenyl)-9H-purin-6-yl]amino}-cyclope-
ntyl)methyl sulfamate [0297] I-108
((1R,2R,3S,4R)-2,3-dihydroxy-4-{[6-(phenylethynyl)pyrimidin-4-yl]amino}-c-
yclopentyl)methyl sulfamate [0298] I-109
((1S,2S,4R)-2-hydroxy-4-{[2-(1-naphthyl)-3H-imidazo[4,5-b]pyridin-7-yl]ox-
y}-cyclopentyl)methyl sulfamate [0299] I-110
(1S,2S,4R)-2-(hydroxymethyl)-4-{[8-(5,6,7,8-tetrahydronaphthalen-1-yl)-9H-
-purin-6-yl]amino}cyclopentanol [0300] I-111
((1S,2S,4R)-4-{[8-(4-chlorophenyl)-9H-purin-6-yl]amino}-2-hydroxycyclopen-
tyl)methyl sulfamate [0301] I-112
{(1S,2S,4R)-2-hydroxy-4-[(8-isoquinolin-4-yl-7H-purin-6-yl)oxy]cyclopenty-
l}-methyl sulfamate [0302] I-113
[(1R,2R,3S,4R)-4-({2-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-5-fluoropyrimi-
din-4-yl}amino)-2,3-dihydroxycyclopentyl]methyl sulfamate [0303]
I-114
{(1S,2S,4R)-2-hydroxy-4-[(6-phenylpyrimidin-4-yl)oxy]cyclopentyl}methyl
sulfamate [0304] I-115
{(1S,2S,4R)-2-hydroxy-4-[(6-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl-
]-amino}pyrimidin-4-yl)oxy]cyclopentyl}methyl sulfamate [0305]
I-117
((1S,2S,4R)-4-{[8-(2,3-dihydro-1-benzofuran-7-yl)-7H-purin-6-yl]amino}-2--
hydroxycyclopentyl)methyl sulfamate [0306] I-118
((1R,2R,3S,4R)-2,3-dihydroxy-4-{[6-(5,6,7,8-tetrahydronaphthalen-1-ylamin-
o)pyrimidin-4-yl]amino}cyclopentyl)methyl sulfamate [0307] I-119
((1S,2S,4R)-2-hydroxy-4-{[6-(1-naphthylmethoxy)pyrimidin-4-yl]oxy}-cyclop-
entyl)methyl sulfamate [0308] I-120
((1S,2S,4R)-4-{[6-(1,3-dihydro-2H-isoindol-2-yl)pyrimidin-4-yl]oxy}-2-hyd-
roxycyclopentyl)methyl sulfamate [0309] I-121
((1S,2S,4R)-2-hydroxy-4-{[8-(1,2,3,4-tetrahydronaphthalen-1-yl)-9H-purin--
6-yl]-amino}cyclopentyl)methyl sulfamate [0310] I-122
[(1S,2S,4R)-2-hydroxy-4-({8-[2-(trifluoromethyl)phenyl]-9H-purin-6-yl}-am-
ino)cyclopentyl]methyl sulfamate [0311] I-123
{(1S,2S,4R)-2-hydroxy-4-[methyl(9-methyl-8-phenyl-9H-purin-6-yl)-amino]cy-
clopentyl}methyl sulfamate [0312] I-124
{(1S,2S,4R)-4-[(6-{[(1S)-3,3-dimethyl-2,3-dihydro-1H-inden-yl]amino}-pyri-
midin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate [0313] I-125
{(1S,2S,4R)-2-hydroxy-4-[(4-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-yl]--
amino}-1,3,5-triazin-2-yl)amino]cyclopentyl}methyl sulfamate [0314]
I-126 ((1S,2S,4R)-2-hydroxy-4-{[8
(5,6,7,8-tetrahydronaphthalen-1-yl)-9H-purin-6-yl]-amino}cyclopentyl)meth-
yl sulfamate [0315] I-127
((1S,2S,4R)-4-{[6-(cyclopentylamino)pyrimidin-4-yl]oxy}-2-hydroxycyclopen-
tyl)methyl sulfamate [0316] I-128
{(1S,2S,4R)-4-[(8-cyclohexyl-9H-purin-6-yl)amino]-2-hydroxycyclopentyl}-m-
ethyl sulfamate [0317] I-129
((1S,2S,4R)-4-{[8-(1-benzyl-1H-pyrazol-4-yl)-7H-purin-6-yl]oxy}-2-hydroxy-
cyclopentyl)methyl sulfamate [0318] I-130
{(1S,2S,4R)-2-hydroxy-4-[(9-methyl-8-phenyl-9H-purin-6-yl)-amino]cyclopen-
tyl}methyl sulfamate [0319] I-131
{(1S,2S,4R)-4-[(8-tert-butyl-9H-purin-6-yl)amino]-2-hydroxycyclopentyl}me-
thyl sulfamate [0320] I-132
{(1S,2S,4R)-4-[(6-benzylpyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl
sulfamate [0321] I-133
((1S,2S,4R)-2-hydroxy-4-{[8(2-methoxyphenyl)-9H-purin-6-yl]amino}-cyclope-
ntyl)methyl sulfamate [0322] I-134
{(1S,2S,4R)-4-[(4-{[(1S)-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl]amino}-1,-
3,5-triazin-2-yl)amino]-2-hydroxycyclopentyl}methyl sulfamate
[0323] I-136
[(1S,2S,4R)-2-hydroxy-4-({8-[(3-methylphenyl)sulfanyl]-7H-purin-6-yl}-oxy-
)cyclopentyl]methyl sulfamate [0324] I-137
[(1S,2S,4R)-4-({8-[2-(dimethylamino)phenyl]-9H-purin-6-yl}amino)-2-hydrox-
ycyclopentyl]methyl sulfamate [0325] I-138
(1S,2S,4R)-4-{[8-(2,3-dihydro-1,4-benzodioxin-5-yl)-9H-purin-6-yl]amino}--
2-(hydroxymethyl)cyclopentanol
[0326] I-139
((1S,2S,4R)-2-hydroxy-4-{[8-(4-pyrrolidin-1-yl-1-naphthyl)-7H-purin-6-yl]-
oxy}-cyclopentyl)methyl sulfamate [0327] I-140
((1S,2S,4R)-2-hydroxy-4-{[8-(1H-indol-3-yl)-7H-purin-6-yl]oxy}cyclopentyl-
)-methyl sulfamate [0328] I-141
((1S,2S,4R)-2-hydroxy-4-{[6-(2-naphthylmethoxy)pyrimidin-4-yl]oxy}-cyclop-
entyl)methyl sulfamate [0329] I-142
{(1S,2S,4R)-2-hydroxy-4-[(6-{[(1R,2S)-2-methoxy-1,2,3,4-tetrahydronaphtha-
len-1-yl]amino}pyrimidin-4-yl)oxy]cyclopentyl}methyl sulfamate
[0330] I-143
{(1S,2S,4R)-2-hydroxy-4-[(6-{[(1S,2R)-2-methoxy-1,2,3,4-tetrahydron-
aphthalen-1-yl]amino}pyrimidin-4-yl)oxy]cyclopentyl}methyl sulfa
mate [0331] I-144
{(1R,2R,3S,4R)-4-[(2-{[(1S)-2,3-dihydro-1H-inden-1-ylamino]carbonyl}pyrid-
in-4-yl)amino]-2,3-dihydroxycyclopentyl}methyl sulfamate [0332]
I-145
((1R,2R,3S,4R)-4-{[2-(2,3-dihydro-1H-indol-1-ylcarbonyl)pyridin-4-yl]amin-
o}-2,3-dihydroxycyclopentyl)methyl sulfamate [0333] I-146
((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-5,6-dihydro-7H-pyr-
rolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
[0334] I-147
{(1S,2S,4R)-4-[(4-{[(1R)-2,2-difluoro-2,3-dihydro-1H-inden-1-yl]ami-
no}-1,3,5-triazin-2-yl)amino]-2-hydroxycyclopentyl}methyl sulfamate
[0335] I-148
{(1S,2S,4R)-4-[(6-{[(1S,2R)-2,7-dimethoxy-1,2,3,4-tetrahydronaphtha-
len-1-yl]-amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl
sulfamate [0336] I-149
{(1S,2S,4R)-4-[(6-{[(1R,2S)-2,7-dimethoxy-1,2,3,4-tetrahydronaphthalen-1--
yl]-amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate
[0337] I-150
{(1S,2S,4R)-2-hydroxy-4-[(6-{[(1R,2S)-2-methoxy-4,4-dimethyl-1,2,3,-
4-tetrahydronaphthalen-1-yl]amino}pyrimidin-4-yl)oxy]cylopentyl}methyl
sulfamate [0338] I-151
{(1S,2S,4R)-2-hydroxy-4-[(6-{[(1S,2R)-2-methoxy-4,4-dimethyl-1,2,3,4-tetr-
ahydronaphthalen-1-yl]amino}pyrimidin-4-yl)oxy]cyclopentyl}methyl
sulfamate [0339] I-152
((1S,3S)-3-{[8-(1-naphthyl)-9H-purin-6-yl]oxy}cyclopentyl)methyl
sulfamate [0340] I-153
[(1S,2S,4R)-4-({4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-1,3,5-triazin-2-y-
l}-amino)-2-hydroxycyclopentyl]methyl sulfamate
General Synthetic Methodology
[0341] The compounds of the present invention can be prepared by
methods known to one of ordinary skill in the art and/or by
reference to the schemes shown below and the synthetic examples
that follow. Exemplary synthetic routes are set forth in Schemes
1-21 below, and in the Examples.
##STR00161##
[0342] Scheme 1 above shows a general route for preparing compounds
of formula (I-B), wherein W is --NH-- and R.sup.c is --OH. Those of
ordinary skill in the art will recognize that compounds of formula
(I-B) wherein Ring A is other than pyrimidine can be prepared by
the same general route, beginning with appropriate starting
materials analogous to ii.
[0343] As shown in Scheme 1, conversion of i to the compounds of
formula iii is accomplished by coupling with the appropriately
substituted pyrimidines at elevated temperature in protic solvents,
such as EtOH or BuOH, using an appropriate base, such as DIPEA or
Et.sub.3N in the presence of microwave irradiation (Method A).
Selective protection of the vicinal diol of iii is effected at this
stage by treatment with 2,2-dimethoxypropane in the presence of an
organic acid, such as p-TsOH in a solvent, such as MeOH or acetone
(Method B). Displacement of the aryl chloride of formula iv is
achieved by coupling with the appropriately substituted
nucleophile, such as an amine, alcohol or thiol at elevated
temperature using microwave irradiation in the absence of solvent
(Method C). Further treatment with freshly prepared
chlorosulfonamide vi affords the sulfamates vii (Method D).
Cleavage of the acetal by treatment with a strong acid, such as
TFA, in the presence of water according to Method E yields
compounds of formula vii.
##STR00162## ##STR00163##
[0344] Compounds of formula (I-A) can be prepared by the methods
described in Scheme 2. Methods for the synthesis of the
intermediate alkene diol ix are known (Nucleosides, Nucleotides
& Nucleic Acids, 2002, 21, 65-72). Upon treatment with m-CPBA,
diol ix is converted to epoxy diol x. Subsequent protection of the
diol using p-anisaldehyde dimethyl acetal in the presence of
pyridinium p-toluenesulfonate provides epoxide xi. Opening of the
epoxide using a mixture of phthalimide and phthalimide potassium
salt in DMSO at elevated temperature affords alcohol xii. This
alcohol is then alkylated by tris(trimethylsilyl)silane and air in
toluene followed by BEt.sub.3 in toluene to give xiv (Method G).
Subsequent deprotection with hydrazine in EtOH at elevated
temperature gives amine xv (Method H).
[0345] Conversion of amine xv to compounds of formula xvi is
accomplished by coupling with the appropriately substituted
pyrimidines at elevated temperature in protic solvents, such as
EtOH or BuOH, using an appropriate base, such as Et.sub.3N in a
sealed tube (Method I). Again, those of ordinary skill in the art
will recognize that compounds of formula xxi and xxii wherein Ring
A is other than pyrimidine can be prepared by the same general
route, using a starting material analogous to ii.
[0346] The treatment of compounds having the general formula xvi
with an amine, such as benzylamine, in the absence of solvent at
elevated temperatures using microwave irradiation results in
deprotection of the diol, and then repeating the process in the
presence of a base, such as DIPEA or Et.sub.3N at elevated
temperatures in a protic solvent, such as EtOH or BuOH using
microwave irradiation affords substituted pyrimidines xviii
(Methods J and K).
[0347] Methods for the synthesis of tert-butyl
chlorosulfonylcarbamate xix are known (Hirayama et al., Biorg. Med.
Chem., 2002, 10, 1509-1523), and this reagent is reacted
selectively with the primary alcohol using a hindered base, such as
2,6-di-tert-butyl-4-methylpyridine, in a solvent, such as ACN, to
afford Boc sulfamates of formula xx (Method L). Removal of the
siloxy group with a protic acid such as TFA (Method M) yields the
compounds of formula xxi.
[0348] Alternatively, compound xii can be directly exposed to the
conditions described in Methods H-M, to afford dihydroxycyclopentyl
methyl sulfamates of formula xxii.
##STR00164##
[0349] Compounds of formula (I-B), wherein W is --NHC(O)-- can be
prepared by the methods shown above in Scheme 3. Methods for the
synthesis of bicyclic lactam xxiii are known (Daluge et al.,
Nucleosides, Nucleotides & Nucleic Acids, 2000, 19, 297-327).
Dihydroxylation using osmium tetroxide in the presence of an
organic N-oxide, such as N-methylmorpholine oxide, in a solvent,
such as acetone, gives diol xxiv. Global protection of both
alcohols using benzyl chloride and a base, such as Et.sub.3N, and a
catalyst, such as DMAP, in a solvent, such as DCM, gives compound
xxv. The resulting bicyclic lactam is reduced using NaBH.sub.4 to
afford Boc-protected amine xxvi, which is then deprotected upon
treatment with HCl in the absence of water. The resulting secondary
amine hydrochloride xxvii is treated with an acyl chloride of
formula xxviii in the presence of a base, such as Et.sub.3N or
DIPEA, in an aprotic solvent, such as DCM to afford amides of
formula xxix according to Method N. The primary alcohol of xxx is
then sulfamoylated by treatment with chlorosulfonamide vi and a
base, such as DBU, in a polar aprotic solvent, such as ACN (Method
O). Global deprotection of both secondary alcohols using ammonia in
a polar solvent, such as MeOH, yields final sulfamates of formula
xxxi (Method P).
##STR00165##
[0350] Compounds of formula (I-B), wherein W is --NH-- and R.sup.c
and R.sup.d are hydrogen can be prepared by the methods shown above
in Scheme 4. Amino diol xxxii (Ober, M.; Muller, H.; Pieck, C.;
Gierlich, J.; Carell, T. J. Am. Chem. Soc. 2005, 127, 18143-18149)
is treated with dichloropyrimidines of formula II according to
Method I to give chloropyrimidines of formula xxxiii. Further
reaction with an appropriately substituted nucleophile according to
Method C or Method K gives compounds of formula xxxiv. These diols
are subsequently selectively sulfamoylated and deprotected
according to Methods L-M as outlined in Scheme 2.
##STR00166##
[0351] Compounds of formula (I-B), wherein Ring A is a triazine
ring, can be prepared as shown in Scheme 5. Coupling of cyanuric
chloride xxxv with a primary or secondary amine in a solvent such
as THF using a base such as DIPEA at reduced temperature affords
dichloride xxxvi. Displacement of one chloride with amine
hydrochloride xxxvii, followed by selective protection of the
vicinal hydroxyl groups using 2,2-dimethoxypropane in the presence
of pyridinium p-toluene sulfonate affords alcohol xxxix. Removal of
the remaining aryl chloride using hydrogen in the presence of
palladium on carbon (Method Q), followed by sulfamoylation using
chlorosulfonamide vi gives sulfamate xli.
##STR00167##
[0352] Compounds of formula (I-A), wherein W is --O-- can be
prepared as depicted above in Scheme 6. Methods for the synthesis
of diol xlii are known (MacKeith et al., Biorg. Med. Chem., 1994,
2, 387-394), and this reagent is bis-protected using TBS-Cl and
Et.sub.3N in the presence of DMAP at elevated temperatures.
Subsequent hydroboration-oxidation using catecholborane and
Wilkinson's catalyst followed by NaOH, hydrogen peroxide and
finally sodium sulfite yields cyclopentanol xliv. This secondary
alcohol is deprotonated with the use of sodium hydride, and then
reacted with dichloropyrimidines of formula II at reduced
temperature to afford coupled chloropyrimidines of formula xlv.
Displacement of the aryl chloride is achieved by coupling with the
appropriately substituted nucleophile, such as an amine, alcohol or
thiol at elevated temperature using microwave irradiation in a
solvent, such as BuOH (Method R). Global deprotection of the silyl
ethers using a fluoride reagent, such as TBAF according to Method S
gives diols of formula xlvii. Compounds of formula xlvii are then
selectively sulfamoylated and deprotected according to Methods L-M
as outlined in Scheme 2.
##STR00168##
[0353] Compounds of formula (I-B), wherein W is --NH-- and
Y.ident.O-- can be prepared as shown above in Scheme 7. Methods for
the synthesis of methyl carbamate xlviii are known (Nicolaou et
al., J. Am. Chem. Soc., 2004, 126, 6234-6235). Deprotection using
an acid, such as HCl in the absence of water affords amino alcohol
il. Compound il is then substituted with the appropriate
substituents according to Methods A, then C-E and carried on to
compounds of formula (I-B) according to Scheme 1.
##STR00169##
[0354] A general route for the synthesis of compounds of formula
(I-B), wherein W is --NH--, Y.dbd.--O-- and R.sup.c is --H is
outlined above in Scheme 8. Compounds of formula I are known (Kita,
et al., J. Org. Chem., 1988, 53, 554-561). Displacement of the aryl
chloride using an appropriately substituted nucleophile according
to Method C gives pyrimidines of formula li. Compound li is then
selectively sulfamoylated and deprotected to give the final
compounds according to Scheme 2 (Methods 1-M).
##STR00170##
[0355] The synthesis of compounds of formula (I-A), wherein W is
--S-- and R.sup.c is --OH is described in Scheme 9. The coupling of
compounds of formula liv with a nudeophile, such as an amine takes
place in a solvent, such as DMF to afford substituted compounds of
formula lv (Method T). Subsequent opening of epoxide xi using a
base, such as potassium carbonate in a solvent, such as DMF affords
alcohol lvi (Method U). Compound lvi is then optionally
deoxygenated (Methods F-G) and substituted with the appropriate
substituents according to Methods J, then L-M and carried on to
compounds of formula (I-A) according to Scheme 2.
##STR00171##
[0356] Compounds of formula (I-A), wherein W is --CH.sub.2-- can be
prepared as shown above in Scheme 10. Methyl pyrimidines of formula
lvii are coupled with a nucleophile, such as an amine according to
Method I to give 2-chloropyrimidines of formula lviii.
Hydro-dechlorination according to Method Q gives methylpyrimidines
of formula lviii. Deprotonation of the methyl group of lviii is
effected by treatment with a strong base, such as phenyllithium,
and this carbanion is used to open epoxide xi (Method V). Resulting
compounds of formula lix are then optionally deoxygenated (Methods
F-G), deprotected and selectively sulfamoylated (Methods J, then
L-M) carried on to compounds of formula (I-A) according to Scheme
2.
##STR00172##
[0357] Compounds of formula (I), wherein W is --CH.sub.2-- and
Y.dbd.--O-- can be prepared above in Scheme 11. Compound lx is
known (Renz, et al., Liebigs Annalen der Chemie, 1986, 6, 957-966).
Coupling with an appropriately substituted nucleophile, such as an
amine according to Method K gives the substituted, fully
deprotected triol lxi. Compounds of formula lxi are then carried on
according to Scheme 2 (Methods L-M).
##STR00173##
[0358] Compounds of formula (I-B) wherein X.dbd.--NH-- can be
prepared by the methods outlined in Scheme 12. Methods for the
synthesis of tert-butyl (aminosulfonyl)-carbamate lxii are known
(Masui, et al., Tet. Lett., 2004, 45, 1853-1856). Compounds of
formula iv are coupled with this carbamate in the presence of an
azodicarboxylate, such as diisobutyl azodicarboxylate in the
presence of triphenylphosphine in a solvent, such as EtOAc to give
Boc-protected compounds of formula lxiii (Method W). These
compounds are then substituted with the appropriate substituents
and globally deprotected to give compounds of formula (I-B)
according to Methods T and E (Schemes 9 and 1).
##STR00174##
[0359] Compounds of formula (I-B) wherein X.dbd.CH.sub.2 can be
prepared by the methods outlined in Scheme 13. Compounds of formula
v are oxidized using an oxidizing agent, such as Dess-Martin
periodinane in a solvent, such as DCM (Method X). Methods for the
synthesis of lxv are known (Carretero, et al., Tetrahedron., 1987,
43, 5125-5134), and this compound is deprotonated using n-BuLi in
THF and added to aldehyde lxiv to afford alkenes of formula lxvi.
Reduction of the double bond using NaBH.sub.4 in EtOH, followed by
heating of the resulting sulfonate ester with Et.sub.3N in DCM
using microwave irradiation yields sulfonic acid lxviii. Treatment
with thionyl chloride at reduced temperature in DCM in the presence
of a catalyst, such as DMF gives sulfonyl chlorides of formula
lxix. Finally, treatment with ammonia in a solvent, such as
1,4-dioxane in the presence of DIPEA in DCM at reduced temperatures
yields sulfonamides of formula lxx.
##STR00175##
[0360] Compounds of formula (I-B) wherein X.dbd.CF.sub.2 can be
prepared by the methods outlined in Scheme 14. Carboxylic acid lxxi
is decarboxylated using sodium sulfate in water to give sulfonyl
fluoride lxxii, which is then converted to the corresponding
sulfonamide using ammonia in 1,4-dioxane. Boc-protection of the
nitrogen using Boc anhydride in the presence of DMAP and Et.sub.3N
in DCM yields Boc sulfonamide lxxiv. Deprotonation of the CF.sub.2H
group using a strong base, such as LiHMDS at reduced temperature in
a solvent, such as THF followed by treatment with triflates of
formula lxxvi (generated by treatment of alcohol lxxv with
trifluoroacetic anhydride and Et.sub.3N in DCM) gives compounds of
formula lxxvii (Method Y). These compounds are then substituted
with the appropriate substituents and globally deprotected to give
compounds of formula (I-B) according to Methods T and E (Schemes 9
and 1).
##STR00176##
[0361] Compounds of formula (I) wherein X.dbd.CHF can be prepared
by the methods outlined in Scheme 15. Methanesulfonyl chloride is
coupled with bis(2,4-dimethoxybenzyl)-amine in the presence of
Et.sub.3N and DMAP in DCM to give sulfonamide lxxvilli. Further
treatment with n-BuLi and HMPA in THF at reduced temperature
followed by N-fluorobenzenesulfonimide gives
fluoromethylsulfonamide lxxix. This compound is then taken on to
compounds of formula (I) by the procedures described in Scheme
14.
##STR00177##
[0362] Compounds of formula (VII-A) wherein W.dbd.NH can be
prepared by the methods outlined in Scheme 16. The sodium salt of
lxxx, which is prepared as in Example 128a-c below, is condensed
with a nitro aromatic lxxxi. Subsequently reduction with Zinc in
acetic acid provides xxxii. Oxidative coupling of an appropriate
aldehyde such as napthaldehyde in the presence of
Na.sub.2S.sub.2O.sub.5 provides compounds of the general formula
lxxxiii. Deprotection with acetic acid in water/THF (Tetrahedron
Lett. 1998, 29, 6331) followed by sulfamation with
chlorosulfonamide and concomitant deprotection of the secondary
hydroxyl provides compounds of the general formula VII-A.
##STR00178##
[0363] Compounds of formula (VII-A) wherein W.dbd.O and
R.sup.k.dbd.--SO.sub.2R.sup.6 can be prepared by the methods
outlined in Scheme 17. The sodium salt of xliv is condensed with
6-chloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purine, which is
subsequently iodinated with NIS in THF to provide compound lxxxiv.
The sodium salt of an aryl thiolate, such as 3-methylbenzenethiol,
is condensed in DMF to provide the intermediate lxxxv which, after
deprotection and sulfamation as previously described, provides
compound lxxxvi. Exposure to oxidative conditions such as Oxone in
aqueous methanol provides compounds of general formula VI.
##STR00179##
[0364] Compounds of formula (VII) wherein W.dbd.O and R.sup.k=aryl
and heteroaryl can be prepared by the methods outlined in Scheme
18. Pd-mediated coupling of intermediates of the form lxxxiv with
boronic acids provides compounds of form lxxxvii. Deprotection
followed by sulfamation with a chlorosulfonamide or
diphenylcarbamoylsulfamoyl chloride (prepared in a manner similar
to U.S. Pat. Appl. Publ. (2005), US 2005282797 A1) followed by
removal of the secondary siloxy group with a protic acid, such as
HCl, provides compounds of the general formula VII.
##STR00180##
[0365] (S)--N-(2,3-dihydro-1H-inden-1-yl)indolin-4-amine is
synthesized as illustrated in Scheme 19. Reduction of
2-(4,6-dichloropyrimidin-5-yl)acetaldehyde with sodium borohydride
provides alcohol lxxxviii, which is subsequently condensed with an
appropriate aminoindane such as (S)-2,3-dihydro-1H-inden-1-amine to
provide the substituted pyrimidine lxxxix. Displacement under
Mitsunobu type conditions with phthalimide and DIAD, followed by
removal of the phthaloyl group with hydrazine, provides the amine
intermediate xc. Cyclization under basic conditions provides the
final compound
(S)--N-(2,3-dihydro-1H-inden-1-yl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-
-4-amine.
##STR00181##
[0366] Compounds of formula (VI) wherein W.dbd.NH can be prepared
by the methods outlined in Scheme 20. Amine lxxx is condensed with
chlorosubstituted heterocycles of type xci to provide a product
represented as xcii. Deprotection of the primary siloxy group with
aqueous acetic acid followed by sulfamation with chlorosulfonamide
or diphenylcarbamoylsulfamoyl chloride provides intermediates of
form xciii. Removal of the primary hydroxyl group with a Fluoride
source, such as TBAF, or protic acid, such as HCl provides the
final compound of formula VI.
##STR00182##
[0367] As shown in Scheme 21, conversion of xciv (Ruediger, E;
Martel, A; Meanwell, N; Solomon, C; Turmel, B. Tetrahedron Lett.
2004, 45, 739-742) to the compounds of formula I-A wherein W.dbd.NH
is accomplished by palladium catalyzed hydrogenation followed by
mesylate formation to give xcv. Hydrogenolysis of the primary
benzyl group followed by displacement of the mesylate using sodium
azide in DMF yields xcvi. Exposure of xcvi to hydrogenation
conditions yields the desired amino alcohol xcvii, which can
subsequently be used in coupling reactions with a
chloro-substituted heterocycle such as ii. Displacement of the aryl
chloride of formula xcviii is achieved by coupling with the
appropriately substituted nucleophile, such as an amine, alcohol or
thiol at elevated temperature using microwave irradiation in the
absence of solvent (see Method C). Further treatment with freshly
prepared chlorosulfonamide vi followed by cleavage of the
TBS-protecting group using a suitable reagent, such as TBAF, HF
pyridine, or HCl. affords the sulfamates I-A as represented by
xcxix.
Uses of Compounds of the Invention
[0368] The compounds of this invention are useful inhibitors of E1
enzyme activity. In particular, the compounds are designed to be
inhibitors of NAE, UAE, and/or SAE. Inhibitors are meant to include
compounds which reduce the promoting effects of E1 enzymes in ubl
conjugation to target proteins (e.g., reduction of ubiquitination,
neddylation, sumoylation), reduce intracellular signaling mediated
by ubl conjugation, and/or reduce proteolysis mediated by ubl
conjugation (e.g., inhibition of cullin-dependent ubiquitination
and proteolysis (e.g., the ubiquitin-proteasome pathway)). Thus,
the compounds of this invention may be assayed for their ability to
inhibit the E1 enzyme in vitro or in vivo, or in cells or animal
models according to methods provided in further detail herein, or
methods known in the art. The compounds may be assessed for their
ability to bind or mediate E1 enzyme activity directly.
Alternatively, the activity of compounds may be assessed through
indirect cellular assays, or assays measuring downstream effects of
E1 activation to assess inhibition of downstream effects of E1
inhibition (e.g., inhibition of cullin-dependent ubiquitination and
proteolysis). For example, activity may be assessed by detection of
ubl-conjugated substrates (e.g., ubl-conjugated E2s, neddylated
cullins, ubiquitinated substrates, sumoylated substrates);
detection of downstream protein substrate stabilization (e.g.,
stabilization of p27, stabilization of I.kappa.B); detection of
inhibition of UPP activity; detection of downstream effects of
protein E1 inhibition and substrate stabilization (e.g., reporter
assays, e.g., NF.kappa.B reporter assays, p27 reporter assays).
Assays for assessing activities are described below in the
Experimental section and/or are known in the art.
[0369] One embodiment of this invention relates to a composition
comprising a compound of this invention or a pharmaceutically
acceptable salt thereof, and a pharmaceutically acceptable carrier.
It will be appreciated that the compounds of this invention may be
derivatized at functional groups to provide prodrug derivatives
which are capable of conversion back to the parent compounds in
vivo. Examples of such prodrugs include the physiologically
acceptable and metabolically labile ester derivatives, such as
methoxymethyl esters, methylthiomethyl esters, or pivaloyloxymethyl
esters derived from a hydroxyl group of the compound or a carbamoyl
moiety derived from an amino group of the compound. Additionally,
any physiologically acceptable equivalents of the present
compounds, similar to the metabolically labile esters or
carbamates, which are capable of producing the parent compounds
described herein in vivo, are within the scope of this
invention.
[0370] If pharmaceutically acceptable salts of the compounds of the
invention are utilized in these compositions, the salts preferably
are derived from inorganic or organic acids and bases. For reviews
of suitable salts, see, e.g., Berge et al, J. Pharm. Sci. 66:1-19
(1977) and Remington: The Science and Practice of Pharmacy, 20th
Ed., ed. A. Gennaro, Lippincott Williams & Wilkins, 2000.
[0371] Nonlimiting examples of suitable acid addition salts include
the following: acetate, adipate, alginate, aspartate, benzoate,
benzene sulfonate, bisulfate, butyrate, citrate, camphorate,
camphor sulfonate, cyclopentanepropionate, digluconate,
dodecylsulfate, ethanesulfonate, fumarate, lucoheptanoate,
glycerophosphate, hemisulfate, heptanoate, hexanoate,
hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate,
lactate, maleate, methanesulfonate, 2-naphthalenesulfonate,
nicotinate, oxalate, pamoate, pectinate, persulfate,
3-phenyl-propionate, picrate, pivalate, propionate, succinate,
tartrate, thiocyanate, tosylate and undecanoate.
[0372] Suitable base addition salts include, without limitation,
ammonium salts, alkali metal salts, such as sodium and potassium
salts, alkaline earth metal salts, such as calcium and magnesium
salts, salts with organic bases, such as dicyclohexylamine salts,
N-methyl-D-glucamine, and salts with amino acids such as arginine,
lysine, and so forth.
[0373] In certain particular embodiments, the invention relates to
a base addition salt of a compound of formula I formed by
deprotonation of the sulfamate (X.dbd.O) moiety, the sulfamide
(X.dbd.NH) moiety, or the sulfonamide (X.dbd.CH.sub.2) moiety, as
applicable. In some such embodiments, the invention relates to a
sodium or potassium salt of a compound of formula I.
[0374] Also, basic nitrogen-containing groups may be quaternized
with such agents as lower alkyl halides, such as methyl, ethyl,
propyl, and butyl chloride, bromides and iodides; dialkyl sulfates,
such as dimethyl, diethyl, dibutyl and diamyl sulfates, long chain
halides such as decyl, lauryl, myristyl and stearyl chlorides,
bromides and iodides, aralkyl halides, such as benzyl and phenethyl
bromides and others. Water or oil-soluble or dispersible products
are thereby obtained.
[0375] The pharmaceutical compositions of the invention preferably
are in a form suitable for administration to a recipient subject,
preferably a mammal, more preferably a human. The term
"pharmaceutically acceptable carrier" is used herein to refer to a
material that is compatible with the recipient subject, and is
suitable for delivering an active agent to the target site without
terminating the activity of the agent. The toxicity or adverse
effects, if any, associated with the carrier preferably are
commensurate with a reasonable risk/benefit ratio for the intended
use of the active agent.
[0376] The pharmaceutical compositions of the invention can be
manufactured by methods well known in the art such as conventional
granulating, mixing, dissolving, encapsulating, lyophilizing, or
emulsifying processes, among others. Compositions may be produced
in various forms, including granules, precipitates, or
particulates, powders, including freeze dried, rotary dried or
spray dried powders, amorphous powders, tablets, capsules, syrup,
suppositories, injections, emulsions, elixirs, suspensions or
solutions. Formulations may optionally contain stabilizers, pH
modifiers, surfactants, solubilizing agents, bioavailability
modifiers and combinations of these.
[0377] Pharmaceutically acceptable carriers that may be used in
these compositions include, but are not limited to, ion exchangers,
alumina, aluminum stearate, lecithin, serum proteins, such as human
serum albumin, buffer substances such as phosphates or carbonates,
glycine, sorbic acid, potassium sorbate, partial glyceride mixtures
of saturated vegetable fatty acids, water, salts or electrolytes,
such as protamine sulfate, disodium hydrogen phosphate, potassium
hydrogen phosphate, sodium chloride, zinc salts, colloidal silica,
magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based
substances, polyethylene glycol, sodium carboxymethylcellulose,
polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers,
polyethylene glycol and wool fat.
[0378] According to a preferred embodiment, the compositions of
this invention are formulated for pharmaceutical administration to
a mammal, preferably a human being. Such pharmaceutical
compositions of the present invention may be administered orally,
parenterally, by inhalation spray, topically, rectally, nasally,
buccally, vaginally or via an implanted reservoir. The term
"parenteral" as used herein includes subcutaneous, intravenous,
intraperitoneal, intramuscular, intra-articular, intra-synovial,
intrasternal, intrathecal, intrahepatic, intralesional and
intracranial injection or infusion techniques. Preferably, the
compositions are administered orally, intravenously, or
subcutaneously. The formulations of the invention may be designed
to be short-acting, fast-releasing, or long-acting. Still further,
compounds can be administered in a local rather than systemic
means, such as administration (e.g., by injection) at a tumor
site.
[0379] Pharmaceutical formulations may be prepared as liquid
suspensions or solutions using a liquid, such as, but not limited
to, an oil, water, an alcohol, and combinations of these.
Solubilizing agents such as cyclodextrins may be included.
Pharmaceutically suitable surfactants, suspending agents, or
emulsifying agents, may be added for oral or parenteral
administration. Suspensions may include oils, such as but not
limited to, peanut oil, sesame oil, cottonseed oil, corn oil and
olive oil. Suspension preparation may also contain esters of fatty
acids such as ethyl oleate, isopropyl myristate, fatty acid
glycerides and acetylated fatty acid glycerides. Suspension
formulations may include alcohols, such as, but not limited to,
ethanol, isopropyl alcohol, hexadecyl alcohol, glycerol and
propylene glycol. Ethers, such as but not limited to,
poly(ethyleneglycol), petroleum hydrocarbons such as mineral oil
and petrolatum; and water may also be used in suspension
formulations.
[0380] Sterile injectable forms of the compositions of this
invention may be aqueous or oleaginous suspension. These
suspensions may be formulated according to techniques known in the
art using suitable dispersing or wetting agents and suspending
agents. The sterile injectable preparation may also be a sterile
injectable solution or suspension in a non-toxic parenterally
acceptable diluent or solvent, for example as a solution in
1,3-butanediol. Among the acceptable vehicles and solvents that may
be employed are water, Ringer's solution and isotonic sodium
chloride solution. In addition, sterile, fixed oils are
conventionally employed as a solvent or suspending medium. For this
purpose, any bland fixed oil may be employed including synthetic
mono- or di-glycerides. Fatty acids, such as oleic acid and its
glyceride derivatives are useful in the preparation of injectables,
as are natural pharmaceutically-acceptable oils, such as olive oil
or castor oil, especially in their polyoxyethylated versions. These
oil solutions or suspensions may also contain a long-chain alcohol
diluent or dispersant, such as carboxymethyl cellulose or similar
dispersing agents which are commonly used in the formulation of
pharmaceutically acceptable dosage forms including emulsions and
suspensions. Other commonly used surfactants, such as Tweens, Spans
and other emulsifying agents or bioavailability enhancers which are
commonly used in the manufacture of pharmaceutically acceptable
solid, liquid, or other dosage forms may also be used for the
purposes of formulation. Compounds may be formulated for parenteral
administration by injection such as by bolus injection or
continuous infusion. A unit dosage form for injection may be in
ampoules or in multi-dose containers.
[0381] The pharmaceutical compositions of this invention may be
orally administered in any orally acceptable dosage form including,
but not limited to, capsules, tablets, aqueous suspensions or
solutions. When aqueous suspensions are required for oral use, the
active ingredient is combined with emulsifying and suspending
agents. If desired, certain sweetening, flavoring or coloring
agents may also be added. For oral administration in a capsule
form, useful diluents include lactose and dried cornstarch. In the
case of tablets for oral use, carriers that are commonly used
include lactose and corn starch. Lubricating agents, such as
magnesium stearate, are also typically added. Coatings may be used
for a variety of purposes; e.g., to mask taste, to affect the site
of dissolution or absorption, or to prolong drug action. Coatings
may be applied to a tablet or to granulated particles for use in a
capsule.
[0382] Alternatively, the pharmaceutical compositions of this
invention may be administered in the form of suppositories for
rectal administration. These may be prepared by mixing the agent
with a suitable non-irritating excipient which is solid at room
temperature but liquid at rectal temperature and therefore will
melt in the rectum to release the drug. Such materials include
cocoa butter, beeswax and polyethylene glycols.
[0383] The pharmaceutical compositions of this invention may also
be administered topically, especially when the target of treatment
includes areas or organs readily accessible by topical application,
including diseases of the eye, the skin, or the lower intestinal
tract. Suitable topical formulations are readily prepared for each
of these areas or organs.
[0384] Topical application for the lower intestinal tract may be
effected in a rectal suppository formulation (see above) or in a
suitable enema formulation. Topically-transdermal patches may also
be used. For topical applications, the pharmaceutical compositions
may be formulated in a suitable ointment containing the active
component suspended or dissolved in one or more carriers. Carriers
for topical administration of the compounds of this invention
include, but are not limited to, mineral oil, liquid petrolatum,
white petrolatum, propylene glycol, polyoxyethylene,
polyoxypropylene compound, emulsifying wax and water.
Alternatively, the pharmaceutical compositions may be formulated in
a suitable lotion or cream containing the active components
suspended or dissolved in one or more pharmaceutically acceptable
carriers. Suitable carriers include, but are not limited to,
mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters
wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and
water.
[0385] For ophthalmic use, the pharmaceutical compositions may be
formulated as micronized suspensions in isotonic, pH adjusted
sterile saline, or, preferably, as solutions in isotonic, pH
adjusted sterile saline, either with our without a preservative
such as benzylalkonium chloride. Alternatively, for ophthalmic
uses, the pharmaceutical compositions may be formulated in an
ointment such as petrolatum.
[0386] The pharmaceutical compositions of this invention may also
be administered by nasal aerosol or inhalation. Such compositions
are prepared according to techniques well known in the art of
pharmaceutical formulation and may be prepared as solutions in
saline, employing benzyl alcohol or other suitable preservatives,
absorption promoters to enhance bioavailability, fluorocarbons,
and/or other conventional solubilizing or dispersing agents.
[0387] The pharmaceutical compositions of this invention are
particularly useful in therapeutic applications relating to
disorders as described herein (e.g., proliferation disorders, e.g.,
cancers, inflammatory, neurodegenerative disorders). Preferably,
the composition is formulated for administration to a patient
having or at risk of developing or experiencing a recurrence of the
relevant disorder being treated. The term "patient", as used
herein, means an animal, preferably a mammal, more preferably a
human. Preferred pharmaceutical compositions of the invention are
those formulated for oral, intravenous, or subcutaneous
administration. However, any of the above dosage forms containing a
therapeutically effective amount of a compound of the invention are
well within the bounds of routine experimentation and therefore,
well within the scope of the instant invention. In certain
embodiments, the pharmaceutical composition of the invention may
further comprise another therapeutic agent. Preferably, such other
therapeutic agent is one normally administered to patients with the
disorder, disease or condition being treated.
[0388] By "therapeutically effective amount" is meant an amount of
compound or composition sufficient, upon single or multiple dose
administration, to cause a detectable decrease in E1 enzyme
activity and/or the severity of the disorder or disease state being
treated. "Therapeutically effective amount" is also intended to
include an amount sufficient to treat a cell, prolong or prevent
advancement of the disorder or disease state being treated (e.g.,
prevent additional tumor growth of a cancer, prevent additional
inflammatory response), ameliorate, alleviate, relieve, or improve
a subject's symptoms of the a disorder beyond that expected in the
absence of such treatment. The amount of E1 enzyme inhibitor
required will depend on the particular compound of the composition
given, the type of disorder being treated, the route of
administration, and the length of time required to treat the
disorder. It should also be understood that a specific dosage and
treatment regimen for any particular patient will depend upon a
variety of factors, including the activity of the specific compound
employed, the age, body weight, general health, sex, and diet of
the patient, time of administration, rate of excretion, drug
combinations, the judgment of the treating physician, and the
severity of the particular disease being treated. In certain
aspects where the inhibitor is administered in combination with
another agent, the amount of additional therapeutic agent present
in a composition of this invention typically will be no more than
the amount that would normally be administered in a composition
comprising that therapeutic agent as the only active agent.
Preferably, the amount of additional therapeutic agent will range
from about 50% to about 100% of the amount normally present in a
composition comprising that agent as the only therapeutically
active agent.
[0389] One embodiment of the invention relates to a method of
inhibiting or decreasing E1 enzyme activity in a sample comprising
contacting the sample with a compound of this invention, or
composition comprising a compound of the invention. The sample, as
used herein, includes, without limitation, sample comprising
purified or partially purified E1 enzyme, cultured cells or
extracts of cell cultures; biopsied cells or fluid obtained from a
mammal, or extracts thereof; and body fluid (e.g., blood, serum,
saliva, urine, feces, semen, tears) or extracts thereof. Inhibition
of E1 enzyme activity in a sample may be carried out in vitro or in
vivo, in cellulo, or in situ.
[0390] In another embodiment, the invention provides a method for
treating a patient having a disorder, a symptom of a disorder, at
risk of developing, or experiencing a recurrence of a disorder,
comprising administering to the patient a compound or
pharmaceutical composition according to the invention. Treating can
be to cure, heal, alleviate, relieve, alter, remedy, ameliorate,
palliate, improve or affect the disorder, the symptoms of the
disorder or the predisposition toward the disorder. While not
wishing to be bound by theory, treating is believed to cause the
inhibition of growth, ablation, or killing of a cell or tissue in
vitro or in vivo, or otherwise reduce capacity of a cell or tissue
(e.g., an aberrant cell, a diseased tissue) to mediate a disorder,
e.g., a disorder as described herein (e.g., a proliferative
disorder, e.g., a cancer, inflammatory disorder). As used herein,
"inhibiting the growth" or "inhibition of growth" of a cell or
tissue (e.g., a proliferative cell, tumor tissue) refers to
slowing, interrupting, arresting or stopping its growth and
metastases and does not necessarily indicate a total elimination of
growth.
[0391] Disease applications include those disorders in which
inhibition of E1 enzyme activity is detrimental to survival and/or
expansion of diseased cells or tissue (e.g., cells are sensitive to
E1 inhibition; inhibition of E1 activity disrupts disease
mechanisms; reduction of E1 activity stabilizes protein which are
inhibitors of disease mechanisms; reduction of E1 activity results
in inhibition of proteins which are activators of disease
mechanisms). Disease applications are also intended to include any
disorder, disease or condition which requires effective cullin
and/or ubiquitination activity, which activity can be regulated by
diminishing E1 enzyme activity (e.g., NAE, UAE activity).
[0392] For example, methods of the invention are useful in
treatment of disorders involving cellular proliferation, including,
but not limited to, disorders which require an effective
cullin-dependent ubiquitination and proteolysis pathway (e.g., the
ubiquitin proteasome pathway) for maintenance and/or progression of
the disease state. The methods of the invention are useful in
treatment of disorders mediated via proteins (e.g., NF.kappa.B
activation, p27.sup.Kip activation, p21.sup.WAF/CIP1 activation,
p53 activation) which are regulated by E1 activity (e.g., NAE
activity, UAE activity, SAE activity). Relevant disorders include
proliferative disorders, most notably cancers and inflammatory
disorders (e.g., rheumatoid arthritis, inflammatory bowel disease,
asthma, chronic obstructive pulmonary disease (COPD),
osteoarthritis, dermatosis (e.g., atopic dermatitis, psoriasis),
vascular proliferative disorders (e.g., atherosclerosis,
restenosis) autoimmune diseases (e.g., multiple sclerosis, tissue
and organ rejection)); as well as inflammation associated with
infection (e.g., immune responses), neurodegenerative disorders
(e.g., Alzheimer's disease, Parkinson's disease, motor neurone
disease, neuropathic pain, triplet repeat disorders, astrocytoma,
and neurodegeneration as result of alcoholic liver disease),
ischemic injury (e.g., stroke), and cachexia (e.g., accelerated
muscle protein breakdown that accompanies various physiological and
pathological states, (e.g., nerve injury, fasting, fever, acidosis,
HIV infection, cancer affliction, and certain
endocrinopathies)).
[0393] The compounds and pharmaceutical compositions of the
invention are particularly useful for the treatment of cancer. As
used herein, the term "cancer" refers to a cellular disorder
characterized by uncontrolled or disregulated cell proliferation,
decreased cellular differentiation, inappropriate ability to invade
surrounding tissue, and/or ability to establish new growth at
ectopic sites. The term "cancer" includes, but is not limited to,
solid tumors and bloodborne tumors. The term "cancer" encompasses
diseases of skin, tissues, organs, bone, cartilage, blood, and
vessels. The term "cancer" further encompasses primary and
metastatic cancers.
[0394] In some embodiments, the cancer is a solid tumor.
Non-limiting examples of solid tumors that can be treated by the
methods of the invention include pancreatic cancer; bladder cancer;
colorectal cancer; breast cancer, including metastatic breast
cancer; prostate cancer, including androgen-dependent and
androgen-independent prostate cancer; renal cancer, including,
e.g., metastatic renal cell carcinoma; hepatocellular cancer; lung
cancer, including, e.g., non-small cell lung cancer (NSCLC),
bronchioloalveolar carcinoma (BAC), and adenocarcinoma of the lung;
ovarian cancer, including, e.g., progressive epithelial or primary
peritoneal cancer; cervical cancer; gastric cancer; esophageal
cancer; head and neck cancer, including, e.g., squamous cell
carcinoma of the head and neck; melanoma; neuroendocrine cancer,
including metastatic neuroendocrine tumors; brain tumors,
including, e.g., glioma, anaplastic oligodendroglioma, adult
glioblastoma multiforme, and adult anaplastic astrocytoma; bone
cancer; and soft tissue sarcoma.
[0395] In some other embodiments, the cancer is a hematologic
malignancy. Non-limiting examples of hematologic malignancy include
acute myeloid leukemia (AML); chronic myelogenous leukemia (CML),
including accelerated CML and CML blast phase (CML-BP); acute
lymphoblastic leukemia (ALL); chronic lymphocytic leukemia (CLL);
Hodgkin's disease (HD); non-Hodgkin's lymphoma (NH-L), including
follicular lymphoma and mantle cell lymphoma; B-cell lymphoma;
T-cell lymphoma; multiple myeloma (MM); Waldenstrom's
macroglobulinemia; myelodysplastic syndromes (MDS), including
refractory anemia (RA), refractory anemia with ringed siderblasts
(RARS), (refractory anemia with excess blasts (RAEB), and RAEB in
transformation (RAEB-T); and myeloproliferative syndromes.
[0396] In some embodiments, the compound or composition of the
invention is used to treat a patient having or at risk of
developing or experiencing a recurrence in a cancer selected from
the group consisting of colorectal cancer, ovarian cancer, lung
cancer, breast cancer, gastric cancer, prostate cancer, and
pancreatic cancer. In certain preferred embodiments, the cancer is
selected from the group consisting of lung cancer, colorectal
cancer, ovarian cancer and hematologic cancers.
[0397] Depending on the particular disorder or condition to be
treated, in some embodiments, the E1 enzyme inhibitor of the
invention is administered in conjunction with additional
therapeutic agent or agents. In some embodiments, the additional
therapeutic agent(s) is one that is normally administered to
patients with the disorder or condition being treated. As used
herein, additional therapeutic agents that are normally
administered to treat a particular disorder or condition are known
as "appropriate for the disorder or condition being treated."
[0398] The E1 inhibitor of the invention may be administered with
the other therapeutic agent in a single dosage form or as a
separate dosage form. When administered as a separate dosage form,
the other therapeutic agent may be administered prior to, at the
same time as, or following administration of the E1 inhibitor of
the invention.
[0399] In some embodiments, the E1 enzyme inhibitor of the
invention is administered in conjunction with a therapeutic agent
selected from the group consisting of cytotoxic agents,
radiotherapy, and immunotherapy appropriate for treatment of
proliferative disorders and cancer. Non-limiting examples of
cytotoxic agents suitable for use in combination with the E1 enzyme
inhibitors of the invention include: antimetabolites, including,
e.g., capecitibine, gemcitabine, 5-fluorouracil or
5-fluorouracil/leucovorin, fludarabine, cytarabine, mercaptopurine,
thioguanine, pentostatin, and methotrexate; topoisomerase
inhibitors, including, e.g., etoposide, teniposide, camptothecin,
topotecan, irinotecan, doxorubicin, and daunorubicin; vinca
alkaloids, including, e.g., vincristine and vinblastin; taxanes,
including, e.g., paclitaxel and docetaxel; platinum agents,
including, e.g., cisplatin, carboplatin, and oxaliplatin;
antibiotics, including, e.g., actinomycin D, bleomycin, mitomycin
C, adriamycin, daunorubicin, idarubicin, doxorubicin and pegylated
liposomal doxorubicin; alkylating agents such as melphalan,
chlorambucil, busulfan, thiotepa, ifosfamide, carmustine,
lomustine, semustine, streptozocin, decarbazine, and
cyclophosphamide; including, e.g., CC-5013 and CC-4047; protein
tyrosine kinase inhibitors, including, e.g., imatinib mesylate and
gefitinib; proteasome inhibitors, including, e.g., bortezomib;
thalidomide and related analogs; antibodies, including, e.g.,
trastuzumab, rituximab, cetuximab, and bevacizumab; mitoxantrone;
dexamethasone; prednisone; and temozolomide.
[0400] Other examples of agents the inhibitors of the invention may
be combined with include anti-inflammatory agents such as
corticosteroids, TNF blockers, I1-1 RA, azathioprine,
cyclophosphamide, and sulfasalazine; immunomodulatory and
immunosuppressive agents such as cyclosporine, tacrolimus,
rapamycin, mycophenolate mofetil, interferons, corticosteroids,
cyclophosphamide, azathioprine, methotrexate, and sulfasalazine;
antibacterial and antiviral agents; and agents for Alzheimer's
treatment such as donepezil, galantamine, memantine and
rivastigmine.
[0401] In order that this invention be more fully understood, the
following preparative and testing examples are set forth. These
examples are for the purpose of illustration only and are not to be
construed as limiting the scope of the invention in any way.
EXAMPLES
Abbreviations
[0402] AA ammonium acetate [0403] AcOH acetic acid [0404] ACN
acetonitrile [0405] d days [0406] DBU
1,8-diazabicyclo[5.4.0]undec-7-ene [0407] DCM dichloromethane
[0408] DEAD diethylazodicarboxylate [0409] DIAD
diisopropylazodicarboxylate [0410] DIPEA N,N-diisopropylethylamine
[0411] DMAP N,N-dimethyl-4-aminopyridine [0412] DMF
dimethylformamide [0413] DMSO dimethylsulfoxide [0414] Et.sub.2O
diethyl ether [0415] EtOAc ethyl acetate [0416] EtOH ethanol [0417]
Et.sub.3N triethylamine [0418] FA formic acid [0419] H.sub.2O water
[0420] h hours [0421] HCl hydrochloric acid [0422] LC/MS liquid
chromatography mass spectrum [0423] MeOH methanol [0424] MeOD
d.sub.4-methanol [0425] MgSO.sub.4 magnesium sulfate [0426] m-CPBA
meta-chloroperbenzoic acid [0427] min minutes [0428] MS mass
spectrum [0429] MWI microwave irradiation [0430] Na.sub.2CO.sub.3
sodium carbonate [0431] NaHCO.sub.3 sodium bicarbonate [0432] NaOH
sodium hydroxide [0433] NIS N-iodosuccinimide [0434] TBAF
tetra-n-butylammonium fluoride [0435] TEA triethylamine [0436]
p-TsOH para-toluenesulfonic acid [0437] rt room temperature [0438]
TFA trifluoroacetic acid [0439] THF tetrahydrofuran
Analytical LC-MS Methods
[0440] Spectra were obtained on a Hewlett-Packard HP1100 using the
following conditions: FA Standard: Phenominex Luna 5 .mu.m C18
50.times.4.6 mm column at 2.5 ml/min gradient of ACN containing 0
to 100 percent 0.1% Formic Acid in H.sub.2O for 3 min AA Standard:
Phenominex Luna 5 .mu.m C18 50.times.4.6 mm column at 2.5 ml/min
gradient of ACN containing 0 to 100 percent 10 mM Ammonium Acetate
in H.sub.2O for 3 min. FA Waters: Waters Symmetry C18 3.5 .mu.m 4.6
mm.times.100 mm column at 1 ml/min gradient of ACN containing 0 to
95 percent 0.1% Formic Acid in H.sub.2O for 10 min AA Waters:
Waters Symmetry C18 3.5 .mu.m 4.6 mm.times.100 mm column at 1
ml/min gradient of ACN containing 0 to 75 percent 0.1% 10 mM
Ammonium Acetate in methanol for 10 min FA Long: Waters Symmetry
C18 3.5 .mu.m 4.6 mm.times.100 mm column at 1 ml/min gradient of
ACN containing 5 to 100 percent 0.1% Formic Acid in H.sub.2O for 12
min AA Long: Waters Symmetry C18 3.5 .mu.m 4.6 mm.times.100 mm
column at 1 ml/min gradient of ACN containing 5 to 100 percent 10
mM Ammonium Acetate in HO20 for 12 min
Example 1
[(1R,2R,3S,4R)-4-({6-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}--
amino)-2,3-dihydroxycyclopentyl]methyl sulfamate (Compound
I-29)
Step a
(1R,2S,3R,5R)-3-[(6-Chloropyrimidin-4-yl)amino]-5-(hydroxymethyl)-cyclopen-
tane-1,2-diol
[0441] A mixture of
(1R,2S,3R,5R)-3-amino-5-(hydroxymethyl)cyclopentane-1,2-diol
hydrochloride (200 mg, 1.09 mmol), 4,6-dichloropyrimidine (240. mg,
1.61 mmol) and Et.sub.3N (0.380 mL, 2.73 mmol) in EtOH (3.00 mL)
was heated to 150.degree. C. for 15 min using MWI. The crude
mixture was purified via silica gel chromatography eluting with a
gradient of 0 to 15% MeOH in DCM to afford the title compound (255
mg, 90%). LC/MS: R.sub.t=1.13 min, ES.sup.+260. (AA standard).
Step b
{(3aR,4R,6R,6aS)-6-[(6-Chloropyrimidin-4-yl)amino]-2,2-dimethyltetrahydro--
3aH-cyclopenta[d][1,3]dixool-4-yl}methanol
[0442] A solution of
(1R,2S,3R,5R)-3-[(6-chloropyrimidin-4-yl)amino]-5-(hydroxymethyl)cyclopen-
tane-1,2-diol (255 mg, 0.982 mmol), p-toluenesulfonic acid
monohydrate (187 mg, 0.982 mmol) and 2,2-dimethoxypropane (0.670
mL, 0.545 mmol) in MeOH (5.00 mL) was stirred overnight. The
reaction was quenched via addition of saturated aqueous NaHCO.sub.3
solution (10 mL) and MeOH was removed in vacuo. The aqueous mixture
was extracted with DCM (4.times.20 mL) and the combined organics
were concentrated in vacuo. The crude mixture was purified via
silica gel chromatography eluting with a gradient of 0 to 10% MeOH
in DCM to afford the title compound (135 mg, 45.8%). LC/MS:
R.sub.t=1.77 min, ES.sup.+ 300. (AA standard).
Step c
[(3aR,4R,6R,6aS)-6-({6-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]pyrimidin-4-yl-
}-amino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methanol
[0443] A mixture of
{(3aR,4R,6R,6aS)-6-[(6-chloropyrimidin-4-yl)amino]-2,2-dimethyltetrahydro-
-3aH-cyclopenta[d][1,3]dioxol-4-yl}methanol (200 mg, 0.667 mmol)
and (S)-(+)-1-aminoindan (0.188 mL, 1.47 mmol) were heated to
180.degree. C. for 3 h in a sealed tube using MWI. The mixture was
dissolved in DCM and the resulting suspension was washed with
H.sub.2O followed by saturated ammonium chloride solution. The
organic layer was dried over MgSO.sub.4, filtered and concentrated
in vacuo. The residue was purified via silica gel chromatography
eluting with a gradient of 0 to 10% MeOH in EtOAc to afford the
title compound as an amorphous solid (218 mg, 82.4%). LC/MS:
R.sub.t=1.44 min, ES.sup.+ 397 (AA standard).
Step d
[(3aR,4R,6R,6aS)-6-({6-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]pyrimidin-4-yl-
}-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]methyl
sulfamate
[0444] A 2.00 M solution of chlorosulfonamide in ACN was prepared
as follows: FA (2.30 mL, 61.0 mmol) was added dropwise, with
stirring to chlorosulfonyl isocyanate (5.20 mL, 59.7 mmol) under an
atmosphere of nitrogen at 0.degree. C. After the addition was
complete and the mixture had solidified, ACN (22.5 mL) was added.
The resulting solution was left to stand under a vented source of
nitrogen overnight at rt.
[0445] To a solution of
[(3aR,4R,6R,6aS)-6-({6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]pyrimidin-4-y-
l}amino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]-methano-
l (100. mg, 0.252 mmol) and Et.sub.3N (0.0527 mL, 0.378 mmol) in
DCM (2.50 mL) was added dropwise a 2.00 M solution of
chlorosulfonamide in ACN (0.190 mL, 0.380 mmol) at 0.degree. C. and
the mixture was stirred for 2 h. The reaction was diluted with DCM,
quenched with H.sub.2O and the organic layer was separated, then
concentrated in vacuo. The residue was purified via silica gel
chromatography eluting with a gradient of 0 to 10% MeOH in DCM to
afford the title compound (65.0 mg, 54%). LC/MS: R.sub.t=1.58 min,
ES.sup.+ 476 (AA standard).
Step e
[(1R,2R,3S,4R)-4-({6-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}--
amino)-2,3-dihydroxycyclopentyl]methyl sulfamate (Compound
I-29)
[0446] A solution of
[(3aR,4R,6R,6aS)-6-({6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]pyrimidin-4-y-
l}amino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]-methyl
sulfamate (60.0 mg, 0.126 mmol) was treated with a 9:1 mixture of
trifluoroacetic acid in H.sub.2O (5.00 mL, 58.4 mmol) and the
mixture was stirred for 10 min before being concentrated in vacuo.
The crude material was purified via reverse phase C18 preparative
HPLC eluting with a gradient of 5 to 70% of 0.1% FA/95% ACN/5%
H.sub.2O in 0.1% FA/99% H2O/1% ACN over 16 min to afford the title
compound (27.0 mg, 49%). .sup.1H NMR (400 MHz, DMSO-d6, .delta.):
8.13 (s, 1H), 7.98 (s, 1H), 7.44 (s, 2H), 7.28-7.02 (m, 5H), 6.72
(bs, 1H), 5.53 (s, 1H), 5.41 (s, 1H), 4.63 (d, J=5.3 Hz, 1H), 4.09
(dd, J=5.1, 95 Hz, 1H), 3.97 (dd, J=7.0, 9.5 Hz, 1H), 3.81 (bs,
1H), 3.71-3.60 (m, 2H), 3.01-2.87 (m, 1H), 2.87-2.70 (m, 1H),
2.47-2.37 (m, 1H), 2.30-2.09 (m, 2H), 1.89-1.72 (m, 1H), 1.19-1.05
(m, 1H) ppm. LC/MS: R.sub.t=1.13 min, ES.sup.+ 436 (AA
standard).
Example 2
{(1R,2R,3S,4R)-4-[(6-{[(1S)-3,3-Dimethyl-2,3-dihydro-1H-inden-1-yl]amino}--
pyrimidin-4-yl)amino]-2,3-dihydroxycyclopentyl}methyl sulfamate
(Compound I-21)
Step a
(2R)-2-{[(1S)-3,3-Dimethyl-2,3-dihydro-1H-inden-1-yl]amino}-2-phenylethano-
l
[0447] To a solution of 3,3-dimethylindan-1-one (925 mg, 5.77 mmol)
and (R)-(-)-2-phenylglycinol (893 mg, 6.51 mmol) in toluene (10.0
mL) was added p-toluenesulfonic acid monohydrate (625 mg, 0.328
mmol). The reaction was heated to reflux under an atmosphere of
nitrogen for 90 min. At this point, the mixture was cooled and
diluted with toluene (10.0 mL). The mixture was washed with
saturated aqueous NaHCO.sub.3 solution and H.sub.2O. The organic
layer was concentrated in vacuo and the residue was dissolved in
THF (10.0 mL) and cooled to 0.degree. C. AcOH (1.13 mL, 19.9 mmol)
was added, followed by sodium borohydride (251 mg, 6.64 mmol) and
the reaction was allowed to warm to 23.degree. C. overnight. The
mixture was partitioned between DCM and saturated aqueous
NaHCO.sub.3 solution. The organic layer was concentrated and silica
gel chromatography eluting with a gradient of 5 to 35% EtOAc in DCM
afforded the title compound (1.49 g, 74%). LC/MS: R.sub.t=1.92 min,
ES.sup.+ 282 (AA standard).
Step b
(1S)-3,3-Dimethylindan-1-amine
[0448] A solution of
(2R)-2-{[(1S)-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl]amino}-2-phenylethan-
ol (1.44 g, 5.13 mmol) in MeOH (40.0 mL) was added to a stirred
solution of lead tetraacetate (3.75 g, 8.03 mmol) in MeOH (60.0 mL)
at 0.degree. C. dropwise over 20 min. After stirring for 45 min,
the reaction was quenched via addition of a 10% solution of
Na.sub.1CO, in H.sub.2O (76.0 mL) and the mixture was stirred for
10 min. DCM (200 mL) was then added and the layers were separated.
The aqueous layer was extracted with DCM (50.0 mL). The combined
organic layers were concentrated in vacuo and the residue was
dissolved in EtOH (190. mL) and treated with a 10.4 M aqueous
solution of HCl (5.70 mL, 59.3 mmol). The resulting mixture was
then heated to reflux for 16 h. The cooled reaction was
concentrated in vacuo and partitioned between H.sub.2O (150. mL)
and Et.sub.2O (50.0 mL). The aqueous layer was adjusted to pH 10
via addition of Na.sub.2CO.sub.3 and extracted with Et.sub.2O
(3.times.50.0 mL). The combined organic layers were concentrated in
vacuo and silica gel chromatography eluting with a gradient of 0 to
10% MeOH in DCM to afford the title compound as a pale yellow oil
(420. mg, 51%). .sup.1H NMR (CD.sub.3OD, 300 MHz) .delta.:
7.34-7.14 (m, 4H), 4.45-4.37 (m, 1H), 2.38 (dd, J=7.1, 12.4 Hz,
1H), 1.73 (bs, 2H), 1.60 (dd, J=8.7, 12.4 Hz, 1H), 1.39 (s, 3H),
1.19 (s, 3H) ppm.
Step c
{(1R,2R,3S,4R)-4-[(6-{[(1S)-3,3-Dimethyl-2,3-dihydro-1H-inden-1-yl]amino}--
pyrimidin-4-yl)amino]-2,3-dihydroxycyclopentyl}methyl sulfamate
(Compound I-21)
[0449] The title compound was prepared following the procedure
described in Example 1a-e using (1S)-3,3-dimethylindan-1-amine in
step c. .sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.: 7.95 (s, 1H),
7.28-7.15 (m, 4H), 5.62 (s, 1H), 5.38 (bs, 1H), 4.22-4.12 (m, 2H),
3.92 (bs, 1H), 3.88 (dd, J=5.5, 5.5 Hz, 1H), 3.78 (dd, J=5.5, 5.5
Hz, 1H), 2.46-2.27 (m, 3H), 1.84-1.76 (m, 1H), 1.39 (s, 3H),
1.35-1.27 (m, 2H), 1.25 (s, 3H) ppm. LC/MS: R.sub.t=1.42 min,
ES.sup.+ 464 (AA standard).
Example 3
{(1R,2R,3S,4R)-4-[(6-{[(1S)-4-Chloro-2,3-dihydro-1H-inden-1-yl]amino}-pyri-
midin-4-yl)amino]-2,3-dihydroxycyclopentyl}methyl sulfamate
(Compound I-24)
[0450] The title compound was prepared following the procedure
described in Example 2a-c using 4-chloroindan-1-one in step a.
.sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.:& 8.01 (s, 1H),
7.26-7.15 (m, 4H), 5.69 (s, 1H), 5.44 (bs, 1H), 4.17 (dddd, J=5.2,
9.7, 9.7, 9.8 Hz, 2H), 3.95 (bs, 1H), 3.88 (t, J=5.4 Hz, 1H), 3.79
(t, J=5.6 Hz, 1H), 3.12-3.04 (m, 1H), 2.88 (ddd, J=8.2, 8.2, 16.4
Hz, 1H), 2.66-2.56 (m, 1H), 2.43-2.28 (m, 2H), 1.99-1.88 (m, 1H),
1.38-1.28 (m, 1H) ppm. LC/MS: R.sub.t=1.08 min, ES.sup.+ 470. (FA
standard).
Example 4
{(1R,2R,3S,4R)-4-[(6-{[(1S)-5,6-difluoro-2,3-Dihydro-1H-inden-1-yl]amino}--
pyrimidin-4-yl)amino]-2,3-dihydroxycyclopentyl}methyl sulfamate
(Compound I-17)
[0451] The title compound was prepared following the procedure
described in Example 2a-c using 5,6-difluoroindan-1-one in step a.
.sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.: 7.96 (s, 1H), 7.14-7.02
(m, 3H), 5.62-5.58 (m, 1H), 5.39 (s, 1H), 5.28 (bs, 1H), 4.22-4.13
(m, 2H), 3.89 (dd, J=5.5, 5.5 Hz, 1H), 3.78 (dd, J=5.4, 5.4 Hz,
1H), 3.00-2.91 (m, 1H), 2.88-2.77 (m, 1H), 2.64-2.55 (m, 1H),
2.44-2.32 (m, 1H), 1.97-1.86 (m, 1H), 1.43-1.20 (m, 2H) ppm. LC/MS:
R=1.02 min, ES.sup.+ 472 (FA standard).
Example 5
{(1R,2R,3S,4R)-4-[(6-{[(1S)-4,7-difluoro-2,3-dihydro-1H-inden-1-yl]amino}--
pyrimidin-4-yl)amino]-2,3-dihydroxycyclopentyl}methyl sulfamate
(Compound I-6)
[0452] The title compound was prepared following the procedure
described in Example 2a-c using 4,7-difluoroindan-1-one in step a.
.sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.: 7.95 (s, 1H), 7.02-6.86
(m, 2H), 5.62-5.50 (m, 2H), 4.23-4.12 (m, 2H), 3.92 (bs, 1H), 3.88
(dd, J=5.5, 5.5 Hz, 1H), 3.78 (dd, J=5.5, 5.5 Hz, 1H), 3.16-3.05
(m, 1H), 2.95-2.85 (m, 1H), 2.62-2.50 (m, 1H), 2.45-2.28 (m, 2H),
2.11-2.00 (m, 1H), 1.37-1.25 (m, 1H) ppm. LC/MS: R.sub.t=0.94 min,
ES.sup.+ 472 (FA standard).
Example 6
{(1R,2R,3S,4R)-4-[(6-{[(1S)-4-fluoro-2,3-dihydro-1H-inden-1-yl]amino}-pyri-
midin-4-yl)amino]-2,3-dihydroxycylopentyl}methyl sulfamate
(Compound I-1)
[0453] The title compound was prepared following the procedure
described in Example 2a-c using 4-fluoroindan-1-one in step a.
.sup.1H NMR (CD.sub.3OD, 300 MHz) .delta.: 8.06 (s, 1H), 7.29-7.17
(m, 1H), 7.15-7.06 (m, 1H), 7.03-6.91 (m, 1H), 5.75 (s, 1H), 5.42
(bs, 1H), 4.27-4.11 (m, 1H), 4.08-3.89 (m, 2H), 3.89-3.80 (m, 1H),
3.16-3.02 (m, 1H), 2.96-2.80 (m, 1H), 2.73-2.55 (m, 1H), 2.47-2.27
(m, 2H), 2.06-1.89 (m, 1H), 1.47-1.23 (m, 1H) ppm. LC/MS:
R.sub.t=0.94 min, ES.sup.+ 454 (FA standard).
Example 7
[(1R,2R,3S,4R)-4-({6-[(1R)-2,3-Dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}--
amino)-2,3-dihydroxycyclopentyl]methyl sulfamate (Compound I-8)
[0454] The title compound was prepared following the procedure
described in Example 1a-e using (R)-(-)-1-aminoindan in step c.
.sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.: 7.96 (s, 1H), 7.27-7.12
(m, 4H), 5.66 (s, 1H), 5.30 (bs, 1H), 4.23-4.13 (m, 2H), 3.95 (bs,
1H), 3.90 (dd, J=5.5, 5.5 Hz, 1H), 3.80 (dd, J=5.6, 5.6 Hz, 1H),
3.05-2.94 (m, 1H), 2.92-2.81 (m, 1H), 2.63-2.50 (m, 1H), 2.45-2.28
(m, 2H), 1.96-7.80 (m, 1H), 1.38-1.27 (m, 1H) ppm. LC/MS:
R.sub.t=1.07 min, ES.sup.+ 436 (FA standard).
Example 8
((1R,2R,3S,4R)-4-{[6-(Benzylamino)pyrimidin-4-yl]amino}-2,3-dihydroxycyclo-
pentyl)methyl sulfamate (Compound I-27)
[0455] The title compound was prepared following the procedure
described in Example 1a-e using benzylamine in step c. .sup.1H NMR
(CD.sub.3OD, 300 MHz) .delta.: 7.92 (s, 1H), 7.35-7.16 (m, 5H),
5.49 (s, 1H), 4.42 (s, 2H), 4.21-4.07 (m, 2H), 3.91 (bs, 1H), 3.87
(dd, J=5.2, 5.2 Hz, 1H), 3.74 (dd, J=5.6, 5.6 Hz, 1H), 2.39-2.19
(m, 2H), 1.46-1.11 (m, 1H) ppm. LC/MS: R.sub.t=1.14 min, ES.sup.-
408 (AA standard).
Example 9
[(1R,2R,3S,4R)-4-({6-[Benzyl(methyl)amino]pyrimidin-4-yl}amino)-2,3-dihydr-
oxycyclopentyl]methyl sulfamate (Compound I-22)
[0456] The title compound was prepared following the procedure
described in Example 1a-e using N-methylbenzyl amine in step c.
.sup.1H NMR (CD.sub.3OD, 300 MHz) .delta.: 7.99 (s, 1H), 7.34-7.14
(m, 5H), 5.62 (s, 1H), 4.75 (s, 2H), 4.23-4.09 (m, 2H), 4.01-3.90
(m, 1H), 3.87 (dd, J=5.5, 5.5 Hz, 1H), 3.76 (dd, J=5.5, 5.5 Hz,
1H), 2.99 (s, 3H), 2.42-2.25 (m, 2H), 1.35-1.20 (1H) ppm. LC/MS:
R.sub.t=1.27 min, ES.sup.- 422 (AA standard).
Example 10
{(1R,2R,3S,4R)-4-[(6-{[(1S)-5-Chloro-2,3-dihydro-1H-inden-1-yl]amino}-pyri-
midin-4-yl)amino]-2,3-dihydroxycyclopentyl}methyl sulfamate
(Compound I-19)
[0457] The title compound was prepared following the procedure
described in Example 2a-c using 5-chloroindan-1-one in step a.
.sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.: 7.94 (s, 1H), 7.34-7.18
(m, 2H), 7.18-7.12 (m, 1H), 5.62 (s, 1H), 5.30 (bs, 1H), 3.88 (dd,
J=5.5, 5.5 Hz, 1H), 3.77 (dd, J=5.5, 5.5 Hz, 1H), 3.03-294 (m, 1H),
2.92-2.81 (m, 1H), 2.61-2.51 (m, 1H), 2.42-2.26 (m, 2H), 1.97-1.84
(m, 1H), 1.35-1.22 (m, 1H) ppm. LC/MS: R.sub.t=1.44 min, ES.sup.-
470. (AA standard).
Example 11
[(1R,2R,3S,4R)-2,3-Dihydroxy-4-({6-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl-
amino]pyrimidin-4-yl}amino)cyclopentyl]methyl sulfamate (Compound
I-12)
[0458] The title compound was prepared following the procedure
described in Example 1a-e using
(S)-(+)-1,2,3,4-tetrahydro-1-napthylamine in step c. .sup.1H NMR
(CD.sub.3OD, 400 MHz) .delta.: 7.93 (s, 1H), 7.27-7.20 (m, 1H),
7.18-7.06 (m, 3H), 5.59 (s, 1H), 4.99 (bs, 1H), 4.23-4.11 (m, 2H),
3.92 (bs, 1H), 3.88 (dd, J=5.5, 5.5 Hz, 1H), 3.77 (dd, J=55, 5.5
Hz, 1H), 2.90-2.70 (m, 2H), 2.43-2.26 (m, 2H), 2.08-1.76 (m, 5H),
1.35-1.22 (m, 1H) ppm. LC/MS: R.sub.t=1.33 min, ES.sup.+ 450. (AA
standard).
Example 12
{(1R,2R,3S,4R)-2,3-Dihydroxy-4-[(6-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-inde-
n-1-yl]amino}pyrimidin-4-yl)amino]cyclopentyl}methyl sulfamate
(Compound I-2)
Step a
tert-Butyl
[(1R,2S-2-hydroxy-2,3-dihydro-1H-inden-1-yl]carbamate
[0459] (1R,2S)-1-Aminoindan-2-ol (1.83 g, 12.3 mmol) was dissolved
in DCM (70.0 mL) and TEA (3.42 mL, 24.5 mmol) was added.
Di-tert-butyldicarbonate (2.81 g, 12.9 mmol) was added and the
reaction mixture was stirred for 5 h. The solution was concentrated
in vacuo and purified via silica gel chromatography eluting with a
gradient of 0 to 100% EtOAc in hexanes to afford the title compound
(3.12 g, 100%). LC/MS: R.sub.t=1.55 min, ES.sup.+ 250. (AA
standard).
Step b
tert-Butyl
[(1R,2S-2-methoxy-2,3-dihydro-1H-inden-1-yl]-carbamate
[0460] A mixture of tert-butyl
[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-carbamate (680. mg,
2.73 mmol), DMF (21.1), barium monoxide (5.02 g, 32.7 mmol), barium
hydroxide (2.80 g, 16.4 mmol) and iodomethane (1.70 mL, 27.3 mmol)
was stirred overnight. LC/MS showed no starting material. The
reaction was quenched via addition of a saturated solution of
NaHCO.sub.3 and was extracted with DCM. The organic layer was
washed with H.sub.2O (3.times.), dried over sodium sulfate and
concentrated in vacuo. The residue was purified via silica gel
chromatography eluting with a gradient of 0 to 50% EtOAc in hexanes
to afford the title compound (178 mg, 25%). LC/MS: R.sub.t=1.24
min, ES.sup.+ 264 (AA standard).
Step c
(1R,2S)-2-Methoxyindan-1-amine
[0461] To tert-butyl
[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]carbamate (253 mg,
0.961 mmol) was added a 4.00 M solution of HCl in 1,4-dioxane (5.00
mL) and the mixture was stirred for 10 min, after which a white
solid crashed out. The suspension was concentrated in vacuo and
co-evaporated with toluene to afford a white solid, which was
dissolved in H.sub.2O. The solution was adjusted to pH 10. via
addition of Na.sub.2CO.sub.3. The mixture was then extracted with
Et.sub.2O (3.times.30 mL) and the organic extracts were
concentrated in vacuo to afford the title compound (150. mg, 99%).
LC/MS: R.sub.t=0.85 min, ES.sup.+ 164 (AA standard).
Step d
{(1R,2R,3S,4R)-2,3-Dihydroxy-4-[(6-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-inde-
n-1-yl]amino}pyrimidin-4-yl)amino]cyclopentyl}methyl sulfamate
(Compound I-2)
[0462] The title compound was prepared following the procedure
described in Example 2a-c using (1R,2S)-2-methoxyindan-1-amine in
step a. .sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.: 7.97 (s, 1H),
7.28-7.10 (m, 4H), 5.36 (bs, 1H), 4.21-4.10 (m, 3H), 3.93 (bs, 1H),
3.86 (t, J=5.4 Hz, 1H), 3.77 (t, J=5.6 Hz, 1H), 3.32 (s, 3H),
3.12-2.95 (m, 2H), 2.44-2.26 (m, 2H), 1.38-1.25 (m, 1H) ppm. LC/MS:
R.sub.t=0.94 min, ES.sup.+ 466 (FA standard).
Example 13
[(1R,2R,3S,4R)-4-({6-[(Cyclohexylmethyl)amino]pyrimidin-4-yl}amino)-2,3-di-
hydroxycyclopentyl]methyl sulfamate (Compound I-14)
[0463] The title compound was prepared following the procedure
described in Example 1a-e using cyclohexanemethylamine in step c.
.sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.: 8.08 (s, 1H), 5.69 (s,
1H), 4.22-4.13 (m, 2H), 4.00 (bs, 1H), 3.89 (dd, J=5.2, 5.2 Hz,
1H), 3.82 (dd, J=6.2, 6.5 Hz, 1H), 3.18-3.07 (m, 2H), 2.42-2.29 (m,
2H), 1.83-1.53 (m, 7H), 1.44-1.14 (m, 5H), 1.07-0.92 (m, 2H) ppm.
LC/MS: R.sub.t=1.31 min, ES.sup.- 414 (AA standard).
Example 14
[(1R,2R,3S,4R)-2,3-dihydroxy-4-({2-[(3-methyl-2,3-dihydro-1H-inden-1-yl)-a-
mino]pyrimidin-4-yl}amino)cyclopentyl]methyl sulfamate (Compound
I-10)
Step a
3-Methylindan-1-one oxime
[0464] To a solution of 3-methylindan-1-one (221 mg, 1.51 mmol) and
hydroxylamine hydrochloride (295 mg, 4.25 mmol) in MeOH (4.00 mL)
was added a solution of NaOH (200 mg, 5.00 mmol) in H.sub.2O (2.00
mL) and the mixture was stirred at 80.degree. C. for 2 h. The
cooled reaction was concentrated in vacuo to remove most of the
MeOH, and the residue was partitioned between DCM and H.sub.2O. The
organic layer was concentrated in vacuo to afford the title
compound as a waxy solid (232 mg, 95%). LC/MS: R.sub.t=1.51 min,
ES.sup.+ 162 (AA standard).
Step b
3-Methylindan-1-amine
[0465] A mixture of methylindan-1-one oxime (223 mg, 1.38 mmol) and
10% palladium on carbon (14.7 mg, 50% water wet) in MeOH (5.00 mL)
was stirred under an atmosphere of hydrogen overnight. The mixture
was then filtered through celite, washed through with MeOH and the
combined filtrates were concentrated in vacuo to afford the title
compound (195 mg, 96%). .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.:
7.39-7.14 (m, 4H), 4.26 (dd, J=7.2, 9.4 Hz, 1H), 3.13-2.96 (m, 1H),
2.71 (ddd, J=6.9, 6.9, 12.5 Hz, 1H), 1.75 (bs, 2H), 1.35 (d, J=6.8
Hz, 3H), 1.25 (ddd, J=9.9, 9.9, 11.7 Hz, 1H) ppm.
Step c
[(1R,2R,3S,4R)-2,3-dihydroxy-4-({2-[(3-methyl-2,3-dihydro-1H-inden-1-yl)-a-
mino]pyrimidin-4-yl}amino)cyclopentyl]methyl sulfamate (Compound
I-10)
[0466] The title compound was prepared following the procedure
described in Example 1a-e using 2,4-dichloropyrimidine in step a
and 3-methylindan-1-amine in step c. .sup.1H NMR (CD.sub.3OD, 300
MHz) .delta.: 7.65-7.36 (m, 1H), 7.34-7.04 (m, 5H), 6.23-5.99 (m,
1H), 5.62 (bs, 1H), 4.53-4.36 (m, 1H), 4.22-4.09 (m, 2H), 3.94-3.81
(m, 2H), 3.25-3.08 (m, 1H), 2.94-2.76 (m, 1H), 1.66-1.44 (m, 1H),
1.44-1.20 (m, 6H) ppm. LC/MS: R.sub.t=1.19 min, ES.sup.+ 450. (AA
standard).
Example 15
{(1R,2R,3S,4R)-4-[(2-{[1S)-3,3-Dimethyl-2,3-dihydro-1H-inden-1-yl]amino}-p-
yrimidin-4-yl)amino]-2,3-dihydroxycyclopentyl}methyl sulfamate
(Compound I-15)
[0467] The title compound was prepared following the procedure
described in Example 1a-e using 2,4-dichloropyrimidine in step a
and (1S)-3,3-dimethylindan-1-amine in step c. .sup.1H NMR
(CD.sub.3OD, 400 MHz) .delta.: 8.47 (s, 1H), 7.59 (s, 1H),
7.32-7.17 (m, 4H), 6.06 (bs, 1H), 5.64 (bs, 1H), 4.36 (bs, 1H),
4.21-4.09 (m, 2H), 3.91-3.81 (m, 2H), 2.47 (dd, J=7.3, 12.4 Hz,
1H), 2.41-2.23 (m, 2H), 1.91 (bs, 1H), 1.41 (s, 3H), 1.26 (s, 3H),
0.99-0.88 (m, 1H) ppm. LC/MS: R.sub.t=1.24 min, ES.sup.+ 464 (AA
standard).
Example 16
[(1R,2R,3S,4R)-4-({2-[(Cyclohexylmethyl)amino]pyrimidin-4-yl}amino)-2,3-di-
hydroxycyclopentyl]methyl sulfamate (Compound I-4)
[0468] The title compound was prepared following the procedure
described in Example 1a-e using 2,4-dichloropyrimidine in step a
and cyclohexanemethylamine in step c. .sup.1H NMR (CD.sub.3OD, 400
MHz) .delta.: 7.50 (d, J=7.3 Hz, 1H), 6.04 (d, J=7.1 Hz, 1H), 4.42
(dd, J=7.9, 13.8 Hz, 1H), 4.22-1.43 (m, 2H), 3.93-9.85 (m, 2H),
3.68 (s, 1H), 2.48-2.28 (m, 2H), 1.84-1.55 (m, 7H), 1.37-1.13 (m,
5H), 1.07-0.93 (m, 2H) ppm. LC/MS: R.sub.t=1.11 min, ES.sup.+ 416
(AA standard).
Example 17
[(1R,2R,3S,4R)-4-({2-[Benzyl(methyl)amino]pyrimidin-4-yl}amino)-2,3-dihydr-
oxycyclopentyl]methyl sulfamate (Compound I-20)
[0469] The title compound was prepared following the procedure
described in Example 1a-e using 2,4-dichloropyrimidine in step a
and N-methylbenzyl amine in step c.
[0470] .sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.: 7.59 (d, J=6.8
Hz, 1H), 7.38-7.25 (m, 5H), 6.14 (d, J=6.6 Hz, 1H), 5.03-4.95 (m,
1H), 4.37 (bs, 1H), 4.14 (d, J=4.6 Hz, 2H), 3.89-3.85 (m, 2H), 3.68
(s, 2H), 3.15 (s, 3H), 2.86 (s, 1H), 2.35-2.22 (m, 2H), 1.28 (bs,
1H) ppm. LC/MS: R.sub.t=1.16 min, ES.sup.+ 424 (AA standard).
Example 18
((1R,2R,3S,4R)-4-{[2-(Benzylamino)pyrimidin-4-yl]amino}-2,3-dihydroxycyclo-
pentyl)methyl sulfamate (Compound I-7)
[0471] The title compound was prepared following the procedure
described in Example 1a-e using 2,4-dichloropyrimidine in step a
and benzylamine in step c. .sup.1H NMR (CD.sub.3OD, 400 MHz)
.delta.: 7.58 (d, J=5.4 Hz, 1H), 7.36-7.26 (m, 4H), 7.24-7.18 (m,
1H), 5.90 (d, J=6.3 Hz, 1H), 4.63-4.47 (m, 2H), 4.26 (bs, 1H),
4.18-4.07 (m, 2H), 3.86 (dd, J=5.3, 5.3 Hz, 1H), 3.80 (dd, J=5.9,
6.3 Hz, 1H), 2.34-2.19 (m, 2H), 1.31-1.14 (m, 1H) ppm. LC/MS:
R.sub.t=1.07 min, ES.sup.+ 410. (AA standard).
Example 19
[(1R,2R,3S,4R)-4-({6-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]-2-methylpyrimid-
in-4-yl}amino)-2,3-dihydroxycyclopentyl]methyl sulfamate and
{(1R,2R,3S,4R)-4-[(6-amino-2-methylpyrimidin-4-yl)amino]-2,3-dihydroxycyc-
lopentyl}methyl sulfamate (Compounds I-18 and I-13)
[0472] The title compounds were prepared following the procedure
described in Example 1a-e using 4,6-dichloro-2-methylpyrimidine in
step a and (S)-(+)-1-aminoindan in step c. Analytical data for
[(1R,2R,3S,4R)-4-({6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-2-methylpyrimi-
din-4-yl}amino)-2,3-dihydroxycyclopentyl]methyl sulfamate (Compound
I-18): .sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.: 7.31-7.14 (m,
4H), 5.54 (s, 1H), 5.29 (bs, 1H), 4.22-4.11 (m, 2H), 3.92 (bs, 1H),
3.90 (dd, J=5.2, 5.2 Hz, 1H), 3.78 (dd, J=5.7, 5.7 Hz, 1H),
3.06-2.96 (m, 1H), 2.93-2.82 (m, 1H), 2.63-2.52 (m, 1H), 2.40-2.31
(m, 2H), 2.29 (s, 3H), 1.98-1.85 (m, 2H), 1.43-1.24 (m, 2H) ppm.
LC/MS: R.sub.t=1.29 min, ES.sup.+ 450. (AA standard). Analytical
data for
{(1R,2R,3S,4R)-4-[(6-amino-2-methylpyrimidin-4-yl)amino]-2,3-dihydroxycyc-
lopentyl}-methyl sulfamate (Compound I-13): .sup.1H NMR
(CD.sub.3OD, 400 MHz) .delta.: 7.45 (s, 1H), 5.49 (s, 1H),
4.25-4.11 (m, 2H), 3.95 (bs, 1H), 3.92 (dd, J=5.3, 5.8 Hz, 1H),
3.78 (dd, J=5.8, 5.8 Hz, 1H), 2.69 (s, 1H), 2.44-2.31 (m, 1H), 2.27
(s, 3H), 1.45-1.24 (m, 1H) ppm. LC/MS: R.sub.t=0.76 min, ES.sup.+
334 (AA standard).
Example 20
((1R,2R,3S,4R)-4-{[6-(Benzylamino)-2-methylpyrimidin-4-yl]amino}-2,3-dihyd-
roxycyclopentyl)methyl sulfamate (Compound I-30)
[0473] The title compound was prepared following the procedure
described in Example 1a-e using 2,4-dichloropyrimidine in step a
and benzylamine in step c. .sup.1H NMR (CD.sub.3OD, 300 MHz)
.delta.: 7.41-7.31 (m, 4H), 7.31-7.22 (m, 1H), 5.55 (s, 1H), 4.52
(s, 2H), 4.21-4.09 (m, 2H), 3.87 (dd, J=4.9, 4.9 Hz, 1H), 3.79 (dd,
J=5.9, 6.8 Hz, 1H), 2.42 (s, 3H), 2.37-2.21 (m, 2H), 1.41-1.21 (m,
2H) ppm. LC/MS: R.sub.t=1.16 min, ES.sup.+ 424 (AA standard).
Example 21
[(1R,2S,4R)-4-({6-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}amin-
o)-2-hydroxycyclopentyl]methyl sulfamate (Compound I-25)
Step a
(1S,2R,4R)-4-[(6-Chloropyrimidin-4-yl)amino]-2-(hydroxymethyl)cyclopentano-
l
[0474] To a neat mixture of
(1S,2R,4R)-4-amino-2-(hydroxymethyl)cyclopentanol (3.00 g, 22.9
mmol) and 4,6-dichloropyrimidine (3.70 g, 24.8 mmol) was added
isopropyl alcohol (30.0 mL) and Et.sub.3N (8.00 mL, 57.4 mmol) and
the resulting mixture was heated to 90.degree. C. for 1 h. The
mixture was then cooled to 23.degree. C., filtered and concentrated
in vacuo. The residue was purified via silica gel chromatography
eluting with a gradient of 5 to 7% MeOH in DCM, and the compound
was recrystallized from EtOAc to afford the title compound as a
white solid (3.30 g, 59%). LC/MS: R.sub.t=0.84 min, ES.sup.+ 244
(AA standard).
Step b
(1S,2R,4R)-4-({6-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}amino-
)-2-(hydroxymethyl)cyclopentanol
[0475] A mixture of
(1S,2R,4R)-4-[(6-chloropyrimidin-4-yl)amino]-2-(hydroxymethyl)cyclopentan-
ol (500. mg, 2.05 mmol), 1-butanol (4.00 mL) and
(S)-(+)-1-aminoindan (0.806 mL, 6.16 mmol) was heated to
200.degree. C. for 90 min in a sealed tube using MWI. The mixture
was concentrated in vacuo and purified via silica gel
chromatography eluting with a gradient of 5 to 25% MeOH in DCM to
afford the title compound as an amorphous solid (513 mg, 73%).
LC/MS: R.sub.t=1.20 min, ES.sup.+ 341 (AA standard).
Step c
tert-Butyl (chlorosulfonyl)carbamate
[0476] To a stirred solution of chlorosulfonyl isocyanate (3.20 mL,
36.0 mmol) in benzene (15.0 mL) in a water bath at 23.degree. C.
was added tert-butyl alcohol (3.50 mL, 36.2 mmol) dropwise via
syringe under an atmosphere of nitrogen. After 2 h, the mixture was
diluted with hexanes (30.0 mL) and the resulting white precipitate
was filtered and washed with hexanes (3.times.20 mL). The collected
solid was dried in a vacuum desiccator under house vacuum for 10
min to afford the title compound as a white solid (5.08 g, 65%).
The product was stored under nitrogen in a freezer. .sup.1H NMR
(300 MHz, CDCl.sub.3, .delta.): 8.44 (bs, 1H), 1.57 (s, 9H) ppm.
LC/MS: R.sub.t=0.939 min, ES.sup.+ 215 (AA standard). Reference: F.
Hirayama et al., Biorg. Med. Chem., 2002, 10, 1509-1523.
Step d
tert-Butyl
({[(1R,2S,4R)-4({6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]pyrimid-
in-4-yl}amino)-2-hydroxycyclopentyl]methoxy}sulfonyl)carbamate
[0477] A neat mixture of
(1S,2R,4R)-4-({6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}amin-
o)-2-(hydroxymethyl)cyclopentanol (100. mg, 0.294 mmol) and
2,6-di-tert-butyl-4-methylpyridine (181 mg, 0.881 mmol) was
dissolved in ACN (5.00 mL) before tert-butyl
(chlorosulfonyl)carbamate (95.0 mg, 0.441 mmol, as prepared in
Example 21c) was added. The reaction was stirred for 2 h before
being quenched via addition of MeOH (2 mL). The resulting mixture
was concentrated in vacuo and purified via silica gel
chromatography eluting with a gradient of 10 to 20% MeOH in DCM to
afford the title compound as an amorphous solid (50.0 mg, 33%).
LC/MS: R.sub.t=1.24 min, ES.sup.+ 520. (AA standard).
Step e
[(1R,2S,4R)-4-({6-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}amin-
o)-2-hydroxycyclopentyl]methyl sulfamate (Compound I-25)
[0478] To a solution of tert-butyl
({[(1R,2S,4R)-4-({6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}a-
mino)-2-hydroxycyclopentyl]methoxy}sulfonyl)carbamate (50.0 mg,
0.0962 mmol) in DCM (2.00 mL) was added trifluoroacetic acid (0.500
mL, 6.49 mmol), and the mixture was stirred for 30 min. The mixture
was concentrated in vacuo and the residue was purified via silica
gel chromatography eluting with 10% MeOH in DCM, and the product
was dissolved in MeOH and treated with solid NaHCO.sub.3. The
suspension was filtered and the filtrate was purified via silica
gel chromatography eluting with 10% MeOH/DCM to afford the title
compound as an amorphous solid (12.0 mg, 30%). .sup.1H NMR
(CD.sub.3OD, 400 MHz) .delta.: 7.94 (s, 1H), 7.29-7.12 (m, 4H),
5.53 (s, 1H), 5.32 (bs, 1H), 4.23-4.08 (m, 4H), 3.06-2.96 (m, 1H),
2.93-2.82 (m, 1H), 2.61-2.50 (m, 1H), 2.45-2.34 (m, 1H), 2.26-2.15
(m, 1H), 2.08-1.98 (m, 1H), 1.95-1.78 (m, 2H), 1.37-1.25 (m, 2H)
ppm. LC/MS: R.sub.t=1.29 min, ES.sup.+ 420. (AA standard).
Example 22
{(1R,2R,3S,4R)-2,3-Dihydroxy-4-[8-phenyl-9H
purin-6-yl)amino]cyclopentyl}-methyl sulfamate (Compound I-9)
[0479] The title compound was prepared following the procedure
described in Example 1a-b, then 1d-e using
6-chloro-8-phenyl-9H-purine in step a. .sup.1H NMR (DMSO-d6, 400
MHz) .delta.: 13.4 (s, 1H), 8.28-8.10 (m, 4H), 7.76-7.64 (m, 1H),
7.58-7.40 (m, 7H), 4.89-4.75 (m, 1H), 4.70-4.59 (m, 1H), 4.59-4.50
(m, 1H), 4.15-4.07 (m, 2H), 4.06-3.99 (m, 1H), 3.91 (bs, 1H),
3.80-3.74 (m, 2H), 3.17 (d, J=5.2 Hz, 1H), 2.34-2.15 (m, 3H),
1.37-1.21 (m, 2H) ppm. LC/MS: R.sub.t=1.14 min, ES.sup.+ 421 (AA
standard).
Example 23
[(1R,2R,3S,4R)-2,3-Dihydroxy-4-(9H-purin-6-ylamino)cyclopentyl]methyl
sulfamate (Compound I-3)
Step a
[(3aR,4R,6R,6aS)-6-Amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]diox-
ol-4-yl]methanol
[0480] The title compound was prepared following the procedure
described in Example 1b using
(1R,2S,3R,5R)-3-amino-5-(hydroxymethyl)cyclopentane-1,2-diol
hydrochloride. .sup.1H NMR (CDCl.sub.3, 300 MHz) .delta.: 4.76 (d,
J=5.5 Hz, 1H), 4.20 (d, J=4.8 Hz, 1H), 3.70 (dd, J=3.9, 11.3 Hz,
1H), 356-3.47 (m, 2H), 3.05 (bs, 2H), 2.53-2.35 (m, 2H), 1.41 (s,
3H), 1.33-1.21 (m, 5H) ppm.
Step b
[(3aR,4R,6R,6aS)-2,2-Dimethyl-6-(9H-purin-6-ylamino)tetrahydro-3aH-cyclope-
nta[d][1,3]dioxol-4-yl]methanol
[0481] The title compound was prepared following the procedure
described in Example 1a using
[(3aR,4R,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dio-
xol-4-yl]methanol. LC/MS: R.sub.t=1.39 min, ES.sup.+ 306 (AA
standard).
Step c
[(1R,2R,3S,4R)-2,3-Dihydroxy-4-(9H-purin-6-ylamino)cyclopentyl]methyl
sulfamate (Compound I-3)
[0482] A suspension of
[(3aR,4R,6R,6aS)-2,2-dimethyl-6-(9H-purin-6-ylamino)tetrahydro-3aH-cyclop-
enta[d][1,3]dioxol-4-yl]methanol (288 mg, 0.943 mmol) and Et.sub.3N
(0.400 mL, 2.87 mmol) in DCM (5.00 mL) was cooled to 0.degree. C. A
2.00 M solution of chlorosulfonamide in ACN (0.94 mL, 1.88 mmol, as
prepared in Example 1d) was added dropwise, and DMF (1.50 mL) was
added to bring the mixture into solution. The solution was allowed
to warm to 23.degree. C. and was stirred for 5 h before being
concentrated in vacuo to dryness. The crude mixture was treated
with a 1.00 M solution of HCl in H.sub.2O (5.00 mL, 5.00 mmol) and
stirred for 10 min. The mixture was concentrated to dryness and
purified via reverse phase C18 preparative HPLC eluting with a
gradient of 0 to 40% of 0.1% FA/95% ACN/5% H.sub.2O in 0.1% FA/99%
H.sub.2O/1% ACN over 16 min to afford the title compound (95.0 mg,
29%). .sup.1H NMR (DMSO-d6, 400 MHz) .delta.: 12.9 (bs, 1H),
8.25-8.01 (m, 2H), 7.68-7.29 (m, 3H), 5.12-4.30 (m, 3H), 4.10 (dd,
J=5.8, 9.6 Hz, 1H), 4.01 (dd, f=7.0, 9.6 Hz, 1H), 3.85 (dd, J=5.6,
5.6, 1H), 3.75 (dd, J=5.2, 5.2 Hz, 1H), 2.35-2.13 (m, 2H),
1.33-1.19 (m, 1H) ppm. LC/MS: R.sub.t=1.02 min, ES.sup.+ 345 (AA
standard).
Example 24
[(1S,2S,4R)-4-({6-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}amin-
o)-2-hydroxycyclopentyl]methyl sulfamate (Compound I-5)
Step a
(1R,2R,3S,5S)-3-(Hydroxymethyl)-6-oxabicyclo[3.1.0]hexan-2-ol
[0483] (1S,5S)-5-(Hydroxymethyl)cyclopent-2-en-1-ol (3.19 g, 27.9
mmol) was dissolved in DCM (143 mL) and the solution was cooled to
0.degree. C. 3-Chloroperbenzoic acid (7.52 g, 33.5 mmol) was added
and the mixture was stirred at 23.degree. C. for 4 h. TLC indicated
complete conversion. Silica gel (20 g) was added, the mixture was
concentrated to dryness and was purified via silica gel
chromatography eluting with a gradient of 0 to 100% EtOAc in DCM to
afford the title compound (2.75 g, 76%). .sup.1H NMR (CDCl.sub.3,
300 MHz) .delta.: 4.58 (d, J=8.1 Hz, 1H), 3.69 (s, 1H), 3.68 (s,
1H), 3.60 (s, 1H), 3.52 (s, 1H), 2.47-2.40 (m, 1H), 2.14 (ddd,
J=1.5, 10.2, 15.3 Hz, 1H), 2.01 (dd, J=1.5, 15.3 Hz, 1H), 1.62 (bs,
2H) ppm. LC/MS: R.sub.t=0.37 min, ES.sup.+ 131 (AA standard).
Step b
(1aS,1bR,5aS,6aS)-3-(4-Methoxyphenyl)hexahydrooxireno[4,5]cyclopental[1,2--
d][1,3]dioxine
[0484] (1R,2R,3S,5S)-3-(Hydroxymethyl)-6-oxabicyco[3.1.0]hexan-2-ol
(3.65 g, 21.0 mol) was dissolved in DCM (121 mL) and the solution
was cooled to 0.degree. C. 1-(Dimethoxymethyl)-4-methoxybenzene
(10.7 mL, 63.1 mmol) was added followed by pyridinium
p-toluenesulfonate (530. mg, 2.11 mmol). The mixture was stirred at
23.degree. C. overnight. TLC indicated complete conversion. The
reaction mixture was concentrated in vacuo and the residue was
purified via silica gel chromatography eluting with a gradient of 0
to 50% EtOAc in hexanes to afford the title compound (4.10 g, 78%).
.sup.1H NMR (CDCl.sub.3, 400 MHz) .delta. 7.44 (d, J=8.8 Hz, 2H),
6.89 (d, J=8.8 Hz, 2H), 5.93 (1H, s), 4.58 (d, J=8.4 Hz, 1H), 4.05
(s, 1H), 4.03 (s, 1H), 3.80 (s, 3H), 3.71 (d, J=2.4 Hz, 1H), 3.51
(d, J=2.4 Hz, 1H), 2.50-2.48 (m, 1H), 1.87 (ddd, J=1.6, 8.0, 14.8
Hz, 1H), 1.77 (d, J=14.8 Hz, 1H) ppm. LC/MS: R.sub.t=1.68 min,
ES.sup.+ 249 (AA standard).
Step c
2-[(4aS,6R,7S,7aR)-7-Hydroxy-2-(4-methoxyphenyl)-hexahydrocyclopenta[d][1,-
3]dioxin-6-yl]-1H-isoindole-1,3(2H)-dione
[0485] To a neat mixture of
(1aS,1bR,5aS,6aS)-3-(4-methoxyphenyl)-hexahydrooxireno[4,5]cyclopenta[1,2-
-d][1,3]dioxine (600. mg, 2.42 mmol), phthalimide (1.07 g, 7.25
mmol) and phthalimide potassium salt (1.34 g, 7.25 mmol) was added
DMSO (15.0 mL) and the mixture was stirred at 120.degree. C. for 18
h. The mixture was concentrated in vacuo, treated with H.sub.2O and
extracted with EtOAc. The organic layer was dried over MgSO.sub.4,
filtered and concentrated in vacuo. The residue was purified via
silica gel chromatography eluting with a gradient of 0 to 15% EtOAc
in DCM to afford the title compound as a white solid (602 mg, 63%).
LC/MS: R.sub.t=1.68 min, ES.sup.+ 396 (AA standard).
Step d
O-[(4aS,6R,7S,7aR)-6-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)-2-(4-methoxy-
phenyl)hexahydrocyclopenta[d][1,3]dioxin-7-yl]O-phenyl
thiocarbonate
[0486] To a stirred solution of
2-[(4aS,6R,7S,7aR)-7-hydroxy-2-(4-methoxyphenyl)-hexahydrocyclopenta[d][1-
,3]dioxin-6-yl]-1H-isoindole-1,3(2H)-dione (1.26 g, 3.19 mmol) in
DCM (150. mL) was added DMAP (1.17 g, 9.54 mmol) and phenyl
chlorothionoformate (0.661 mL, 4.78 mmol) under an atmosphere of
argon. After 2 h, the mixture was concentrated in vacuo and the
residue was purified via silica gel chromatography eluting with a
gradient of 0 to 5% EtOAc in DCM to afford the title compound as a
white amorphous solid (1.64 g, 97%). LC/MS: R.sub.t=2.21 min,
ES.sup.+ 532 (AA standard).
Step e
2-[(4aS,6R,7aS-2-(4-Methoxyphenyl)hexahydrocyclopenta[d][1,3]dioxin-6-yl]--
1H-isoindole-1,3(2H)-dione
[0487] To a solution of
O-[(4aS,6R,7S,7aR)-6-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-2-(4-methox-
yphenyl)hexahydrocyclopenta[d][1,3]dioxin-7-yl]O-phenyl
thiocarbonate (56.9 mg, 0.107 mmol) in toluene (4.00 mL) was added
tris(trimethylsilyl)silane (0.0700 mL, 0.227 mmol). Air (2.00 mL)
was bubbled through the solution and a 1.00 M solution of
triethylborane in hexane (0.0320 mL, 0.0320 mmol) was added and the
reaction was stirred for 2 h. More tris(trimethylsilyl)silane
(0.0700 mL, 0.227 mmol) and 1.00 M triethylborane in hexane (0.0300
mL, 0.0300 mmol) were added, and the mixture was stirred another 6
h. The mixture was then concentrated in vacuo and the residue was
purified via silica gel chromatography eluting with a gradient of 0
to 20% EtOAc in DCM to afford the title compound (16.9 mg, 42%).
LC/MS: R.sub.t=2.03 min, ES.sup.+ 380. (AA standard).
Step f
(4aS,6R,7aS)-2-(4-Methoxyphenyl)hexahydrocyclopenta[d][1,3]dioxin-6-amine
[0488] A mixture of
2-[(4aS,6R,7aS)-2-(4-methoxyphenyl)-hexahydrocyclopenta[d][1,3]dioxin-6-y-
l]-1H-isoindole-1,3(2H)-dione (390. mg, 1.03 mmol), EtOH (11.3 mL)
and hydrazine (0.0362 mL, 1.13 mmol) was stirred at 90.degree. C.
for 18 h. The resulting mixture was purified via silica gel
chromatography eluting with a gradient of 10 to 50% MeOH in DCM.
LC/MS: R.sub.t=1.08 min, ES.sup.+ 250. (AA standard).
Step g
6-Chloro-N-[(4aS,6R,7aS)-2-(4-methoxyphenyl)-hexahydrocyclopenta[d][1,3]di-
oxin-6-yl]pyrimidin-4-amine
[0489] A sealed tube containing
(4aS,6R,7aS)-2-(4-methoxyphenyl)-hexahydrocyclopenta[d][1,3]dioxin-6-amin-
e (120. mg, 0.481 mmol), 4,6-dichloropyrimidine (143 mg, 0.963
mmol), DIPEA (0.0920 mL, 0.528 mmol) and EtOH (30.0 mL) was heated
to 110.degree. C. for 20 h. The cooled mixture was concentrated in
vacuo and the residue was purified via silica gel chromatography
eluting with a gradient of 0 to 5% MeOH in DCM (120. mg, 69%).
LC/MS: R.sub.t=1.74 min, ES.sup.+ 362 (AA standard).
Step h
(1S,2S,4R)-4-[(6-Chloropyrimidin-4-yl)amino]-2-hydroxymethyl)cyclopentanol
[0490] A neat mixture of
6-chloro-N-[(4aS,6R,7aS)-2-(4-methoxyphenyl)-hexahydrocyclopenta[d][1,3]d-
ioxin-6-yl]pyrimidin-4-amine (120. mg, 0.332 mmol) and
(S)-(+)-1-aminoindan (0.170 mL, 1.33 mmol) was heated to
180.degree. C. for 6 h in a sealed tube using MWI. The reaction was
purified via silica gel chromatography eluting with a gradient of 0
to 15% MeOH in DCM to afford the title compound (33.1 mg, 41%).
LC/MS: R.sub.t=0.90 min, ES.sup.+ 244 (AA standard).
Step i
(1S,2S,4R)-4-({6-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}amino-
)-2-(hydroxymethyl)cyclopentanol
[0491] A mixture of
(1S,2S,4R)-4-[(6-chloropyrimidin-4-yl)amino]-2-(hydroxymethyl)cyclopentan-
ol (33.1 mg, 0.136 mmol),
6-chloro-N-[(4aS,6R,7aS)-2-(4-methoxyphenyl)hexahydrocyclopenta[d][1,3]di-
oxin-6-yl]pyrimidin-4-amine (81.6 mg, 0.226 mmol),
(S)-(+)-1-aminoindan (0.222 mL, 1.73 mmol) and 1-butanol (1.00 mL)
was heated to 180.degree. C. for 6 h in a sealed tube using MWI.
The reaction was purified via silica gel chromatography eluting
with a gradient of 0 to 15% MeOH in DCM to afford the title
compound (77.8 mg, 63%). LC/MS: R.sub.t=1.29 min, ES.sup.+ 341 (AA
standard).
Step j
[(1S,2S,4R)-4-({6-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}amin-
o)-2-hydroxycyclopentyl]methyl sulfamate (Compound I-5)
[0492] The title compound was prepared following the procedure
described in Example 21d-e using
(1S,2S,4R)-4-({6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}-ami-
no)-2-(hydroxymethyl)cyclopentanol and THF in step d. .sup.1H NMR
(CD.sub.3OD, 400 MHz) .delta.: 7.94 (s, 1H), 7.38-7.12 (m, 5H),
5.51 (s, 1H), 5.32 (bs, 1H), 4.37-4.32 (m, 1H), 4.29 (dd, J=7.7,
9.7 Hz, 1H), 4.27-4.18 (m, 1H), 4.12 (dd, J=7.3, 9.7 Hz, 1H),
3.05-2.96 (m, 1H), 2.93-2.82 (m, 1H), 2.60-2.51 (m, 1H), 2.51-2.42
(m, 1H), 2.21 (ddd, J=1.8, 7.6, 13.9 Hz, 1H), 2.04-1.85 (m, 2H),
1.81 (ddd, J=4.9, 7.1, 13.8 Hz, 1H), 1.74-1.64 (m, 1H), 1.44 (s,
1H) ppm. LC/MS: R.sub.t=1.38 min, ES.sup.+ 420. (AA standard).
Example 25
[(1S,2S,3S,4R)-4-({6-[1S)-2,3-Dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}-a-
mino)-2,3-dihydroxycyclopentyl]methyl sulfamate (Compound I-11)
[0493] The title compound was prepared following the procedure
described in Example 24 steps a-c, followed by steps f-g, and
finally steps i-j. .sup.1H NMR (CD.sub.3OD, 300 MHz) .delta.: 7.94
(s, 1H), 7.30-7.11 (m, 4H), 5.60 (s, 1H), 5.30 (bs, 1H), 4.32 (dd,
J=7.9, 9.4 Hz, 1H), 4.14-3.96 (m, 3H), 3.89 (dd, J=3.8, 7.7 Hz,
1H), 3.08-2.95 (m, 1H), 2.87 (ddd, J=8.0, 8.0, 15.8 Hz, 1H),
2.62-2.44 (m, 2H), 2.15-2.01 (m, 1H), 1.96-1.81 (m, 1H), 1.70-1.57
(m, 1H) ppm. LC/MS: R.sub.t=1.32 min, ES.sup.+ 436 (AA
standard).
Example 26
[(1R,2R,3S,4R)-4-({4-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]-1,3,5-triazin-2-
-yl}-amino)-2,3-dihydroxycyclopentyl]methyl sulfamate (Compound
I-26)
Step a
4,6-Dichloro-N-[(1S)-2,3-dihydro-1H-inden-1-yl]-1,3,5-triazin-2-amine
[0494] To a solution of cyanuric chloride (631 mg, 3.42 mmol) in
THF (2.00 mL) at 0.degree. C. was added (S)-(+)-1-aminoindan (0.385
mL, 3.00 mmol) and DIPEA (0.596 mL, 3.42 mmol) and the mixture was
stirred at 0.degree. C. for 2 h. The reaction was then poured into
H.sub.2O extracted with DCM and the organic layer was dried over
MgSO.sub.4, filtered and concentrated in vacuo. The residue was
purified via silica gel chromatography eluting with a gradient of 0
to 20% EtOAc in hexanes to afford the title compound as a yellow
solid (738 mg, 87%). LC/MS: R.sub.t=1.99 min, ES.sup.+ 281 (FA
standard).
Step b
(1R,2S,3R,5R)-3-({4-Chloro-6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-1,3,5-t-
riazin-2-yl}amino)-5-(hydroxymethyl)cyclopentane-1,2-diol
[0495] A mixture of
4,6-dichloro-N-[(1S)-2,3-dihydro-1H-inden-1-yl]-1,3,5-triazin-2-amine
(735 mg, 2.61 mmol),
(1R,2S,3R,5R)-3-amino-5-(hydroxymethyl)cyclopentane-1,2-diol
hydrochloride (400. mg, 218 mmol), potassium carbonate (602 mg,
4.36 mmol) and 1,4-dioxane (3.60 mL) in a sealed tube was heated to
150.degree. C. for 20 mins using MWI. Silica gel chromatography
eluting with a gradient of 2 to 7% MeOH in DCM afforded the title
compound as a white solid (750. mg, 88%). LC/MS: R.sub.t=1.42 min,
ES.sup.+ 392 (FA standard).
Step c
[(3aR,4R,6R,6aS)-6-({4-Chloro-6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-1,3,-
5-triazin-2-yl}amino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol--
4-yl]-methanol
[0496] The title compound was prepared following the procedure
described in Example 1b using
(1R,2S,3R,5R)-3-({4-chloro-6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-1,3,5--
triazin-2-yl}amino)-5-(hydroxymethyl)cyclopentane-1,2-diol. LC/MS:
R.sub.t=1.81 min, ES.sup.+ 432 (FA standard).
Step d
[(3aR,4R,6R,6aS)-6-({4-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]-1,3,5-triazin-
-2-yl}-amino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]met-
hanol
[0497] To a solution of
[(3aR,4R,6R,6aS)-6-({4-Chloro-6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-1,3-
,5-triazin-2-yl}amino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-
-4-yl]methanol (182 mg, 0.421 mmol) in EtOH (2.91 mL) was added 10%
palladium on carbon (44.8 mg) and the mixture was placed under an
atmosphere of hydrogen for 2 d. Filtration of the mixture through a
pad of celite, followed by silica gel chromatography eluting with
5% MeOH in DCM afforded the title compound as a white solid (80.0
mg, 48%). LC/MS: R.sub.t=1.24 min, ES.sup.+ 398 (FA standard).
Step e
[(1R,2R,3S,4R)-4-({4-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]-1,3,5-triazin-2-
-yl}-amino)-2,3-dihydroxycyclopentyl]methyl sulfamate
[0498] The title compound was prepared following the procedure
described in Example 1d using
[(3aR,4R,6R,6aS)-6-({4-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]-1,3,5-triazi-
n-2-yl}amino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]met-
hanol and pyridine. .sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.:
8.16-7.83 (m, 1H), 737-7.11 (m, 3H), 5.68-5.45 (m, 1H), 4.39-4.00
(m, 3H), 3.91-3.77 (m, 1H), 3.06-2.92 (m, 1H), 2.92-2.75 (m, 1H),
2.61-2.48 (m, 1H), 2.40-2.20 (m, 2H), 2.02-1.79 (m, 2H), 1.37-1.17
(m, 1H) ppm. LC/MS: R.sub.t=1.07 min, ES.sup.+ 437 (FA
standard).
Example 27
[(1R,2R,3S,4R)-2,3-Dihydroxy-4-(isonicotinoylamino)cyclopentyl]methyl
sulfamate (Compound I-28)
Step a
tert-Butyl
(1R,4S,5R,6S)-5,6-dihydroxy-3-oxo-2-azabicyclo[2.2.1]heptane-2--
carboxylate
[0499] To a solution of tert-butyl
(1R,4S)-3-oxo-2-azabicyclo[2.2.1]hept-5-ene-2-carboxylate (500. mg,
2.39 mmol) in acetone (20.0 mL) was added a 4% aqueous solution of
osmium tetroxide in H.sub.2O (0.015 mL, 0.00239 mmol). To the
resulting mixture was added a 10.2 M aqueous solution of
N-methylmorpholine N-oxide (0.262 mL, 2.67 mmol) dropwise over 1 h.
At this point, a 0.240 M solution of aqueous sodium bisulfite (1.00
mL, 0.240 mmol) was added, the mixture was filtered through celite
and concentrated in vacuo. The residue was purified via silica gel
chromatography eluting with a gradient of 20 to 70% EtOAc in DCM to
afford the title compound (420. mg, 72%). LC/MS: R.sub.t=0.94 min,
ES.sup.+ 244 (FA standard).
Step b
tert-Butyl
(1R,4S,5R,6S)-5,6-bis(benzoyloxy)-3-oxo-2-azabicyclo[2.2.1]hept-
ane-2-carboxylate
[0500] A solution of tert-butyl
(1R,4S,5R,6S)-5,6-dihydroxy-3-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylat-
e (2.00 g, 8.22 mmol), pyridine (5.00 mL, 61.8 mmol), Et.sub.3N
(2.29 mL, 16.4 mmol) and DMAP (100. mg, 0.818 mmol) in DCM (5.00
mL) was cooled to 0.degree. C. and benzoyl chloride (4.77 mL, 41.1
mmol) was added dropwise. The mixture was allowed to warm to
23.degree. C. and stir for 2 h. The reaction was then diluted with
DCM, washed with saturated aqueous NaHCO.sub.3 (3.times.), copper
(II) sulfate solution (3.times.) and water (3.times.). The organic
layer was then dried over sodium sulfate, filtered and concentrated
in vacuo. The residue was purified via silica gel chromatography
eluting with a gradient of 5 to 40% EtOAc in hexanes to afford the
title compound (2.92 g, 79%). LC/MS: R.sub.t=2.15 min, ES.sup.+ 452
(FA standard).
Step c
(1R,2S,3R,5R)-3-[(tert-Butoxycarbonyl)amino]5-(hydroxymethyl)cyclopentane--
1,2-diyl dibenzoate
[0501] To a solution of tert-butyl
(1R,4S,5R,6S)-5,6-bis(benzoyloxy)-3-oxo-2-azabicyclo[2.2.1]heptane-2-carb-
oxylate (2.09 g, 4.62 mmol) in MeOH (60.0 mL) was added sodium
borohydride (700. mg, 18.5 mmol) at 0.degree. C. and the reaction
was allowed to warm to rt. After 1.5 h, the mixture was quenched
with 1.00N HCl solution (20.0 mL), and concentrated in vacuo. The
aqueous layer was extracted with DCM (3.times.50 mL) and the
combined organic layers were washed with H.sub.2O (100. mL), dried
over MgSO.sub.4 and concentrated in vacuo. The residue was purified
via silica gel chromatography eluting with a gradient of 20 to 60%
EtOAc in hexanes to afford the title compound (1.50 g, 80%). LC/MS:
R.sub.t=1.95 min, ES.sup.+ 456 (FA standard).
Step d
(1R,2S,3R,5R)-3-Amino-5-hydroxymethyl)cyclopentane-1,2-diyl
dibenzoate hydrochloride
[0502]
(1R,2S,3R,5R)-3-[(tert-Butoxycarbonyl)amino]-5-(hydroxymethyl)-cycl-
opentane-1,2-diyl dibenzoate (1.42 g, 3.11 mmol) was treated with a
4.00 M solution of HCl in 1,4-dioxane (17.0 mL, 69.3 mmol) and the
reaction was stirred for 35 min. The reaction mixture was
concentrated in vacuo and Et.sub.2O was added to precipitate the
product, which was washed with Et.sub.2O to afford the title
compound as a white solid (1.05 g, 90%). LC/MS: R.sub.t=1.06 min,
ES.sup.+ 356 (FA standard).
Step e
(1S,2R,3R,5R)-3-(Hydroxymethyl)-5(isonicotinoylamino)cyclopentane-1,2-diyl
dibenzoate
[0503] A solution of
(1R,2S,3R,5R)-3-amino-5-(hydroxymethyl)cyclopentane-1,2-diyl
dibenzoate hydrochloride (150. mg, 0.380 mmol) in DCM (10.0 mL) at
0.degree. C. was treated with Et.sub.3N (0.170 mL, 1.22 mmol) and
stirred for 20 min. Isonicotinoyl chloride (88.0 mg, 0.490 mmol)
was then added and the mixture was stirred for 2 h. The reaction
was treated with saturated aqueous solution of ammonium chloride
(50 mL) and extracted with DCM (2.times.50 mL). The combined
organic layers were dried over sodium sulfate, filtered and
concentrated in vacuo. The resulting residue was purified via
silica gel chromatography eluting with a gradient of 0 to 10% MeOH
in DCM to afford the title compound (100. mg, 60%). LC/MS:
R.sub.t=1.49 min, ES.sup.+ 461 (FA standard).
Step f
(1S,2R,3R,5R)-3-{[(Aminosulfonyl)oxy]methyl}-5-(isonicotinoylamino)cyclope-
ntane-1,2-diyl dibenzoate
[0504] To a solution of
(1S,2R,3R,5R)-3-(hydroxymethyl)-5-(isonicotinoylamino)cyclopentane-1,2-di-
yl dibenzoate (160. mg, 0.350 mmol) in ACN (10.0 mL) at 0.degree.
C. was added DBU (0.0600 mL, 0.401 mmol) and the mixture was
stirred for 15 min. A freshly prepared 1.40M solution of
chlorosulfonamide (0.500 mL, 0.700 mmol, as prepared in Example 1d)
was then added dropwise via syringe and the mixture was stirred for
2.5 h at 0.degree. C. before being allowed to warm to rt. The
mixture was concentrated in vacuo and the residue was purified via
silica gel chromatography eluting with a gradient of 0 to 10% MeOH
in DCM to afford the title compound (50.0 mg, 27%). LC/MS:
R.sub.t=1.57 min, ES.sup.+ 540. (FA standard).
Step g
[(1R,2R,3S,4R)-2,3-dihydroxy-4-(isonicotinoylamino)cyclopentyl]methyl
sulfamate (Compound I-28)
[0505] A solution of
(1S,2R,3R,5R)-3-{[(aminosulfonyl)oxy]methyl}-5-(isonicotinoylamino)cyclop-
entane-1,2-diyl dibenzoate (61.1 mg, 0.113 mmol) in a 7.00 M
solution of ammonia in MeOH (1.50 mL, 10.5 mmol) was stirred for 2
days. The reaction mixture was then concentrated in vacuo and
purified via reverse phase C18 preparative HPLC eluting with a
gradient of 5 to 70% of 0.1% FA/95% ACN/5% H.sub.2O in 0.1% FA/99%
H.sub.2O/1% ACN over 16 min to afford the title compound (15.0 mg,
40%). .sup.1H NMR (CD.sub.3OD, 300 MHz) .delta.: 8.67 (m, 2H), 7.78
(m, 2H), 4.34-4.32 (m, 1H), 4.19-4.17 (m, 2H), 3.93-3.92 (m, 2H),
2.38-2.31 (m, 1H), 1.76-1.72 (m, 1H), 1.43-1.38 (m, 1H) ppm. LC/MS:
R.sub.t=0.76 min, ES.sup.+ 332 (FA standard).
Example 28
{(1R,2R,3S,4R)-2,3-Dihydroxy-4-[(pyridin-2-ylcarbonyl)amino]cyclopentyl}-m-
ethyl sulfamate (Compound I-23)
[0506] The title compound was prepared following the procedure
described in Example 27a-e using pyridine-2-carbonyl chloride in
step c. .sup.1H NMR (CD.sub.3OD, 300 MHz) .delta.: 8.62 (s, 1H),
8.09-8.06 (m, 1H), 7.97-7.94 (m, 1H), 7.55-7.51 (m, 1H), 4.34-4.32
(m, 1H), 4.19-4.18 (m, 2H), 3.95-3.93 (m, 2H), 2.64 (s, 1H),
2.38-2.35 (m, 2H) ppm. LC/MS: R.sub.t=1.23 min, ES.sup.+ 332 (FA
standard).
Example 29
{(1R,2R,3S,4R)-2,3-Dihydroxy-4-[(pyridin-3-ylcarbonyl)amino]cyclopentyl}-m-
ethyl sulfamate (Compound I-16)
[0507] The title compound was prepared following the procedure
described in Example 27a-e using nicotinoyl chloride in step c.
.sup.1H NMR (CD.sub.3OD, 300 MHz) .delta.: 8.97 (s, 1H), 8.67-8.66
(m, 1H), 8.26-8.23 (m, 1H), 7.55-7.50 (m, 1H), 4.35-4.11 (m, 3H),
3.95-3.92 (m, 2H), 2.36-2.34 (m, 2H), 1.43-1.38 (m, 1H) ppm. LC/MS:
R.sub.t=0.83 min, ES.sup.+ 332 (FA standard).
[0508] The following additional compounds were also prepared.
Example 30
[(1S,2S,4R)-4-({6-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}oxy)-
-2-hydroxycyclopentyl]methyl sulfamate (Compound I-31)
[0509] The title compound was prepared in a manner similar to
Example 34 using (S)-2-aminoindane. The title compound was prepared
as a 4:1 mixture of desired compound and
(1S,2S,4R)-4-({6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}oxy)-
-2-(hydroxymethyl)cyclopentyl sulfamate. Analytical data for
[(1S,2S,4R)-4-({6-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}oxy-
)-2-hydroxycyclopentyl]methyl sulfamate: .sup.1H NMR (CD.sub.3OD,
300 MHz) .delta.: 8.13 (s, 1H), 7.28-7.12 (m, 4H), 5.85 (s, 1H),
5.33-5.31 (m, 1H), 4.42-4.36 (m, 1H), 4.32 (dd, J=7.5, 9.7 Hz, 1H),
4.15 (dd, J=7.2, 9.7 Hz, 1H), 3.06-2.97 (m, 1H), 2.93-2.82 (m, 1H),
2.62-2.47 (m, 2H), 2.32-2.24 (m, 1H), 2.15 (s, 1H), 2.13-1.79 (m,
4H) ppm. LC/MS: R.sub.t=1.38 min, ES.sup.+ 422 (FA standard).
Analytical data for
(1S,2S,4R)-4-({6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}oxy)-
-2-(hydroxymethyl)cyclopentyl sulfamate: .sup.1H NMR (CD.sub.3OD,
300 MHz) .delta.: 8.13 (s, 1H), 7.28-7.12 (m, 4H), 5.85 (s, 1H),
5.33-5.31 (m, 1H), 5.14-5.07 (m, 1H), 4.59 (s, 1H), 3.78 (dd,
J=7.1, 11.0 Hz, 1H), 3.61 (dd, J=7.0, 11.1 Hz, 1H), 3.06-2.97 (m,
1H), 2.73-2.61 (m, 1H), 2.61-2.47 (m, 2H), 2.32-2.24 (m, 1H), 2.17
(s, 1H), 2.13-1.80 (m, 3H) ppm. LC/MS: R.sub.t=1.38 min, ES.sup.+
422 (FA standard).
Example 31
[(1S,2S,4R)-4-({6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-5-methylpyrimidin--
4-yl}oxy)-2-hydroxycyclopentyl]methyl sulfamate (Compound I-32)
[0510] The title compound was prepared in a manner similar to
Example 34 using (S)-2-aminoindane and
4,6-dichloro-5-methylpyrimidine. .sup.1H NMR (CD.sub.3OD, 300 MHz)
.delta.: 8.10 (s, 1H), 7.26-7.07 (m, 4H), 5.74 (t, J=7.9 Hz, 1H),
5.59-5.49 (m, 1H), 4.45-4.37 (m, 1H), 4.34 (dd, J=7.5, 9.8 Hz, 1H),
4.16 (dd, J=7.2, 9.7 Hz, 1H), 3.08-2.94 (m, 1H), 2.93-2.79 (m, 1H),
2.65-2.46 (m, 2H), 2.37-2.23 (m, 1H), 2.18-2.13 (m, 3H), 2.13-1.90
(m, 2H), 1.89 (s, 3H) ppm. LC/MS: R.sub.t=1.55 min, ES.sup.+ 435
(FA standard).
Example 32
[(1S,2S,4S)-4-({6-[(1S)-2,3-dihydro-1H
inden-1-ylamino]pyrimidin-4-yl}methyl)-2-hydroxycyclopentyl]methyl
sulfamate (Compound I-33)
[0511] The title compound was prepared according to Example 85.
.sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.: 8.34 (s, 1H), 7.27-7.15
(m, 4H), 6.41 (bs, 1H), 5.65-5.48 (m, 1H), 4.30-4.25 (m, 2H), 4.09
(dd, J=4.1, 4.1 Hz, 1H), 3.07-3.00 (m, 1H), 2.94-2.85 (m, 1H),
2.72-2.55 (m, 4H), 2.43-2.35 (m, 1H), 1.93-1.85 (m, 2H), 1.75-1.67
(m, 1H), 1.58-1.51 (m, 2H) ppm. LC/MS: R.sub.t=1.38 min, ES.sup.+
419 (AA standard).
Example 33
((1S,3S)-3-{[8-(1-naphthyl)-9H-purin-6-yl]oxy}cyclopentyl)methyl
sulfamate (Compound I-152)
Step a
6-chloro-8-(1-naphthyl-9H-purine
[0512] A mixture of 6-chloro-4,5-diaminopyrimidine (519 mg, 0.00359
mol) and 1-naphthalenecarboxylic acid (618 mg, 0.00359 mol) in
phosphoryl chloride (2.0 mL, 0.021 mol) was heated at 110.degree.
C. under an atmosphere of nitrogen for 5.5 hours. The reaction was
cooled and the residue was washed several times with ether. The
residue was dissolved in CH.sub.2Cl.sub.2 and aqueous NaHCO.sub.3.
The layers were separated and the aqueous was extracted with EtOAc
(1.times.) and CH.sub.2Cl.sub.2 (1.times.). The combined organics
were washed with saturated aqueous NaHCO.sub.3, brine, dried
(Na.sub.2SO.sub.4), filtered, and collected in vacuo to obtain 810
mg (80%) of an orange solid. LC/MS: R.sub.t=1.68 min, ES.sup.+ 261
(FA standard).
Step b
6-chloro-8-(1-naphthyl-9-(tetrahydro-2H-pyran-2-yl)-9H-purine
[0513] To a solution of 6-chloro-8-(1-naphthyl)-9H-purine (810 mg,
0.0029 mol) in THF (32.4 mL, 0.399 mol) was added pyridinium
p-toluenesulfonate (70 mg, 0.0003 mol) and dihydropyran (11.0 mL,
0.121 mol) and the mixture was heated at 60.degree. C. overnight.
The reaction was cooled, quenched by addition of saturated aqueous
NaHCO.sub.3 and the mixture was extracted with EtOAc (3.times.).
The organic layers were combined, dried (Na.sub.2SO.sub.4),
filtered and concentrated. The dark residue was purified by flash
chromatography (10 to 40% EtOAc/hexanes) to obtain 534.5 (51%) mg
of a light yellow solid. LC/MS: R.sub.t=2.03 min, ES.sup.+ 365 (FA
standard).
Step c
(1S,3S)-3-(hydroxymethyl)cyclopentanol
[0514] To a solution of methyl
(1S,3S)-3-hydroxycyclopentanecarboxylate (472.3 mg, 0.003276 mol)
in THF (13.2 mL) at 0.degree. C. was added LiAlH.sub.4(145 mg,
0.00382 mol) (WARNING: SIGNIFICANT GAS EVOLUTION). The mixture was
stirred for 1 hour at 0.degree. C., then quenched at 0.degree. C.
by dropwise addition of water (145 .mu.L, 0.00805 mol), 15% aqueous
NaOH (145 .mu.L) and water (435 .mu.L). The resulting gray
suspension was stirred vigorously overnight. The resulting off
white suspension was filtered through celite and rinsed with THF
and MeOH. The combined organics were concentrated to obtain 454.3
mg (>99%) an off-yellow solid. The material was carried on
without further purification.
Step d
(1S,3S)-3-({[tert-butyl(dimethyl)silyl]oxy}methyl)cyclopentanol
[0515] To a solution of (1S,3S)-3-(hydroxymethyl)cyclopentanol
(453.0 mg, 0.003276 mol) and 1H-imidazole (669 mg, 0.00983 mol) in
DMF (35.8 mL) under an atmosphere of nitrogen was added
tert-butyldimethylsilyl chloride (494 mg, 0.00328 mol). The mixture
was stirred for 1.25 hours, then tert-butyldimethylsilyl chloride
(49 mg, 0.00033 mol) was added. After an additional hour of
stirring, the reaction was quenched with water, extracted with
ethyl acetate (3.times.), dried with anhydrous Na.sub.2SO.sub.4,
filtered, and concentrated. The residue was filtered through a plug
of silica with 30% EtOAc/hexanes to obtain 234.1 mg (31%) of the
title compound.
Step e
6-{[(1S,3S)-3-({[tert-butyl(dimethyl)silyl]oxy}methyl)cyclopentyl]oxy}-8-(-
1-naphthyl)-9-(tetrahydro-2H-pyran-2-yl)-9H-purine
[0516] To a solution of
(1S,3S)-3-({[tert-butyl(dimethyl)silyl]oxy}methyl)-cyclopentanol
(111.0 mg, 0.0004817 mol) (azeotroped with toluene) in DMF (3.6 mL)
at 0.degree. C. under an atmosphere of nitrogen was added sodium
hydride (24.1 mg, 0.000602 mol). The mixture was stirred for 15
min. To this cold solution was added a solution of
6-chloro-8-(1-naphthyl)-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (163
mg, 0.000401 mol) in DMF (1.8 mL). The flask was rinsed with DMF
(1.0 mL)) and this was added to the reaction as well. The resulting
mixture was stirred for 20 h. The reaction mixture was quenched
with water and the mixture was extracted with EtOAc (3.times.). The
combined organic layers were dried over Na.sub.2SO.sub.4, filtered
and collected in vacuo. The residue was purified by flash
chromatography (10 to 40% EtOAc/hexanes) to obtain 156.9 mg (70%)
of the title compound as a white solid.
Step f
((1S,3S)-3-{[8-(1-naphthyl)-9H-purin-6-yl]oxy}cyclopentyl)methanol
[0517] To a stirred solution of
6-{[(1S,3S)-3-({[tert-butyl(dimethyl)silyl]oxy}methyl)-cyclopentyl]oxy}-8-
-(1-naphthyl)-9-(tetrahydro-2H-pyran-2-yl)-9H-purine (156.9 mg,
0.0002808 mol) in THF (3.8 mL) was added water (3.8 mL) and AcOH
(7.6 mL), and the reaction mixture was stirred for 7 hours. The
reaction mixture was quenched by the slow addition of saturated
NaHCO.sub.3, and the resulting mixture was extracted with EtOAc
(3.times.). The combined organic layers were washed with brine,
dried (Na.sub.2SO.sub.4), filtered and concentrated. The residue
was purified by flash chromatography (0 to 5%
MeOH/CH.sub.2Cl.sub.2) to obtain 85.7 mg (85%) of the title
compound as a white solid. LC/MS: R.sub.t=1.51 min, ES.sup.+ 361
(FA standard).
Step g
((1S,3S)-3-{[8-(1-naphthyl)-9H-purin-6-yl]oxy}cyclopentyl)methyl
sulfamate (Compound I-152)
[0518] To a solution of
((1S,3S)-3-{[8-(1-naphthyl)-9H-purin-6-yl]oxy}cyclopentyl)-methanol
(66.1 mg, 0.000183 mol) in DMA (8.12 mL) at 0.degree. C. was added
chlorosulfonamide (106 mg, 0.000917 mol) in CH.sub.3CN (2.0 mL).
The reaction was stirred at 0.degree. C. for 10 mins, then
23.degree. C. for 3 hours. The reaction was quenched with water and
extracted with EtOAc (3.times.). The combined organics were washed
with water (2.times.), dried (Na.sub.2SO.sub.4), filtered, and
concentrated. The residue was purified by flash chromatography (0
to 6% MeOH/CH.sub.2Cl.sub.2) to obtain 56.3 mg (70%) of the title
compound as a white solid. .sup.1H NMR (CD.sub.3OD, 400 MHz)
.delta.: 8.52-8.48 (m, 2H), 8.10-8.07 (m, 1H), 8.01-7.98 (m, 1H),
7.90-7.87 (m, 1H), 7.65-7.57 (m, 3H), 5.89-5.85 (m, 1H), 4.12-4.07
(m, 2H), 2.75-2.66 (m, 1H), 2.30-2.21 (m, 2H), 2.16-2.01 (m, 2H),
1.93-1.85 (m, 1H), 1.62-1.53 (m, 1H) ppm. LC/MS: R.sub.t=1.38 min,
ES.sup.+ 442 (FA standard).
Example 34
{(1S,2S,4R)-2-hydroxy-4-[(6-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]-
-amino}pyrimidin-4-yl)oxy]cyclopentyl}methyl sulfamate (Compound
I-115)
Step h
4-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl-
)silyl]oxy}-methyl)cyclopentyl]oxy}-6-chloropyrimidine
[0519] To a suspension of sodium hydride (75.6 mg, 0.00189 mol) in
THF (2 mL) at 0.degree. C. under an atmosphere of nitrogen was
added
(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl)si-
lyl]oxy}methyl)cyclopentanol (0.60 g, 0.0017 mol) in 1.5 mL THF
dropwise at 0.degree. C. The mixture was stirred at 0.degree. C.
for 10 min. To this was next added 4,6-dichloro-pyrimidine (0.225
g, 0.00151 mol) in 2 mL THF at 0.degree. C. The suspension was
stirred at 0.degree. C. for 2 hrs. The reaction was quenched with 9
mL saturated aqueous NH.sub.4Cl and extracted with t-BuOMe
(3.times.). The organic layers were combined and washed with brine,
dried over anhydrous MgSO.sub.4 and then concentrated to give 0.804
g of an oil. The residue was purified by flash chromatography (0 to
10% EtOAc/hexanes) to give 0.63 g (80%) of the title compound.
Step b
6-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl-
)silyl]oxy}-methyl)cyclopentyl]oxy}-N-[(1R,2S)-2-methoxy-2,3-dihydro-1H-in-
den-1-yl]-pyrimidin-4-amine
[0520] A mixture of
4-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethy-
l)silyl]oxy}methyl)cyclopentyl]oxy}-6-chloropyrimidine (260.0 mg,
0.0005494 mol), (1R,2S)-2-methoxyindan-1-amine (0.359 g, 0.00220
mol) and triethylamine (115 .mu.L, 0.000824 mol) in 1-butanol (0.97
mL, 0.011 mol) was subjected to microwave irradiation (300 watts,
200.degree. C.) for 30 minutes. The resulting dark brown mixture
was filtered and concentrated. The residue was purified by flash
chromatography (0 to 15% EtOAc/hexanes) to give 0.26 g (79%) of the
title compound. LC/MS: R.sub.t=3.42 min, ES.sup.+ 600 (AA
standard).
Step c
{(1S,2S,4R)-2-{[tert-butyl(dimethyl)silyl]oxy}-4-[(6-{[(1R,2S)-2-methoxy-2-
,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]cyclopentyl}methanol
[0521] A solution of
6-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethy-
l)silyl]oxy}methyl)cyclopentyl]oxy}-N-[(1R,2S)-2-methoxy-2,3-dihydro-1H-in-
den-1-yl]pyrimidin-4-amine (0.32 g, 0.00053 mol) in THF (2.88 mL),
water (2.88 mL), and acetic acid (8.64 mL) was stirred for 3 days.
The reaction was concentrated and azeotroped 2.times. with toluene.
The residue was purified by flash chromatography (30 to 80%
EtOAc/hexanes) give 0.20 g (77%) of the title compound. LC/MS:
R.sub.t=1.59 min, ES.sup.+ 486 (FA standard).
Step d
{(1S,2S,4R)-2-{[tert-butyl(dimethyl)silyl]oxy}-4-[(6-{[(1R,2S)-2-methoxy-2-
,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]cyclopentyl}methyl
sulfamate
[0522] The title compound was prepared following the procedure
described in Example 1 step d. LC/MS: R.sub.t=2.16 min, ES.sup.+
565 (FA standard).
Step e
{(1S,2S,4R)-2-hydroxy-4-[(6-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]-
-amino}pyrimidin-4-yl)oxy]cyclopentyl}methyl sulfamate (Compound
I-115)
[0523] To a solution of
{(1S,2S,4R)-2-{[tert-butyl(dimethyl)silyl]oxy}-4-[(6-{[(1R,2S)-2-methoxy--
2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]cyclopentyl}methyl
sulfamate (0.239 g, 0.000423 mol) in pyridine (3.44 mL) and THF
(3.44 mL) was added pyridine hydrofluoride (0.953 mL, 0.0106 mol)
dropwise. After stirring the reaction for 2 hours, an additional
amount of pyridine hydrofluoride (0.50 mL, 0.0055 mol) was added.
After 2.75 hours the reaction was quenched by slow dropwise
addition of saturated aqueous NaHCO.sub.3 and extracted with EtOAc
(4.times.). The combined organic phases were dried (NaSO.sub.4),
filtered and concentrated. The residue was purified by flash
chromatography (0 to 10% MeOH/CH.sub.2Cl.sub.2) and then by
preparative plate chromatography (EtOAc) to obtain 100 mg (52%) of
the title compound. .sup.1H NMR (CD.sub.3OD, 400 MHz) .delta. 8.15
(s, 1H), 7.24-7.15 (m, 4H), 5.98 (s, 1H), 5.34 (bs, 1H), 4.41-4.38
(m, 1H), 4.32 (dd, 1H, J=7.5, 9.7 Hz), 4.24-4.20 (m, 1H), 4.17 (dd,
1H, J=7.3, 9.8 Hz), 3.35 (s, 3H), 3.13-3.00 (m, 3H), 2.57-2.48 (m,
1H), 2.31-2.25 (m, 1H) 2.12-1.93 (m, 4H) ppm. LC/MS: R.sub.t=1.33
min, ES.sup.+ 451 (FA standard).
Example 35
{(1S,2S,4R)-2-hydroxy-4-[(4-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-yl]-a-
mino}-1,3,5-triazin-2-yl)amino]cyclopentyl}methyl sulfamate
(Compound I-125)
Step a
(1S,3S,4S)-3-[(benzyloxy)methyl]-4-{[tert-butyl(dimethyl)]oxy}cyclopentano-
l
[0524] A suspension of
(1R,4S)-3-[(benzyloxy)methyl]-4-{[tert-butyl(dimethyl)silyl]-oxy}cyclopen-
t-2-en-1-ol (7.54 g, 0.0225 mol) (Ruediger, E; Martel, A; Meanwell,
N; Solomon, C; Turmel, B. Tetrahedron Lett. 2004, 45, 739-742),
sodium carbonate (5.7 g, 0.054 mol) and 10% Pd/C (2 g, 0.002 mol)
in EtOAc (90 mL) was stirred under an atmosphere of hydrogen for
three hours. The reaction flask was purged with nitrogen and the
mixture was filtered through celite with EtOAc. The filtrate was
concentrated to obtain 7.16 g (76%) of the title compound as a 4:1
mixture of diastereomers (desired:undesired).
Step b
(1S,3S,4S)-3-[(benzyloxy)methyl]-4-{[tert-butyl(dimethyl)silyl]oxy}cyclope-
ntyl methanesulfonate
[0525] To a stirred solution of
(1S,3S,4S)-3-[(benzyloxy)methyl]-4-{[tert-butyl(dimethyl)silyl]oxy}cyclop-
entanol (2.04 g, 0.00606 mol) in CH.sub.2Cl.sub.2 (96 mL) was added
pyridine (2.4 mL, 0.030 mol), DMAP (100 mg, 0.001 mol), and
methanesulfonyl chloride (700 .mu.L, 0.0091 mol) under an
atmosphere of nitrogen. The mixture was stirred 23.degree. C. for
45 minutes, then warmed to 40.degree. C. for 3 hours. To the
reaction was added DMAP (100 mg, 0.001 mol) and methanesulfonyl
chloride (700 .mu.L, 0.0091 mol). After stirring for 40 min, the
reaction was cooled then concentrated in vacuo. The residue was
purified by flash chromatography (0 to 15% EtOAc/hexanes) to obtain
1.39 g (55%) of the title compound as one diastereomer (separated
undesired diastereomer from step a).
Step c
({(1S,2S,4R)-4-azido-2-[(benzyloxy)methyl]cyclopentyl}oxy)(tert-butyl)-dim-
ethylsilane
[0526] To a solution of
(1S,3S,4S)-3-[(benzyloxy)methyl]-4-{[tert-butyl(dimethyl)-silyl]oxy}cyclo-
pentanol (138.9 mg, 0.0004127 mol) and PPh.sub.3 (118 mg, 0.000451
mol) in THF (2.7 mL) at 0.degree. C. was slowly added DEAD (71.1
.mu.L, 0.000451 mol). The reaction was stirred for 5 minutes, then
diphenylphosphonic azide (97.4 .mu.L, 0.000452 mol) was added
dropwise. The mixture was stirred for one hour. The reaction was
partitioned with water and EtOAc. The layers were separated and the
aqueous extracted with EtOAc (2.times.). The combined organics were
washed with brine (1.times.), dried (Na.sub.2SO.sub.4), filtered,
and collected in vacuo. The residue was purified by flash
chromatography (0 to 10% EtOAc/hexanes) to obtain 93.5 mg (63%) of
the title compound.
Step d
(1R,3S,4S)-3-[(benzyloxy)methyl]-4-{[tert-butyl(dimethyl)silyl]oxy}-cyclop-
entanamine
[0527] A suspension of
({(1S,2S,4R)-4-azido-2-[(benzyloxy)methyl]cyclopentyl}-oxy)(tert-butyl)di-
methylsilane (2.20 g, 0.00608 mol) and 10% Pd/C (0.16 g, 0.00015
mol) in EtOAc (23.9 mL) was stirred under an atmosphere of hydrogen
overnight. The reaction was purged with nitrogen and the mixture
filtered through celite with EtOAc. The filtrate was concentrated
to obtain 2.01 g (98%) of the title compound.
Step e
4,6-dichloro-N-[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]-1,3,5-triazin-
-2-amine
[0528] To a solution of (1R,2S)-2-methoxyindan-1-amine (242.8 mg,
0.001488 mol) in THF (1 mL) was added cyanuric chloride (313 mg,
0.00170 mol) at 0.degree. C., followed by DIPEA (300 .mu.L, 0.002
mol) and the reaction was stirred at 0.degree. C. for 1.5 hours.
The reaction was poured into water and extracted with
CH.sub.2Cl.sub.2. The organic layer was dried (Na.sub.2SO.sub.4),
filtered and concentrated. The residue was purified by flash
chromatography (0 to 15% EtOAc/hexanes) to obtain 229.1 mg (49%) of
the title compound. LC/MS: R.sub.t=2.03 min, ES.sup.+ 311 (FA
standard).
Step f
N-((1R,3S,4S)-3-[(benzyloxy)methyl]-4-{[tert-butyl(dimethyl)silyl]oxy}-cyc-
lopentyl)-6-chloro-N'-[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]-1,3,5--
triazine-2,4-diamine
[0529] To a solution of
(1R,3S,4S)-3-[(benzyloxy)methyl]-4-{[tert-butyl(dimethyl)-silyl]oxy}cyclo-
pentanamine (486.5 mg, 0.001450 mol) and triethylamine (0.55 mL,
0.0040 mol) in THF (2.1 mL) was added
4,6-dichloro-N-[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]-1,3,5-triazi-
n-2-amine (410 mg, 0.0013 mol) and the mixture was stirred for 2
hours. The reaction was concentrated and the residue was purified
by flash chromatography (0 to 25% EtOAc/hexanes) to obtain 250 mg
(31%) of the title compound. LC/MS: R.sub.t=2.96 min, ES* 610 (FA
standard).
Step g
{(1S,2S,4R)-2-{[tert-butyl(dimethyl)silyl]oxy}-4-[(4-{[(1R,2S)-2-methoxy-2-
,3-dihydro-1H-inden-1-yl]amino}-1,3,5-triazin-2-yl)amino]cyclopentyl}metha-
nol
[0530] A suspension of
N-((1R,3S,4S)-3-[(benzyloxy)methyl]-4-{[tert-butyl(dimethyl)-silyl]oxy}cy-
clopentyl)-6-chloro-N'-[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]-1,3,5-
-triazine-2,4-diamine (250 mg, 0.00041 mol) and 10% Pd/C (44 mg,
0.000041 mol) in methanol (1.61 mL) was stirred under an atmosphere
of hydrogen for 2 days. The reaction was purged with nitrogen and
filtered through celite with EtOAc. The filtrate was concentrated
to obtain a yellow oil. The oil was taken up in CH.sub.2Cl.sub.2
and saturated NaHCO.sub.3. The layers were separated and the
aqueous was extracted with CH.sub.2Cl.sub.2 (1.times.). The
combined organics were dried over Na.sub.2SO.sub.4, filtered, and
concentrated. The residue was purified by flash chromatography (0
to 10% MeOH/CH.sub.2C2) to obtain 114 mg (57%) of the title
compound. LC/MS: R.sub.t=1.68 min, ES.sup.+ 486 (FA standard).
Step h
[(1S,2S,4R)-2-hydroxy-4-[(4-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]-
-amino]-1,3,5-triazin-2-yl)amino]cyclopentyl}methyl sulfamate
[0531] The title compound was prepared following the procedure
described in Example 34 steps d-e. .sup.1H NMR (compound exists as
a .about.1:1 mixture of rotamers by .sup.1H NMR) (CD.sub.3OD, 400
MHz) .delta.: 8.03 and 7.92 [(d, J=4.6 Hz and s), 1H], 7.25-7.15
(m, 4H), 5.69 and 5.57 [(d, J=5.1 Hz and m), 1H], 4.67-4.54 (m,
1H), 4.31-4.19 (m, 3H), 4.13-4.06 (m, 1H), 3.37 (s, 3H), 4.13-2.98
(m, 2H), 2.53-2.43 (m, 1H), 2.19-2.14 (m, 1H), 2.06-1.98 (m, 1H),
1.85-1.72 (m, 2H) ppm. LC/MS: R.sub.t=1.07 min, ES.sup.+ 451 (FA
standard).
Example 36
[(1S,2S,4R)-4-({4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-1,3,5-triazin-2-yl-
}-amino)-2-hydroxycyclopentyl]methyl sulfamate (Compound I-153)
[0532] The title compound was prepared in a fashion analogous to
Example 35. .sup.1H NMR (compound exists as a .about.1:1 mixture of
rotamers by .sup.1H NMR) (CD.sub.3OD, 400 MHz) .delta.: 8.03-8.00
and 7.91 [(m and s), 1H], 7.26-7.14 (m, 4H), 5.66-5.50 (m, 1H),
4.65-4.57 (m, 1H), 4.33-4.25 (m, 2H), 4.12-4.08 (m, 1H), 3.04-2.99
(m, 1H), 2.92-2.80 (m, 1H), 2.61-2.44 (m, 2H), 2.22-2.16 (m, 1H),
2.04-1.71 (m, 4H) ppm. LC/MS: R.sub.t=1.07 min, ES.sup.+ 421 (FA
standard).
Example 37
[(1S,2S,4R)-2-hydroxy-4-({6-[(1S)-1,2,3,4-tetrahydronaphthalen-1-ylamino]p-
yrimidin-4-yl}oxy)cyclopentyl]methyl sulfamate (Compound I-40)
[0533] The title compound was prepared in a fashion analogous to
Example 34, steps a-c (using
(S)-(+)-1,2,3,4-tetrahydro-1-naphthylamine in step b) and Example
65, step d to obtain the title compound. .sup.1H NMR (CD.sub.3OD,
400 MHz) .delta.: 8.12 (s, 1H), 7.22-7.08 (m, 4H), 5.77 (s, 1H),
5.30 (bs, 1H), 4.40-4.28 (m, 2H), 4.17-4.13 (m, 1H), 2.89-2.71 (m,
2H), 2.54-2.47 (m, 1H), 2.29-2.21 (m, 1H), 2.10-1.79 (m, 8H) ppm.
LC/MS: R.sub.t=6.66 min, ES.sup.+ 435 (FA long).
Example 38
((1S,2S,4R)-4-{[6-(1,3-dihydro-2H-isoindol-2-yl)pyrimidin-4-yl]oxy}-2-hydr-
oxycyclopentyl)methyl sulfamate (Compound I-120)
[0534] The title compound was prepared in a fashion analogous to
Example 34, steps a-c (using isoindoline in step b) and Example 65,
step d to obtain the title compound. .sup.1H NMR (D6-DMSO, 300 MHz)
.delta.: 8.27 (s, 1H), 7.40-7.29 (m, 4H), 5.81 (s, 1H), 5.47 (bs,
1H), 4.81 (d, 1H, J=4.4 Hz), 4.74 (bs, 4H), 4.24-4.18 (m, 2H),
4.03-3.97 (m, 1H), 2.38 (bs, 1H), 2.22-2.14 (m, 1H), 2.01-1.77 (m,
3H) ppm. LC/MS: R.sub.t=6.40 min, ES.sup.+ 407 (FA long).
Example 39
((1S,2S,4R)-4-{[6-(3,4-dihydroisoquinolin-2(1H)-yl)pyrimidin-4-yl]oxy}-2-h-
ydroxycyclopentyl)methyl sulfamate (Compound I-61)
[0535] The title compound was prepared in a fashion analogous to
Example 34, steps a-c (using tetrahydroisoquinoline in step b) and
Example 65, step d to obtain the title compound. .sup.1H NMR
(CD3OD, 400 MHz) .delta.: 8.17 (s, 1H), 7.17-7.14 (m, 4H), 5.93 (s,
1H), 4.63 (s, 2H), 4.39-4.30 (m, 2H), 4.18-4.13 (m, 1H), 3.78-3.75
(m, 2H), 3.30 (s, 1H), 2.90-2.87 (m, 2H), 2.54-2.47 (m, 1H),
2.30-2.24 (m, 1H), 2.09-1.91 (m, 3H) ppm. LC/MS: R.sub.t=7.05 min,
ES+ 421 (FA long).
Example 40
[(1S,2S,4R)-2-hydroxy-4-(pyrimidin-4-yloxy)cyclopentyl]methyl
sulfamate (Compound I-97)
Step a
4-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl-
)silyl]oxy}methyl)cyclopentyl]oxy}pyrimidine
[0536] A suspension of
4-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethy-
l)silyl]oxy}methyl)cyclopentyl]oxy}-6-chloropyrimidine (115.5 mg,
0.0002441 mol), sodium carbonate (62 mg, 0.00058 mol) and 10% Pd/C
(26 mg, 0.000024 mol) in methanol (1.1 mL) was stirred under an
atmosphere of hydrogen for 2 days. The reaction was purged with
nitrogen and filtered through celite with EtOAc. The filtrate was
concentrated and the residue was purified by flash chromatography
(0 to 15% EtOAc/hexanes) to obtain 80 mg (70%) of the title
compound.
Step b
[(1S,2S,4R)-2-hydroxy-4-(pyrimidin-4-yloxy)cyclopentyl]methyl
sulfamate
[0537] The title compound was prepared in a fashion analogous to
Example 34, step b and Example 65, step d to obtain the title
compound. .sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.: 8.70 (s, 1H),
8.40 (d, J=6.1 Hz, 1H), 6.83 (dd, J=1, 6.1 Hz, 1H), 5.66-5.61 (m,
1H), 4.41-4.38 (m, 1H), 4.33 (dd, J=7.3, 9.8 Hz), 4.16 (dd, J=7.2,
9.7 Hz), 2.58-2.48 (m, 1H), 236-2.30 (m, 1H), 2.11-2.03 (m, 2H),
2.00-1.94 (m, 1H) ppm. LC/MS: R.sub.t=4.08 min, ES+ 290 (FA
long).
Example 41
[(1S,2S,4R)-4-({6-[(4-chlorobenzyl)oxy]pyrimidin-4-yl}oxy)-2-hydroxycyclop-
entyl]methyl sulfamate (Compound I-89)
Step a
4-{[(1R,3S,4S)-3-({[tert-butyl(dimethyl)silyl]oxy}methyl)-4-(1,1,2,2-tetra-
methylpropoxy)cyclopentyl]oxy}-6-[(4-chlorobenzyl)oxy]pyrimidine
[0538] To a solution of
4-{([(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimeth-
yl)silyl]oxy}methyl)cyclopentyl]oxy}-6-chloropyrimidine (0.205 g,
0.000433 mol) and 4-chlorobenzyl alcohol (0.130 g, 0.000910 mol) in
DMF (1 mL) under at atmosphere of nitrogen was added sodium hydride
(36.4 mg, 0.000910 mol) (60% in oil). The reaction was stirred for
3.5 hours. The reaction was quenched with water and extracted with
EtOAc. The organic layer was washed with brine, dried (MgSO.sub.4),
filtered and concentrated. The residue by purified by flash
chromatography (0 to 7% EtOAc/hexanes) to obtain 98 mg (40%) of the
title compound.
Step b
[(1S,2S,4R)-4-({6-[(4-chlorobenzyl)oxy}pyrimidin-4-yl]oxy)-2-hydroxycyclop-
entyl]methyl sulfamate
[0539] The title compound was prepared in a fashion analogous to
Example 34, step b and Example 65, step d (followed by TBAF removal
of secondary silyl group) to obtain the title compound. .sup.1H NMR
(CD.sub.3OD, 400 MHz) .delta.: 6.82 (s, 1H), 5.88-5.79 (m, 4H),
4.62 (s, 1H), 3.98-3.95 (bs, 1H), 3.81 (s, 2H), 2.84-2.75 (m, 2H),
2.64-2.58 (m, 1H), 1.04-0.91 (m, 1H), 0.79-0.72 (m, 1H), 0.63-0.37
(m, 3H) ppm. LC/MS: R.sub.t=8.62 min, ES+ 430 (FA long).
Example 42
N-({(1S,2S,4R)-2-hydroxy-4-[(6-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1--
yl]amino}pyrimidin-4-yl)oxy]cyclopentyl}methyl)sulfamide (Compound
I-82)
Step a
tert-butyl
(aminosulfonyl)([(1S,2S,4R)-2-{[tert-butyl(dimethyl)silyl]oxy}--
4-[(6-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)--
oxy]cyclopentyl}methyl)carbamate
[0540] To a solution of
{(1S,2S,4R)-2-{[tert-butyl(dimethyl)silyl]oxy}-4-[(6-{[(1R,2S)-2-methoxy--
2,3-dihydro-(1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]cyclopentyl}methanol
(105.3 mg, 0.0002168 mol), N-Boc-sulfonamide (58.9 mg, 0.000300
mol) and triphenylphosphine (85.3 mg, 0.000325 mol) in EtOAc (4.15
mL) under an atmosphere of nitrogen was added diethyl
azodicarboxylate (51.9 .mu.L, 0.000330 mol). The mixture was
stirred for four hours. The solvent was removed and the orange
residue was purified by flash chromatography (10 to 50%
EtOAc/hexanes) to obtain 135.2 mg (94%) of the title compound.
Step b
tert-butyl
(aminosulfonyl)({(1S,2S,4R)-2-hydroxy-4-[(6-{[(1R,2S)-2-methoxy-
-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-+yl)oxy]cyclopentyl}methyl)carb-
amate
[0541] To a solution of tert-butyl
(aminosulfonyl)({(1S,2S,4R)-2-{[tert-butyl(dimethyl)silyl]oxy}-4-[(6-{[(1-
R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}-pyrimidin-4-yl)oxy]cyclop-
entyl}methyl)carbamate (331.5 mg, 0.0004094 mol) in THP (1.84 mL,
0.0228 mol) and pyridine (1.84 mL) at 0.degree. C. was added
pyridine hydrofluoride (0.25 mL, 0.0028 mol) dropwise. The mixture
was allowed to slowly warm to 23.degree. C. and stirred for 19
hours. To the reaction was added pyridine hydrofluoride (0.25 mL,
0.0028 mol) and the mixture was stirred an additional 6 hours. The
reaction was quenched by the dropwise addition of saturated aqueous
NaHCO.sub.3. The mixture was partitioned with additional saturated
aqueous NaHCO.sub.3 and EtOAc, separated, and the aqueous was
extracted with EtOAc (2.times.) and CH.sub.2Cl.sub.2 (2.times.).
The combined organics were washed with brine, dried over
Na.sub.2SO.sub.4, filtered and concentrated. The residue was
purified by flash chromatography (30 to 70% EtOAc/hexanes) to
collect 34.5 mg (15%) of the title compound. LC/MS: R.sub.t=1.64
min, ES+ 550 (FA standard).
Step c
N-({(1S,2S,4R)-2-hydroxy-4-[(6-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-1-inden--
yl]-amino}pyrimidin-4-yl)oxy]cyclopentyl}methyl)sulfamide
[0542] To a solution of
tert-butyl(aminosulfonyl)({(1S,2S,4R)-2-hydroxy-4-[(6-{[(1R,2S)-2-methoxy-
-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]cyclopentyl}-methyl)ca-
rbamate (34.5 mg, 0.0000628 mol) in Cl.sub.2Cl.sub.2 (1.4 mL) was
added trifluoroacetic acid (0.70 mL, 0.0091 mol) and the mixture
was stirred for 15 minutes. The mixture was diluted with toluene
and evaporated to dryness. The residue was purified by flash
chromatography (0 to 10% MeOH/CH.sub.2Cl.sub.2) to obtain 23.8 mg
(84%) of the title compound as a white residue. .sup.1H NMR
(CD.sub.3OD, 400 MHz) .delta.: 8.15 (s, 1H), 7.24-7.14 (m, 4H),
5.98 (s, 1H), 5.57 (bs, 1H), 5.29 (bs, 1H), 4.38-4.35 (m, 1H),
4.23-4.20 (m, 1H), 3.34 (s, 3H), 3.25-3.20 (m, 1H), 3.13-3.00 (m,
3H), 2.42-2.33 (m, 1H), 2.29-2.24 (m, 1H), 2.10-1.94 (m, 3H) ppm.
LC/MS: R.sub.t=1.16 min, ES+ 450 (FA standard).
Example 43
[(1R,2R,3S,4R)-4-({4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-6-methyl-1,3,5--
triazin-2-yl}amino)-2,3-dihydroxycyclopentyl]methyl sulfamate
(Compound I-45)
Step a
4-chloro-N-[(1S)-2,3-dihydro-1H-inden-1-yl]-6-methyl-1,3,5-triazin-2-amine
[0543] To a solution of 2,4-dichloro-6-methyl-1,3,5-triazine (0.90
g, 0.0055 mol) in DMF (3.50 mL) and toluene (1.5 mL) at 0.degree.
C. was added (S)-(+)-1-aminoindan (0.64 mL, 0.0050 mol) followed by
DIPEA (0.991 mL, 0.00569 mol). The mixture was stirred at 0.degree.
C. for 30 min. The reaction was poured into water and extracted
with CH.sub.2Cl.sub.2. The organic layer was dried over MgSO.sub.4,
filtered and concentrated. The residue was purified by flash
chromatography (0 to 15% EtOAc/hexanes) to afford 0.69 g (53%) of
the title compound.
Step b
N-[(3aS,4R,6S,6aR)-6-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2,2-dimethyl-
tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]-N'-[(1S)-2,3-dihydro-1H-inde-
n-1-yl]-6-methyl-1,3,5-triazine-2,4-diamine
[0544] A mixture of
(3aS,4R,6R,6aR)-6-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2,2-dimethylte-
trahydro-3aH-cyclopenta[d][1,3]dioxol-4-amine (141.8 mg, 0.0004703
mol),
4-chloro-N-[(1S)-2,3-dihydro-1H-inden-1-yl]-6-methyl-1,3,5-triazin-2-amin-
e (127.1 mg, 0.0004876 mol) and potassium carbonate (0.130 g,
0.000940 mol) in 1,4-dioxane (0.77 mL) was subjected to microwave
irradiation (300 watts, 160.degree. C.) for 30 minutes. The mixture
was filtered with CH.sub.2Cl.sub.2 and concentrated. The residue
was purified by flash chromatography (10 to 100% EtOAc/hexanes) to
obtain 60 mg (24%) of the title compound. LC/MS: R.sub.t=2.03 min,
ES+ 279 (FA standard).
Step c
[(3aR,4R,6R,6aS)-6-({4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-6-methyl-1,3,-
5-triazin-2-yl}amino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol--
4-yl]-methanol
[0545] To a solution of
N-[(3aS,4R,6S,6aR)-6-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2,2-dimethy-
ltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]-N'-[(1S)-2,3-dihydro-1H-ind-
en-1-yl]-6-methyl-1,3,5-triazine-2,4-diamine (0.23 g, 0.00044 mol)
in THF (1 mL) was added 1.00 M of TBAF in THF (1.31 mL). The
reaction was stirred for 30 minutes. The solution was concentrated
and the residue purified by flash chromatography (0 to 4%
MeOH/EtOAc) to afford 210 mg (>99%) of the title compound.
LC/MS: R.sub.t=1.24 min, ES+412 (FA standard).
Step d
[(1R,2R,3S,4R)-4-({4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-6-methyl-1,3,5--
triazin-2-yl}amino)-2,3-dihydroxycyclopentyl]methyl sulfamate
[0546] The title compound was prepared in a fashion analogous to
Example 65, step d. .sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.:
7.29-7.16 (m, 4H), 5.65 (t, J=7.5 Hz, 1H), 4.35 (dd, J=7.7, 14.9
Hz, 1H), 4.14 (s, 1H), 3.92-3.84 (m, 1H), 3.10-3.00 (m, 1H),
2.95-2.84 (m, 1H), 2.63-2.52 (m, 1H), 2.35-2.33 (m, 2H), 2.30 (s,
3H), 2.08-1.90 (m, 1H), 1.39-1.28 (m, 1H) ppm. LC/MS: R.sub.t=1.13
min, ES+451 (FA standard).
Example 44
{(1S,2S,4R)-2-hydroxy-4-[(6-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]-
-amino}pyrimidin-4-yl)amino]cyclopentyl}methyl sulfamate (Compound
I-47)
Step d
N-[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl)-
silyl]oxy}methyl)cyclopentyl]-6-chloropyrimidin-4-amine
[0547] To a solution of
(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl)si-
lyl]oxy}methyl)cyclopentanamine (0.400 g, 1.11 mmol) in EtOH (3.0
mL) was added 4,6-dichloro-pyrimidine (0.199 g, 1.33 mmol) and
Et.sub.3N (0.310 mL, 2.22 mmol). The reaction was heated to
140.degree. C. for 1 h in a sealed tube using microwave irradiation
then concentrated in vacuo. The residue was dissolved in
CH.sub.2Cl.sub.2 and purified by flash chromatography
(CH.sub.2Cl.sub.2) to afford the title compound (0.300 g, 57%).
Step b
N-[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl)-
silyl]oxy}-methyl)cyclopentyl]-N'-[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden--
1-yl]-pyrimidine-4,6-diamine
[0548] A mixture of
N-[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl-
)silyl]oxy}methyl)cyclopentyl]-6-chloropyrimidin-4-amine (0.114 g,
2.42 mmol), (1R,2S)-2-methoxyindan-1-amine (0.170 g, 1.04 mmol) and
Na.sub.2CO.sub.3 (0.10 g, 0.97 mmol) was heated to 180.degree. C.
for 2 h in a sealed tube using an oil bath. The reaction was cooled
and filtered. The filtrate was concentrated in vacuo. The residue
was purified by flash chromatography (50 to 60% EtOAc/hexanes) to
afford the title compound as a beige foam (0.066 g, 46%). LC/MS:
R.sub.t=2.20 min, ES.sup.+ 599 (Formic Acid).
Step c
{(1R,2R,4S)-2-{[tert-butyl(dimethyl)silyl]oxy}-4-[(6-{[(1S,2R)-2-methoxy-2-
,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)amino]cyclopentyl}methanol
[0549] To a solution of
N-[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl-
)silyl]oxy}methyl)cyclopentyl]-N'-[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden--
1-yl]pyrimidine-4,6-diamine (0.188 g, 0.314 mmol) in THF (1.70 mL)
and 120 (1.70 mL) was added AcOH (5.08 mL). The solution was
stirred overnight then concentrated in vacuo and purified by flash
chromatography (0 to 5% MeOH/EtOAc) to obtain the title compound
(0.112 g, 74%). LC/MS: R.sub.t=1.46 min, ES.sup.+ 485 (Formic
Acid).
Step d
{(1S,2S,4R)-2-hydroxy-4-[(6-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]-
-amino}pyrimidin-4-yl)amino]cyclopentyl}methyl sulfamate (Compound
I-47)
[0550] A solution of
{(1R,2R,4S)-2-{[tert-butyl(dimethyl)silyl]oxy}-4-[(6-{[(1S,2R)-2-methoxy--
2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)amino]cyclopentyl}methanol
(0.112 g, 0.231 mmol) (azetroped with toluene) and pyridine (0.0374
mL, 0.462 mmol) in anhydrous acetonitrile (2.3 mL) was cooled to
0.degree. C. A 2 N solution of chlorosulfonamide in acetonitrile
(0.116 mL) was added dropwise and the reaction was stirred for 3 h.
Additional 2 N solution of chlorosulfonamide in acetonitrile (0.026
mL) and pyridine (0.0041 g, 0.052 mol) were added and the reaction
was stirred for 1 h then quenched with methanol. The solution was
concentrated in vacuo and purified by flash chromatography (0 to
10% MeOH/DCM) to afford the title compound as a white solid (0.059
g, 57%). .sup.1H NMR (CD.sub.3OD, 400 MHz, .delta.): 8.26 (s, 1H);
8.01 (s, 1H); 7.26-7.16 (m, 3H); 5.70 (s, 1H); 5.47-5.33 (bs, 1H);
4.35 (t, J=4.5 Hz, 1H); 4.31 (d, J=7.5 Hz, 1H); 4.28 (d, J=7.5 Hz,
1H); 4.25-4.21 (m, 1H); 4.15-4.11 (dd, J=7.3 Hz; J=2.5 Hz, 1H);
3.36 (s, 3H); 3.16-3.00 (m, 2H); 2.54-2.45 (m, 1H); 2.26-2.19 (m,
18); 2.10-1.98 (m, 1H); 1.87-1.78 (m, 1H); 1.77-1.69 (m, 1H).
LC/MS: R.sub.t=1.11 min, ES.sup.+ 450 (FA standard).
Example 45
{(1S,2S,4R)-4-[(6-{[(1S)-3,3-dimethyl-2,3-dihydro-1H-inden-yl]amino}-pyrim-
idin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate (Compound
I-124)
[0551] The title compound was prepared in a fashion analogous to
Example 34 steps a-e using (1S)-3,3-dimethylindan-1-amine in step b
to obtain the title compound. .sup.1H NMR (CD.sub.3OD, 400 MHz,
.delta.): 8.14 (s, 1H); 7.28-7.15 (m, 4H); 5.83 (s, 1H); 5.59 (bs,
1H); 5.31 (bs, 1H); 4.39 (dt, J=5.0 Hz; J=2.0 Hz, 1H); 4.32 (dd,
J=7.3 Hz; J=2.5 Hz, 1H); 4.16 (dd, J=7.3 Hz; J=2.5 Hz, 1H);
2.57-2.47 (m, 1H); 2.46-2.39 (m, 1H); 2.31-2.24 (m, 1H); 2.12-1.90
(m, 3H); 1.82-1.75 (m, 1H); 1.39 (s, 3H); 1.25 (s, 3H). LC/MS:
R.sub.t=1.51 min, ES.sup.+ 449 (FA standard).
Example 46
{(1S,2S,4R)-4-[(4-{[(1S)-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl]amino}-1,3-
,5-triazin-2-yl)amino]-2-hydroxycyclopentyl}methyl sulfamate
(Compound I-134)
Step a
4,6-dichloro-N-[(1S)-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl]-1,3,5-triazin-
-2-amine
[0552] To a solution of (1S)-3,3-dimethylindan-1-amine (0.67 g, 4.2
mmol) in THF (3 mL) cooled to 0.degree. C. was added cyanuric
chloride (0.874 g, 4.74 mmol) resulting in a white solid. DIPEA
(0.724 mL, 4.16 mmol) was added and the yellow mixture was stirred
for 1.5 hours. The reaction was quenched with H.sub.2O and
extracted with DCM (3.times.). The combined organic layers were
dried (Na.sub.2SO.sub.4), filtered and collected in vacuo to give a
pale yellow oil. The residue was purified by flash chromatography
(0 to 25% EtOAc/hexanes) to afford the title compound (0.771 g,
60%) as a white solid. LC/MS: R.sub.t=2.20 min, ES.sup.+ 310 (FA
standard).
Step b
N-[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl)-
silyl]oxy}-methyl)cyclopentyl]-6-chloro-N'-[(1S)-3,3-dimethyl-2,3-dihydro--
1H-inden-1-yl]-1,3,5-triazine-2,4-diamine
[0553] To a solution of
(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl)si-
lyl]oxy}methyl)cyclopentanamine (0.200 g, 0.556 mmol), TEA (0.21
mL, 1.50 mmol) in THF (0.80 mL) was added
4,6-dichloro-N-[(1S)-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl]-1,3,5-triazi-
n-2-amine (0.160 g, 0.500 mol). The reaction was stirred for 3.5 h
then concentrated in vacuo. The residue was purified by preparative
TLC (10% EtOAc/hexanes) followed by DCM. The relevant band was cut
and washed using acetone, filtered, and concentrated in vacuo to
afford the title compound (0.228 g, 71%). LC/MS: R.sub.t=2.77 min,
ES.sup.+ 633 (FA standard).
Step c
[(1R,2R,4S)-2-{[tert-butyl(dimethyl)silyl]oxy}-4-[(4-chloro-6-{[(1R)-3,3-d-
imethyl-2,3-dihydro-1H-inden-1-yl]amino]-1,3,5-triazin-2-yl)amino]cyclopen-
tyl}methanol
[0554] The title compound was prepared following the procedure
described in Example 44 step c using
N-[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl-
)silyl]oxy}methyl)cyclopentyl]-6-chloro-N'-[(1S)-3,3-dimethyl-2,3-dihydro--
1H-inden-1-yl]-1,3,5-triazine-2,4-diamine. LC/MS: R.sub.t=2.20 min,
ES.sup.+ 518, 520 (FA standard).
Step d
{(1S,2S,4R)-2-{[tert-Butyl(dimethyl)silyl]oxy}-4-[(4-{[(1S)-3,3-dimethyl-2-
,3-dihydro-1H-inden-1-yl]amino}-1,3,5-triazin-2-yl)amino]cyclopentyl}metha-
nol
[0555] To a solution of
{(1R,2R,4S)-2-{[tert-butyl(dimethyl)silyl]oxy}-4-[(4-chloro-6-{[(1R)-3,3--
dimethyl-2,3-dihydro-1H-inden-1-yl]amino}-1,3,5-triazin-2-yl)amino]cyclope-
ntyl}-methanol (0.083 g, 0.16 mmol) in EtOH (1.11 mL) was added Pd
(10% on carbon) (0.0170 g, 0.0160 mmol) and the mixture was stirred
under an atmosphere of hydrogen for 4 d. The reaction was purged
with nitrogen for 30 minutes then Pd(OH).sub.2 (20% on carbon dry
weight) (0.022 g, 0.016 mmol) was added and the mixture was stirred
for 4 h under an atmosphere of hydrogen. Filtration of the mixture
through a pad of celite, followed by flash chromatography (50-100%
EtOAc/hexanes) afforded the title compound (0.027 g, 35%). LC/MS:
R.sub.t=1.81 min, ES.sup.+ 484 (FA standard).
Step e
{(1S,2S,4R)-4-[(4-{[(1S)-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl]amino}-1,3-
,5-triazin-2-yl)amino]-2-hydroxycyclopentyl}methyl sulfamate
(Compound I-134)
[0556] The title compound was prepared following the procedure
described in Example 44 step d using
{(1S,2S,4R)-2-{[tert-butyl(dimethyl)silyl]oxy}-4-[(4-{[(S)-3,3-dimethyl-2-
,3-dihydro-1H-inden-1-yl]amino}-1,3,5-triazin-2-yl)amino]cyclopentyl}metha-
nol. .sup.1H NMR (CD.sub.3OD, 400 MHz, .delta.): 8.17-7.81 (m, 1H);
7.27-7.15 (m, 4H); 5.71-5.57 (m, 1H); 4.65-4.49 (m, 1H); 4.36-4.23
(m, 2H); 4.20-4.00 (m, 1H); 2.53-2.33 (m, 2H); 2.25-2.10 (m, 1H);
2.06-1.68 (m, 4H); 1.39 (s, 3H); 1.24 (s, 3H). LC/MS: R.sub.t=1.90
min ES.sup.+ 449 (FA standard).
Example 47
{(1S,2S,4R)-2,3-dihydroxy-4-[(4-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-
-yl]amino}-1,3,5-triazin-2-yl)amino]cyclopentyl}methyl sulfamate
(Compound I-55)
[0557] The title compound was prepared following the procedure
described in Example 46 (step e) using
{(3aR,4R,6R,6aS)-6-[(4-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]amin-
o}-1,3,5-triazin-2-yl)amino]-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]-
dioxol-4-yl}methanol (prepared as in Example 26). .sup.1H NMR
(CD.sub.3OD, 400 MHz, .delta.): 8.10-7.95 (m, 1H); 7.30-7.14 (m,
4H); 5.72-5.56 (m, 1H); 4.36-4.08 (m, 4H); 3.95-3.78 (m, 2H); 3.37
(s, 3H); 3.15-2.93 (m, 2H); 2.42-2.17 (m, 2H); 1.37-1.78 (m, 1H).
LC/MS: R.sub.t=1.07 min ES.sup.+ 467 (FA standard).
Example 48
((1R,2R,3S,4R)-2,3-dihydroxy-4-{[6-(phenylethynyl)pyrimidin-4-yl]amino}-cy-
clopentyl)methyl sulfamate (Compound I-108)
Step a
(1R,2S,3R,5R)-3-[(6-chloropyrimidin-4-yl)amino]-5-(hydroxymethyl)cyclopent-
ane-1,2-diol
[0558] To a solution of
(1R,2S,3R,5R)-3-amino-5-(hydroxymethyl)cyclopentane-1,2-diol*HCl
(1.00 g, 5.44 mmol) and 2-amino-4,6-dichloropyrimidine (0.982 g,
5.99 mmol) in isopropyl alcohol (8 mL) was added Et.sub.3N (1.90
mL, 13.6 mmol). The reaction was heated to 90.degree. C. for 1 h in
an oil bath then cooled, filtered and concentrated in vacuo. The
residue was dissolved in CH.sub.2Cl.sub.2 and purified by flash
chromatography (20 to 50% MeOH/CH.sub.1Cl.sub.2) to afford the
title compound as an off-white solid (2.025 g, >99%). LC/MS:
R.sub.t=0.81 min ES.sup.+ 260 (FA standard).
Step b
(1S,2R,3R,5R)-3-(hydroxymethyl)-5-[(6-iodopyrimidin-4-yl)-amino]cyclopenta-
ne-1,2-diol
[0559] To a solution of
(1R,2S,3R,5R)-3-[(6-chloropyrimidin-4-yl)amino]-5-(hydroxymethyl)cyclopen-
tane-1,2-diol (1.880 g, 7.239 mmol) in hydroiodic acid (23.9 mL)
was added sodium iodide (5.42 g, 36.2 mmol). The mixture heated to
70.degree. C. for 10 min then concentrated and azeotroped using
toluene (3.times.). The residue was dissolved in acetone and
NaHCO.sub.3 was added. The suspension was filtered and the filtrate
was concentrated in vacuo to obtain the title compound (24 g,
>99%). LC/MS: R.sub.t=0.76 min ES.sup.+ 352 (FA standard).
Step c
{(3aR,4R,6R,6aS)-6-[(6-iodopyrimidin-4-yl)amino]-2,2-dimethyltetrahydro-3a-
H-cyclopenta[d][1,3]dioxol-4-yl}methanol
[0560] The title compound was prepared following the procedure
described in Example 1 step b using
(1S,2R,3R,5R)-3-(hydroxymethyl)-5-[(6-iodopyrimidin-4-yl)-amino]cyclopent-
ane-1,2-diol. LC/MS: R.sub.t=1.24 min ES.sup.+ 392 (FA
standard).
Step d
N-[(3aS,4R,6R,6aR)-6-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2,2-dimethyl-
tetrahydro-3aH-cyclopental[d][1,3]dioxol-4-yl]iodopyrimidin-4-amine
[0561] To a solution of
{(3aR,4R,6R,6aS)-6-[(6-iodopyrimidin-4-yl)amino]-2,2-dimethyltetrahydro-3-
aH-cyclopenta[d][1,3]dioxol-4-yl}methanol (1.321 g, 3.38 mmol) and
1H-imidazole (0.552 g, 8.10 mmol) in DMF (16.9 mL) was added
tert-butyldimethylsilyl chloride (0.534 g, 3.54 mmol) and the
reaction was stirred overnight. The solution was diluted with
H.sub.2O and extracted with EtOAc (3.times.). The combined organic
layers were washed with brine, dried (Na.sub.2SO.sub.4), filtered,
and concentrated in vacuo. The crude mixture was purified by flash
chromatography (10 to 40% EtOAc/hexanes) to afford the title
compound (1.465 g, 86%). LC/MS: R.sub.t=2.47 min ES.sup.+ 506 (FA
Standard).
Step e
N-[(3aS,4R,6R,6aR)-6-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2,2-dimethyl-
tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]-6-(phenylethynyl)-pyrimidin--
4-amine
[0562] To a solution of
N-[(3aS,4R,6R,6aR)-6-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2,2-dimethy-
ltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]-6-iodopyrimidin-4-amine
(0.300 g, 0.594 mmol) in DMF (2.46 mL) was added CuI (0.0113 g,
0.0594 mmol) and bis(triphenylphosphine)palladium(II) chloride
(0.0292 g, 0.0415 mmol). The tube was sealed and flushed with
argon. Et.sub.3N (0.165 mL, 1.19 mol) was added and the reaction
was stirred for 1 h. Phenylacetylene (0.216 mL, 1.96 mmol) was
added and the reaction was stirred overnight. The suspension was
filtered and the filtrate was concentrated in vacuo. The crude
mixture was purified by flash chromatography (10 to 40%
EtOAc/hexanes) to afford the title compound as a yellow oil (0.238
g, 84%). LC/MS: R.sub.t=2.47 min, ES.sup.+ 480 (FA standard).
Step f
((3aR,4R,6R,6aS)-2,2-dimethyl-6-{[6-(phenylethynyl)pyrimidin-4-yl]amino}-t-
etrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methanol
[0563] To a solution of
N-[(3aS,4R,6R,6aR)-6-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2,2-dimethy-
ltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]-6-(phenylethynyl)pyrimidin--
4-amine (0.275 g, 0.573 mmol) in THF (2 mL) and pyridine (2 mL) in
a teflon vial was added pyridine hydrofluoride (1.3 mL, 0.014 mol)
dropwise. The reaction was stirred for 1.5 h then quenched using a
saturated aqueous Na.sub.2CO.sub.3 solution (15 mL) and EtOAc. The
aqueous layer was extracted with EtOAc (3.times.20 mL). The
combined organic layers were dried (Na.sub.2SO.sub.4), filtered and
concentrated in vacuo. The residue was purified by flash
chromatography (0 to 5% MeOH/EtOAc) to afford the title compound as
a yellow solid (0.172 g, 82%). LC/MS: R.sub.t=1.29 min, ES.sup.+
366 (FA standard).
Step g
((1R,2R,3S,4R)-2,3-dihydroxy-4-{[6-(phenylethynyl)pyrimidin-4-yl]amino}-cy-
clopentyl)methyl sulfamate (Compound I-108)
[0564] The title compound was prepared following the procedure
described in Example 1 steps d-e using
((3aR,4R,6R,6aS)-2,2-dimethyl-6-{[6-(phenylethynyl)pyrimidin-4-yl]amino}t-
etrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methanol. .sup.1H NMR
(CD.sub.3OD, 400 MHz, .delta.): 8.36 (s, 1H); 7.80-7.54 (m, 2H);
7.45-7.38 (m, 3H); 6.69 (bs, 1H); 4.33 (bs, 1H); 4.23-4.14 (m, 2H);
3.92-3.88 (m, 1H); 3.86-3.81 (m, 1H); 3.32-3.28 (m, 2H); 2.46-2.30
(m, 2H); 1.39-1.27 (m, 1H). LC/MS: R.sub.t=1.09 min, ES.sup.+ 405
(FA standard).
Example 49
[(1S,2S,4R)-2-hydroxy-4({6-[(1-naphthylmethyl)amino]pyrimidin-4-yl}-oxy)cy-
clopentyl]methyl sulfamate (Compound I-42)
[0565] The title compound was prepared in a fashion analogous to
Example 34 steps a-e using 1-naphthalenemethylamine in step b to
obtain the title compound. .sup.1H NMR (CD.sub.3OD, 400 MHz,
.delta.): 8.13 (s, 1H); 8.04 (d, J=9.0 Hz, 1H); 7.87 (d, J=7.5 Hz,
1H); 7.79 (d, J=8.0 Hz, 1H); 7.54-7.39 (m, 5H); 5.75 (s, 1H);
5.31-5.26 (m, 1H); 4.94 (s, 2H); 4.39-4.25 (m, 2H); 4.17-4.06 (m,
1H); 2.52-2.42 (m, 1H); 2.26-2.19 (m, 1H); 2.05-1.84 (m, 2H).
LC/MS: R.sub.t=159 min, ES.sup.+ 445 (FA standard).
Example 50
((1S,2S,4R)-2-hydroxy-4-{[6-(1-naphthylmethoxy)pyrimidin-4-yl]oxy}-cyclope-
ntyl)methyl sulfamate (Compound I-119)
Step a
4-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-{[tert-butyl(dimethyl)-
silyl]oxy}-methyl)cyclopentyl]oxy}-6-(1-naphthylmethoxy)pyrimidine
[0566] To a solution of
4-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethy-
l)silyl]oxy}methyl)cyclopentyl]oxy}-6-chloropyrimidine (0.200 g,
0.423 mmol) and 1-naphthalenemethanol (0.140 g, 0.888 mmol) in DMF
(1 mL) was added sodium hydride (0.0355 g, 0.888 mmol) and stirred
for 3 h. The mixture was diluted with H.sub.2O and extracted with
EtOAc. The combined organic layers were washed with brine, dried
(Na.sub.2SO.sub.4, filtered, and concentrated in vacuo. The residue
was purified by flash chromatography (0 to 20% EtOAc/hexanes) to
afford the title compound (0.139 g, 55%).
P Step b
[(1S,2S,4R)-2-hydroxy-4-({6-[(1-naphthylmethyl)amino]pyrimidin-yl}-oxy)cyc-
lopentyl]methyl sulfamate
[0567] The title compound was prepared following the procedure
described in Example 44 (steps c-d) and Example 48 (step f) using
4-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)-silyl]oxy}-4-({[tert-butyl(dimeth-
yl)silyl]oxy}methyl)cyclopentyl]oxy}-6-(1-naphthylmethoxy)pyrimidine.
.sup.1H NMR (CD.sub.3OD, 400 MHz, .delta.): 8.39 (s, 1H); 8.01 (d,
J=8.8 Hz, 1H); 7.88-7.81 (m, 2H); 7.57 (d, J=7.0 Hz, 1H); 7.53-7.40
(m, 3H); 6.14 (s, 1H); 5.79 (s, 2H); 5.50-5.42 (m, 1H); 4.35-4.31
(m, 1H); 4.30-4.25 (m, 1H); 4.15-4.03 (m, 1H); 2.53-2.42 (m, 1H);
2.30-2.21 (m, 1H); 2.08-1.87 (m, 3H). LC/MS: R.sub.t=1.82 min, ES
446 (FA standard).
Example 51
((1S,2S,4R)-2-hydroxy-4-{[6-(2-phenylethyl)pyrimidin-4-yl]amino}cyclopenty-
l)-methyl sulfamate (Compound I-81)
Step a
N-[(1R,3S,4S)-3{[tert-butyl(dimethyl)siyl]oxy}-4-({[tert-butyl(dimethyl)si-
lyl]oxy}-methyl)cyclopentyl]-6-iodopyrimidin-4-amine
[0568] The title compound was prepared following the procedure
described in Example 44 step a using 4,6-diiodopyrimidine heating
to 150.degree. C. for 300 sec.
Step b
N-[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl)-
silyl]oxy}-methyl)cyclopentyl]-6-(phenylethynyl)pyrimidin-4-amine
[0569] The title compound was prepared following the procedure
described in Example 48 step e. LC/MS: R.sub.t=3.56 min, ES.sup.+
538 (FA standard).
Step c
N-[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl)-
silyl]oxy}-methyl)cyclopentyl]-6-(2-phenylethynyl)pyrimidin-4-amine
[0570] The title compound was prepared following the procedure
described in Example 3d using
N-[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl-
)-silyl]oxy}methyl)cyclopentyl]-6-(phenylethynyl)pyrimidin-4-amine
and Pd(OH).sub.2 on carbon (20% dry weight). LC/MS: R.sub.t=2.30
min, ES.sup.+ 542 (FA standard).
Step d
((1S,2S,4R)-2-hydroxy-4-{[6-(2-phenylethyl)pyrimidin-4-yl]amino}cyclopenty-
l)-methyl sulfamate (Compound I-81)
[0571] The title compound was prepared following the procedure
described in Example 46 steps c and e and Example 48 step f.
.sup.1H NMR (CD.sub.3OD, 400 MHz, .delta.): 8.30 (s, 1H); 7.26-7.20
(m, 2H); 7.18-7.13 (m, 3H); 6.18 (s, 1H): 4.35-4.26 (m, 2H);
4.15-4.06 (m, 1H); 2.97-2.90 (m, 2H); 2.85-2.76 (m, 2H); 2.51-2.41
(m, 1H); 2.24-2.15 (m, 1H); 1.82-1.73 (m, 1H); 1.70-1.60 (m, 1H);
0.94-0.85 (m, 1H). LC/MS: R.sub.t=1.38 min, ES.sup.+ 393 (FA
standard).
Example 52
((1S,2S,4R)-2-hydroxy-4-{[6-(2-naphthylmethoxy)pyrimidin-4-yl]oxy}-cyclope-
ntyl)methyl sulfamate (Compound I-141)
[0572] The title compound was prepared following the procedure
described in Example 50 using 2-naphthalenemethanol. .sup.1H NMR
(CD.sub.3OD, 400 MHz, .delta.): 8.39 (s, 1H); 7.88 (s, 1H);
7.86-7.81 (m, 3H); 7.52 (dd, J=8.5 Hz, J=1.76 Hz, 1H); 7.49-7.44
(m, 2H); 6.19 (s, 1H); 5.53-5.48 (m, 1H); 4.38-4.35 (m, 1H);
4.34-4.29 (m, 1H); 4.17-4.12 (m, 1H); 2.56-2.46 (m, 1H); 232-2.26
(m, 1H); 2.09-1.91 (m, 3H). LC/MS: R.sub.t=1.82 min ES.sup.+ 446
(FA standard).
Example 53
{(1S,2S,4R)-2-hydroxy-4-[(6-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]-
-oxy}pyrimidin-4-yl)oxy]cyclopentyl}methyl sulfamate (Compound
I-96)
Step a
(1R,2S)-1-[(6-chloropyrimidin-4-yl)oxy]indan-2-ol and
(1R,2S)-2-[(6-chloropyrimidin-4-yl)oxy]indan-1-ol
[0573] The title compounds were prepared following the procedure
described in Example 34 step a using (1R,2S)-indane-1,2-diol (0.5
g, 3.00 mmol) (Yanagimnachi, K. S; Stafford, D; Dexter, A; Sinskey,
A; Drew, S; Stephanopoulos, G. European Journal of Biochemistry.
2001, 268, 4950-4960) as a 1.2:1 ratio of 2-O-pyrimidine to
1-O-pyrimidine.
Step b
4-chloro-6-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]oxy}pyrimidine
and
4-chloro-6-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]oxy}pyrimidi-
ne and
4-chloro-6-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]oxy}pyrimi-
dine
[0574] To a flame dried flask containing 4 .ANG. molecular sieves
(0.700 g) cooled under nitrogen and equipped with a reflux
condenser was added silver(I) oxide (3 g, 10.0 mmol),
(1R,2S)-1-[(6-chloropyrimidin-4-yl)oxy]indan-2-ol (0.365 g, 1.39
mmol), and Et.sub.2O (10 mL). MeI (3.08 mL, 49.5 mmol) was
pre-purified through an alumina plug and added to the mixture. The
reaction was heated to 40.degree. C. for 2 h. The reaction was
diluted with Et.sub.2O, filtered through a pad of celite and
concentrated in vacuo. The residue was purified by flash
chromatography (15 to 30% EtOAc/hexanes) to obtain the title
compounds as a 1:1 mixture (0.540 g, 70%).
Step c
4-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl-
)sily]oxy}-methyl)cyclopentyl]oxy}-6-({[1R,2S)-2-methoxy-2,3-dihydro-1H-in-
den-1-yl]oxy}-pyrimidine, and tert-butyl
{[(1S,2S,4R)-2-{[tert-butyl(dimethyl)silyl]oxy}-4-(3-{[(1R,2S)-1-methoxy--
2,3-dihydro-1H-inden-2-yl]oxy}phenoxy)cyclopentyl]-methoxy}dimethylsiline,
and
4-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dim-
ethyl)silyl]oxy}methyl)cyclopentyl]oxy}-6-{[(1S,2R)-2-methoxy-2,3-dihyrdro-
-1H-inden-1-yl]oxy}pyrimidine, and tert-butyl
{[(1S,2S,4R)-2-{[tert-butyl(dimethyl)silyl]oxy}-4-(3-{[1S,2R)-1-methoxy-2-
,3-dihydro-1H-inden-2-yl]-oxy}phenoxy)cyclopentyl]methoxy}dimethylsilane
[0575] To a solution of
(1R,3S,4S)-3-{[tert-butyl(dimethyl)sily]oxy}-4-({[tert-butyl(dimethyl)sil-
yl]oxy}methyl)cyclopentanol (0.334 g, 0.928 mmol) and sodium
hydride (0.0779 g, 1.95 mmol) in DMF (3 mL) was added
4-chloro-6-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]oxy}pyrimidine
(0.539 g, 1.95 mmol). The mixture was stirred for 5 h then quenched
with H.sub.2O and extracted with EtOAc (3.times.). The combined
organic layers were washed with brine, dried (MgSO.sub.4) and
concentrated in vacuo. The residue was purified by flash
chromatography (0 to 30% EtOAc/hexanes) to obtain the title
compounds (0.124 g, 22%).
Step d
{(1S,2S,4R)-2-hydroxy-4-[(6-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]-
oxy}-pyrimidin-4-yl)oxy]cyclopentyl}methyl sulfamate, and
{(1S,2S,4R)-2-hydroxy-4-[(6-{([(1R,2S)-1-methoxy-2,3-dihydro-1H-inden-2-y-
l]oxy}pyrimidin-4-yl)-oxy]cyclopentyl}methyl sulfamate, and
{(1S,2S,4R)-2-hydroxy-4-[(6-{[(1S,2R)-2-methoxy-2,3-dihydro-1H-inden-1-yl-
]oxy}pyrimidin-4-yl)oxy]cyclopentyl}methyl sulfamate, and
{(1S,2S,4R)-2-hydroxy-4-[(6-([(1S,2R)-1-methoxy-2,3-dihydro-1H-inden-2-yl-
]oxy)pyrimidin-4-yl)oxy]cyclopentyl}methyl sulfamate (Compounds
I-96, I-79, I-98, I-77)
[0576] The title compounds were prepared using the procedure
described in Example 51 step d using
4-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethy-
l)silyl]oxy}methyl)cyclopentyl]oxy}-6-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-i-
nden-1-yl]oxy}-pyrimidine, and
tert-butyl{[(1S,2S,4R)-2-{[tert-butyl(dimethyl)silyl]oxy}-4-(3-{[(1R,2S)--
1-methoxy-2,3-dihydro-1H-inden-2-yl]oxy}phenoxy)cyclopentyl]methoxy}dimeth-
ylsilane, and
4-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethy-
l)silyl]oxy}methyl)cyclopentyl]oxy}-6-{[(1S,2R)-2-methoxy-2,3-dihydro-1H-i-
nden-1-yl]oxy}pyrimidine, and
tert-butyl{[(1S,2S,4R)-2-{[tert-butyl(dimethyl)silyl]oxy}-4-(3-{[(1S,2R)--
1-methoxy-2,3-dihydro-1H-inden-2-yl]oxy}phenoxy)cyclopentyl]methoxy}dimeth-
ylsilane.
Example 54
{(1S,2S,4R)-2-hydroxy-4-[(6-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]-
-oxy}pyrimidin-4-yl)oxy]cyclopentyl}methyl sulfamate (Compound
I-96)
[0577] .sup.1H NMR (CD.sub.3OD, 400 MHz, .delta.): 8.44 (s, 1H);
7.45 (d, J=7.3 Hz, 1H); 7.32-7.25 (m, 2H); 7.23-7.17 (m, 1H); 6.53
(d, J=5.0 Hz, 1H); 6.12 (s, 1H); 5.52-5.47 (m, 1H); 4.39-4.36 (m,
1H); 4.35-4.27 (m, 2H); 4.14 (dd, J=9.8 Hz, J=2.5 Hz, 1H); 3.37 (s,
3H); 3.20-3.06 (m, 2H); 2.56-2.47 (m, 1H); 2.34-2.25 (m, 1H);
2.11-1.89 (m, 3H). LC/MS: R.sub.t=1.64 min, ES.sup.+ 452 (FA
standard).
Example 55
{(1S,2S,4R)-2-hydroxy-4-[(6-{([(1R,2S)-1-methoxy-2,3-dihydro-1H-inden-2-yl-
]-oxy}pyrimidin-4-yl)oxy]cyclopentyl}methyl sulfamate (Compound
I-79)
[0578] .sup.1H NMR (CD.sub.3OD, 400 MHz, .delta.): 8.40 (s, 1H);
7.40 (d, J=7.3 Hz, 1H); 7.33-7.23 (m, 3H); 6.13 (s, 1H); 5.78 (q,
J=5.77 Hz, J=5.52 Hz, 1H); 5.54-5.47 (m, 1H); 4.94 (d, J=4.77 Hz,
1H); 4.41-4.36 (m, 1H); 4.35-4.29 (m, 1H); 4.18-4.12 (m, 1H); 3.38
(s, 3H); 3.28-3.23 (m, 1H); 3.20-3.12 (m, 1H); 2.57-2.47 (m, 1H);
2.33-2.25 (m, 1H); 2.10-1.90 (m, 3H). LC/MS: R.sub.t=1.64 min,
ES.sup.+ 452 (FA standard).
Example 56
{(1S,2S,4R)-2-hydroxy-4-[(6-{[(1S,2R)-2-methoxy-2,3-dihydro-1H-inden-1-yl]-
-oxy}pyrimidin-4-yl)oxy]cyclopentyl}methyl sulfamate (Compound
I-98)
[0579] .sup.1H NMR (CD.sub.3OD, 400 MHz, .delta.): 8.44 (s, 1H);
7.45 (d, J=7.5 Hz, 1H); 7.32-7.25 (m, 2H); 7.23-7.16 (m, 1H); 6.53
(d, J=5.0 Hz, 1H); 6.12 (s, 1H); 5.53-5.47 (m, 1H); 4.40-4.35 (m,
1H); 4.34-4.27 (m, 2H); 4.15 (dd, J=7.3 Hz, J=5.1 Hz, 1H); 3.37 (s,
3H); 3.19-3.06 (m, 2H); 2.56-2.47 (m, 1H); 2.33-2.25 (m, 1H);
2.10-1.90 (m, 3H). LC/MS: R.sub.t=1.65 min, ES.sup.+ 452 (FA
standard).
Example 57
{(1S,2S,4R)-2-hydroxy-4-[(6-([(1S,2R)-1-methoxy-2,3-dihydro-1H-inden-2-yl]-
-oxy)pyrimidin-4-yl)oxy]cyclopentyl}methyl sulfamate (Compound
I-77)
[0580] .sup.1H NMR (CD.sub.3OD, 400 MHz, .delta.): 8.40 (s, 1H);
7.41 (d, J=7.0 Hz, 1H); 7.33-7.23 (m, 3H); 6.13 (s, 1H); 5.81-5.76
(m, 1H); 5.55-5.48 (m, 1H); 4.94 (d, J=5.0 Hz, 1H); 4.41-4.36 (m,
1H); 4.32 (dd, J=9.8 Hz; J=2.3 Hz, 1H); 4.15 (dd, J=9.8 Hz; J=2.5
Hz, 1H); 3.38 (s, 3H); 3.28-3.22 (m, 1H); 3.20-3.12 (m, 1H);
257-2.47 (m, 1H); 2.33-2.26 (m, 1H); 2.10-1.93 (m, 3H). LC/MS:
R.sub.t=1.64 min, ES.sup.+ 452 (FA Standard).
Example 58
{(1S,2S,4R)-2-hydroxy-4-[(6-phenylpyrimidin-4-yl)oxy]cyclopentyl}methyl
sulfamate (Compound I-114)
Step a
4-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl-
)silyl]oxy}-methyl)cyclopentyl]oxy}-6-phenylpyrimidine
[0581] A flask containing
4-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethy-
l)silyl]oxy}methyl)cyclopentyl]oxy}-6-chloropyrimidine (0.300 g,
0.634 mmol), phenylboronic acid (0.0696 g, 0.570 mmol), a 2.00 M
solution of K.sub.2CO.sub.3 in H.sub.2O (0.317 mL), EtOH (0.0944
mL) and toluene (1.417 mL) was purged with argon for 20 minutes.
Tetrakis(triphenylphosphine)palladium(0) (0.0264 g, 0.0229 mmol)
was added and the mixture was refluxed overnight. The reaction was
cooled and diluted with H.sub.2O. The aqueous layer was extracted
with CH.sub.2Cl.sub.2 (3.times.). The combined organics were washed
with brine, dried (MgSO.sub.2) and concentrated in vacuo. The
residue was purified by flash chromatography (0 to 10%
EtOAc/hexanes) to afford the title compound (0.224 g, 76%).
Step b
{(1S,2S,4R)-2-hydroxy-4-[(6-phenylpyrimidin-4-yl)oxy]cyclopentyl}methyl
sulfamate (Compound I-114)
[0582] The title compound was prepared as described in Example 46
steps c and e and Example 48 step f using
4-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethy-
l)silyl]oxy}methyl)cyclopentyl]oxy}-6-phenylpyrimidine. .sup.1H NMR
(CD.sub.3OD, 400 MHz, .delta.): 8.73 (s, 1H); 8.03-7.98 (m, 2H);
7.51-7.47 (m, 3H); 7.21 (s, 1H); 5.70-5.65 (m, 1H); 4.44-4.39 (m,
1H); 4.35 (dd, J=7.5 Hz, J=2.3 Hz, 1H); 4.17 (dd, J=7.3 Hz, J=2.5
Hz, 1H); 3.30 (q, J=3.3 Hz, J=1.6 Hz, 1H); 2.62-2.51 (m, 1H);
2.38-2.30 (m, 1H); 2.17-1.96 (m, 3H). LC/MS: R=1.55 min, ES.sup.+
366 (FA standard).
Example 59
{(1S,2S,4R)-4-[(6-benzylpyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl
sulfamate (Compound I-132)
Step a
4-benzyl-6-{[(1R-3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl-
(dimethyl)-silyl]oxy}methyl)cyclopentyl]oxy}pyrimidine
[0583] To a solution of
4-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethy-
l)silyl]oxy}methyl)cyclopentyl]oxy}-6-chloropyrimidine (0.264 g,
0.559 mmol) and ferric acetylacetonate (0.0395 g, 0.112 mmol) in
THF (9 mL) was added a 1.00 M solution of benzylmagnesium bromide
in THF (2.52 mL) and the mixture was stirred overnight. The
reaction was quenched using NH.sub.4Cl and extracted with EtOAc
(3.times.). The combined organic layers were dried
(Na.sub.2SO.sub.4), filtered and concentrated in vacuo. The residue
was purified by flash chromatography (0 to 15% EtOAc/hexanes) to
afford the title compound as a clear oil. (0.254 g, 86%).
Step b
{(1S,2S,4R)-4-[(6-benzylpyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl
sulfamate (Compound I-132)
[0584] The title compound was prepared as described in Example 46
steps c and e and Example 48 step f using
4-benzyl-6-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-buty-
l(dimethyl)silyl]oxy}methyl)cyclopentyl]oxy}pyrimidine. .sup.1H NMR
(CD.sub.3OD, 400 MHz, .delta.): 8.69 (s, 1H); 7.38-7.22 (m, 6H);
6.41 (s, 1H); 5.65-5.58 (m, 1H); 4.52-4.47 (m, 1H); 4.45-4.39 (m,
1H); 4.31-4.25 (m, 1H); 4.03 (s, 2H); 2.63-2.53 (m, 1H); 2.37-2.28
(m, 1H); 2.16-1.84 (m, 4H). LC/MS: R.sub.t=1.42 min, ES.sup.+ 380
(FA standard).
Example 60
((1R,2R,3S,4R)-2,3-dihydroxy-4-{[6-(2-phenylethyl)pyrimidin-4-yl]amino}-cy-
clopentyl)methyl sulfamate (Compound I-86)
Step a
((3aR,4R,6R,6aS)-2,2-dimethyl-6-{[6-(2-phenylethyl)pyrimidin-4-yl]amino}-t-
etrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methanol
[0585] The title compound was prepared following the procedure
described in Example 46 step d using
((3aR,4R,6R,6aS)-2,2-dimethyl-6-{[6-(phenylethynyl)pyrimidin-4-yl]amino}t-
etrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methanol.
Step b
((1R,2R,3S,4R)-2,3-dihydroxy-4-{[6-(2-phenylethyl)pyrimidin-4-yl]amino}-cy-
clopentyl)methyl sulfamate (Compound I-86)
[0586] The title compound was prepared following the procedure
described in Example 48 step g using
((3aR,4R,6R,6aS)-2,2-dimethyl-6-{[6-(2-phenylethyl)pyrimidin-4-yl]-amino}-
tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methanol. .sup.1H NMR
(CD.sub.3OD, 400 MHz, .delta.): 8.45 (s, 1H); 7.30-7.16 (m, 5H);
6.41 (bs, 1H); 4.41 (bs, 1H); 4.19-4.12 (m, 2H); 3.90-3.85 (m, 1H);
3.83-3.78 (m, 1H); 3.38 (s, 2H); 3.03-2.86 (m, 4H); 2.41-2.29 (m,
2H); 1.37-1.26 (m, 1H). LC/MS: R.sub.t=0.99 min, ES.sup.+ 409 (FA
standard).
Example 61
[(1S,3R,4R)-3-({6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}amin-
o)-4-hydroxycyclopentyl]methyl sulfamate (Compound I-76)
Step a
(1R,2R,4R)-2-amino-4-(hydroxymethyl)cyclopentanol
[0587] A solution of (1R,3R,5S)-6-oxabicyclo[3.1.0]hex-3-ylmethanol
(0.419 g, 3.67 mmol) (Feeya, David. Journal of Organic Chemistry,
1981, 46, 3512-3519) in ammonium hydroxide (7.22 mL) was heated to
65.degree. C. overnight. The solution was concentrated in vacuo and
azeotroped with toluene (3.times.) to afford the title compound as
a clear oil (0.473 g, 98%).
Step b
1R,2R,4R)-4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2({6-[(1S)-2,3-dihydr-
o-1H-inden-1-ylamino]pyrimidin-4-yl}amino-cyclopentol
[0588] The title compound was prepared following the procedure
described in Example 48 steps c-d using
(1R,2R,4R)-2-amino-4-(hydroxymethyl)cyclopentanol.
Step c
(1R,2R,4R)-4-({[tert-butyl(dimethyl)silyl]oxy}methyl-2-({6-[(1S)-2,3-dihyd-
ro-1H-inden-1-ylamino]pyrimidin-4-yl}amino)cyclopentyl acetate
[0589] To a solution of
(1R,2R,4R)-4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-({6-[(1S)-2,3-dih-
ydro-1H-inden-1-ylamino]pyrimidin-4-yl}amino)cyclopentanol (0.193
g, 0.424 mmol), N,N-dimethylaminopyridine (4.7 mg, 0.039 mmol) and
pyridine (0.281 mL, 3.48 mmol) in DCM (2.1 mL) was added acetic
anhydride (0.044 mL, 0.46 mmol) and the mixture stirred overnight.
The reaction was diluted with CH.sub.2Cl.sub.2 (10 mL) and H.sub.2O
(20 mL) then stirred for 10 m. The organic layer was separated and
the aqueous layer was extracted with CH.sub.2Cl.sub.2 and combined
organics were washed with H.sub.2O. The organic layer was dried
(MgSO.sub.4), filtered and concentrated in vacuo to obtain the
title compound. LC/MS: R.sub.t=1.74 min, ES.sup.+ 498 (FA
Standard).
Step d
[(1S,3R,4R)-3-({6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}amin-
o)-4-hydroxycyclopentyl]methyl sulfamate (Compound I-76)
[0590] The title compound was prepared following the procedure
described in Example 57 step d using
(1R,2R,4R)-4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-({6-[(1S)-2,3-dih-
ydro-1H-inden-1-ylamino]pyrimidin-4-yl}amino)cyclopentyl acetate.
.sup.1H NMR (CD.sub.3OD, 400 MHz, .delta.): 7.95 (s, 1H); 7.28-7.14
(m, 4H); 5.66-5.61 (m, 1H); 5.30 (bs, 1H); 4.07 (s, 1H); 4.05 (s,
1H); 4.02 (q, J=53 Hz, 1H); 3.82 (bs, 1H); 3.05-2.96 (m, 1H);
2.92-2.82 (m, 1H); 2.63-2.52 (m, 2H); 2.41-2.30 (m, 1H); 1.39-1.28
(m, 1H). LC/MS: R.sub.t=0.94 min, ES.sup.+ 420 (FA standard).
Example 62
[(1R,3R,4R)-3-({6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}-ami-
no)-4-hydroxycyclopentyl]methyl sulfamate (Compound I-58)
[0591] The title compound was prepared following the procedure
described in Example 59 steps a-d using
(1S,2S,4R)-2-amino-4-(hydroxymethyl)cyclopentanol. .sup.1H NMR
(CD.sub.3OD, 400 MHz, .delta.): 7.95 (s, 1H); 7.29-7.13 (m, 5H);
5.61 (d, J=5.0 Hz, 1H); 5.30 (bs, 1H); 4.08 (s, 1H); 4.06 (s, 1H);
4.01 (q, J=6.3 Hz, 1H); 3.82 (bs, 1H); 3.04-2.95 (m, 1H); 2.92-2.83
(m, 1H); 2.61-2.46 (m, 2H); 2.25-2.17 (m, 1H); 2.06-1.96 (m, 1H);
1.93-1.82 (m, 1H); 1.80-1.70 (m, 1H); 1.49-1.40 (m, 1H). LC/MS:
R.sub.t=0.94 min, ES.sup.+ 420 (FA standard).
Example 63
{(1R,2R,3S,4R)-4-[{6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}--
(methyl)amino]-2,3-dihydroxycyclopentyl}methyl sulfamate (Compound
I-106)
Step a
N-[(3aS,4R,6R,6aR)-6-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2,2-dimethyl-
tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]-6-chloro-N-methylpyrimidin-4-
-amine
[0592] To a mixed solution of
N-[(3aS,4R,6R,6aR)-6-({[tert-butyl(dimethyl)sily]oxy}-methyl)-2,2-dimethy-
ltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]-6-chloropyrimidin-4-amine
(405 mg, 0.98 mmol) in THF (10.0 mL) and DMF (2.50 mL) was added
sodium hydride (47.0 mg, 1.17 mmol) under an atmosphere of Argon,
and the mixture was stirred for 15 minutes. Methyl iodide (0.08 mL,
1.27 mmol) was added to the mixture, and the resulting mixture was
stirred for 1 h. After quenching by addition of brine (20.0 mL),
the mixture was extracted with ethyl acetate (3.times.40.0 mL). The
organic layers were combined, dried over MgSO.sub.4, filtered, and
evaporated under vacuum. The residue was purified via silica gel
column chromatography eluting with a gradient of 5 to 15% ethyl
acetate in DCM to afford the title compound (381 mg, 91%) as a
colorless oil. LC/MS: R.sub.t=2.55 min, ES.sup.+ 428.3 (AA
standard).
Step b
{(3aR,4R,6R,6aS)-6-[(6-chloropyrimidin-4-yl)(methyl)amino]-2,2-dimethyltet-
rahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl}methanol
[0593] To a stirred solution of
N-[(3aS,4R,6R,6aR)-6-({[tert-butyl(dimethyl)silyl]oxy}-methyl)-2,2-dimeth-
yltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]-6-chloro-N-methylpyrimidin-
-4-amine (400 mg, 0.93 mmol) in THF (10.0 mL) was added 1M solution
of tetra-n-butylammonium fluoride in THF (1.00 mL, 1.00 mmol), and
the mixture was stirred for 2 h. After quenching by addition of
brine (20.0 mL), the resulting mixture was extracted with ethyl
acetate (3.times.40.0 mL). The organic layers were combined, dried
over MgSO.sub.4, filtered, and evaporated under vacuum. The residue
was purified via silica gel column chromatography eluting with a
gradient of 40 to 100% ethyl acetate in DCM to afford the title
compound (261 mg, 89%) as a colorless oil. LC/MS: R.sub.t=1.24 min,
ES.sup.+ 314.2 (AA standard).
Step c
{(3aR,4R,6R,6aS)-6-[{6-[(1S)-2,3-dihydro-1H-inden-ylamino]pyrimidin-4-yl}--
(methyl)amino]-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl}-m-
ethanol
[0594]
{(3aR,4R,6R,6aS)-6-[(6-chloropyrimidin-4-yl)(methyl)amino]-2,2-dime-
thyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl}methanol (130 mg,
0.41 mmol) was weighed into a microwave reaction tube and dissolved
in 1-butanol (1.50 mL). To this solution was added
N,N-diisopropylethylamine (0.22 mL, 1.24 mmol) and
(S)-(+)-1-aminoindan (0.16 mL, 1.24 mmol) and the mixture was
heated in a sealed tube under microwave irradiation at 200.degree.
C. for 4 h. The reaction mixture was concentrated under vacuum, and
the residue was purified via silica gel column chromatography
eluting with a gradient of 2 to 5% methanol in DCM to afford the
title compound (40.5 mg, 24%) as a colorless oil. LC/MS:
R.sub.t=1.49 min, ES.sup.+ 411.5 (AA standard).
Step d
{(3aR,4R,6R,6aS)-6-[{6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]pyrimidin-4-yl-
}-(methyl)amino]-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl}-
methyl sulfamate
[0595] The title compound was prepared following the procedure
described in Example 1 step d. LC/MS: R.sub.t=1.68 min, ES.sup.+
490.3 (AA standard).
Step e
{(1R,2R,3S,4R)-4-[{6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]pyrimidin-4-yl}--
(methyl)amino]-2,3-dihydroxycyclopentyl}methyl sulfamate (Compound
I-106)
[0596] To a stirred solution of
{(3aR,4R,6R,6aS)-6-[{6-[(1S)-2,3-dihydro-1H-inden-1-yl-amino]pyrimidin-4--
yl}(methyl)amino]-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl-
}methyl sulfamate (12.0 mg, 0.02 mmol) in methanol (3.00 mL) was
added 1.00 M hydrochloric acid (0.10 mL), and the mixture was
stirred for 8 h. After quenching by vacuum. The residue was
purified via silica gel column chromatography eluting with a
gradient of 5 to 10% methanol in DCM to afford the title compound
(7.80 mg, 71%). .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 8.01 (s,
1H), 7.27-7.13 (m, 4H), 5.67 (s, 1H), 5.42-5.34 (m, 1H), 4.88-4.75
(m, 1H), 4.17 (d, 2H, J=5.6 Hz), 4.04 (dd, 1H, J=8.8, 6.1 Hz), 3.88
(dd, 1H, J=5.8, 4.1 Hz), 3.05-2.96 (m, 1H), 2.89 (s, 3H), 2.93-2.83
(m, 1H), 2.62-2.52 (m, 1H), 2.34-2.24 (m, 1H), 2.01 (dt, 1H,
d=13.0, 8.3 Hz), 1.94-1.83 (m, 1H), 1.44 (ddd, 1H, J=13.0, 10.8,
9.1). LC/MS: R.sub.t=5.79 min, ES.sup.+ 450.2 (AA Waters).
Example 64
[(1R,2R,3S,4R)-4-({2-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-5-fluoropyrimid-
in-4-yl}amino)-2,3-dihydroxycyclopentyl]methyl sulfamate (Compound
I-113)
Step a
(1R,2S,3R,5R)-3-[(2-chloro-5-fluropyrimidin-4-yl)amino]-5-hydroxymethyl)-c-
yclopentane-1,2-diol
[0597] The title compound was prepared following the procedure
described in Example 1 using 2,4-dichloro-5-fluoropyrimidine in
step a. LC/MS: R.sub.t=0.89 min, ES.sup.+ 278.0 (FA standard).
Step b
{(3aR,4R,6R,6aS)-6-[(2-chloro-5-fluoropyrimidin-4-yl)amino]-2,2-dimethylte-
trahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl}methanol
[0598] The title compound was prepared following the procedure
described in Example 1 using
(1R,2S,3R,5R)-3-[(2-chloro-5-fluoropyrimidin-4-yl)amino]-5-(hydroxymethyl-
)cyclopentane-1,2-diol in step b. LC/MS: R.sub.t=1.42 min, ES.sup.+
318.1 (FA standard).
Step c
[(3aR,4R,6R,6aS)-6-({2-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-5-fluoropyrim-
idin-4-yl}amino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]-
methanol
[0599] The title compound was prepared following the procedure
described in Example 1 using
{(3aR,4R,6R,6aS)-6-[(2-chloro-5-fluoropyrimidin-4-yl)amino]-2,2-dimethylt-
etrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl}methanol in step c.
LC/MS: R.sub.t=1.20 min, ES.sup.+ 415.6 (FA standard).
Step d
[(1R,2R,3S,4R)-4-({2-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-5-fluoropyrimid-
in-4-yl}amino)-2,3-dihydroxycyclopentyl]methyl sulfamate (Compound
I-113)
[0600] The title compound was prepared following the procedure
described in Example 65 step d. (63.5 mg, 62%) .sup.1H-NMR (400
MHz, CD.sub.3OD) .delta.: 8.29 (bs, 1H), 7.65 (d, 1H, J=4.6 Hz),
7.29-7.13 (m, 4H), 5.43 (t, 1H, J=7.3 Hz), 4.44-4.37 (m, 1H), 4.17
(dd, 1H, J=9.8, 5.1 Hz), 4.13 (dd, 1H, J=9.8, 5.3 Hz), 3.93-3.86
(m, 2H), 3.01 (ddd, 1H, J=16.0, 8.8, 3.5 Hz), 2.87 (dt, 1H, J=16.0,
8.0 Hz), 2.62-2.53 (m, 1H), 2.35-2.24 (m, 2H), 1.98-1.87 (m, 1H),
1.40-1.27 (m, 1H). LC/MS: R.sub.t=4.21 min, ES.sup.+ 454.2 (FA
long).
Example 65
{(1S,2S,4R)-4-[(5-fluoro-6-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]--
amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate
(Compound I-83)
Step a
4-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl
sily]oxy}-4-({[tert-butyl(dimethyl)silyl]oxy}-methyl)cyclopentyl]oxy}-6-c-
hloro-5-fluoropyrimidine
[0601] To a stirred suspension of sodium hydride (37.4 mg, 0.93
mmol) in THF (5.00 mL) was added a solution of
(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl)si-
lyl]oxy}methyl)cyclopentanol (285 mg, 0.79 mmol) in THF (2.50 mL)
at 0.degree. C. under an atmosphere of Argon, and the mixture was
stirred for 15 minutes. To this cooled suspension was added a
solution of 4,6-dichloro-5-fluoropyrimidine (120 mg, 0.72 mmol) in
THF (2.50 mL) at 0.degree. C., and the resulting mixture was
stirred for 19 h at 23.degree. C. After quenching by addition of
saturated NH.sub.2Cl solution (50.0 mL), the mixture was extracted
with ethyl acetate (3.times.70.0 mL). The organic layers were
combined, dried over MgSO.sub.4, filtered, and evaporated under
vacuum. The residue was purified via silica gel column
chromatography eluting with a gradient of 5 to 7% ethyl acetate in
hexanes to afford the title compound (295 mg, 79%). .sup.1H-NMR
(400 MHz, CDCl) .delta.: 8.32 (s, 1H), 5.67-5.61 (m, 1H), 4.41-4.37
(m, 1H), 3.73 (dd, 1H, J=9.8, 7.1 Hz), 3.59 (dd, 1H, 1=9.8, 6.6
Hz), 2.33-2.25 (m, 1H), 2.10-1.96 (m, 2H), 1.90 (ddd, 1H, J=13.8,
7.7, 1.8 Hz), 1.55 (s, 18H), 0.89 (s, 6H), 0.88 (s, 6H).
Step b
6-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl-
)siyl]oxy}-methyl)cyclopentyl]oxy}-5-fluoro-N-[(1R,2S)-2-methoxy-2,3-dihyd-
ro-1H-inden-1-yl]pyrimidin-4-amine
[0602]
4-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(d-
imethyl)silyl]-oxy}methyl)cyclopentyl]oxy}-6-chloro-5-fluoropyrimidine
(260 mg, 0.53 mmol), (1R,2S)-2-methoxyindan-1-amine (364 mg, 2.12
mmol), and sodium carbonate (224 mg, 2.12 mmol) was weighed into a
microwave reaction tube. This mixture was heated in a sealed tube
under microwave irradiation at 180.degree. C. for 2 h. The reaction
mixture was diluted with DCM (100 mL), and the suspension was
filtered. The filtrate was washed with saturated NH4Cl solution
(100 mL), and the organic layer was dried over MgSO.sub.4. This
suspension was filtered, and evaporated under vacuum. The residue
was purified via silica gel column chromatography eluting with a
gradient of 0 to 10% methanol in DCM to afford the title compound
(313 mg, 91%).
Step c
{(1S,2S,4R)-2-{[tert-butyl(dimethyl)silyl]oxy}-4-[(5-fluoro-6-{[(1R,2S)-2--
methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]cyclopentyl}met-
hanol
[0603] The title compound was prepared following the procedure
described in Example 34 using
6-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethy-
l)-silyl]oxy}methyl)cyclopentyl]oxy}-5-fluoro-N-[(1R,2S)-2-methoxy-2,3-dih-
ydro-1H-inden-1-yl]pyrimidin-4-amine in step c. LC/MS: R.sub.t=2.60
min, ES.sup.+ 504.5 (FA standard).
Step d
{(1S,2S,4R)-4-[(5-fluoro-6-{[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]--
amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate
(Compound I-83)
[0604] To a stirred solution of
{(1S,2S,4R)-2-{[tert-butyl(dimethyl)silyl]oxy}-4-[(5-fluoro-6-{[(1R,2S)-2-
-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)-oxy]cyclopentyl}m-
ethanol (190 mg, 0.36 mmol) in THF (5.40 mL) was added
triethylamine (0.08 mL, 0.54 mmol) and
[(diphenylamino)carbonyl]sulfamoyl chloride (186 mg, 0.54 mmol) at
0.degree. C. under an atmosphere of Argon, and the mixture was
stirred for 30 min. The reaction mixture was added 1.00 M
Hydrochloric acid in (5.40 mL) at 23.degree. C., and the resulting
mixture was stirred for 16 h. The reaction mixture was quenched by
addition of saturated NaHCO.sub.3 solution (80.0 mL) and extracted
with ethyl acetate (3.times.100 mL). The organic layers were
combined, dried over MgSO.sub.4, filtered, and evaporated under
vacuum. The residue was purified via silica gel column
chromatography eluting with a gradient of 0 to 10% methanol in DCM
to afford the title compound (91.0 mg, 51%). .sup.1H-NMR (400 MHz,
CD.sub.3OD) .delta.: 8.01 (s, 1H), 7.25-7.13 (m, 4H), 5.72 (d, 1H,
J=6.5 Hz), 5.65-5.58 (m, 1H), 4.43-4.38 (m, 1H), 4.33 (dd, 1H,
J=9.7, 7.6 Hz), 4.22 (dt, 1H, J=5.0, 2.4 Hz), 4.16 (dd, 1H, J=9.7,
7.3 Hz), 3.35 (s, 3H), 3.14 (dd, 1H, J=16.6, 2.4 Hz), 3.02 (dd, 1H,
J=16.6, 5.0 Hz), 2.60-2.49 (m, 1H), 2.31 (ddd, 1H, d=14.8, 6.8, 2.3
Hz), 2.12 (ddd, 1H, J=14.8, 5.0, 4.7), 2.08-1.95 (m, 2H). LC/MS:
R.sub.t=6.76, ES.sup.+ 469.3 (FA long).
Example 66
{(1S,2S,4R)-4-[(6-{[(1S)-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl]amino}-5-f-
luoropyrimidin-4-yl)amino]-2-hydroxycyclopentyl}methyl sulfamate
(Compound I-71)
Step a
N-[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-([{tert-butyl(dimethyl)-
silyl]oxy}-methyl)cyclopentyl]-6-chloro-5-fluoropyrimidin-4-amine
[0605] A solution of 4,6-dichloro-5-fluoropyrimidine (102 mg, 0.61
mmol),
(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl)si-
lyl]oxy}methyl)-cyclopentanamine (200 mg, 0.56 mmol), and
triethylamine (0.16 mL, 1.11 mmol) in ethanol (2.00 mL) was heated
in a sealed tube under microwave irradiation at 140.degree. C. for
1 h. The reaction mixture was concentrated under vacuum, and the
residue was purified by flash chromatography (0 to 15% ethyl
acetate/hexanes) to afford the title compound (213 mg, 70%) as a
light yellow solid. LC/MS: R.sub.t=2.60 min, ES.sup.+ 490.5 (AA
standard).
Step b
N-[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl)-
silyl]oxy}-methyl)cyclopentyl]-N'-[(1S)-3,3-dimethyl-2,3-dihydro-1H-inden--
yl]-5-fluoropyrimidine-4,6-diamine
[0606] A mixture of
N-[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl-
)silyl]oxy}methyl)cyclopentyl]-6-chloro-5-fluoropyrimidin-4-amine
(205 mg, 0.38 mmol), (1S)-3,3-dimethylindan-1-amine (243 mg, 1.51
mmol), and sodium carbonate (160 mg, 1.51 mmol) was stirred at
180.degree. C. for 3 h in an oil bath. The reaction mixture was
diluted with DCM and the suspension was filtered. The filtrate was
concentrated under vacuum and the residue was purified by flash
chromatography (5 to 10% ethyl acetate/hexanes) to afford the title
compound (213 mg, 70%) as a colorless amorphous solid.
Step c
{(1S,2S,4R)-2-{[tert-butyl(dimethyl)silyl]oxy}-4-[(6-{[(1S)-3,3-dimethyl-2-
,3-dihydro-1H-inden-1-yl]amino}-5-fluoropyrimidin-4-yl)amino]cylopentyl}-m-
ethanol
[0607] The title compound was prepared following the procedure
described in Example 34 step c. LC/MS: R.sub.t=2.51 min, ES.sup.+
501.5 (AA standard).
Step d
{(1S,2S,4R)-4-[(6-{[(1S)-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl]amino}-5-f-
luoropyrimidin-4-yl)amino]-2-hydroxycyclopentyl}methyl sulfamate
(Compound I-71)
[0608] The title compound was prepared following the procedure
described in Example 65 step d. (63.5 mg, 62%). .sup.1H-NMR (400
MHz, CD.sub.3OD) .delta.: 7.84 (d, 1H, J=1.2 Hz), 7.25-7.15 (m,
4H), 5.68 (dd, 1H, J=8.8, 7.7 Hz), 4.67 (ddd, 1H, J=16.3, 8.0, 4.3
Hz), 4.37-4.33 (m, 1H), 4.31 (dd, 1H, J=9.8, 7.8 Hz), 4.13 (dd, 1H,
J=9.8, 7.1 Hz), 2.58-2.47 (m, 1H), 2.40 (dd, 1H, J=12.3, 7.3 Hz),
2.22 (ddd, 1H, J=13.8, 7.8, 1.8 Hz), 2.04 (ddd, 1H, J=13.5, 10.1,
4.5 Hz), 1.91-1.81 (m, 2H), 1.73 (ddd, 1H, J1=13.5, 8.7, 4.0 Hz),
1.40 (s, 3H), 1.23 (s, 3H). LC/MS: R.sub.t=7.53 min, ES.sup.+ 466.2
(FA long).
Example 67
((1R,2R,3S,4R)-2,3-dihydroxy-4-{[6-(5,6,7,8-tetrahydronaphthalen-1-ylamino-
)pyrimidin-4-yl]amino}cyclopentyl)methyl sulfamate (Compound
I-118)
Step a
(1S,2R,3R,5R)-3-(hydroxymethyl)-5-{[6-(5,6,7,8-tetrahydronaphthalen-1-ylam-
ino)pyrimidin-4-yl]amino}cyclopentane-1,2-diol
[0609] The title compound was prepared following the procedure
described in Example 1 steps a and c using
5,6,7,8-tetrahydro-1-naphthylamine in step c. LC/MS: R=1.29 min,
ES.sup.+ 371.3 (AA standard).
Step b
((3aR,4R,6R,6aS)-2,2-dimethyl-{[6-(5,6,7,8-tetrahydronaphthalen-1-ylamino)-
pyrimidin-4-yl]amino}tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)-methano-
l
[0610] To a stirred solution of
(1S,2R,3R,5R)-3-(hydroxymethyl)-5-{[6-(5,6,7,8-tetrahydronaphthalen-1-yla-
mino)pyrimidin-4-yl]amino}cyclopentane-1,2-diol (70.0 mg, 0.19
mmol) in acetone (5.00 mL) was added 2,2-dimethoxypropane (0.21 mL,
1.70 mmol) and pyridinium p-toluenesulfonate (57.0 mg, 0.23 mmol),
and the mixture was stirred for 55 h. The reaction mixture was
quenched by addition of saturated NaHCO.sub.3 solution (50.0 mL)
and then extracted with ethyl acetate (3.times.50.0 mL). The
organic layers were combined, dried over MgSO.sub.4, filtered, and
evaporated under vacuum. The residue was purified by flash
chromatography (2 to 10% Methanol/DCM) to afford the title compound
(72.0 mg, 85%) as a light yellow amorphous solid. LC/MS:
R.sub.t=1.59 min, ES.sup.+ 411.3 (AA standard).
Step c
((1R,2R,3S,4R)-2,3-dihydroxy-4-{[6-(5,6,7,8-tetrahydronaphthalen-1-ylamino-
)pyrimidin-4-yl]amino}cyclopentyl)methyl sulfamate (Compound
I-118)
[0611] The title compound was prepared following the procedure
described in Example 65 step d. .sup.1H-NMR (400 MHz, CD.sub.3OD)
.delta.: 7.96 (s, 1H), 7.13-7.02 (m, 2H), 6.97 (d, 1H, J=7.2 Hz),
5.46 (s, 1H), 4.18-4.08 (m, 2H), 4.02-3.87 (m, 1H), 3.85 (dd, 1H,
J=5.5, 4.0 Hz), 3.73 (dd, 1H, J=5.8, 5.5 Hz), 2.82-2.76 (m, 2H),
2.65-2.59 (m, 2H), 2.37-2.25 (m, 2H), 1.82-1.74 (m, 4H), 1.30-1.20
(m, 1H). LC/MS: R.sub.t=5.04 min, ES.sup.+ 450.2 (FA long)
Example 68
{(1S,2S,4R)-4-[(6-{[(1S)-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl]amino}-pyr-
imidin-4-yl)amino]-2-hydroxycyclopentyl}methyl sulfamate (Compound
I-65)
Step a
(1S,3S,4S)-3-[(benzyloxy)methyl]-{[tert-butyl(dimethyl)
silyl]oxy}cyclopentanol
[0612] A suspension of
(1R,4S)-3-[(benzyloxy)methyl]-4-{[tert-butyl(dimethyl)silyl]-oxy}cyclopen-
t-2-en-1-ol (1.47 g, 0.00439 mol), sodium carbonate (1.1 g, 0.010
mol) and 10% Pd/C (0.3 g, 0.0003 mol) in EtOAc (20 mL, 0.2 mol) was
stirred under an atmosphere of Hydrogen overnight. The reaction was
purged with nitrogen and filtered through celite with EtOAc. The
filtrate was concentrated to obtain 1.45 g (98%) of the title
compound as a 5:1 mixture of diastereomers (desired:undesired).
Step b
(1S,3S,4S)-3-[(benzyloxy)methyl]-4-{[tert-butyl(dimethyl)silyl]oxy}cyclope-
ntyl methanesulfonate
[0613] The title compound was prepared following the procedure
described in Example 35 step b.
Step c
(1S,2S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-(hydroxymethyl)cyclopentyl-
) methanesulfonate
[0614] A suspension of
(1S,3S,4S)-3-[(benzyloxy)methyl]-4-{[tert-butyl(dimethyl)silyl]-oxy}cyclo-
pentyl methanesulfonate (690 mg, 0.0017 mol) and Palladium
hydroxide, 20 wt. % Pd on carbon (160 mg, 0.00012 mol) in methanol
(10 mL, 0.2 mol) was stirred under an atmosphere of hydrogen for 2
hours. The reaction was purged with nitrogen and filtered the
mixture through celite with DCM. The filtrate was concentrated to
obtain 350 mg (65%).
Step d
((1S,2S,4R)-4-azido-2-{[tert-butyl(dimethyl)silyl]oxy}cyclopentyl)methanol
[0615] To a solution of
(1S,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-(hydroxymethyl)-cyclopent-
yl methanesulfonate (0.470 g, 0.00145 mol) in N,N-Dimethylformamide
(6 mL, 0.08 mol) was added sodium azide (0.4 g, 0.006 mol)
23.degree. C., and the mixture was heated at 55.degree. C. for 3
hours. The reaction was cooled to 23.degree. C., quenched by
addition of water and extracted with Et.sub.2O (3.times.), dried
(Na.sub.2SO.sub.4), filtered and concentrated. The residue was
purified by flash chromatography (10 to 25% ethyl acetate/hexane)
to obtain 211 mg (53.7%).
Step e
((1S,2S,4R)-4-amino-2-{[tert-butyl(dimethyl)silyl]oxy}cyclopentyl)methanol
[0616] A suspension of
((1S,2S,4R)-4-azido-2-{[tert-butyl(dimethyl)silyl]oxy}-cyclopentyl)methan-
ol (0.211 g, 0.000777 mol) and 10% Pd/C (0.047 g, 0.000044 mol) in
EtOAc (6 mL, 0.06 mol) was stirred under an atmosphere of Hydrogen
overnight. The reaction was purged with nitrogen and filtered the
mixture through celite with DCM. The filtrate was concentrated to
obtain 167 mg (87.5%) of the title compound.
Step f
{(1S,2S,4R)-2-{[tert-butyl(dimethyl)silyl]oxy}-4-[(6-chloropyrimidin-4-yl)-
amino]-cyclopentyl}methanol
[0617] A mixture of
((1S,2S,4R)-4-amino-2-{[tert-butyl(dimethyl)silyl]oxy}cyclopentyl)-methan-
ol (0.132 g, 0.000538 mol), pyrimidine, 4,6-dichloro-(0.096 g,
0.00064 mol) and triethylamine (0.1 mL, 0.001 mol) in ethanol (1.5
mL, 0.025 mol) was subjected to microwave irradiation (140.degree.
C.) for 60 minutes. The resulting dark brown mixture was
concentrated. The residue was purified by flash chromatography (0
to 10% MeOH/DCM) to give 158 mg (82%).
Step g
{(1S,2S,4R)-4-[(6-{[(1S)-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl]amino}-pyr-
imidin-4-yl)amino]-2-hydroxycyclopentyl}methyl sulfamate (Compound
I-65)
[0618] The title compound was prepared following the procedure
described in Example 44 (steps b and d) using
(1S)-3,3-dimethylindan-1-amine. .sup.1H NMR (CD.sub.3OD, 400 MHz)
.delta.: 8.15 (s, 1H), 7.33-7.21 (m, 4H), 5.66 (s, 1H), 4.39-4.36
(m, 1H), 4.31 (dd, J=7.3, 9.7 Hz, 1H), 4.13 (dd, J=7.4, 9.7 Hz,
1H), 2.53-2.44 (m, 2H), 2.27-2.22 (m, 1H), 2.08-2.01 (m, 1H),
1.91-1.84 (m, 2H), 1.78-1.72 (m, 1H), 1.41 (s, 3H), 1.27 (s, 3H)
ppm. LC/MS: R.sub.t=1.54 min, ES.sup.+ 448.38 (AA standard).
Example 69
{(1S,2S,4R)-2-hydroxy-4-[(6-{[(1S,2S)-2-methyl-2,3-dihydro-1H-inden-1-yl]--
amino}pyrimidin-4-yl)oxy]cyclopentyl}methyl sulfamate (Compound
I-43)
[0619] The title compound was prepared following the procedure
described in Example 34 using
(1S,2S)-2-methyl-2,3-dihydro-1H-inden-1-amine (Zhang, Z.; Zhu, G.;
Jiang, Q.; Xiao, D.; Zhang, Z. J. Org. Chem. 1999, 64, 1774) in
step b. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.: 8.13 (s, 1H),
7.28-7.14 (m, 4H), 5.88 (s, 1H), 5.56 (bs, 1H), 5.32 (bs, 1H),
4.40-4.30 (m, 2H), 4.18-4.12 (m, 1H), 3.10-3.02 (m, 1H), 2.90-2.78
(m, 1H), 2.68-2.62 (m, 1H), 2.57-2.47 (m, 1H), 2.31-2.23 (m, 1H),
2.11-1.91 (m, 3H), 0.91 (d, J=7.03 Hz, 3H) ppm. LC/MS: R.sub.t=1.65
min, ES.sub.+435 (AA standard).
Example 70
{(1S,2S,4R)-4-[(4-{[(1R)-2,2-difluoro-2,3-dihydro-1H-inden-1-yl]amino}-1,3-
,5-triazin-2-yl)amino]-2-hydroxycyclopentyl}methyl sulfamate
(Compound I-147)
[0620] The title compound was prepared following the procedure in
Example 46 steps a-d using (1R)-5-chloro-2,2-difluoroindan-1-amine
in step a. The sulfamation was carried out according to the
procedure in Example 65 step d to give the title compound. .sup.1H
NMR (CD.sub.3OD 400 MHz) .delta.: 8.05 (d, 0.5H), 7.95 (s, 0.5H),
7.30-7.28 (m, 4H), 6.06-5.89 (m, 1H), 4.62-4.59 (m, 1H), 4.27-4.24
(m, 2H), 4.14-4.08 (m, 1H), 3.50-3.41 (m, 2H), 2.49 (bs, 1H),
2.22-2.14 (m, 1H), 2.05-1.97 (m, 1H), 1.87-1.80 (m, 1H), 1.76-1.70
(m, 1H) ppm. LC/MS: R.sub.t=5.61 min, ES.sup.+ 457 (FA long).
Example 71
{(1S,2S,4R)-2-hydroxy-4-[(6-{[(1R,2S)-2-methoxy-1,2,3,4-tetrahydronaphthal-
en-1-yl]amino}pyrimidin-4-yl)oxy]cyclopentyl}methyl sulfamate
(Compounds I-142 and I-143)
[0621] The title compound was prepared as a 1:1 mixture of
diastereomers following the procedures in Example 34.
Rel-(1R,2S)-2-methoxy-1,2,3,4-tetrahydronaphthalen-1-amine,
generated by adapting the following literature precedent: Marcune,
B. F.; Karady, S.; Reider, P. J.; Miller, R. A.; Biba, M.;
DiMichele, L.; Reamer, R. A. J. Org. Chem. 2003, 68, 8088-8091, was
used as a coupling partner in step b. The mixture was then
separated by chiral HPLC (Chiralpak AD 20.times.250, eluent
85/15/0.1% hex/EtOH/DEA at 20 mL/min). Analytical data for
{(1S,2S,4R)-2-hydroxy-4-[(6-{[(1R,2S)-2-methoxy-1,2,3,4-tetrahydronaphtha-
len-1-yl]amino}pyrimidin-4-yl)oxy]cyclopentyl}methyl sulfamate
(Compound I-142): .sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.: 8.13
(d, J=0.8 Hz, 1H), 7.20 (d, J=7.3 Hz, 1H), 7.15-7.01 (m, 3H), 5.93
(s, 1H), 5.48 (bs, 1H), 5.34-5.31 (m, 1H), 4.40-4.37 (m, 1H), 4.32
(dd, J=7.6, 9.8 Hz, 1H), 4.15 (dd, J=7.5, 9.6 Hz, 1H), 3.77-3.74
(m, 1H), 3.41 (s, 3H), 3.00-2.92 (m, 1H), 2.78-2.71 (min, 1H),
2.55-2.48 (m, 1H), 2.31-2.19 (m, 2H), 2.12-1.90 (m, 4H) ppm. LC/MS:
R.sub.t=6.22 min, ES.sup.+ 465 (FA long). Analytical data for
{(1S,2S,4R)-2-hydroxy-4-[(6-{[(1S,2R)-2-methoxy-1,2,3,4-tetrahydronaphtha-
len-1-yl]amino}pyrimidin-4-yl)-oxy]cyclopentyl}methyl sulfamate
(Compound I-143): .sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.: 8.13
(d, J=0.8 Hz, 1H), 7.19 (d, J=7.3 Hz, 1H), 7.15-7.08 (m, 3H), 5.93
(s, 1H), 5.50 (bs, 1H), 5.34-5.31 (m, 1H), 4.40-4.37 (m, 1H), 4.32
(dd, J=7.2, 9.8 Hz, 1H), 4.16 (dd, J=7.3, 9.8 Hz, 1H), 3.77-3.74
(m, 1H), 3.41 (s, 3H), 3.00-2.92 (m, 1H), 2.78-2.71 (m, 1H),
2.55-2.49 (m, 1H), 2.31-2.19 (m, 2H), 2.12-1.90 (m, 4H) ppm. LC/MS:
R.sub.t=6.09 min, ES.sup.+ 465 (FA long).
Example 72
{(1R,2R,3S,4R)-4-[(6-{[(1R,2R)-2-(benzyloxy)cyclopentyl]amino}pyrimidin-4--
yl)-amino]-2,3-dihydroxycyclopentyl}methyl sulfamate (Compound
I-85)
[0622] The title compound was prepared following the procedure
described in Example 1, steps a-c using
(1R,2R)-(+)-2-benzyloxycyclopentylamine and Example 65, step d.
.sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 7.90 (s, 1H), 7.34-7.22
(m, 5H), 5.59 (s, 1H), 4.58 (d, 1H, J=14.5 Hz), 4.55 (d, 1H, J=14.5
Hz), 4.18 (dd, 1H, J=9.8, 4.8 Hz), 4.13 (dd, 1H, J=9.8, 5.5 Hz),
4.05-3.96 (m, 1H), 3.95-3.84 (m, 3H), 3.76 (t, 1H, J=5.5 Hz),
2.41-2.25 (m, 2H), 2.20-2.10 (m, 2H), 1.99-1.90 (m, 1H), 1.83-1.68
(m, 3H), 1.56-1.45 (m, 1H), 1.29 (dt, 1H, J=12.5, 8.3 Hz). LC/MS:
R.sub.t=5.17 min, ES.sup.+ 473.2 (FA long)
Example 73
{(1R,2R,3S,4R)-4-[(6-{[(1S,2S)-2-(benzyloxy)cyclopentyl]amino}pyrimidin-4--
yl)-amino]-2,3-dihydroxycyclopentyl}methyl sulfamate (Compound
I-92)
[0623] The title compound was prepared following the procedure
described in Example 1, steps a-c using
(1S,2S)-(+)-2-benzyloxycyclopentylamine and Example 65, step d.
.sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 7.91 (s, 1H), 7.33-7.21
(m, 5H), 5.57 (s, 1H), 4.57 (s, 2H), 4.19 (dd, 1H, J=9.6, 4.7 Hz),
4.14 (dd, 1H, J=9.6, 5.5 Hz), 4.06-3.90 (m, 2H), 3.90-3.83 (m, 2H),
3.77 (t, 1H, J=5.5 Hz), 2.45-2.28 (m, 2H), 2.20-2.10 (m, 2H),
2.00-1.88 (m, 1H), 1.82-1.68 (m, 3H), 1.54-1.43 (m, 1H), 1.31 (dt,
11, J=12.6, 8.4 Hz). LC/MS: R.sub.a=1.16 min, ES.sup.+ 494.2 (FA
standard).
Example 74
((1S,2S,4R)-4-{[6-({(1S,2S)-2-[(dimethylamino)carbonyl]-2,3-dihydro-1H-ind-
en-1-yl}amino)pyrimidin-4-yl]oxy}-2-hydroxycyclopentyl)methyl
sulfamate (Compound I-66)
Step a
tert-butyl
rel-(2aR,7bR)-2-oxo-2,2a,3,7b-tetrahydro-1H-indeno[1,2-b]azete--
1-carboxylate
[0624] To a mixed solution of
rel-(2aR,7bR)-1,2a,3,7b-tetrahydro-2H-indeno[1,2-b]azet-2-one (1.20
g, 7.54 mmol) and N,N-dimethylaminopyridine (0.20 g, 2.00 mmol) in
acetonitrile (24.0 mL) was added di-tert-butyldicarbonate (3.29 g,
15.1 mmol) at 0.degree. C. under an atmosphere of Argon, and the
mixture was stirred for 1 h at 23.degree. C. The reaction mixture
was added DCM (ca.200 mL) and then the organic layer was washed
with saturated NaHCO.sub.3 solution and brine. After drying over
MgSO.sub.4, the suspension was filtered and the filtrate was
evaporated under vacuum. The residue was purified by flash
chromatography (10 to 30% ethyl acetate/hexanes) to afford the
title compound (1.85 g, 90%) as a light pink solid. .sup.1H-NMR
(400 MHz, CDCL.sub.3) .delta.: 7.58 (d, 1H, J=7.5 Hz), 7.36-7.23
(m, 3H), 5.34 (d, 1H, J=5.0 Hz), 3.98 (ddd, 1H, J=10.5, 5.0, 2.4
Hz), 3.38 (dd, 1H, J=17.4, 1.2 Hz), 3.13 (dd, 1H, J=17.4, 10.5 Hz),
1.52 (s, 9H).
Step b
tert-butyl
rel-{1R,2R)-2-[(dimethylamino)carbonyl]-2,3-dihydro-1H-inden-1--
yl}-carbamate
[0625] To tert-butyl
rel-(2aR,7bR)-2-oxo-2,2a,3,7b-tetrahydro-1H-indeno[1,2-b]azete-1-carboxyl-
ate (200 mg, 0.77 mmol) was added 2.00 M dimethylamine in THF (1.90
mL, 3.80 mmol) in the sealed tube, and the mixture was microwaved
at 120.degree. C. for 30 minutes. The reaction mixture was
concentrated under vacuum, and then the residue was washed with
small amount of hexane to give the title compound (226 mg, 91%) as
a white solid.
Step c
rel-(1R,2R)-1-amino-N,N-dimethylindane-2-carboxamide
[0626] To a stirred solution of tert-butyl
rel-{(1R,2R)-2-[(dimethylamino)carbonyl]-2,3-dihydro-1H-inden-1-yl}carbam-
ate (690 mg, 2.15 mmol) in DCM (25.0 mL) was added zinc dibromide
(970 mg, 4.31 mmol) and ethanol (0.25 mL, 4.31 mmol), and the
mixture was stirred for 18 h. The reaction mixture was quenched by
addition of water (20.0 mL) and the resulting mixture was stirred
for 2 h. To this mixture was added 1.00 M NaOH (30.0 mL) and
extracted with DCM (3.times.100 mL). The organic layers were
combined, dried over MgSO.sub.4, filtered, and evaporated under
vacuum. The residue was purified by flash chromatography (10 to 30%
Methanol/DCM) to afford the title compound (438 mg, 95%) as a
colorless oil. LC/MS: R.sub.t=0.89 min, ES.sup.+ 205.2 (AA
standard).
Step d
((1S,2S,4R)-4-{[6-({(1S,2S)-2-[(dimethylamino)carbonyl]-2,3-dihydro-1H-ind-
en-1-yl}amino)pyrimidin-4-yl]oxy}-2-hydroxycyclopentyl)methyl
sulfamate (Compound I-66)
[0627] The title compound was prepared following the procedure
described in Example 34, steps a-c and Example 65, step d.
.sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 8.18 (s, 1H), 7.28-7.16
(m, 4H), 6.14-5.94 (bs, 1H), 5.81-5.71 (bs, 1H), 5.31-5.23 (bs,
1H), 439-4.35 (m, 1H), 4.31 (dd, 1H, J=9.7, 7.5 Hz), 4.13 (dd, 1H,
J=9.7, 7.3 Hz), 3.98 (dd, 1H, J=15.6, 7.8 Hz), 3.53 (dd, 1H,
J1=16.1, 7.3 Hz), 3.17 (s, 3H), 3.01 (dd, 1H, J=16.1, 8.1 Hz), 2.73
(s, 3H), 2.56-2.44 (m, 1H), 2.29-2.20 (m, 1H), 2.04-1.88 (m, 3H).
LC/MS: R.sub.t=5.70 min, ES.sup.+ 492.2 (FA long).
Example 75
(1S,2S,4R)-4-{[6-({(1S,2R)-2-[(dimethylamino)methyl]-2,3-dihydro-1H-inden--
1-yl}amino)pyrimidin-4-yl]oxy}-2-hydroxycyclopentyl)methyl
sulfamate (Compound I-53)
Step a
rel-(1R,2S)-2-[(dimethylamino)methyl]indan-1-amine
[0628] To a stirred suspension of lithium tetrahydroaluminate (256
mg, 6.74 mmol) in THF (20.0 mL) was added a solution of
rel-(1R,2R)-1-amino-N,N-dimethylindane-2-carboxamide (580 mg, 2.70
mmol) in TH-F (10.0 mL) at 0.degree. C. under an atmosphere of
Argon, and then the mixture was stirred for 1 h at 60.degree. C.
following by stirring for 14 h at 23.degree. C. The reaction
mixture was quenched by addition of water and 1.00 M NaOH (5.00
mL), and the resulting mixture was stirred for 2 h. This suspension
was filtered through a Celite pad, and the filtrate was
concentrated in vacuo. The residue was purified by flash
chromatography (5 to 20% Methanol/DCM with 1% NH.sub.4OH) to afford
the title compound (438 mg, 95%) as a light brown oil.
Step b
(1S,2S,4R)-4-{[6-({(1S,2R)-2-[(dimethylamino)methyl]-2,3-dihydro-1H-inden--
1-yl}amino)pyrimidin-4-yl]oxy}-2-hydroxycyclopentyl)methyl
sulfamate (Compound I-53)
[0629] The title compound was prepared following the procedure
described in Example 34, steps a-c using
rel-(1R,2S)-2-[(dimethylamino)methyl]indan-1-amine and Example 65,
step d. .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 8.14 (s, 1H),
7.28-7.14 (m, 4H), 5.90-5.78 (be, 1H), 5.70-5.40 (bs, 1H),
5.38-5.28 (bs, 1H), 4.41-4.36 (m, 1H), 4.32 (dd, 1H, J=9.8, 7.5
Hz), 4.15 (dd, 1H, J=9.8, 7.3 Hz), 3.09-3.00 (m, 1H), 2.94-2.82 (m,
2H), 2.57-2.46 (m, 1H), 2.37 (br d, 2H, J=6.2 Hz), 2.30-2.20 (m,
1H), 2.22 (s, 6H), 2.11-1.91 (m, 3H). LC/MS: R.sub.t=4.34 min,
ES.sup.+ 478.2 (FA long).
Example 76
{(1S,2S,4R)-4-[(2-{[(1S)-5-chloro-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl]--
amino}pyridin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate
(Compound I-35)
Step a
1-(4-chlorophenyl)-3-methylbutan-2-ol
[0630] To a suspension of magnesium (2.98 g, 0.123 mol) in ether
(30 mL) was added iodine (0.165 g, 0.000651 mol). To this was
slowly added a solution of 4-chlorobenzyl bromide (24.00 g, 0.1168
mol) in ether (100 mL). Upon addition of approximately 1 mL of
solution an exotherm was noted and the mixture reached reflux. The
addition of solution was slowly continued to maintain a gentle
reflux (.about.90 min). On completion of addition, the reaction was
heated for 30 minutes at 45.degree. C. The reaction was then cooled
to 0.degree. C. Isobutyraldehyde (12.7 mL, 0.140 mol) in ether (10
mL) was then added slowly over 2 hours. On completion of the
addition the reaction was allowed to warm to 23.degree. C. and
stirred overnight. The reaction was quenched with ice (.about.200
g) and acidified with 2M HCl (.about.100 ml). This was extracted
twice with ether and the organic phase was evaporated. The residue
was purified by flash chromatography (0 to 10%
MeOH/CH.sub.2Cl.sub.2) to afford the title compound (9.89 g,
43%).
Step b
6-chloro-1,1-dimethylindane
[0631] To a solution of concentrated sulfuric acid (3.00 mL, 0.056
mol) in water (0.28 mL, 0.0156 mol) was added
1-(4-chlorophenyl)-3-methylbutan-2-ol (1.00 g, 0.00503 mol) over 30
minutes. Additional sulfuric acid was added to dissolve the solid.
The mixture was stirred for 2 hours. The mixture was poured onto
ice then extracted with ether. The organic phase was washed
(water), dried (MgSO.sub.4), filtered, and concentrated. The
residue was filtered through a plug of silica with CH.sub.2Cl.sub.2
to afford the title compound (0.568 g, 63%).
Step c
5-chloro-3,3-dimethylindan-1-one
[0632] To a solution of 6-chloro-1,1-dimethylindane (6.00 g, 0.0332
mol) in acetone (100 mL, 2 mol) was added 1.5 M of magnesium
sulfate in water (30 mL) and potassium permanganate (123 g, 0.0780
mol). The reaction was stirred overnight, the resulting deposit was
filtered, and the solution was concentrated to a reduced volume.
The solution was extracted with EtOAc (3.times.100 ml) and the
organic layer was concentrated. Purification by flash
chromatography (10% EtOAc/hexanes) afforded the title compound
(4.33 g, 67%) as a white solid.
Step d
(2R-2-{[(1S)-5-chloro-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl]amino}-2-phen-
ylethanol
[0633] To a mixture of 5-chloro-3,3-dimethylindan-1-one (4.33 g,
0.0222 mol) and (R)-(-)-2-phenylglycinol (3.2 g, 0.0234 mol) in
toluene (200 mL) was added p-toluenesulfonic acid monohydrate (241
mg, 0.00127 mol). The reaction was stirred at reflux (140.degree.
C.) under an atmosphere of nitrogen overnight, cooled and diluted
with toluene. The mixture was washed with saturated aqueous
NaHCO.sub.3 and water and the organic phase was concentrated. The
residue was dissolved in THF (200 mL) under an atmosphere of
nitrogen and cooled at 0.degree. C. To this was added acetic acid
(3.79 mL, 0.0667 mol) and sodium borohydride (1.26 g, 0.0334 mol).
The reaction was stirred under at atmosphere of nitrogen overnight.
The reaction was partitioned between CH.sub.2Cl.sub.2 and saturated
aqueous NaHCO.sub.3 solution, separated, and the organic phase was
evaporated. The residue was purified by flash chromatography (20 to
100% EtOAc/hexanes) to afford the title compound (6.25 g, 90%) as a
white solid.
Step e
(1S)-5-chloro-3,3-dimethylindan-1-amine.HCl
[0634] To a solution of lead(IV) acetate (9.92 g, 0.0212 mol) in
methanol (80 mL) at 0.degree. C. under an atmosphere of nitrogen
was added
(2R)-2-{[(1S)-5-chloro-3,3-dimethyl-2,3-dihydro-1H-inden-1-yl]amino}-2-ph-
enylethanol (4.288 g, 0.01358 mol) as a solution in methanol (80
mL) dropwise over 10 min. On completion of the addition, the
mixture was warmed to 23.degree. C. and stirred for 90 mins. To
this was added 0.943 M of sodium carbonate in water (194 mL) and
the mixture stirred for 10 min. CH.sub.2Cl.sub.2 (500 mL), was
added and the mixture was filtered and washed with
CH.sub.2Cl.sub.2. The filtrates were collected, the organic phase
was separated and the aqueous extracted with CH.sub.2Cl.sub.2 (25
ml). The combined organics were evaporated to dryness. The residue
was dissolved in ethanol (500 mL) and 10.4 M of hydrochloric acid
in water (15.6 mL) was added. The mixture was heated to reflux
(95.degree. C.) overnight. The mixture was cooled, evaporated and
the residue was treated with ether and sonicated. The solid was
isolated by filtration, washed with ether and dried to yield the
title compound (2.704 g, 86%) as the HCl salt.
Step f
4-{[(1R,3S,4S-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl)-
silyl]-oxy}methyl)cyclopentyl]oxy}-N-[(1S)-5-chloro-3,3-dimethyl-2,3-dihyd-
ro-1H-inden-1-yl]pyridin-2-amine
[0635] To a mixture of
[1,3-bis(2,6-diisopropylphenyl)imidazolidin-2-yl](chloro)[(2,3-.)-(1Z)-1--
phenylprop-1-ene-2,3-diyl]palladium(2+) (3.4 mg, 0.0000052 mol) and
potassium tert-butoxide (32.0 mg, 0.000286 mol) under an atmosphere
of argon was added
4-{[(1R,3S,4S)-3-[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl-
)silyl]oxy)methyl)-cyclopentyl]oxy}-2-chloropyridine (0.1226 g,
0.0002596 mol) in 1.00 ml DME, followed by
(1S)-5-chloro-3,3-dimethylindan-1-amine (0.048 g, 0.00025 mol) in 1
ml DME. The mixture was stirred overnight, and the solution was
poured into 50 ml EtOAc, washed with 10 ml water and concentrated.
The residue was purified by preparative plate chromatography (70%
EtOAc/hexanes) to afford the title compound (28.0 mg, 18.0%).
Step g
{(1S,2S,4R)-2-{[tert-butyl(dimethyl)silyl]oxy}-4-[(2-{[(1S)-5-chloro-3,3-d-
imethyl-2,3-dihydro-1H-inden-1-yl]amino}pyridin-4-yl)oxy]cyclopentyl}metha-
nol
[0636] The title compound was prepared by a method analogous to
Example 34, step C.
Step h
{(1S,2S,4R)-2-{[tert-butyl(dimethyl)silyl]oxy}-4-[(2-{[(1S)-5-chloro-3,3-d-
imethyl-2,3-dihydro-1H-inden-1-yl]amino}pyridin-4-yl)oxy]cyclopentyl}methy-
l sulfamate
[0637] To a solution of
{(1S,2S,4R)-2-{[tert-butyl(dimethyl)silyl]oxy}-4-[(2-{[(1S)-5-chloro-3,3--
dimethyl-2,3-dihydro-1H-inden-1-yl]amino}pyridin-4-yl)oxy]cyclopentyl}-met-
hanol (28.1 mg, 0.0000543 mol) in DMA (1.00 mL) was added
chlorosulfonamide (0.0251 g, 0.000217 mol) in 0.50 ml acetonitrile.
The mixture was stirred for 30 min then poured into 50 ml EtOAc and
1.00 ml Et.sub.3N. The layers were separated and the organic layer
was washed (water) and concentrated. The residue was purified by
preparative plate chromatography (85% EtOAc/hexanes) to afford the
title compound (28.7 mg, 89%) as a white solid.
Step i
{(1S,2S,4R)-4-[(2-{[(1S)-5-chlor-3,3-dimethyl-2,3-dihydro-1H-inden-yl]amin-
o}-pyridin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate
[0638] A solution of
{(1S,2S,4R)-2-{[tert-butyl(dimethyl)silyl]oxy}-4-[(2-{[(1S)-5-chloro-3,3--
dimethyl-2,3-dihydro-1H-inden-1-yl]amino}pyridin-4-yl)oxy]cyclopentyl}meth-
yl sulfamate (0.0287 g, 0.0000481 mol) in 3.0% (V/V) HCl in ethanol
(25.0 ml) was stirred for 4 hrs. The reaction was concentrated and
dissolved in 50 ml EtOAc and 1.00 ml triethylamine. The solution
was washed with water, concentrated, and the residue was isolated
by preparative plate chromatography (5% MeOH/EtOAc) to afford the
title compound (16.5 mg, 71%) as a white solid. .sup.1H NMR
(CDCl.sub.3, 400 MHz) .delta.: 7.92 (d, 1H, J=5.8 Hz), 7.22-7.20
(m, 1H), 7.17-7.14 (m, 2H), 6.16 (dd, 1H, J=6.0 Hz, J=2.3 Hz) 5.85
(d, 1H, J=2.0 Hz), 5.30 (m, 1H), 4.92 (m, 1H), 4.70 (d, 1H, J=85
Hz), 4.50 (dt, 1H, J=5.0 Hz, J=1.9 Hz), 4.40 (dd, 1H, J=7.3 Hz,
J=2.5 Hz), 4.28 (dd, 1H, J=7.3 Hz, J=2.5 Hz), 2.60 (bs, 1H), 2.50
(q, 1H, J=7.0 Hz), 2.31-2.25 (m, 1H), 2.18-2.12 (m, 1H), 1.95-1.87
(m, 2H), 1.79 (m, 1H), 1.25 (s, 6H). LC/MS: R.sub.t=1.81 min, ES+
482 (AA standard).
Example 77
((1S,2S,4R)-2-hydroxy-4-{[2-(1-naphthyl)-3H-imidazo[4,5-b]pyridin-7-yl]oxy-
}-cyclopentyl)methyl sulfamate (Compound I-109)
Step a
2-amino-4-chloro-3-nitropyridine
[0639] To a solution of 2-amino-4-chloropyridine (5.00 g, 0.0389
mol) in sulfuric acid (40.8 mL) with stirring at 0.degree. C. was
added a solution of nitric acid (2.72 g, 0.0389 mol) and sulfuric
acid (3.89 g, 0.0389 mol). The mixture was stirred (1 hr) then
poured into 200 g ice and 100 ml water. The solid was filtered and
collected. The solution was neutralized with 28% NH.sub.3 in water
to pH .about.5. The solution was extracted with EtOAc (3.times.300
ml). The solid also was dissolved in EtOAc and neutralized with 28%
NH, in H.sub.2O. The organic layers were combined, concentrated
with 30 g silica gel, and purified by flash chromatography (20 to
60% EtOAc/hexanes) to afford the title compound (2.40 g, 36%) as a
yellow solid.
Step b
4-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl-
)silyl]oxy}-methyl)cyclopentyl]oxy}-3-nitropyridin-2-amine
[0640] To a solution of
(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl)si-
lyl]oxy}methyl)cyclopentanol (0.782 g, 0.00217 mol) in THF (30.0
mL) was added NaH (0.156 g, 0.00650 mol) and the mixture was
stirred for 1 h. To this was added 2-amino-4-chloro-3-nitropyridine
(0.376 g, 0.00217 mol) and the mixture was stirred overnight. The
solution was concentrated and the residue was purified by flash
chromatography (25% EtOAc/hexanes) to afford the title compound
(0.381 g, 35%) as a yellow solid.
Step c
4-{[(1R,3S
4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl-
)silyl]oxy}-methyl)cyclopentyl]oxy}pyridine-2,3-diamine
[0641] To a solution of
4-{[(1R,3S,4S)-3-([tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethy-
l)silyl]oxy)methyl)cyclopentyl]oxy}-3-nitropyridin-2-amine (0.361
g, 0.000725 mol) in CH.sub.2Cl.sub.2 (6.00 mL) and acetic acid
(3.00 mL) was added zinc (0.474 g, 0.00725 mol) and the mixture was
stirred for 30 min. The suspension was filtered and the filtrate
was concentrated. The residue was dissolved in 50 ml EtOAc and 3 ml
Et.sub.3N then washed with water (2.times.10 mL). The organic layer
was dried (MgSO.sub.4) and concentrated to afford the crude product
(0.297 g, 88%).
Step d
7-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl-
)silyl]oxy}-methyl)cyclopentyl]oxy}-2-(1-naphthyl)-3H-imidazo[4,5-b]pyridi-
ne
[0642] A mixture of 1-naphthalenecarboxaldehyde (115 mg, 0.000738
mol),
4-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethy-
l)silyl]oxy}methyl)cyclo pentyl]oxy}pyridine-2,3-diamine (115.1 mg,
0.0002460 mol) and sodium metabisulfite (0.140 g, 0.000738 mol) in
acetonitrile (2.00 mL) was subject to microwave irradiation at
180.degree. C. for 25 mins. The mixture was filtered and the
filtrate was concentrated. The residue was purified by preparative
plate chromatography (25% EtOAc/hexanes) to afford the title
compound (0.101 g, 68%) as a white solid.
Step e
((1S,2S,4R)-2-{[tert-butyl(dimethyl)silyl]oxy}-4-{[2-(1-naphthyl)-3H-imida-
zo[4,5-b]pyridin-7-yl]oxy}cyclopentyl)methanol
[0643] The title compound was prepared by a method analogous to
Example 34, step C.
Step f
((1S,2S,4R)-2-hydroxy-4-{[2-(1-naphthyl)-3H-imidazo[4,5-b]pyridin-7-yl]oxy-
}-cyclopentyl)methyl sulfamate (Compound I-109)
[0644] To a solution of
((1S,2S,4R)-2-{[tert-butyl(dimethyl)silyl]oxy}-4-{[2-(1-naphthyl)-3H-imid-
azo[4,5-b]pyridin-7-yl]oxy}cyclopentyl)methanol (0.0624 g, 0.000127
mol) in DMA (2.00 mL) was added chlorosulfonamide (0.0736 g,
0.000637 mol) and the mixture was stirred for 10 min. To this was
added 12 M of hydrochloric acid in water (2.00 mL) dropwise at
0.degree. C. and the mixture was stirred for 10 min. The mixture
was added dropwise to 50 mL of a 2N Na.sub.2CO.sub.3 solution, and
was extracted by CH.sub.2Cl.sub.2 (3.times.30 ml). The combined
organic layers were concentrated and the residue was purified by
flash chromatography (0 to 10% MeOH/EtOAc) to provide the title
compound (14.5 mg, 25%) as a white solid. .sup.1H NMR (CD.sub.3OD,
400 MHz) .delta.: 8.49 (m, 1H), 8.28 (m, 1H), 8.06 (d, 1H, J=8.3
Hz), 7.97 (m, 1H), 7.87 (dd, 1H, J=7.0 Hz, J=1.0 Hz) 7.63-7.54 (m,
3H), 6.89 (d, 1H, J=5.8 Hz) 5.40 (bs, 1H), 4.45 (dt, 1H, J=4.9 Hz,
J=1.9 Hz), 4.35 (dd, 1H, J=7.2 Hz, J=2.5 Hz), 4.19 (dd, 1H, J=7.2
Hz, J=2.5 Hz), 2.62 (m, 1H), 2.44-2.39 (m, 1H), 2.31-2.25 (m, 1H),
2.18-2.14 (m, 2H). LC/MS: R.sub.t=1.55 min, ES+ 455 (AA
standard).
Example 78
((1S,2S,4R)-4-{[6-chloro-2-(1-naphthyl)-3H-imidazo[4,5-b]pyridin-7-yl]amin-
o}-2-hydroxycyclopentyl)methyl sulfamate (Compound I-56)
Step a
N(4)-[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimeth-
yl)silyl]-oxy}methyl)cyclopentyl]-5-chloro-3-nitropyridine-2,4-diamine
[0645] A solution of 4,5-dichloro-3-nitropyridin-2-amine (0.0365 g,
0.000175 mol) (Johansson, H; Lawitz, K; Nikitidis, G; Sjoe, P;
Storm, P. PCT Int. Application WO2004/016611),
(1R,3S,4S)-3-([tert-butyl(dimethyl)silyl]oxy([tert-butyl(dimethyl)silyl]--
oxy)methyl)cyclopentanamine (0.0947 g, 0.000263 mol) and D1PEA
(0.0907 g, 0.000702 mol) in ethanol (10.0 mL) was refluxed
overnight. The reaction was concentrated and purified by flash
chromatography (30% EtOAc/hexanes) to afford the title compound
(0.0768 g, 82%) as a yellow solid.
Step b
N(4)-[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimeth-
yl)silyl]-oxy}methyl)cyclopentyl]-5-chloropyridine-2,3,4-triamine
[0646]
N(4)-[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl-
(dimethyl)-silyl]oxy}methyl)cyclopentyl]-5-chloro-3-nitropyridine-2,4-diam-
ine (0.875 g, 0.00165 mol) and zinc (0.431 g, 0.00659 mol) was
added to acetic acid (40.0 mL, 0.704 mol) with stirring for 10
mins. The mixture was stirred for 10 min and the solid was filtered
off. The filtrate was concentrated, dissolved in EtOAc (50 mL)
washed with water (2.times.10). To the organic phase was added 2 ml
Et.sub.3N and the mixture was washed with 10 mL water. The organic
layer was concentrated and purified by flash chromatography (30%
EtOAc/hexanes) to afford the title compound (0.746 g, 90%) as a
white solid.
Step c
((1S,2S,4R)-4-{[6-chloro-2-(1-naphthyl)-3H-imidazo[4,5-b]pyridin-7-yl]amin-
o}-2-hydroxycyclopentyl)methyl sulfamate (Compound I-56)
[0647] The title compound was prepared in an analogous fashion to
Example 77, steps d-f. .sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.:
9.13 (d, 1H, J=9.9), 8.05-7.92 (m, 4H), 7.65-7.57 (m, 3H), 5.82
(bs, 1H), 4.41 (dt, 1H, J=5.0 Hz, J=1.9 Hz), 4.32 (dd, 1H, J=7.3
Hz, J=2.5 Hz), 4.17 (dd, 1H, J=7.3 Hz, J=2.5 Hz), 3.25 (q, 2H,
J=7.8 Hz), 2.40-2.28 (m, 2H), 2.05-1.94 (m, 2H). LC/MS:
R.sub.t=1.68 min, ES+ 488 (AA standard).
Example 79
((1S,2S,4R)-4-{[6-(cyclopentylamino)pyrimidin-4-yl]oxy}-2-hydroxycyclopent-
yl)methyl sulfamate (Compound I-127)
[0648] The title compound was prepared in a manner analogous to
Example 34, step b using cyclopentanamine and Example 76, steps
g-i. .sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.: 8.08 (s, 1H), 5.74
(s, 1H), 5.31 (bs, 1H), 4.38 (dt, 1H, J=5.0 Hz, J=1.9 Hz), 4.30
(dd, 1H, J=7.2 Hz, J=2.5 Hz), 4.15 (dd, 1H, J=7.2 Hz, J=2.5 Hz),
2.51 (m, 1H), 2.34-2.26 (m, 1H), 2.09-1.96 (m, 6H), 1.76 (m, 2H),
1.64 (m, 2H), 1.51 (m, 2H). LC/MS: R.sub.t=1.46 min ES+373 (AA
standard).
Example 80
[(1S,2S,4R)-4-({2-[(1S)-2,3-dihydro-1H-inden-1-ylamino]pyridin-4-yl}oxy)-2-
-hydroxycyclopentyl]methyl sulfamate (Compound I-94)
Step a
4-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl-
)silyl]oxy}-methyl)cyclopentyl]oxy}-2-chloropyridine
[0649] To a solution of
(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl)si-
lyl]oxy}methyl)cyclopentanol (973.5 mg, 0.002699 mol) in DMF (8.00
mL, 0.103 mol) was added NaH (202 mg, 0.00504 mol) (60% in oil).
After stirring the mixture for 10 minutes,
2-chloro-4-nitro-pyridine (400.0 mg, 0.00252 mol) was added and the
mixture was stirred overnight. The reaction was quenched with water
and extracted with (3.times.50 ml EtOAc). The combined organic
layers were dried (Na.sub.2SO.sub.4), filtered and concentrated in
vacuo. The residue was purified by flash chromatography (0 to 10%
EtOAc/hexanes) to obtain the title compound (0.9859 g, 83%) as a
clear oil.
Step b
4-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)
silyl]oxy}-4-({[tert-butyl(dimethyl)silyl]oxy}-methyl)cyclopentyl]oxy}-N--
[(1S)-2,3-dihydro-1H-inden-1-yl]pyridin-2-amine
[0650] To a mixture of
[1,3-bis(2,6-diisopropylphenyl)imidazolidin-2-yl](chloro)[(2,3-.)-(1Z)-1--
phenylprop-1-ene-2,3-diyl]palladium(2+) (7.8 mg, 0.000012 mol) and
potassium tert-butoxide (73.7 mg, 0.000656 mol) under an atmosphere
of argon was added
4-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethy-
l)silyl]oxy}methyl)-cyclopentyl]oxy}-2-chloropyridine (281.8 mg,
0.0005968 mol) in 1 ml DME. The solution was stirred for 5 mins,
then (S)-(+)-1-aminoindane (0.10 mL, 0.000776 mol) in 1.0 ml DME
was added dropwise over 15 min. The solution was stirred overnight,
then dissolved in 50 mL EtOAc, washed with water, and concentrated.
The residue was purified by flash chromatography (30%
EtOAc/hexanes) to afford the title compound (0.3219 g, 95%) as a
white solid.
Step c
[(1S,2S,4R)-4-({2-[(1S)-2,3-dihydro-1H-inden-1-ylamino]pyridin-4-yl}oxy)-2-
-hydroxycyclopentyl]methyl sulfamate (Compound I-94)
[0651] The title compound was prepared in a manner analogous to
Example 76, steps g-i. .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta.:
7.75 (d, 1H, J=6.0 Hz), 7.27-7.13 (m, 3H), 6.16 (dd, 1H, J=6.3 Hz,
J=2.4 Hz), 5.33 (t, 1H, J=7.5 Hz), 4.95 (m, 1H), 4.50 (dt, 1H,
J=5.1 Hz, J=2.0 Hz), 4.31 (dd, 1H, J=7.3 Hz, J=2.4 Hz), 4.15 (dd,
1H, J=7.3 Hz, J=2.4 Hz), 3.03-2.96 (m, 1H), 2.86 (m, 1H), 2.61-2.46
(m, 2H), 2.29-2.23 (m, 1H), 2.10-2.03 (m, 1H), 2.00-1.95 (m, 1H),
1.90-1.80 (m, 1H), 1.15-1.10 (m, 2H).
Example 81
{(1S,2S,4R)-4-[(6-{[(1R,2S)-2,7-dimethoxy-1,2,3,4-tetrahydronaphthalen-1-y-
l]-amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate
(Compound I-149)
[0652] The title compound was prepared as a 1:1 mixture of with the
compound in example 82 according to Example 34, steps a-d, followed
by HCl-mediated desilylation.
Rel-(1R,2S)-2,7-dimethoxy-1,2,3,4-tetrahydronaphthalen-1-amine,
prepared according to the reference found in Example 71, was used
as a coupling partner in step b. The title compound was then
isolated via chiral HPLC (Chiralcel OD 20.times.250, eluent
88/12/0.2% hex/EtOH/DEA at 20 mL/min). .sup.1H NMR (CD.sub.3OD, 400
MHz) .delta.: 8.14 (d, J=0.7 Hz, 1H), 7.00 (d, J=8.3 Hz, 1H),
6.76-6.71 (m, 2H), 5.94 (s, 1H), 5.32 (bs, 1H), 4.39 (ddd, J=2.2,
5.2, 5.2 Hz, 1H), 4.32 (dd, J=7.4, 9.8 Hz, 1H), 4.15 (dd, J=7.3,
9.8 Hz, 1H), 3.73 (ddd, J=2.1, 3.8, 6.4 Hz, 1H), 3.67 (s, 3H), 3.40
(s, 3H), 2.93-2.80 (m, 2H), 2.67 (ddd, J=5.6, 5.6, 11.6 Hz, 1H),
2.58-2.46 (m, 1H), 2.28 (ddd, J=2.2, 6.8, 14.8 Hz, 1H), 2.25-2.16
(m, 1H), 2.12-1.87 (m, 4H). LC/MS: R.sub.t=1.25 min, ES.sup.+ 495
(FA standard).
Example 82
{(1S,2S,4R)-4-[(6-{[(1S,2R)-2,7-dimethoxy-1,2,3,4-tetrahydronaphthalen-1-y-
l]-amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate
(Compound I-148)
[0653] The title compound was prepared as a 1:1 mixture of with the
compound in example 81 according to Example 34, steps a-d, followed
by HCl-mediated desilylation.
Rel-(1R,2S)-2,7-dimethoxy-1,2,3,4-tetrahydronaphthalen-1-amine,
prepared according to the reference found in Example 71, was used
as a coupling partner in step b. The title compound was then
isolated via chiral HPLC (Chiralcel OD 20.times.250, eluent
88/12/0.2% hex/EtOH/DEA at 20 mL/min). .sup.1H NMR (CD.sub.3OD, 400
MHz) .delta.: 8.14 (d, J=0.7 Hz, 1H), 7.00 (d, J=8.3 Hz, 1H),
6.76-6.71 (m, 2H), 5.94 (s, 1H), 5.32 (bs, 1H), 4.39 (ddd, J=2.1,
5.1, 5.1 Hz, 1H), 4.32 (dd, J=7.5, 9.8 Hz, 1H), 4.15 (dd, J=7.3,
9.8 Hz, 1H), 3.74 (ddd, J=2.1, 3.9, 6.6 Hz, 1H), 3.67 (s, 3H), 3.40
(s, 3H), 2.95-2.82 (m, 2H), 2.67 (ddd, J=5.7, 5.7, 11.5 Hz, 1H),
2.58-2.47 (m, 1H), 2.28 (ddd, J=2.2, 6.8, 14.8 Hz, 1H), 2.25-2.16
(m, 1H), 2.12-1.87 (m, 4H). LC/MS: R.sub.t=1.25 min, ES.sup.+ 495
(FA standard).
Example 83
{(1S,2S,4R)-2-hydroxy-4-[(6-{[(1S,2R)-2-methoxy-4,4-dimethyl-1,2,3,4-tetra-
hydronaphthalen-1-yl]amino}pyrimidin-4-yl)oxy]cyclopentyl}methyl
sulfamate (Compound I-151)
[0654] The title compound was prepared as a 1:1 mixture of with the
compound in example 84 according to example 34, steps a-d, followed
by HCl-mediated desilylation and then treatment with 1.0
equivalents of potassium hydroxide as a solution in methanol to
afford the corresponding potassium salt.
Rel-(1R,2S)-2-methoxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-amine,
prepared according to the reference found in Example 71, was used
as a coupling partner in step b. The title compound was then
isolated via chiral HPLC (Chiralpak AD 20.times.250, eluent
85/15/0.1% hex/EtOH/DEA at 20 mL/min). .sup.1H NMR (CD.sub.3OD, 400
MHz) .delta.: 8.13 (s, 1H), 7.39-7.34 (m, 1H), 7.25-7.18 (m, 2H),
7.13-7.06 (m, 1H), 5.90 (s, 1H), 5.64 (bs, 1H), 5.24 (bs, 1H), 4.40
(ddd, J=1.7, 5.6, 5.6 Hz, 1H), 4.14 (ddd, J=1.3, 8.5, 10.0 Hz, 1H),
4.00 (ddd, J=2.0, 6.4, 10.0 Hz, 1H), 3.78 (ddd, J=3.0, 4.1, 10.4
Hz, 1H), 3.42 (s, 3H), 2.53-2.38 (m, 1H), 2.26 (dddd, J=1.8, 1.8,
6.7, Hz, 1H), 2.12-1.81 (m, 4H), 1.77 (dd, J=2.0, 13.6 Hz, 1H),
1.43 (s, 3H), 1.31 (s, 3H). LC/MS: R.sub.t=1.61 min, ES.sup.+ 493
(FA standard).
Example 84
{(1S,2S,4R)-2-hydroxy-4-[(6-{[(1R,2S)-2-methoxy-4,4-dimethyl-1,2,3,4-tetra-
hydronaphthalen-1-yl]amino}pyrimidin-4-yl)oxy]cylopentyl}methyl
sulfamate (Compound I-150)
[0655] The title compound was prepared as a 1:1 mixture of with the
compound in example 83 according to example 34, steps a-d, followed
by HCl-mediated desilylation and then treatment with 1.0
equivalents of potassium hydroxide as a solution in methanol to
afford the corresponding potassium salt.
Rel-(1R,2S)-2-methoxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-amine,
prepared according to the reference found in Example 71, was used
as a coupling partner in step b. The title compound was then
isolated via chiral HPLC (Chiralpak AD 20.times.250, eluent
85/15/0.1% hex/EtOH/DEA at 20 mL/min). .sup.1H NMR (CD.sub.3OD, 400
MHz) .delta.: 8.14 (s, 1H), 7.40-7.35 (m, 1H), 7.26-7.18 (m, 2H),
7.13-7.07 (m, 1H), 5.91 (s, 1H), 5.65 (bs, 1H), 5.25 (bs, 1H), 4.40
(ddd, J=1.7, 5.6, 5.6 Hz, 1H), 4.14 (ddd, J=1.3, 8.5, 10.0 Hz, 1H),
4.00 (ddd, J=1.8, 6.4, 9.9 Hz, 1H), 3.79 (ddd, J=3.4, 3.4, 10.4 Hz,
1H), 3.42 (s, 3H), 2.52-2.38 (m, 1H), 2.32-2.21 (m, 1H), 2.12-1.81
(m, 4H), 1.78 (dd, J=2.0, 13.5 Hz, 1H), 1.43 (s, 3H), 1.32 (s, 3H).
LC/MS: R.sub.t=1.61 min, ES.sup.+ 493 (FA standard).
Example 85
[(1S,2S,4S)-4-({6-[(1S)-2,3-dihydro-1H
inden-1-ylamino]pyrimidin-4-yl}-methyl)-2-hydroxycyclopentyl]methyl
sulfamate (I-33)
Step a
2-Chloro-N-[(1S)-2,3-dihydro-1H-inden-1-yl]-6-methylpyrimidine-4-amine
[0656] 2,4-Dichloro-6-methylpyrimidine (2.54 g, 0.156 mol) was
dissolved in ethanol (100 mL) and N,N-Diisporopylethylamine (4.07
mL, 0.23 mol) was added followed by (S)-1-Aminoindan (2.00 mL,
0.156 mol). The solution was heated to reflux for 2 hours, TLC
indicated complete conversion. The solvent was removed in vacuo and
the residue was purified using chromatography on silica gel using
gradient 0 to 50% ethyl acetate in hexane to afford the title
compound (1.95 g, 46%). LC/MS: R.sub.t=1.90 min, ES.sup.+ 260 (AA
standard).
Step b
N-[(1S)-2,3-dihydro-1H-inden-1-yl]-6-methylpyrimidine-4-amine
[0657]
2-Chloro-N-[(1S)-2,3-dihydro-1H-inden-1-yl]-6-methylpyrimidine-4-am-
ine (1.95 g, 7.5 mmol) was dissolved in ethanol (5 mL) and 10% Pd/C
(0.140 g, 0.13 mmol) was added. The flask was filled with hydrogen
and stirred overnight. At that time, TLC indicated complete
conversion. Palladium was filtered off and the solvent was removed
in vacuo. The residue was purified using chromatography on silica
gel using gradient 50 to 100% ethyl acetate in hexane to afford the
title compound (1.65 g, 93%). LC/MS: R.sub.t=1.51 min, ES.sup.+ 226
(AA standard).
Step c
(4aS,6S,7S,7aR)-6-{6-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]-pyrimidin-4-yl}-
-methyl)-2-(4-methoxyphenyl)hexahydrocyclopenta[d][1,3]dioxin-7-ol
[0658] N-[(1S)-2,3-dihydro-1H-inden-1-yl]-6-methylpyrimidine-amine
(0.575 g, 2.55 mmol) was dissolved in THF (24 mL) and 1.8M
Phenyllithium in di-n-butyl ether (2.98 mL, 5.36 mmol) was added
and stirred for 1 hour. The mixture was cooled to 0.degree. C. and
a solution of
(1aS,1bR,5aS,6aS)-3-(4-methoxyphenyl)hexahydrooxireno[4,5]cyclopenta[1,2--
d][1,3]dioxine (0.634 g, 2.55 mmol) in THF (15 mL) was slowly
added. The mixture was stirred at 0.degree. C. for 45 minutes and
23.degree. C. for 2 hours. At that time, LCMS indicated-70%
conversion. The reaction was quenched using saturated ammonium
chloride (30 mL), extracted with ethyl acetate (3.times.20 mL),
dried with anhydrous magnesium sulfate, filtered, and evaporated in
vacuo. The residue was purified using chromatography on silica gel
using gradient 50 to 100% ethyl acetate in hexane to afford the
title compound (0.465 g, 38%). LC/MS: R.sub.t=1.77 min, ES.sup.+
474 (AA standard).
Step d
O-[(4aS,6S,7S,7aR)-6-{[(1S)-2,3-Dihydro-1H-inden-1-ylamino]-pyrimidin-4-yl-
}-methyl)-2-(4-methoxyphenyl)hexahydrocyclopenta[d][1,3]dioxin-7-yl]O-phen-
yl thiocarbonate
[0659]
(4aS,6S,7S,7aR)-6-{6-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]-pyrimidi-
n-4-yl}-methyl)-2-(4-methoxyphenyl)hexahydrocyclopenta[d][1,3]dioxin-7-ol
(0.465 g, 0.98 mmol) was dissolved in DCM (17 mL) under an
atmosphere of argon and 4-(dimethylamino)-pyridine (0.24 g, 1.96
mmol) was added followed by phenyl chlorothionocarbonate (0.204 mL,
1.47 mmol). The mixture was stirred for 1 hour. The solvent was
concentrated in vacuo and the residue was purified via silica gel
chromatography eluting with a gradient of 50 to 100% EtOAc in
hexanes on a column pre-treated with 1% TEA in hexanes to afford
the title compound (0.508 g, 84%). LC/MS: R.sub.t=2.38 min,
ES.sup.+ 610 (AA standard).
Step e
N-[(1S)-2,3-Dihydro-1H-inden-yl]-6-{[(4aS,6S,7aS)-2-(4-methoxyphenyl)-hexa-
hydrocyclopenta[d][1,3]dioxin-6-yl]methyl}pyrimidin-4-amine
[0660]
O-[(4aS,6S,7S,7aR)-6-{[(1S)-2,3-Dihydro-1H-inden-1-ylamino]-pyrimid-
in-4-yl}methyl)-2-(4-methoxyphenyl)hexahydrocyclopenta[d][1,3]dioxin-7-yl]-
O-phenyl thiocarbonate (0.508 g, 0.83 mmol) was dissolved in
toluene (14 mL) under an atmosphere of nitrogen and tri-n-butyltin
hydride (0.448 mL, 1.67 mmol) was added followed by
2,2'-azo-bis-isobutyronitrile (0.027 mg, 0.17 mmol). The solution
was heated to reflux for 1 hour, the mixture was cooled down, the
solvent was concentrated to 30 mL and the residue was purified via
silica gel chromatography eluting with a gradient of 50 to 100%
EtOAc in hexanes to afford the title compound (0.280 g, 73%).
LC/MS: R.sub.t=1.94 min, ES.sup.+ 458 (AA standard).
Step f
(1S,2S,4S)-4-({6-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]pyrimidin-4
yl}methyl)-2-(hydroxymethyl)cyclopentanol
[0661]
N-[(1S)-2,3-Dihydro-1H-inden-1-yl]-6-{[(4aS,6S,7aS)-2-(4-methoxyphe-
nyl)-hexahydrocyclopenta[d][1,3]dioxin-6-yl]methyl}pyrimidin-4-amine
(0.280 g, 0.61 mmol) was dissolved in THF (2 mL), water (2 mL) and
AcOH (6 mL, 0.106 mmol) were added. The mixture was stirred under
an atmosphere of argon for 60 h. The mixture was concentrated under
reduced pressure and the residue was purified via silica gel
chromatography eluting with a gradient of 0 to 10% MeOH in DCM to
afford the title compound (0.190 g, 91%). LC/MS: R.sub.t=1.29 min,
ES.sup.+ 340 (AA standard).
Step g
[(1S,2S,4S)-4-({6-[(1S)-2,3-dihydro-1H
inden-1-ylamino]pyrimidin-4-yl}methyl)-2-hydroxycyclopentyl]methyl
sulfamate (I-33)
[0662] The title compound was prepared following the procedure
described in Example 65, step d. .sup.1H NMR (CD.sub.3OD, 400 MHz,
.delta.): 8.34 (s, 1H), 7.27-7.15 (m, 4H), 6.41 (bs, 1H), 5.65-5.48
(m, 1H), 4.30-4.25 (m, 2H), 4.09 (dd, J=4.1, 4.1 Hz, 1H), 3.07-3.00
(m, 1H), 2.94-2.85 (m, 1H), 2.72-2.55 (m, 4H), 2.43-2.35 (m, 1H),
1.93-1.85 (m, 2H), 1.75-1.67 (m, 1H), 1.58-1.51 (m, 2H). LC/MS:
R.sub.t=1.38 min, ES.sup.+ 419 (AA standard).
Example 86
((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-5,6-dihydro-7H-pyrr-
olo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
(Compound I-146)
Step a
2-(4,6-dichloropyrimidin-5-yl)ethanol
[0663] (4,6-dichloropyrimidin-5-yl)acetaldehyde (2.96 g, 15.5 mmol)
was dissolved in methanol (60 mL) and cooled at 0.degree. C. Sodium
tetrahydroborate (0.879 g, 23.2 mmol) was added and the mixture was
stirred for 1 hour. TLC indicated complete conversion. The reaction
was quenched with water (20 mL), methanol was removed in vacuo and
the residue was extracted with ethyl acetate (3.times.30 mL). The
combined organic extracts were dried with magnesium sulfate,
filtered and evaporated. The residue was purified using
chromatography on silica gel using gradient 0 to 100% ethyl acetate
in methylene chloride to afford the title compound (1.90 g, 63%).
LC/MS: R.sub.t=0.93 min, ES.sup.+ 194 (AA standard).
Step b
2-{4-chloro-6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]pyrimidin-5-yl}ethano
[0664] 2-(4,6-dichloropyrimidin-5-yl)ethanol (1.90 g, 9.84 mmol)
was dissolved in 1-butanol (97 mL) and N,N-Diisopropylethylamine
(3.43 mL, 19.7 mmol) and (S)-1-Aminoindane (1.26 mL, 9.84 mmol)
were added. The solution was heated at 130.degree. C. for 3 days.
Solvent was removed in vacuo and the residue was purified using
chromatography on silica gel using gradient 0 to 100% ethyl acetate
in methylene chloride to afford the title compound (2.80 g, 98%).
LC/MS: R.sub.t=1.63 min, ES.sup.+ 290 (AA standard).
Step c
2-(2-{4-chloro-6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]pyrimidin-5-yl}ethyl-
)-1H-isoindole-1,3(2H)-dione
[0665]
2-{4-chloro-6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]pyrimidin-5-yl}e-
thanol (2.80 g, 9.66 mmol), phthalimide (1.56 g, 10.6 mmol) and
triphenylphosphine (2.79 g, 10.6 mmol) were dissolved in THF (105
mL) and the solution was cooled at 0.degree. C. DIAD (2.09 mL, 10.6
mmol) was added dropwise and the mixture was stirred 23.degree. C.
for 1 hour. The solvent was removed in vacuo and the residue was
purified using chromatography on silica gel using gradient 10 to
50% ethyl acetate in hexane to afford the title compound (3.50 g,
86%). LC/MS: R.sub.t=2.12 min, ES.sup.+ 419 (AA standard).
Step d
5-(2-aminoethyl)-6-chloro-N-[(1S)-2,3-dihydro-1H-inden-1-yl]pyrimidin-4-am-
ine
[0666]
2-(2-{4-chloro-6-[(1S)-2,3-dihydro-1H-inden-1-ylamino]pyrimidin-5-y-
l}ethyl)-1H-isoindole-1,3(2H)-dione (3.50 g, 8.32 mmol) was
suspended in ethanol (102 mL) and hydrazine hydrate (1.62 mL, 33.3
mmol) was added. The mixture was heated to reflux for 1 hour. At
that time, LCMS indicated complete conversion. The mixture was
cooled to 23.degree. C., crystals were filtered off, the residue
was evaporated in vacuo and purified using chromatography on silica
gel using gradient 0 to 20% MeOH in methylene chloride to afford
the title compound (1.20 g, 50%). LC/MS: R.sub.t=1.29 min, ES.sup.+
289 (AA standard).
Step e
N-[(1S)-2,3-dihydro-1H-inden-1-yl]-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin--
4-amine
[0667] 5-(2-aminoethyl)-6-chloro-N
[(1S)-2,3-dihydro-1H-inden-1-yl]pyrimidin-4-amine (1.00 g, 3.46
mmol) and N,N-diisopropylethylamine (1.21 mL, 6.92 mmol) were
dissolved in 1,4-dioxane (19 mL) and the solution was heated in a
pressure tube at 160.degree. C. for 48 hours. At that time, LCMS
indicated complete conversion. Solvent was removed in vacuo and the
residue was purified using chromatography on silica gel using
gradient 0 to 20% MeOH in methylene chloride to afford the title
compound (0.81 g, 93%). LC/MS: R.sub.t=1.55 min, ES.sup.+ 253 (AA
standard).
Step f
7-[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-{[tert-butyl(dimethyl)s-
ilyl]oxy}-methyl)cyclopentenyl-N-[(1S)-2,3-Dihydro-1H-inden-1-yl]-6,7-dihy-
dro-5H-pyrrolo[2,3-d]pyrimidin-4-amine
[0668]
N-[(1S)-2,3-dihydro-1H-inden-1-yl]-6,7-dihydro-5H-pyrrolo[2,3-d]pyr-
imidin-4-amine (0.460 mg, 1.82 mmol) was dissolved in DMF (20 mL)
and NaI (60%, 0.146 g, 3.65 mmol) was added. The mixture was heated
at 60.degree. C. for 5 minutes.
(1S,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-{[tert-butyl(dimethyl)sil-
yl]oxy}methyl)cyclopentenyl methanesulfonate (0.800 g, 1.82 mmol)
in DMF (10 mL) was added and the resulting mixture was heated at
100.degree. C. for 2 hours. The solution was cooled to 23.degree.
C., quenched with saturated brine (20 mL), extracted with ethyl
acetate (3.times.30 mL), dried with magnesium sulfate, filtered and
evaporated in vacuo. The residue was purified using chromatography
on silica gel using gradient 0 to 30% ethyl acetate in hexane to
afford the title compound (0.22 g, 20%). LC/MS: R.sub.t=7.17 min,
ES.sup.+ 596 (AA Nonpolar: Phenominex Luna 5 um C18 50.times.4.6 mm
column at 2.5 ml/min gradient of ACN containing 50 to 0% 10 mM
Ammonium Acetate in H.sub.2O for 3 min.)
Step g
((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-5,6-dihydro-7H-pyrr-
olo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
(Compound I-146)
[0669] The title compound was prepared following the procedures
described in Example 34, step c and Example 65, step d. .sup.1H NMR
(CD.sub.3OD, 400 MHz) .delta.: 7.93 (s, 1H), 7.23-7.12 (m, 4H),
5.64-5.60 (m, 1H), 4.87-4.83 (m, 1H), 4.34-4.31 (m, 1H), 4.29 (dd,
J=7.6, 9.6 Hz, 1H), 4.13 (dd, J=7.2, 9.6 Hz, 1H), 3.58-3.53 (m,
2H), 3.03-2.95 (m, 1H), 2.90-2.77 (m, 3H), 2.59-2.42 (m, 2H),
2.00-1.97 (m, 2H), 1.91-1.82 (m, 3H). LC/MS: R.sub.t=4.98 min,
ES.sup.+ 446 (FA long).
Example 87
((1R,2R,3S,4R)-4-{[2-(2,3-dihydro-1H-indol-1-ylcarbonyl)pyridin-4-yl]amino-
}-2,3-dihydroxycyclopentyl)methyl sulfamate (Compound I-145)
[0670] .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.: 8.20-8.00 (m,
2H), 7.30-6.70 (m, 5H), 4.26-4.02 (m, 3H), 3.88-3.78 (m, 2H),
3.17-3.11 (m, 2H) 2.50-2.30 (m, 2H), 1.40-1.20 (m, 3H), ppm. LC/MS:
R.sub.t=0.95 min, ES.sup.+ 449 (AA standard).
Example 88
{(1R,2R,3S,4R)-4-[(2-{[(1S)-2,3-dihydro-1H-inden-1-ylamino]carbonyl}pyridi-
n-4-yl)amino]-2,3-dihydroxycyclopentyl}methyl sulfamate (Compound
I-144)
[0671] .sup.1H NMR (CD.sub.3OD, 300 MHz) .delta.: 8.05 (d, J=7.5
Hz, 1H), 7.50 (bs, 1H), 7.32-7.16 (m, 4H), 6.97-6.92 (m, 1H), 5.64
(t, J=7.54 Hz, 1H), 4.17 (d, J=5.09 Hz, 2H), 4.09-3.80 (m, 3H),
3.15-3.04 (m, 1H), 3.00-2.87 (m, 1H), 2.66-2.54 (m, 1H), 2.45-2.29
(m, 2H), 2.11-1.97 (m, 1H), 1.44-1.34 (m, 1H) ppm. LC/MS:
R.sub.t=1.35 min, ES.sup.+ 463 (AA standard).
Example 89
((1S,2S,4R)-4-{[8-(3-chlorophenyl)-9H-purin-6-yl]amino}-2-hydroxycyclopent-
yl)methyl sulfamate (Compound I-60)
Step a
6-chloro-4,5-diaminopyrimidine
[0672] A suspension of 5-Amino-4,6-dichloropyrimidine (3 g, 0.02
mol) in ammonia (25 mL, 7N/MeOH, 0.175 mole) was heated at
118.degree. C. overnight (under pressure). The reaction was cooled
to 23.degree. C., filtered and washed with ethanol to obtain 1.92 g
(70%).
Step b
6-chloro-8-(3-chlorophenyl)-9H-purine
[0673] To a mixture of 6-Chloro-4,5-diaminopyrimidine (0.70 g, 4.84
mmol) and 3-chlorobenzoic acid (0.76 g, 4.84 mmol) in the flask was
added phosphoryl chloride (40.0 mL), and the resulting mixture was
stirred for 16 h at 100.degree. C. The reaction mixture was
evaporated to remove excess phosphoryl chloride, and the residue
was added to water (20 mL). The precipitate was filtered and
purified by flash chromatography (0 to 5% Methanol/DCM) to afford
the title compound (1.28 g, 31%) as a yellow solid. LC/MS: R 1.59
min, ES.sup.+ 265.0 (FA standard).
Step c
N-[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl)-
silyl]oxy}-methyl)cyclopentyl]-(3-chlorophenyl)-9H-purin-6-amine
[0674] A solution of 6-chloro-8-(3-chlorophenyl)-9H-purine (155 mg,
0.58 mmol),
(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dime-
thyl)silyl]oxy}methyl)-cyclopentanamine (200 mg, 056 mmol) (Example
128, steps a-c), and N,N-diisopropylethylamine (0.20 mL, 1.17 mmol)
in ethanol (2.00 mL) was microwaved at 160.degree. C. for 30
minutes. The reaction mixture was concentrated under vacuum, and
the residue was purified by flash chromatography (0 to 5%
Methanol/DCM) to afford the title compound (275 mg, 76%) as a light
yellow solid.
Step d
((1S,2S,4R)-2-{[tert-butyl(dimethyl)silyl]oxy}-4-{[8-(3-chlorophenyl)-9H-p-
urin-6-yl]amino}cyclopentyl)methanol
[0675] The title compound was prepared following the procedure
described in Example 34, step c. LC/MS: R.sub.t=2.07 min, ES.sup.+
474.2 (AA standard).
Step e
((1S,2S,4R)-4-{[8-(3-chlorophenyl)-9H-purin-6-yl]amino}-2-hydroxycyclopent-
yl)methyl sulfamate (Compound I-60)
[0676] The title compound was prepared following the procedure
described in Example 65, step d. .sup.1H-NMR (400 MHz, CD.sub.3OD)
.delta.: 8.22 (s, 1H), 8.09 (s, 1H), 8.00-7.94 (m, 1H), 7.54-7.48
(m, 2H), 4.93-4.84 (m, 1H), 4.44-4.40 (m, 1H), 4.35 (dd, 1H, J=9.7,
7.8 Hz), 4.17 (dd, 1H, J=9.7, 7.3 Hz), 2.64-2.54 (m, 1H), 2.35
(ddd, 1H, J=14.0, 7.6, 1.2 Hz), 2.20-2.10 (m, 1H), 1.96 (ddd, 1H,
J=14.0, 7.0, 4.8 Hz), 1.86 (ddd, 1H, J=13.0, 8.2, 3.8 Hz). LC/MS:
R.sub.t=5.48 min, ES.sup.+ 439.1 (PA long)
Example 90
((1S,2S,4R)-4-{[8-(2,6-dimethoxyphenyl)-9H-purin-6-yl]amino}-2-hydroxycycl-
opentyl)methyl sulfamate (Compound I-93)
[0677] The title compound was prepared following the procedure
described in Example 89 (steps a-e) using 2,6-dimethoxybenzoic
acid. .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 8.21 (s, 1H), 7.46
(t, 1H, J=8.6 Hz), 6.78 (d, 2H, J=8.6 Hz), 4.90-4.79 (m, 1H),
4.43-4.38 (m, 1H), 4.34 (dd, 1H, J=9.6, 7.5 Hz), 4.17 (dd, 1H,
J=9.6, 7.3 Hz), 3.81 (s, 6H), 2.62-2.52 (m, 1H), 2.34 (ddd, 1H,
J=14.0, 7.5, 1.7 Hz), 2.15 (ddd, 1H, J=13.8, 10.3, 8.9), 1.93 (ddd,
1H, J=14.0, 6.5, 5.3 Hz), 1.84 (ddd, 1H, J=13.8, 8.6, 3.8 Hz).
LC/MS: R.sub.t=4.30 min, ES.sup.+ 465.2 (FA long).
Example 91
[(1S,2S,4R)-2-hydroxy-4-({8-[2-(trifluoromethyl)phenyl]-9H-purin-6-yl}-ami-
no)cyclopentyl]methyl sulfamate (Compound I-122)
[0678] The title compound was prepared following the procedure
described in Example 89 (steps a-e) using
.alpha.,.alpha.,.alpha.-Trifluoro-o-toluic acid. .sup.1H-NMR (400
MHz, CD.sub.3OD) .delta.: 8.26 (s, 1H), 7.92 (dd, 1H, J1=7.0, 1.9
Hz), 7.82-7.71 (m, 3H), 4.96-4.85 (m, 1H), 4.43-4.38 (m, 1H), 4.34
(dd, 1H, J=9.8, 7.4 Hz), 4.16 (dd, 1H, J1=9.8, 7.3 Hz), 2.63-2.52
(m, 1H), 2.34 (ddd, 1H, J=14.0, 7.5, 1.8 Hz), 2.15 (ddd, 1H,
J1=13.5, 10.6, 8.8 Hz), 1.95 (ddd, 1H, J=14.0, 7.1, 5.0 Hz), 1.85
(ddd, 1H, J=13.5, 8.6, 3.8 Hz). LC/MS: R.sub.t=5.17 min, ES.sup.+
473.2 (FA long).
Example 92
((1S,2S,4R)-2-hydroxy-4-{[8-(2-phenoxyphenyl)-9H-purin-6-yl]amino}-cyclope-
ntyl)methyl sulfamate (Compound I-37)
[0679] The title compound was prepared following the procedure
described in Example 89 (steps a-e) using 2-phenoxybenzoic acid.
.sup.1H-NMR (400 MHz, THF-d8) .delta.: 8.40 (br d, 1H, J=7.5 Hz),
8.18 (bs, 1H), 7.43-7.34 (m, 3H), 7.25-7.13 (m, 4H), 6.94 (d, 1H,
J1=8.3 Hz), 6.87 (br d, 1H, J=7.5 Hz), 5.17-4.93 (m, 1H), 4.41-4.35
(m, 1H), 4.35 (dd, 1H, J=9.8, 7.7 Hz), 4.13 (dd, 1H, J=9.8, 7.3
Hz), 2.63-2.52 (m, 1H), 2.35-2.25 (m, 1H), 2.20-2.06 (m, 1H),
2.01-1.91 (m, 1H), 1.87 (ddd, 1H, J=133, 8.8, 4.4 Hz). LC/MS:
R.sub.t=5.83 min, ES.sup.+ 497.2 (FA long).
Example 93
((1S,2S,4R)-2-hydroxy-4-{[8-(1-naphthyl)-9H-purin-6-yl]amino}cyclopentyl)--
methyl sulfamate (Compound I-49)
[0680] The title compound was prepared following the procedure
described in Example 89 (steps a-e) using 1-naphthalenecarboxylic
acid. .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 8.70-8.55 (bs,
1H), 8.26 (s, 1H), 8.02 (d, 1H, J=8.3 Hz), 7.98-7.93 (m, 1H), 7.84
(dd, 1H, J=7.1, 1.1 Hz), 7.61-7.52 (m, 3H), 5.01-4.80 (m, 1H),
4.41-4.37 (m, 1H), 4.34 (dd, 1H, J=9.5, 7.6 Hz), 4.16 (dd, 1H,
J=9.5, 7.3 Hz), 2.61-2.50 (m, 1H), 2.34 (ddd, 1H, J=14.0, 7.6, 1.5
Hz), 2.20-2.10 (m, 1H), 1.94 (ddd, 1H, J=14.0, 7.0, 4.9 Hz), 1.84
(ddd, 1H, J=13.1, 8.3, 3.8 Hz). LC/MS: R.sub.t=5.48 min, ES.sup.+
455.1 (FA long).
Example 94
{(1S,2S,4R)-4-[(8-dibenzo[b,d]furan-4-yl-9H-purin-6-yl)amino]-2-hydroxycyc-
lopentyl}methyl sulfamate (Compound I-39)
[0681] The title compound was prepared following the procedure
described in Example 89 (steps a-e) using dibenzofuran-4-carboxylic
acid. .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 8.25 (s, 1H),
8.15-8.07 (m, 2H), 8.04 (d, 1H, J=7.9 Hz), 7.74 (d, 1H, J=8.2 Hz),
7.56-7.50 (m, 1H), 7.46 (t, 1H, J=7.6 Hz), 7.40 (dd, 1H, J=7.9, 7.2
Hz), 4.91-4.77 (m, 1H), 4.47-4.43 (m, 1H), 4.38 (dd, 1H, J1=9.8,
7.5 Hz), 4.20 (dd, 1H, J=9.8, 7.2 Hz), 2.67-2.56 (m, 1H), 2.38
(ddd, 1H, J=14.0, 7.8, 1.2 Hz), 2.24-2.13 (m, 1H), 1.99 (ddd, 1H,
J=14.0, 6.7, 5.0 Hz), 1.89 (ddd, 1H, J=13.0, 8.4, 3.7 Hz). LC/MS:
R.sub.t=5.74 min, ES.sup.+ 495.0 (FA long).
Example 95
{(1S,2S,4R)-4-[(8-biphenyl-3-yl-9H-purin-6-yl)amino]-2-hydroxycyclopentyl}-
-methyl sulfamate (Compound I-105)
[0682] The title compound was prepared following the procedure
described in Example 89 (steps a-e) using biphenyl-3-carboxylic
acid. .sup.1H-NMR (400 MHz, THF-d8) .delta.: 12.38-12.25 (bs, 1H),
10.95-10.80 (bs, 1H), 8.38 (t, 1H, J1=1.8 Hz), 8.17 (s, 1H), 8.05
(d, 1H, J=7.3 Hz), 7.72-7.68 (m, 3H), 7.55 (t, 1H, J=7.6 Hz),
7.48-7.43 (m, 2H), 7.35 (tt, 1H, J=7.3, 1.3 Hz), 6.87 (br d, 1H,
J1=6.5 Hz), 6.57-6.45 (bs, 2H), 5.15-4.90 (m, 1H), 4.37-431 (m,
1H), 4.31 (dd, 1H, J=9.5, 7.8 Hz), 4.09 (dd, 1H, J=95, 7.3 Hz),
3.95-3.85 (bs, 1H), 231-2.21 (m, 1H), 2.16-2.04 (m, 1H), 1.94 (ddd,
1H, J1=13.1, 8.0, 4.4 Hz), 1.84 (ddd, 1H, J=13.3, 8.8, 4.2 Hz).
LC/MS: R.sub.t=6.17 min, ES.sup.+ 481.0 (FA long).
Example 96
((1S,2S,4R)-2-hydroxy-4-{[8
(5,6,7,8-tetrahydronaphthalen-1-yl)-9H-purin-6-yl]-amino}cyclopentyl)meth-
yl sulfamate (Compound I-126)
[0683] The title compound was prepared following the procedure
described in Example 89 (steps a-e) using
5,6,7,8-tetrahydro-naphthalene-1-carboxylic acid. .sup.1H-NMR (400
MHz, CD.sub.3OD) .delta.: 8.22 (s, 1H), 7.38-7.32 (m, 1H),
7.25-7.19 (m, 2H), 4.92-4.82 (m, 1H), 4.42-4.38 (m, 1H), 4.34 (dd,
1H, J1=9.5, 7.8 Hz), 4.16 (dd, 1H, J=9.5, 7.3 Hz), 2.93-2.83 (m,
4H), 2.62-2.51 (m, 1H), 2.33 (ddd, 1H, J=13.8, 7.5, 1.8 Hz), 2.15
(ddd, 1H, J=13.5, 10.3, 8.8 Hz), 1.94 (ddd, 1H, J1=13.8, 7.1, 4.8
Hz), 1.88-1.73 (m, 5H). LC/MS: R.sub.t=5.22 min, ES.sup.+ 459.1 (FA
long).
Example 97
((1S,2S,4R)-2-hydroxy-4-{[8-(1-naphthyl)-9H-purin-6-yl]oxy}cyclopentyl)met-
hyl sulfamate (Compound I-87)
[0684] The title compound was prepared following the procedures
described in Example 33 (steps a-b, e-f) and Example 65 (step d)
using
(1R,3S,4S)-3-{[tert-butyl(dimethyl)-silyl]oxy}-4-({[tert-butyl(dimethyl)s-
ilyl]oxy}methyl)cyclopentanol. .sup.1H-NMR (400 MHz, CD.sub.3OD)
.delta.: 8.53-8.46 (m, 1H), 8.52 (s, 1H), 8.08 (d, 1H, J=8.0 Hz),
8.01-7.96 (m, 1H), 7.88 (dd, 1H, J=7.3, 1.2 Hz), 7.65-7.55 (m, 3H),
5.98-5.91 (m, 1H), 4.90-4.85 (m, 1H), 4.48-4.43 (m, 1H), 4.36 (dd,
1H, J=9.8, 7.5 Hz), 4.20 (dd, 1H, J1=9.8, 7.2 Hz), 2.71-2.60 (m,
1H), 2.44 (ddd, 1H, J=15.0, 6.7, 1.9 Hz), 2.27 (ddd, 1H, J=15.0,
5.0, 4.5 Hz), 2.20-2.13 (m, 1H). LC/MS: R.sub.t=6.48 min, ES.sup.+
456.0 (FA long).
Example 98
{(1S,2S,4R)-4-[(8-biphenyl-2-yl-9H-purin-6-yl)amino]-2-hydroxycyclopentyl}-
-methyl sulfamate (Compound I-48)
[0685] The title compound was prepared following the procedure
described in Example 89 (steps a-e) using 2-biphenylcarboxylic
acid. .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 8.14 (s, 1H), 7.73
(dd, 1H, J1=7.6, 1.1 Hz), 7.65-7.60 (m, 1H), 7.57-7.50 (m, 2H),
7.30-7.24 (m, 3H), 7.22-7.18 (m, 2H), 4.88-4.77 (m, 1H), 4.41-4.36
(m, 1H), 4.33 (dd, 1H, J=9.7, 7.5 Hz), 4.15 (dd, 1H, J1=9.7, 7.5
Hz), 2.60-2.48 (m, 1H), 2.34-2.25 (m, 1H), 2.16-2.04 (m, 1H),
1.94-1.85 (m, 1H), 1.84-1.74 (m, 1H). LC/MS: R.sub.t=5.43 min,
ES.sup.+ 481.0 (FA long).
Example 99
((1S,2S,4R)-4-{[8-(2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl)-9H-purin-6--
yl]-amino}-2-hydroxycyclopentyl)methyl sulfamate (Compound
I-100)
[0686] The title compound was prepared following the procedure
described in Example 89 (steps a-e) using
2,2-dimethyl-2,3-dihydro-1-benzofuran-7-carboxylic acid.
.sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 8.30-8.19 (m, 1H),
8.06-8.02 and 7.90-7.80 (each bs, total 1H), 7.34-7.28 (m, 1H),
6.99 (t, 1H, J=6.5 Hz), 4.90-4.80 (m, 1H), 4.45-4.40 (m, 1H), 4.35
(dd, 1H, J=9.7, 7.7 Hz), 4.18 (dd, 1H, J1=9.7, 7.5 Hz), 3.15 (bs,
2H), 2.64-2.52 (m, 1H), 2.44-2.30 (m, 1H), 2.23-2.10 (m, 1H),
2.01-1.90 (m, 1H), 1.86 (ddd, 1H, J=13.0, 8.2, 3.7 Hz), 1.64 (bs,
3H), 1.61 (s, 3H). LC/MS: R.sub.t=5.17 min, ES.sup.+ 475.3 (FA
long).
Example 100
[(1S,2S,4R)-4-({8-[4(dimethylamino)-1-naphthyl]-9H-purin-6-yl}amino)-2-hyd-
roxycyclopentyl]methyl sulfamate (Compound I-64)
[0687] The title compound was prepared following the procedure
described in Example 89 (steps a-e) using
4-dimethylaminonaphthalene-1-carboxylic acid. .sup.1H-NMR (400 MHz,
CD.sub.3OD) .delta.: 8.70-8.58 (bs, 1H), 8.34-8.28 (m, 1H), 8.25
(s, 1H), 7.77 (d, 1H, J=7.9 Hz), 7.60-7.53 (m, 1H), 7.21 (d, 1H,
J1=7.9 Hz), 4.98-4.84 (m, 1H), 4.44-4.39 (m, 1H), 4.35 (dd, 1H,
J=9.8, 7.6 Hz), 4.17 (dd, 1H, J=9.8, 7.3 Hz), 2.64-2.53 (m, 1H),
2.35 (ddd, 1H, J=14.0, 7.6, 1.6 Hz), 2.22-2.12 (m, 1H), 1.97 (ddd,
1H, J1=14.0, 7.0, 5.0 Hz), 1.87 (ddd, 1H, J=12.5, 8.6, 3.5 Hz).
LC/MS: R.sub.t=5.39 min, ES.sup.+ 498.0 (FA long).
Example 101
((1S,2S,4R)-2-hydroxy-4-{[8-(3-methoxyphenyl)-9H-purin-6-yl]amino}-cyclope-
ntyl)methyl sulfamate (Compound I-99)
[0688] The title compound was prepared following the procedure
described in Example 89 (steps a-e) using 3-Methoxybenzoic acid.
.sup.1H-NMR (400 MHz, MeOD, .delta.): 8.22 (s, 1H), 7.62 (m, 2H),
7.43 (t, J=7.9 Hz, 1H), 7.07 (dd, J=2.3 Hz, 8.3 Hz, 1H), 4.42 (t,
J=4.3 Hz, 1H), 4.35 (dd, J=7.7 Hz, 9.7 Hz, 1H), 4.17 (dd, J=7.3 Hz,
9.7 Hz, 1H), 3.89 (s, 1H), 2.59 (m, 1H), 2.35 (ddd, J=1.1 Hz, 7.6
Hz, 14.2 Hz, 1H), 2.16 (td, 1H, J=9.4 Hz, 13.3 Hz), 1.96 (ddd,
J=5.1 Hz, J=6.9 Hz, J=14.0 Hz, 1H), 1.86 (ddd, J=3.8 Hz, 8.5 Hz,
13.1 Hz, 1H). LC/MS: R.sub.t=1.33 min, ES.sup.+ 435 (AA
standard).
Example 102
{(1S,2S,4R)-4-[(8-benzyl-9H-purin-6-yl)amino]-2-hydroxycyclopentyl}methyl
sulfamate (Compound I-88)
[0689] The title compound was prepared following the procedure
described in Example 89 (steps a-e) using Benzeneacetic acid.
.sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 8.17 (s, 1H), 7.35-7.21
(m, 5H), 4.84-4.71 (m, 1H), 4.40-4.35 (m, 1H), 4.33 (dd, J=7.5, 9.8
Hz, 1H), 4.19 (s, 2H), 4.14 (dd, J=7.3, 9.8 Hz, 1H), 2.59-2.45 (m,
1H), 2.34-2.23 (m, 1H), 2.17-2.04 (m, 1H), 1.92-1.82 (m, 1H),
1.82-1.72 (m, 1H) ppm. LC/MS: R.sub.t=3.94 min, ES.sup.+ 419 (FA
Waters).
Example 103
((1S,2S,4R)-2-hydroxy-4-{[8-(1,2,3,4-tetrahydronaphthalen-1-yl)-9H-purin-6-
-yl]-amino}cyclopentyl)methyl sulfamate (Compound I-121)
[0690] The title compound was prepared following the procedure
described in Example 89 (steps a-e) using
1,2,3,4-Tetrahydro-1-naphthalenyl hydroperoxide. .sup.1H NMR (400
MHz, CD.sub.3OD) .delta.: 8.17 (s, 1H), 7.26-7.03 (m, 3H),
6.93-6.83 (m, 1H), 4.82-4.70 (m, 1H), 4.47-4.28 (m, 3H), 4.17-4.10
(m, 1H), 3.00-2.79 (m, 2H), 2.57-2.43 (m, 1H), 2.33-2.04 (m, 4H),
1.98-1.68 (m, 5H) ppm. LC/MS: R.sub.t=4.30 min, ES.sup.+ 459 (FA
Waters).
Example 104
[(1S,2S,4R)-4-({8-[2-(dimethylamino)phenyl]-9H-purin-6-yl}amino)-2-hydroxy-
cyclopentyl]methyl sulfamate (Compound I-137)
[0691] The title compound was prepared following the procedure
described in Example 89 (steps a-e) using 2-Dimethylaminobenzoic
acid. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.: 8.23 (a, 1H),
8.06-7.93 (m, 1H), 7.48-7.39 (m, 1H), 7.35-7.28 (m, 1H), 7.20-7.12
(m, 1H), 4.45-4.39 (m, 1H), 4.36 (dd, J=7.8, 9.8 Hz, 1H), 4.18 (dd,
J=73, 9.5 Hz, 1H), 2.68 (s, 6H), 2.63-2.52 (m, 1H), 2.40-2.29 (m,
1H), 2.21-2.09 (m, 1H), 1.99-1.90 (m, 1H), 1.89-1.80 (m, 1H) ppm.
LC/MS: R.sub.t=3.28 min, ES.sup.+ 448 (FA Waters).
Example 105
((1S,2S,4R)-4-{[8-(2,3-dihydro-1,4-benzodioxin-5-yl)-9H-purin-6-yl]amino}--
2-hydroxycyclopentyl)methyl sulfamate (Compound I-41)
[0692] The title compound was prepared following the procedure
described in Example 89 (steps a-e) using
2,3-Dihydro-1,4-benzodioxine-5-carboxylic acid. .sup.1H NMR
(DMSO-d.sub.6, 400 MHz) .delta.: 8.30-7.79 (m, 2H), 7.69-7.61 (m,
1H), 7.06-6.89 (m, 3H), 4.94-4.15 (m, 9H), 2.46-2.40 (m, 1H),
2.26-1.84 (m, 4H), 1.82-1.67 (m, 2H) ppm. LC/MS: R.sub.t=3.93 min,
ES.sup.+ 463 (FA Waters).
Example 106
[(1S,2S,4R)-4-({8-[2-(benzyloxy)phenyl]-9H-purin-6-yl}amino)-2-hydroxycycl-
opentyl]methyl sulfamate (Compound I-68)
[0693] The title compound was prepared following the procedure
described in Example 89 (steps a-e) using 2-Benzyloxybenzoic acid.
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta.: 8.38-8.02 (m, 2H),
7.49-7.07 (m, 8H), 5.63-5.29 (m, 2H), 4.44-4.39 (m, 1H), 4.35 (dd,
J=7.8, 9.8 Hz, 1H), 4.17 (dd, J=7.3, 9.8 Hz, 1H), 2.65-2.48 (m,
1H), 2.41-2.28 (m, 1H), 2.22-2.10 (m, 1H), 2.02-1.78 (m, 2H) ppm.
LC/MS: R.sub.t=4.71 min, ES.sup.+ 511 (FA Waters).
Example 107
{(1S,2S,4R)-4-[(8-cyclohexyl-9H-purin-6-yl)amino]-2-hydroxycyclopentyl}-me-
thyl sulfamate (Compound I-128)
[0694] The title compound was prepared following the procedure
described in Example 89 (steps a-e) using Cyclohexanecarboxylic
acid. .sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.: 8.16 (s, 1H),
4.82-4.77 (m, 1H), 4.42-4.39 (m, 1H), 4.34 (dd, J=7.6, 9.7 Hz, 1H),
4.16 (dd, J=7.3, 9.7 Hz, 1H), 2.89-2.83 (m, 1H), 2.59-2.52 (m, 1H),
2.35-2.29 (m, 1H), 2.17-2.07 (m, 3H), 1.95-1.75 (m, 5H), 1.67-1.27
(m, 5H) ppm. LC/MS: R.sub.t=1.30 min, ES.sup.+ 411.08 (AA
standard).
Example 108
{(1S,2S,4R)-4-[(8-tert-butyl-9H-purin-6-yl)amino]-2-hydroxycyclopentyl}met-
hyl sulfamate (Compound I-131)
[0695] The title compound was prepared following the procedure
described in Example 89 (steps a-e) using Trimethylacetic acid.
.sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.: 8.17 (s, 1H), 4.83-4.76
(m, 1H), 4.42-4.39 (m, 1H), 4.34 (dd, J=7.5, 9.5 Hz, 1H), 4.16 (dd,
J=7.3, 9.8 Hz, 1H), 2.59-2.53 (m, 1H), 2.35-2.30 (m, 1H), 2.17-2.09
(m, 1H), 1.95-1.88 (m, 1H), 1.85-1.78 (m, 1H), 1.44 (s, 9H) ppm.
LC/MS: R.sub.t=1.08 min, ES.sup.+ 385.24 (AA standard).
Example 109
((1S,2S,4R)-4-{[8-(4-chlorophenyl)-9H-purin-6-yl]amino}-2-hydroxycyclopent-
yl)methyl sulfamate (Compound I-111)
Step a
6-chloro-8-(4-chlorophenyl)-9H-purine
[0696] To a solution of 6-Chloro-4,5-diaminopyrimidine (1 g, 0.007
mol) (Example 89, step a) in 1,4-Dioxane (60 mL, 0.8 mol) was added
4-Chlorobenzaldehyde (2.2 g, 0.016 mol) and Ferric chloride (2.5 g,
0.015 mol) mixed with 28.6 g silica gel, and the mixture was heated
at 100.degree. C. for 20 hours. The reaction was cooled to
23.degree. C., filtered and washed with 10% ethanol/ethyl acetate
and concentrated. The residue was dissolved in ethyl acetate and
washed with water, brine, and concentrated. The residue was
triturated in diethyl ether to obtain 272 mg (10%). LC/MS:
R.sub.t=1.54 min, ES.sup.+ 265 (AA standard).
Step b
((1S,2S,4R)-4-{[8-(4-chlorophenyl)-9H-purin-6-yl]amino}-2-hydroxycyclopent-
yl)methyl sulfamate (Compound I-111)
[0697] The title compound was prepared following the procedure
described in Example 89 (steps c-d) and Example 1, step d. .sup.1H
NMR (CD.sub.3OD, 400 MHz) .delta.: 8.22 (s, 1H), 8.03 (d, J=8.5 Hz,
2H), 7.55 (d, J=8.5 Hz, 2H), 4.90-4.85 (m, 1H), 4.43-4.41 (m, 1H),
4.35 (dd, J=7.6, 9.7 Hz, 1H), 4.17 (dd, J=73, 9.7 Hz, 1H),
2.62-2.56 (m, 1H), 2.37-2.31 (m, 1H), 2.20-2.12 (m, 1H), 2.00-1.93
(m, 1H), 1.89-1.82 (m, 1H) ppm. LC/MS: R.sub.t=1.35 min, ES.sup.+
439.29 (AA standard).
Example 110
{(1S,2S,4R)-2-hydroxy-4-[(8-phenyl-9H-purin-6-yl)amino]cyclopentyl}methyl
sulfamate (Compound I-69)
[0698] The title compound was prepared following the procedures
described in Example 109 (step a) using benzaldehyde and Example 1
(step d) followed by TBAF deprotection of the TBS group. .sup.1H
NMR (CD.sub.3OD, 400 MHz) .delta.: 8.22 (s, 1H), 8.06-8.04 (m, 2H),
7.56-7.51 (m, 3H), 4.90-4.84 (m, 1H), 4.43-4.41 (m, 1H), 4.38-4.33
(m, 1H), 4.20-4.15 (m, 1H), 2.62-2.56 (m, 1H), 2.37-2.31 (m, 1H),
2.20-2.11 (m, 1H), 2.00-1.92 (m, 1H), 1.89-1.81 (m, 1H) ppm. LC/MS:
R.sub.t=1.24 min, ES.sup.+ 405 (AA standard).
Example 111
[(1S,2S,4R)-2-hydroxy-4-({8-[2-(trifluoromethoxy)phenyl]-9H-purin-6-yl}-am-
ino)cyclopentyl]methyl sulfamate (Compound I-62)
[0699] The title compound was prepared following the procedures
described in Example 109 (step a) and Example 89 (steps c-e) using
2-(Trifluoromethoxy)benzaldehyde. .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta.: 8.26 (bs, 1H), 8.05-7.95 (m, 1H), 7.69-7.61 (m, 1H),
7.60-7.50 (m, 2H), 4.45-4.39 (m, 1H), 4.35 (dd, J=7.5, 9.8 Hz, 1H),
4.17 (dd, J=73, 9.5 Hz, 1H), 2.67-2.51 (m, 1H), 2.40-2.29 (m, 1H),
2.22-2.10 (m, 1H), 2.07-1.91 (m, 1H), 1.90-1.81 (m, 1H) ppm. LC/MS:
R.sub.t=5.71 min, ES.sup.+ 489 (AA Waters).
Example 112
((1S,2S,4R)-2-hydroxy-4-{[8(2-methoxyphenyl)-9H-purin-6-yl]amino}-cyclopen-
tyl)methyl sulfamate (Compound I-133)
[0700] The title compound was prepared following the procedure
described in Example 111 using 2-Methoxybenzaldehyde. .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta.: 8.41-8.00 (m, 2H), 7.53-7.44 (m,
1H), 7.24-7.16 (m, 1H), 7.15-7.06 (m, 1H), 4.85-4.76 (m, 1H),
4.45-4.40 (m, 1H), 4.36 (dd, J=7.8, 9.8 Hz, 1H), 4.18 (dd, J=7.3,
9.5 Hz, 1H), 4.05 (bs, 3H), 2.64-2.51 (m, 1H), 2.41-2.30 (m, 1H),
2.22-2.10 (m, 1H), 2.00-1.79 (m, 2H) ppm. LC/MS: R.sub.t=3.93 min,
ES.sup.+ 435 (FA Waters).
Example 113
((1S,2S,4R)-2-hydroxy-4-{[6
(1-naphthyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amino}cyclopentyl)methyl
sulfamate (Compound I-74)
Step a
4-chloro-6-(1-naphthyl)-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine
[0701] To a stirred solution of N,N-diisopropylamine (265 .mu.L,
1.89 mmol) in THF (3.00 mL) was added dropwise 1.60 M
n-butyllithium in hexane (1.17 mL) at -78.degree. C. under an
atmosphere of Argon, and the mixture was stirred for 20 minutes at
-78.degree. C. To this mixture was added dropwise a solution of
4-chloro-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine (500 mg,
1.70 mmol) in THF (5.00 mL), and the mixture was stirred for 1 h at
-78.degree. C. A solution of zinc chloride (278 mg, 2.04 mmol) in
THF (2.00 mL) was added dropwise, and the resulting mixture was
taken out the cooling bath and allowed to stir for 1 h. To a
suspension of tetrakis(triphenylphosphine)palladium(0) (100 mg,
0.08 mmol) in THF (2.00 mL) was added 1-iodonaphthalene (0.30 mL,
2.06 mmol), and the resulting yellow solution was immediately added
to the reaction mixture. The resulting mixture was heated at
80.degree. C. for 1 h. After cooling to 23.degree. C., the reaction
mixture was quenched by the addition of water (70.0 mL) and the
water layer was acidified with 1.00 M hydrochloric acid. The
mixture was extracted with DCM (3.times.100 mL), and the organic
layers were combined. The organic layer was washed with brine,
dried over MgSO.sub.4, filtered, and evaporated under vacuum. The
residue was purified via silica gel column chromatography eluting
with 30% ethyl acetate in hexanes to afford the title compound (665
mg, 82%). LC/MS: R.sub.t=11.11 min, ES.sup.+ 420.0 (FA long).
Step b
4-chloro-6-(1-naphthyl)-7H-pyrrolo[2,3-d]pyrimidine
[0702] To a stirred solution of
4-chloro-6-(1-naphthyl)-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine
(350 mg, 0.73 mmol) in THF (2.50 mL) was added a solution of NaOH
(205 mg, 5.13 mmol) in methanol (1.19 mL), and the mixture was
stirred for 15 minutes. After quenching by addition of saturated
NH.sub.4Cl solution (80.0 mL), the mixture was extracted with ethyl
acetate (3.times.100 mL). The organic layers were combined, dried
over MgSO.sub.4, filtered, and evaporated under vacuum. The residue
was dissolved in a small amount of methanol, and the suspension was
filtered through a glass pad filter. The white solid was dried
under high to afford the title compound (141 mg, 65%).
Step c
((1S,2S,4R)-2-hydroxy-4-{[6
(1-naphthyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-amino}cyclopentyl)methyl
sulfamate (Compound I-74)
[0703] The title compound was prepared following the procedure
described in Example 89 (steps c-e). .sup.1H-NMR (400 MHz,
CD.sub.3OD) .delta.: 8.31-8.25 (m, 1H), 8.16 (s, 1H), 7.96-7.89 (m,
2H), 7.65 (dd, 1H, J=7.0, 0.8 Hz), 7.58-7.49 (m, 3H), 6.91 (s, 1H),
4.92-4.80 (m, 1H), 4.45-4.39 (m, 1H), 4.35 (dd, 1H, J1=9.6, 7.5
Hz), 4.18 (dd, 1H, J=9.6, 7.3 Hz), 2.65-2.53 (m, 1H), 2.34 (ddd,
1H, j=13.8, 7.5, 1.3 Hz), 2.21-2.11 (m, 1H), 2.00 (ddd, 1H, J=13.8,
7.0, 5.1 Hz), 1.87 (ddd, 1H, J1=13.0, 8.6, 4.0 Hz). LC/MS:
R.sub.t=5.22 min, ES.sup.+454.1 (FA long).
Example 114
{(1S,2S,4R)-2-hydroxy-4-[(6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-
cyclopentyl}methyl sulfamate (Compound I-38)
[0704] The title compound was prepared following the procedure
described in Example 113. .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta.: 8.10 (s, 1H), 7.78-7.71 (m, 2H), 7.45-7.38 (m, 2H),
7.33-7.26 (m, 1H), 6.93 (s, 1H), 4.86-4.79 (m, 1H), 4.44-4.39 (m,
1H), 4.35 (dd, J=7.5, 9.5 Hz, 1H), 4.17 (dd, J=7.3, 9.8 Hz, 1H),
2.64-2.52 (m, 1H), 2.36-2.27 (m, 1H), 2.19-2.08 (m, 1H), 2.02-1.93
(m, 1H), 1.88-1.79 (m, 1H) ppm. LC/MS: R.sub.t=4.02 min, ES.sup.+
404 (FA Waters).
Example 115
((1S,2S,4R)-4-{[8(7-chloroquinolin-4-yl)-7H-purin-6-yl]oxy}-2-hydroxycyclo-
pentyl)methyl sulfamate (Compound I-73)
Step a
6-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-({[tert-butyl(dimethyl)s-
ilyl]oxy}-methyl)cyclopentyl]oxy}-9-(tetrahydro-2H-pyran-2-yl)-9H-purine
[0705] In DMF (4 mL, 0.05 mol) was suspended sodium hydride (47 mg,
0.0012 mol) at 0.degree. C., to which was added a solution of
(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl)si-
lyl]oxy}methyl)cyclopentanol (0.200 g, 0.000554 mol) in 2.5 mL DMF.
The mixture was stirred at 0.degree. C. for 10 minutes and was
added a solution of 6-Chloro-9-(tetrahydropyranyl)purine (0.265 g,
0.00111 mol) (Example 33, step b) in 4 mL DMF. The reaction was
stirred at 0.degree. C. for 1 h and warmed to 23.degree. C.
overnight. The reaction was quenched by addition of saturated
aqueous NH.sub.4Cl, and the mixture was extracted with ethyl
acetate, washed with brine, dried (Na.sub.2SO), filtered and
concentrated. The residue was purified by flash chromatography (0
to 5% acetone/toluene) to obtain 271 mg (86.8%).
Step b
6-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl-
)silyl]oxy}-methyl)cyclopentyl]oxy}-8-iodo-9-(tetrahydro-2H-pyran-2-yl)-9H-
-purine
[0706] To a solution of
6-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethy-
l)silyl]oxy}methyl)cyclopentyl]oxy}-9-(tetrahydro-2H-pyran-2-yl)-9H-purine
(288 mg, 0.000512 mol) in THF (10 mL, 0.1 mol) was added
N-Iodosuccinimide (0.576 g, 0.00256 mol), and the mixture was
heated at 70.degree. C. overnight. The reaction was cooled,
quenched by addition of saturated aqueous NaHSO.sub.3 and the
mixture was extracted with DCM (3.times.), washed with water, brine
dried (Na.sub.2SO.sub.4), filtered and concentrated. The residue
was purified by flash chromatography (0 to 10% EtOAc/hexanes) to
obtain 271 mg (76.9%). Reference: Nolsoe, J. M. J.; Gundersen,
L-L.; Rise, F. Acta Chemica Scandinavica, 1999, 53, 366-372.
Step c
4-[6-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimet-
hyl)silyl]-oxy}-methyl)cycolopentyl]oxy}-9-(tetrahydro-2H-pyran-2-yl)-9H-p-
urin-8-yl]-7-chloroquinoline
[0707] To a solution of
6-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethy-
l)silyl]oxy}methyl)cyclopentyl]oxy}-8-iodo-9-(tetrahydro-2H-pyran-2-yl)-9H-
-purine (258.4 mg, 0.0003752 mol) in 1,2-Dimethoxyethane (3.0 mL,
0.029 mol) was added 7-chloroquinoline-4-boronic acid pinacol ester
(0.158 g, 0.000546 mol), barium hydroxide (0.228 g, 0.00133 mol),
water (0.5 mL, 0.03 mol) and
Tetrakis(triphenylphosphine)palladium(0) (0.02 g, 0.00002 mol), and
the mixture was heated at 90.degree. C. overnight. The reaction was
cooled, quenched by addition of water and the mixture was extracted
with DCM (3.times.), washed with water, brine, dried
(Na.sub.2SO.sub.4), filtered and concentrated. The residue was
purified by flash chromatography (0 to 30% EtOAc/hexanes) to obtain
180 mg (66.2%) mg. Reference: Cammidge, A. N.; Crepy, K. V. L.
Tetrahedron, 2004, 60, 4377-4386.
Step d
((1S,2S,4R)-4-{[8(7-chloroquinolin-4-yl)-7H-purin-6-yl]oxy}-2-hydroxycyclo-
pentyl)methyl sulfamate (Compound I-73)
[0708] The title compound was prepared following the procedure
described in Example 89 (steps d-e). .sup.1H NMR (CD.sub.3OD, 400
MHz) .delta.: 9.05 (d, J=4.5 Hz, 1H), 8.91 (d, J=9.1 Hz, 1H), 8.57
(s, 1H), 8.15 (d, J=2.2 Hz, 1H), 7.92 (d, J=4.5 Hz, 1H), 7.72 (dd,
J=2.1, 9.1 Hz, 1H), 6.00-5.95 (m, 1H), 4.48-4.45 (m, 1H), 4.37 (dd,
J=7.6, 9.8 Hz, 1H), 4.21 (dd, J=7.3, 9.7 Hz, 1H), 2.70-2.63 (m,
1H), 2.49-2.43 (m, 1H), 2.31-2.25 (m, 1H), 2.21-2.17 (m, 2H) ppm.
LC/MS: R.sub.t=6.12 min, ES.sup.+ 490.98 (AA long).
Example 116
((1S,2S,4R)-2-hydroxy-4-{[8-(1H-indol-3-yl)-7H-purin-6-yl]oxy}cyclopentyl)-
-methyl sulfamate (Compound I-140)
[0709] The title compound was prepared following the procedure
described in Example 115 using 1-(Phenylsulfonyl)indole-3-boronic
acid pinacol ester. .sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.:
8.41-8.33 (m, 2H), 8.08-8.03 (m, 1H), 7.48-7.45 (m, 1H), 7.26-7.19
(m, 2H), 5.94-5.88 (m, 1H), 4.48-4.42 (m, 1H), 4.38 (dd, J=7.3, 9.8
Hz, 1H), 4.21 (dd, J=7.0, 9.8 Hz, 1H), 2.70-2.63 (m, 1H), 2.46-2.40
(m, 1H), 2.28-2.22 (m, 1H), 2.17-2.140 (m, 2H) ppm. LC/MS:
R.sub.t=5.78 min, ES.sup.+ 445.04 (AA long).
Example 117
[(1S,2S,4R)-4-({8-[4-(dimethylamino)-1-naphthyl]-7H-purin-6-yl}oxy)-2-hydr-
oxycyclopentyl]methyl sulfamate (Compound I-103)
[0710] The title compound was prepared following the procedure
described in Example 115 using
N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1--
amine. .sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.: 8.55-8.52 (m,
1H), 8.50 (s, 1H), 8.30-8.28 (m, 1H), 7.80-7.77 (m, 1H), 7.55-7.53
(m, 2H), 7.20-7.17 (m, 1H), 5.94-5.92 (m, 1H), 4.46-4.43 (m, 1H),
4.36 (dd, J=7.5, 9.8 Hz, 1H), 4.20 (dd, J=7.3, 9.8 Hz, 1H), 2.95
(s, 6H), 2.66-2.60 (m, 1H), 2.46-2.39 (m, 1H), 2.28-2.22 (m, 1H),
2.17 (m, 2H) ppm. LC/MS: R.sub.t=6.75 min, ES.sup.+ 499.16 (AA
long).
Example 118
((1S,2S,4R)-4-{[8-(1-benzyl-1H-pyrazol-4-yl)-7H-purin-6-yl]oxy}-2-hydroxyc-
yclopentyl)methyl sulfamate (Compound I-129)
[0711] The title compound was prepared following the procedure
described in Example 115 using 1-Benzylpyrazole-4-boronic acid
pinacol ester. .sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.: 8.41 (s,
1H), 8.34 (s, 1H), 8.17 (s, 1H), 7.39-7.30 (m, 5H), 5.90-5.85 (m,
1H), 5.43 (s, 2H), 4.46-4.43 (m, 1H), 4.36 (dd, J=7.6, 9.8 Hz, 1H),
4.19 (dd, J=7.2, 9.8 Hz, 1H), 2.66-2.60 (m, 1H), 2.40-2.37 (m, 1H),
2.26-2.19 (m, 1H), 2.15-2.11 (m, 2H) ppm. LC/MS: R.sub.t=5.72 min,
ES.sup.+ 486.13 (AA long).
Example 119
{(1S,2S,4R)-2-hydroxy-4-[(8-isoquinolin-4-yl-7H-purin-6-yl)oxy]cyclopentyl-
}-methyl sulfamate (Compound I-112)
[0712] The title compound was prepared following the procedure
described in Example 115 using 4-Isoquinolineboronic acid pinacol
ester. .sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.: 9.41 (s, 1H),
8.87 (s, 1H), 8.74 (d, J=8.6 Hz, 1H), 8.55 (s, 1H), 8.25 (d, J=8.4
Hz, 1H), 7.94 (m, 1H), 7.82 (m, 1H), 5.98-5.96 (m, 1H), 4.49-4.46
(m, 1H), 4.37 (dd, J=7.5, 9.8 Hz, 1H), 4.20 (dd, J=7.3, 9.7 Hz,
1H), 2.70-2.63 (m, 1H), 2.48-2.42 (m, 1H), 2.32-2.26 (m, 1H),
2.20-2.16 (m, 2H) ppm. LC/MS: R.sub.t=5.15 min, ES.sup.+ 457.08 (AA
long).
Example 120
((1S,2S,4R)-2-hydroxy-4-{[8-(4-pyrrolidin-1-yl-1-naphthyl)-7H-purin-6-yl]o-
xy}-cyclopentyl)methyl sulfamate (Compound I-139)
Step a
1-(4-bromo-1-naphthyl)pyrrolidine
[0713] To a solution of 1,4-dibromonaphthalene (500 mg, 0.002 mol),
Pyrrolidine (0.18 mL, 0.0021 mol),
(R)-(+)-2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl (0.022 g,
0.000035 mol), Sodium tert-butoxide (0.24 g, 0.0024 mol) in Toluene
(5.00 mL, 0.0469 mol) was added
Tris(dibenzylideneacetone)dipalladium(0) (0.008 g, 0.000009 mol),
and the mixture was heated at 70.degree. C. overnight. The reaction
was cooled, quenched by addition of water and the mixture was
extracted with DCM (3.times.), washed with water, brine, dried
(Na.sub.2SO.sub.4), filtered and concentrated. The residue was
purified by flash chromatography (0 to 25% hexanes/DCM) to obtain
400 mg (80%). Reference: Jean, L.; Rouden, J.; Maddaluno, J.;
Lasne, M-C. J. Org. Chem. 2004, 69, 8893-8902.
Step b
1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthyl]pyrrolidine
[0714] To a solution of 1-(4-bromo-1-naphthyl)pyrrolidine (400 mg,
0.001 mol), bis(pinacolato)diboron (0.40 g, 0.0016 mol), potassium
acetate (0.43 g, 0.0043 mol) in N,N-Dimethylformamide (8 mL, 0.1
mol) was added Tetrakis(triphenylphosphine)palladium(0) (0.050 g,
0.000043 mol), and the mixture was heated at 100.degree. C.
overnight. The reaction was cooled, quenched by addition of water
and the mixture was extracted with diethyl ether, washed with
water, brine, dried (Na.sub.2SO.sub.4), filtered and concentrated.
The residue was purified by flash chromatography (0 to 25%
DCM/hexanes) to obtain 221 mg (50%). Reference: Miyashita, K.;
Sakai, T.; Imanishi, T. Org. Lett. 2003, 5, 2683-2686.
Step c
((1S,2S,4R)-2-hydroxy-4-{[8-(4-pyrrolidin-1-yl-1-naphthyl)-7H-purin-6-yl]o-
xy}-cyclopentyl)methyl sulfamate (Compound I-139)
[0715] The title compound was prepared following the procedure
described in Example 115 using
1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthyl]pyrrolidine-
. .sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.: 8.58 (d, J=8.1 Hz,
1H), 8.48 (s, 1H), 8.31 (d, J=8.0 Hz, 1H), 7.75 (d, J=8.4 Hz, 1H),
7.54-7.46 (m, 2H), 7.02 (d, J=8.2 Hz, 1H), 5.95-5.92 (m, 1H),
4.47-4.45 (m, 1H), 4.37 (dd, J=7.5, 9.8 Hz, 1H), 4.20 (dd, J=7.2,
9.8 Hz, 1H), 3.5 (m, 4H), 2.70-2.62 (m, 1H), 2.47-2.40 (m, 1H),
2.31-2.24 (m, 1H), 2.16 (dd, J=5.0, 9.0 Hz, 2H), 2.07-2.04 (m, 4H)
ppm. LC/MS: R.sub.t=7.35 min, ES.sup.+ 525.26 (AA long).
Example 121
[(1S,2S,4R)-2-hydroxy-4-({8-[(3-methylphenyl)sulfanyl]-7H-purin-6-yl}-oxy)-
cyclopentyl]methyl sulfamate (Compound I-136)
Step a
6-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl-
)silyl]oxy}-methyl)cyclopentyl]oxy}-8-[(3-methylphenyl)sulfanyl]-9H-purine
[0716] To a solution of 3-methylbenzenethiol (0.55 mL, 0.0046 mol)
in DMF (10 mL, 0.2 mol) was added sodium hydride (0.093 g, 0.0023
mol). The mixture was stirred at room temperature for 10 minutes
and then
6-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethy-
l)silyl]oxy}methyl)cyclopentyl]oxy}-8-iodo-9-(tetrahydro-2H-pyran-2-yl)-9H-
-purine (400 mg, 0.0006 mol) (Example 115, steps a-b) was added and
the solution was heated at 150.degree. C. for 8 hours. The reaction
was cooled, quenched by addition of water and the mixture was
extracted with ethyl acetate, washed with water, brine, dried
(Na.sub.2SO.sub.4), filtered and concentrated. The residue was
purified by flash chromatography (0 to 30% ethyl acetate/hexanes)
to obtain 296 mg (80%) of the title compound.
Step b
[(1S,2S,4R)-2-hydroxy-4-({8-[(3-methylphenyl)sulfanyl]-7H-purin-6-yl}-oxy)-
cyclopentyl]methyl sulfamate (Compound I-136)
[0717] The title compound was prepared following the procedure
described in Example 89 (steps d-e) .sup.1H NMR (CD.sub.3OD, 400
MHz) .delta.: 8.39 (s, 1H), 7.40-7.20 (m, 4H), 5.84-5.82 (m, 1H),
4.40-4.39 (m, 1H), 4.35-4.30 (m, 1H), 4.17-4.13 (m, 1H), 2.57-2.52
(m, 1H), 2.39-2.33 (m, 1H), 2.33 (a, 3H), 2.19-2.04 (m, 3H) ppm.
LC/MS: R.sub.t=6.35 min, ES.sup.+ 452.04 (AA long).
Example 122
[(1S,2S,4R)-2-hydroxy-4-({8-[(3-methylphenyl)sulfonyl]-9H-purin-6-yl}-oxy)-
cyclopentyl]methyl sulfamate (Compound I-101)
[0718] To a solution of
[(1S,2S,4R)-2-hydroxy-4-({8-[(3-methylphenyl)sulfanyl]-9H-purin-6-yl}oxy)-
cyclopentyl]methyl sulfamate (13 mg, 0.000029 mol) in methanol (1.0
mL, 0.025 mol) at 0.degree. C. was added a solution of Oxone.RTM.
(0.0354 g, 0.0000576 mol) in water (0.5 mL, 0.03 mol). The reaction
was stirred for 4 hours at 0.degree. C. and then warmed to
23.degree. C. overnight. The reaction was partitioned with water
and ethyl acetate:isopropanol. The layers were separated and the
aqueous extracted with ethyl acetate:isopropanol. The combined
organics were washed with water, brine, dried (Na.sub.2SO.sub.4),
filtered, and collected in vacuo. The residue was purified by flash
chromatography (20% MeOH/DCM) to obtain 9 mg (60%). Reference:
Ref.: Ramani R. Ranatunge,* et Al., J. Med. Chem., 2004, 47,
2180-2193. .sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.: 8.54 (s, 1H),
7.94 (s, 1H), 7.91 (d, J=7.5 Hz, 1H), 7.56 (d, J=7.5 Hz, 1H), 7.52
(dd, J=7.6, 133 Hz, 1H), 5.91-5.86 (m, 1H), 4.45-4.42 (m, 1H), 4.34
(dd, J=7.5, 9.8 Hz, 1H), 4.18 (dd, J=7.3, 9.6 Hz, 1H), 2.65-2.59
(m, 1H), 2.44 (s, 3H), 2.41-2.35 (m, 1H), 2.24-2.18 (m, 1H),
2.13-2.09 (m, 2H) ppm. LC/MS: R.sub.t=5.10 min, ES.sup.+ 484.11 (AA
standard).
Example 123
{(1S,2S,4R)-4-[(9-benzyl-9H-purin-6-yl)oxy]-2-hydroxycyclopentyl}methyl
sulfamate (Compound I-80)
Step a
5-Amino-4-benzylamino-6-chloropyrimidine
[0719] To a solution of 5-amino-4,6-dichloropyrimidine (8.4 g,
0.051 mol) in 1-butanol (50.0 mL, 0.547 mol) was added
triethylamine (12 mL, 0.084 mol) and benzylamine (17 mL, 0.15 mol),
and the mixture was heated at 100.degree. C. for 3 hours. The
reaction was cooled at 0 C, filtered and washed with ethanol. The
residue was dissolved in CH.sub.2Cl.sub.2 and washed with saturated
aqueous NaHCO.sub.3, and concentrated. The residue was triturated
in diethyl ether to obtain 11.5 g (96%) of a light brown solid.
Step b
6-T Chloro-9-benzylpurine
[0720] To a solution of 4.0 M of hydrochloric acid in 1,4-dioxane
(2.3 mL) in N,N-dimethylformamide (10.0 mL, 0.129 mol) was added
ethyl orthoformate (2.00 mL, 0.0120 mol) and
N-benzyl-6-chloropyrimidine-4,5-diamine (500 mg, 0.002 mol). The
mixture was stirred for 3 days. The reaction was quenched by
addition of triethylamine (1.5 mL, 0.011 mol), extracted with ethyl
acetate, washed with saturated aqueous sodium bicarbonate, water,
brine, dried (NaO), filtered and concentrated. The residue was
purified by flash chromatography (3 to 5% MeOH/DCM) to obtain 336 g
(60%). LC/MS: R.sub.t=1.49 min, ES.sup.+ 245.08 (AA standard).
Step c
{(1S,2S,4R)-4-[(9-benzyl-9H-purin-6-yl)oxy]-2-hydroxycyclopentyl}methyl
sulfamate (Compound I-80)
[0721] The title compound was prepared following the procedure
described in Example 115 (steps a and d). .sup.1H NMR (CD.sub.3OD,
400 MHz) .delta.: 8.51 (s, 1H), 8.32 (s, 1H), 7.34-7.28 (m, 5H),
5.93-5.88 (m, 1H), 5.49 (s, 2H), 4.46-4.43 (m, 1H), 4.35 (dd,
J=7.5, 9.9 Hz, 1H), 4.18 (dd, J=7.1, 9.6 Hz, 1H), 2.66-2.59 (m,
1H), 2.43-2.37 (m, 1H), 2.25-2.18 (m, 1H), 2.14-2.10 (m, 2H) ppm.
LC/MS: R.sub.t=6.04 min, ES.sup.+ 420.11 (AA long).
Example 124
((1S,2S,4R)-4-{[8-(2,3-dihydro-1-benzofuran-7-yl)-7H-purin-6-yl]amino}-2-h-
ydroxycyclopentyl)methyl sulfamate (Compound I-117)
[0722] The title compound was prepared following the procedure
described in Example 89 using the appropriate carboxylic acid.
.sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.: 8.29-8.20 (m, 1H),
8.05-7.81 (m, 1H), 7.36 (dd, J=0.9, 7.3 Hz, 1H), 7.01 (t, J=7.7 Hz,
1H), 4.86-4.78 (m, 3H), 4.44-4.41 (m, 1H), 4.36 (dd, J=7.7, 9.6 Hz,
1H), 4.18 (dd, J=7.2, 9.8 Hz, 1H), 3.35-3.31 (m, 2H), 2.63-2.55 (m,
1H), 2.38-2.32 (m, 1H), 2.20-2.12 (m, 1H), 1.99-1.92 (m, 1H),
1.89-1.83 (m, 1H) ppm. LC/MS: R.sub.t=5.75 min, ES.sup.+ 447.14 (AA
long).
Example 125
{(1S,2S,4R)-2-hydroxy-4-[(8-quinolin-8-yl-7H-purin-6-yl)amino]cyclopentyl}-
-methyl sulfamate (Compound I-84)
[0723] The title compound was prepared following the procedure
described in Example 89 using the appropriate carboxylic acid.
.sup.1H NMR (DMSO-d.sub.6, 300 MHz) .delta.: 9.22-9.12 (m, 1H),
8.93-8.76 (m, 1H), 8.62-8.54 (m, 1H), 8.30-8.09 (m, 2H), 7.86-7.69
(m, 2H), 7.40-7.39 (m, 1H), 4.81-4.70 (m, 1H), 4.30-4.19 (m, 2H),
4.08-3.98 (m, 1H), 2.48-2.42 (m, 1H), 2.28-2.20 (m, 1H), 2.13-1.74
(m, 3H) ppm. LC/MS: R.sub.t=6.00 min, ES.sup.+ 456.04 (AA
long).
Example 126
[(1S,2S,4R)-4-({8-[4-(benzyloxy)phenyl]-7H-purin-6-yl}amino)-2-hydroxycycl-
opentyl]methyl sulfamate (Compound I-102)
[0724] The title compound was prepared following the procedure
described in Example 89 using the appropriate carboxylic acid.
.sup.1H NMR (DMSO-d.sub.6,400 MHz) .delta.: 8.15 (s, 1H), 8.03 (d,
J=8.2 Hz, 2H), 7.46-7.30 (m, 5H), 7.15 (d, J=8.8 Hz, 2H), 5.16 (s,
2H), 4.84-4.75 (m, 1H), 4.22-4.16 (m, 2H), 4.00-3.97 (m, 1H),
2.48-2.42 (m, 1H), 2.12-1.69 (m, 4H) ppm. LC/MS: R.sub.t=7.22 min,
ES 511.06 (AA long).
Example 127
((1S,2S,4R)-4-{[8-(2,3-dimethoxyphenyl)-9H-purin-6-yl]amino}-2-hydroxycycl-
opentyl)methyl sulfamate (Compound I-67)
[0725] The title compound was prepared following the procedure
described in Example 89 (steps a-d) using the appropriate
carboxylic acid and Example 1 (step d, using HCl for TBS
deprotection). .sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.: 8.30-8.23
(m, 1H), 7.87-7.61 (m, 1H), 7.25-7.18 (m, 2H), 4.92-4.80 (m, 1H),
4.43-4.40 (m, 1H), 4.38-4.34 (m, 1H), 4.21-4.16 (m, 1H), 3.90 (d,
6H), 2.63-2.54 (m, 1H), 2.40-2.31 (m, 1H), 2.20-2.12 (m, 1H),
2.00-1.91 (m, 1H), 1.90-1.83 (m, 1H) ppm. LC/MS: R.sub.t=5.92 min,
ES.sup.+ 465 (AA long).
Example 128
((1S,2S,4R)-2-hydroxy-4-{methyl[8-(1-naphthyl)-9H-purin-6-yl]amino}-cyclop-
entyl)methyl sulfamate (Compound I-46)
Step a
(1S,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl)sil-
yl]oxy}-methyl)cyclopentyl methanesulfonate
[0726] To a solution of
(1S,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl-(dimethyl)s-
ilyl]oxy}methyl)cyclopentanol (2.02 g, 0.00560 mol) in
CH.sub.2Cl.sub.2 (55.0 mL, 0.858 mol) at 0.degree. C. was added
triethylamine (1.8 mL, 0.013 mol) and methanesulfonyl chloride
(0.650 mL, 0.00840 mol) under an atmosphere of nitrogen. The
mixture was stirred at 0.degree. C. for 30 minutes, and then warmed
to 23.degree. C. for 1 hour. The reaction was quenched by addition
of saturated aqueous sodium bicarbonate, extracted with DCM, dried
(Na.sub.2SO.sub.4), filtered and concentrated to give 2.66 g
(100%).
Step b
[((1S,2S,4R)-4-azido-2-{[tert-butyl(dimethyl)silyl]oxy}cyclopentyl)methoxy-
](tert-butyl)dimethylsilane
[0727] To a solution of
(1S,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl)si-
lyl]oxy}methyl)cyclopentyl methanesulfonate (2.66 g, 0.00606 mol)
in N,N-Dimethylformamide (20 mL, 0.2 mol) was added sodium azide
(1.21 g, 0.0186 mol), and the mixture was heated at 55.degree. C.
for 3 hours. The reaction was cooled to 23.degree. C., quenched by
addition of water and extracted with Et.sub.2O (3.times.), washed
with water, brine, dried (Na.sub.2SO.sub.4), filtered and
concentrated. The residue was purified by flash chromatography (0
to 15% ethyl acetate/hexane) to obtain 2.13 g (91.1%).
Step c
(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl)sil-
yl]oxy}-methyl)cyclopentanamine
[0728] A suspension of
[((1S,2S,4R)-4-azido-2-{[tert-butyl(dimethyl)silyl]oxy}-cyclopentyl)metho-
xy](tert-butyl)dimethylsilane (2.13 g, 0.00552 mol) and 10% Pd/C
(0.27 g, 0.00026 mol) in EtOAc (45.0 mL, 0.461 mol) was stirred
under an atmosphere of hydrogen overnight. The reaction was purged
with nitrogen and filtered the mixture through celite with EtOAc.
The filtrate was concentrated to obtain 1.83 g (92.1%) of the title
compound.
Step d
Benzyl-[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-({[tert-butyl(dimeth-
yl)-silyl]oxy}methyl)cyclopentyl]carbamate
[0729] To a solution of
(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl)si-
lyl]oxy}methyl)cyclopentanamine (0.098 g, 0.00027 mol) in Methylene
chloride (2.0 mL, 0.031 mol) at 0.degree. C. was added
triethylamine (0.076 mL, 0.00054 mol) and benzyl chloroformate
(0.044 mL, 0.00031 mol). The reaction was warmed to 23.degree. C.
overnight. The reaction was quenched by addition of water.sub.3 and
the mixture was extracted with methylene chloride (3.times.). The
organic layers were washed with brine, dried (Na.sub.2SO.sub.4),
filtered and concentrated. The residue was purified by flash
chromatography (0 to 8% EtOAc/hexanes) to obtain 73 mg (54%).
Step e
Benzyl-[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dime-
thyl)-silyl]oxy}methyl)cyclopentyl]methylcarbamate
[0730] To a solution of
benzyl-[(1R,3SAS)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dime-
thyl)silyl]oxy}methyl)cyclopentyl]carbamate (0.073 g, 0.00015 mol)
in N,N-dimethylformamide (2 mL, 0.02 mol) was added sodium hydride
(0.028 g, 0.0012 mol). The suspension was stirred for 10 minutes
and was added methyl iodide (0.023 mL, 0.00037 mol) (purified on
alumina) and the mixture was stirred overnight. The reaction was
quenched by addition of saturated aqueous ammonium chloride and the
mixture was extracted with ethyl acetate, washed with brine, dried
(Na.sub.2SO.sub.4), filtered and concentrated.
Step f
(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl)sil-
yl]oxy}-methyl)-N-methylcyclopentanamine
[0731] A suspension of
benzyl-[(1R,3S,S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dime-
thyl)silyl]oxy}methyl)cyclopentyl]methylcarbamate (0.394 g,
0.000776 mol) and 10% Pd/C (0.04 g, 0.00004 mol) in ethanol (5.0
mL) was stirred under an atmosphere of hydrogen overnight. The
reaction was purged with nitrogen and filtered the mixture through
celite with ethanol. The filtrate was concentrated to obtain 0.290
g (99%).
Step g
((1S,2S,4R)-2-hydroxy-4-{methyl[8-(1-naphthyl)-9H-purin-6-yl]amino}-cyclop-
entyl)methyl sulfamate (Compound I-46)
[0732] The title compound was prepared following the procedures
described in Example 89 (steps c-d) and Example 1 (step d, using
HCl for TBS deprotection). .sup.1H NMR (CD.sub.3OD, 400 MHz)
.delta.: 8.95 (d, J=7.5 Hz, 1H), 8.23 (s, 1H), 8.03 (d, J=8.3 Hz,
1H), 7.97-7.92 (m, 2H), 7.63-7.54 (m, 3H), 6.58-6.44 (m, 1H),
4.43-4.41 (m, 1H), 4.35 (dd, J=7.8, 9.7 Hz, 1H), 4.19 (dd, J=7.5,
9.5 Hz, 1H), 3.38 (s, 3H), 2.68-2.60 (m, 1H), 2.20-1.97 (m, 4H)
ppm. LC/MS: R.sub.t=1.49 min, ES.sup.- 467.16 (AA standard).
Example 129
((1S,2S,4R)-2-hydroxy-4-{[8-(2-methylphenyl)-9H-purin-6-yl]amino}-cyclopen-
tyl)methyl sulfamate (Compound I-107)
[0733] The title compound was prepared following the procedure
described in Example 89 using the appropriate carboxylic acid.
.sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.: 8.23 (s, 1H), 7.60 (d,
J=7.7 Hz, 1H), 7.44-7.32 (m, 3H), 4.43-4.40 (m, 1H), 4.34 (dd,
J=7.5, 9.8 Hz, 1H), 4.17 (dd, J=7.3, 9.8 Hz, 1H), 2.61-2.53 (m,
1H), 2.53 (s, 3H), 2.37-2.31 (m, 1H), 2.20-2.12 (m, 1H), 1.99-1.92
(m, 1H), 1.89-1.82 (m, 1H) ppm. LC/MS: R.sub.t=1.27 min, ES.sup.+
419.20 (AA standard).
Example 130
{(1S,2S,4R)-2-hydroxy-4-[methyl(9-methyl-8-phenyl-9H-purin-6-yl)-amino]cyc-
lopentyl}methyl sulfamate (Compound I-123)
Step a
6-Chloro-9-methyl-8-phenyl-9H-purine
[0734] To a solution of 6-chloro-8-phenyl-7H-purine (0.200 g,
0.000867 mol) (Example 109, step a) in DMF (8.0 mL, 0.10 mol) was
added sodium hydride (0.025 g, 0.0010 mol). The mixture was stirred
for 20 minutes and to this was added methyl iodide (0.065 mL,
0.0010 mol) and the mixture was stirred for 2 hours. The reaction
was quenched by addition of saturated aqueous NH.sub.4Cl, and the
mixture was extracted with ethyl acetate, washed with water, brine,
dried (Na.sub.2SO.sub.4), filtered and concentrated. The residue
was purified by flash chromatography (3 to 10% acetone/toluene) to
obtain 145 mg (68%).
Step b
N-[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl)-
silyl]oxy}-methyl)cyclopentyl]-9-methyl-8-phenyl-9H-purin-6-amine
[0735] The title compound was prepared following the procedure
described in Example 89 (step c).
Step c
N-[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl)-
silyl]oxy}-methyl)cyclopentyl]-N,9-dimethyl-8-phenyl-9H-purin-6-amine
[0736] To a solution of
N-[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(dimethyl-
)silyl]oxy}methyl)cyclopentyl]-9-methyl-8-phenyl-9H-purin-6-amine
(200 mg, 0.0004 mol) in N,N-dimethylformamide (10 mL, 0.1 mol) was
added sodium hydride (0.112 g, 0.00280 mol). The mixture was
stirred for 30 minutes and to this was added methyl iodide (0.05
mL, 0.0008 mol) and the mixture was stirred overnight. The reaction
was quenched by addition of saturated aqueous NH.sub.4Cl, and the
mixture was extracted with ethyl acetate, washed with water, brine,
dried (Na.sub.2SO.sub.4), filtered and concentrated. The residue
was purified by flash chromatography (0 to 10% MeOH/DCM) to obtain
200 mg (100%).
Step d
{(1S,2S,4R)-2-hydroxy-4-[methyl(9-methyl-8-phenyl-9H-purin-6-yl)-amino]cyc-
lopentyl}methyl sulfamate (Compound I-123)
[0737] The title compound was prepared following the procedure
described in Example 89 (steps d-e). .sup.1H NMR (CD.sub.3OD, 400
MHz) .delta.: 8.24 (s, 1H), 7.84-7.80 (m, 2H), 7.57-7.52 (m, 3H),
6.44-6.36 (m, 1H), 4.40-4.38 (m, 1H), 4.33 (dd, J=7.7, 9.8 Hz, 1H),
4.17 (dd, J=7.3, 9.8 Hz, 1H), 3.83 (s, 3H), 3.34 (s, 3H), 2.63-2.56
(m, 1H), 2.16-1.92 (m, 4H) ppm. LC/MS: R.sub.t=1.41 min, ES.sup.+
433 (AA standard).
Example 131
{(1S,2S,4R)-2-hydroxy-4-[(9-methyl-8-phenyl-9H-purin-6-yl)-amino]cyclopent-
yl}methyl sulfamate (Compound I-130)
[0738] The title compound was prepared following the procedures
described in Example 130 (step a) and Example 89 (steps c-e).
.sup.1H NMR (CD.sub.3OD, 400 MHz) .delta.: 8.28 (s, 1H), 7.82-7.80
(m, 2H), 7.60-7.58 (m, 3H), 4.87-4.86 (m, 1H), 4.42-4.39 (m, 1H),
4.36-4.31 (m, 1H), 4.18-4.14 (m, 1H), 3.85 (s, 3H), 2.59-2.54 (m,
1H), 2.36-2.30 (m, 1H), 2.19-2.11 (m, 1H), 2.00-1.91 (m, 1H),
1.87-1.80 (m, 1H) ppm. LC/MS: R.sub.t=1.30 min, ES.sup.+ 417 (AA
standard).
Example 132
{(1S,2S,4R)-2-hydroxy-4-[(7-methyl-8-phenyl-7H-purin-6-yl)-amino]cyclopent-
yl}methyl sulfamate (Compound I-36)
Step a
N-(4,6-dichloropyrimidin-5-yl)benzamide
[0739] A mixture of 5-amino-4,6-dichloropyrimidine (1.15 g, 0.00701
mol) and benzoyl chloride (1.0 mL, 0.0086 mol) was heated at
100.degree. C. overnight. The reaction was cooled and the residue
was triturated with diethyl ether, filtered and collected to obtain
1.6 g (85%).
Step b
N-(4,6-dichloropyrimidin-5-yl)-N-methylbenzamide
[0740] To a solution of N-(4,6-dichloropyrimidin-5-yl)benzamide
(3.0 g, 0.011 mol) in tetrahydrofuran (70 mL, 0.9 mol) was added
cesium carbonate (9.8 g, 0.030 mol). The suspension was stirred for
5 minutes and to this was added methyl iodide (1.4 mL, 0.022 mol)
(purified on aluminum oxide). After stirring for 1 hour, cesium
carbonate (5.0 g, 0.015 mol) and methyl iodide (0.70 mL, 0.011 mol)
(purified on alumina) were added. The reaction was stirred for 2
hours, quenched by addition of saturated aqueous NH.sub.4Cl, and
the mixture was extracted with ethyl acetate, washed with water,
brine, dried (Na.sub.2SO.sub.4), filtered, concentrated and
trituration in diethyl ether to obtain 2.54 g (80%).
Step c
N-(4-amino-6-chloropyrimidin-5-yl)-N-methylbenzamide
[0741] To a solution of
N-(4,6-dichloropyrimidin-5-yl)-N-methylbenzamide (0.455 g, 0.00161
mol) in 1-butanol (5 mL, 0.05 mol) was added ammonium hydroxide
(0.50 mL, 0.013 mol) and the mixture was refluxed for 24 h. To the
reaction was added ammonium hydroxide (1.0 mL, 0.026 mol) and the
mixture was refluxed for 24 h, cooled, extracted with a mixture of
ethyl acetate:isopropanol, washed with saturated aqueous sodium
bicarbonate, brine, dried (Na.sub.2SO.sub.4), filtered,
concentrated and triturated in diethyl ether to obtain 284 mg
(67.1%).
Step d
6-Chloro-7-methyl-8-phenyl-7H-purine
[0742] A suspension of
N-(4-amino-6-chloropyrimidin-5-yl)-N-methylbenzamide (0.285 g,
0.00108 mol) in phosphoryl chloride (8 mL, 0.08 mol) was heated at
115.degree. C. overnight. The mixture was cooled, concentrated and
triturated in diethyl ether to obtain 224 mg (84.4%) yellow solid.
LC/MS: R.sub.t=1.30 min, ES.sup.+ 245.08 (AA standard).
Step e
{(1S,2S,4R)-2-hydroxy-4-[(7-methyl-8-phenyl-7H-purin-6-yl)-amino]cyclopent-
yl}methyl sulfamate (Compound I-36)
[0743] The title compound was prepared following the procedure
described in Example 89 (steps c-e). .sup.1H NMR (CD.sub.3OD, 400
MHz) .delta.: 8.32 (s, 1H), 7.77-7.73 (m, 2H), 7.61-7.57 (m, 3H),
4.98-4.91 (m, 1H), 4.42-4.39 (m, 1H), 4.34 (dd, J=7.8, 9.5 Hz, 1H),
4.16 (dd, J=7.3, 9.9 Hz, 1H), 4.06 (s, 3H), 2.66-2.59 (m, 1H),
2.37-2.31 (m, 1H), 2.21-2.12 (m, 1H), 2.03-1.96 (m, 1H), 1.92-1.85
(m, 1H) ppm. LC/MS: R.sub.t=1.12 min, ES.sup.+ 419.13 (AA
standard).
Example 133
((1S,2S,4R)-4-{[8-(2-chlorophenyl)-9H-purin-6-yl]amino}-2-hydroxycyclopent-
yl)methyl sulfamate (Compound I-34)
[0744] The title compound was prepared following the procedures
described in Example 89 (steps a, c-d), Example 109 (step a), and
Example 1 (step d, using TBAF for TBS group deprotection). .sup.1H
NMR (CD.sub.3OD, 400 MHz) .delta.: 8.25 (s, 1H), 7.82-7.88 (m, 1H),
7.61 (d, J=8.0 Hz, 1H), 7.55-7.47 (m, 2H), 4.42-4.41 (m, 1H), 4.35
(dd, J=7.7, 9.6 Hz, 1H), 4.17 (dd, J=7.5, 9.6 Hz, 1H), 2.61-2.55
(m, 1H), 2.37-2.32 (m, 1H), 2.20-2.12 (m, 1H), 1.99-1.92 (m, 1H),
1.89-1.82 (m, 1H) ppm. LC/MS: R.sub.t=4.35 min, ES.sup.+ 439 (FA
long).
Example 134
{(1S,2S,4R)-2-hydroxy-4-[(8-phenyl-9H-purin-6-yl)oxy]cyclopentyl}methyl
sulfamate (Compound I-63)
Step a
9-benzyl-6-{[(1R,3S,4S)-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-butyl(d-
imethyl)-silyl]oxy}methyl)cyclopentyl]oxy}-8-phenyl-9H-purine
[0745] The title compound was prepared following the procedures
described in Example 123 (step a), Example 109 (step a), and
Example 115 (step a).
Step b
{(1S,2S,4R)-2-{[tert-butyl(dimethyl)silyl]oxy}-4-[(8-phenyl-9H-puri-6-yl)--
oxy]cyclopentyl}methanol
[0746] A suspension of
9-benzyl-6-{[(1R,3S,4S)-3-{[tert-butyl(dimethyl)silyl]oxy}-4-({[tert-buty-
l(dimethyl)silyl]oxy}methyl)cyclopentyl]oxy}-8-phenyl-9H-purine
(0.161 g, 0.000249 mol), 10% Pd/C (0.04 g, 0.00004 mol) and formic
acid (0.1 mL, 0.003 mol) in methanol (11.0 mL, 0.272 mol) was
stirred under an atmosphere of nitrogen overnight. Added formic
acid (0.2 mL, 0.005 mol) and 10% Pd/C (0.04 g, 0.00004 mol) to the
reaction and stirred 24 h. Added 10% Pd/C (0.060 g, 0.000056 mol)
and formic acid (0.2 mL, 0.005 mol) to the reaction and stirred an
additional 24 h The reaction was purged with nitrogen and filtered
the mixture through celite with DCM. The filtrate was concentrated,
purified by flash chromatography (30 to 50% ethyl acetate/hexane)
to obtain 30 mg (27%). LC/MS: R.sub.t=2.08 min, ES.sup.+ 441.18 (AA
standard).
Step c
{(1S,2S,4R)-2-hydroxy-4-[(8-phenyl-9H-purin-6-yl)oxy]cyclopentyl}methyl
sulfamate (Compound I-63)
[0747] The title compound was prepared following the procedure
described in Example 89 (step e). .sup.1H NMR (CD.sub.3OD, 400 MHz)
.delta.: 8.47 (s, 1H), 8.16-8.11 (m, 2H), 7.57-7.54 (m, 3H),
5.94-5.90 (m, 1H), 4.49-4.45 (m, 1H), 4.37 (dd, J=7.5, 9.5 Hz, 1H),
4.20 (dd, J=7.5, 9.6 Hz, 1H), 2.70-2.64 (m, 1H), 2.46-2.40 (m, 1H),
2.30-2.24 (m, 1H), 2.18-2.14 (m, 2H) ppm. LC/MS: R.sub.t=1.15 min,
ES.sup.+ 406.11 (AA standard).
Example 135
{(1S,2S,4R)-2-hydroxy-4-[(2-phenyl[1,3]oxazolo[5,4-d]pyrimidin-7-yl)-amino-
]cyclopentyl}methyl sulfamate (Compound I-90)
Step a
7-Chloro-2-phenyl[1,3]oxazolo[5,4-d]pyrimidine
[0748] A mixture of 5-amino-4,6-dichloropyrimidine (1.05 g, 0.00640
mol) and benzoyl chloride (0.89 mL, 0.0077 mol) was subjected to
microwave irradiation (100.degree. C.) for 2 hours. The reaction
was cooled and the residue was triturated with diethyl ether,
filtered and collected to obtain 1.15 g (77.5%) of a yellow solid.
LC/MS: R.sub.t=1.84 min, ES.sup.+ 232.19 (AA standard).
Step c
{(1S,2S,4R)-2-hydroxy-4-[(2-phenyl[1,3]oxazolo[5,4-d]pyrimidin-7-yl)-amino-
]cyclopentyl}methyl sulfamate (Compound I-90)
[0749] The title compound was prepared following the procedures
described in Example 89 (steps c-d) and Example 1 (step d, using
TBAF for the TBS group deprotection). .sup.1H NMR (CD.sub.3OD, 400
MHz) .delta.: 8.28 (s, 1H), 8.19-8.16 (m, 2H), 7.58-7.53 (m, 3H),
4.89-4.86 (m, 1H), 4.43-4.40 (m, 1H), 4.34 (dd, J=7.8, 9.5 Hz, 1H),
4.17 (dd, J=7.3, 9.6 Hz, 1H), 2.64-2.55 (m, 1H), 2.35-2.27 (m, 1H),
2.18-2.09 (m, 1H), 2.01-1.95 (m, 1H), 1.89-1.83 (m, 1H) ppm. LC/MS:
R.sub.t=1.44 min, ES.sup.+ 406.31 (AA standard).
Example 136
Enzyme Preparation
[0750] All protein accession numbers provided herein refer to the
Entrez Protein database maintained by the National Center for
Biotechnology Information (NCBI), Bethesda, Md.
Generation of E1 Enzymes
[0751] Following manufacturer instructions, baculoviruses were
generated with the Bac-to-Bac Expression System (Invitrogen) for
the following proteins: untagged NAE.alpha. (APPBP1;
NP.sub.--003896.1), N-terminally His-tagged NAE.beta. (UBEIC;
NP.sub.--003959.3), untagged SAE.alpha. (SAE1; NP.sub.--005491.1),
N-terminally His-tagged SAE.beta. (UBA2; NP.sub.--005490.1),
N-terminally His-tagged murine UAE (UBE1X; NP.sub.--033483).
NAE.alpha./His-NAE.beta. and SAE.alpha./His-SAE.beta. complexes
were generated by co-infection of Sf9 cells, which were harvested
after 48 hours. His-mUAE was generated by single infection of Sf9
cells and harvested after 72 hours. Expressed proteins were
purified by affinity chromatography (Ni-NTA agarose, Qiagen) using
standard buffers.
Generation of E2 Enzymes
[0752] Ubc12 (UBE2M; NP.sub.--003960.1), Ubc9 (UBE2I;
NP.sub.--003336.1), Ubc2 (UBE2A; NP.sub.--003327.2) were subcloned
into pGEX (Pharmacia) and expressed as N-terminally GST tagged
fusion proteins in E. coli. Expressed proteins were purified by
conventional affinity chromatography using standard buffers.
Generation of Ubl Proteins
[0753] Nedd8 (NP.sub.--006147), Sumo-1 (NP.sub.--003343) and
Ubiquitin (with optimized codons) were subcloned into pFLAG-2
(Sigma) and expressed as N-terminally Flag tagged fusion proteins
in E. coli. Expressed proteins were purified by conventional
chromatography using standard buffers.
Example 137
E1 Enzyme Assays
Nedd8-Activating Enzyme (NAE) HTRF Assay.
[0754] The NAE enzymatic reaction totaled 50 L and contained 50 mM
HEPES (pH 7.5), 0.05% BSA, 5 mM MgC, 20 .mu.M ATP, 250 .mu.M GSH,
0.01 .mu.M Ubc12-GST, 0.075 .mu.M Nedd8-Flag and 0.20 nM
recombinant human NAE enzyme. The enzymatic reaction mixture, with
and without compound inhibitor, was incubated at room temperature
24.degree. C. for 105 minutes in a 384-well plate before
termination with 25 .mu.L of Stop/Detection buffer (0.1M HEPES pH
7.5, 0.05% Tween20, 20 mM EDTA, 410 mM KF, 0.53 nM
Europium-Cryptate labeled monoclonal anti-FLAG M2 antibody (CisBio
International) and 8.125 .mu.g/mL PHYCOLINK goat anti-GST
allophycocyanin (XL-APC) antibody (Prozyme)). After incubation for
1 hour at 24.degree. C., quantification of the FRET was performed
on the Analyst.TM. HT 96.384 (Molecular Devices).
[0755] Compounds I-1 to I-153 were tested in this assay. Compounds
I-1, I-2, I-3, I-5, I-6, I-8 to I-12, I-14, I-15, I-17, I-18, I-19,
I-21, I-24 to 1-27, I-29, I-32, I-34, I-37 to 1-43, I-45, I-46,
I-47, I-49, I-55, I-56, I-60, I-62 to 1-65, I-67, I-68, I-69, I-71,
I-73, I-74, I-82, I-83, I-84, I-87, I-88, I-90, I-93, I-99, I-100,
I-101, I-102, I-103m, I-105 to I-109, I-111, I-112, I-115, I-117,
I-118, I-121, I-122, I-124, I-125, I-126, I-128 to I-131, I-133,
I-134, I-136, I-137, I-139, I-140, I-142, I-143, I-146, I-147,
I-150, I-151, and I-153 exhibited IC.sub.50 values less than or
equal to 500 nM in this assay. Compounds I-4, I-7, I-16, I-28,
I-33, I-35, I-36, I-48, I-53, I-54, I-59, I-66, I-77, I-79, I-80,
I-81, I-86, I-92, I-94, I-96, I-98, I-110, I-113, I-114, I-119,
I-120, I-123, I-127, I-132, I-138, I-141, I-148, I-149, and I-152
exhibited IC, values greater than 500 nM and less than 10 .mu.M in
this assay. Compounds I-13, I-20, I-22, I-23, I-30, I-31, I-58,
I-61, I-76, I-85, I-89, I-97, I-144, and I-145 exhibited IC.,
values greater than 10 .mu.M in this assay.
Sumo-Activating Enzyme (SAE) HTRF Assay.
[0756] The SAE enzymatic reaction was conducted as outlined above
for NAE except that Ubc12-GST and Nedd8-Flag were replaced by 0.01
.mu.M Ubc9-GST and 0.125 .mu.M Sumo-Flag respectively and the
concentration of ATP was 0.5 .mu.M. Recombinant human SAE (0.11 nM)
was the source of enzyme.
Ubiquitin-Activating Enzyme (UAE) HTRF Assay.
[0757] The UAE enzymatic reaction was conducted as outlined above
for NAE except that Ubc12-GST and Nedd8-Flag were replaced by 0.005
.mu.M Ubc2-GST and 0.125 .mu.M Ubiquitin-Flag respectively and the
concentration of ATP was 0.1 .mu.M. Recombinant mouse UAE (0.3 nM)
was the source of enzyme.
Example 138
Cellular Assays
Anti-Proliferation Assay (WST)
[0758] Calu-6 (2400/well) or other tumor cells in 80 .mu.L of
appropriate cell culture medium (MEM for Calu6, Invitrogen)
supplemented with 10% fetal bovine serum (Invitrogen) was seeded in
wells of a 96-well cell culture plate and incubated for 24 hours in
a tissue culture incubator. Compound inhibitors were added in 20
.mu.L culture media to the wells and the plates was incubated for
72 hours at 37.degree. C. 10% final concentration of WST-1 reagent
(Roche) was added to each well and incubated for 3.5 hours (for
Calu6) at 37.degree. C. The optical density for each well was read
at 450 nm using a spectrophotometer (Molecular Devices). Percent
inhibition was calculated using the values from a DMSO control set
to 100% viability.
Anti-Proliferation Assay (ATPLite)
[0759] Calu-6 (1500 cells/well) or other tumor cells were seeded in
72 .mu.L of appropriate cell culture medium (MEM for Calu6,
Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen)
in wells of a 384-well Poly-D-Lysine coated cell culture plate.
Compound inhibitors were added in 8 .mu.L 10% DMSO/PBS to the wells
and the plates were incubated for 72 hours at 37.degree. C. Cell
culture medium was aspirated, leaving 25 .mu.L in each well. 25
.mu.L of ATPlite 1Step.TM. reagent (Perkin Elmer) was added to each
well. The luminescence for each well was read using the LeadSeeker
Microplate Reader (Molecular Devices). Percent inhibition was
calculated using the values from a DMSO control set to 100%
viability.
Example 139
In vivo Assays
In Vivo Tumor Efficacy Model
[0760] Calu6 (5.times.10.sup.6 cells), HCT116 (2.times.10.sup.6
cells) or other tumor cells in 100 .mu.L phosphate buffered saline
were aseptically injected into the subcutaneous space in the right
dorsal flank of female Ncr nude mice (age 5-8 weeks, Charles River)
using a 26-gauge needle. Beginning on day 7 after inoculation,
tumors were measured twice weekly using a vernier caliper. Tumor
volumes were calculated using standard procedures
(0.5.times.(length.times.width.sup.2)). When the tumors reached a
volume of approximately 200 mm.sup.3 mice were randomized into
groups and injected intravenously in the tail vein with compound
inhibitor (100 .mu.L) at various doses and schedules.
Alternatively, compound inhibitor may be delivered to mice by
intraperitoneal or subcutaneous injection or oral administration.
All control groups received vehicle alone. Tumor size and body
weight was measured twice a week and the study terminated when the
control tumors reached approximately 2000 mm.sup.3.
[0761] The patent and scientific literature referred to herein
establishes knowledge that is available to those with skill in the
art. Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood by one of
ordinary skill in the art to which this invention belongs. The
issued patents, applications, and references that are cited herein
are hereby incorporated by reference to the same extent as if each
was specifically and individually indicated to be incorporated by
reference. In the case of inconsistencies, the present disclosure,
including definitions, will control.
[0762] While a number of embodiments of this invention have been
described, it is apparent that the provided basic examples may be
altered to convey other embodiments, which utilize the compounds
and methods of this invention. It will thus be appreciated that the
scope of this invention has been represented herein by way of
example and is not intended to be limited by the specific
embodiments, rather is defined by the appended claims.
* * * * *